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Summary  
SUMMARY 
The general aims of this research project were to expand the knowledge on epidemiology and 
pathophysiology of atypical myopathy (AM) in order to improve the prevention and management of 
affected cases. 
Data were collected through the Atypical Myopathy Alert Group. In order to correctly 
categorize reported cases, a decisional diagnostic algorithm was developed. Cases categorized as 
“confirmed or having a strong suspicion to suffer from AM” (AM group) were used in the following 
studies. 
A first study (Study 1) has described AM with respect to its spatiotemporal distribution, 
history and clinical data and its different expressions between European countries. This study allows 
an improved general knowledge on epidemiology of AM. An exploratory analysis of European AM 
cases (Study 2) was conducted to search for indicators of risk factors by comparing AM cases versus 
horses reported to have AM but finally categorized as “having another final diagnosis or a low 
probability to have AM” (the non-AM group). This comparison of AM versus non-AM cases can also 
be used to improve diagnostic criteria. Data collection of survivors and assessment of prognosis was 
attempted in a third study (Study 3). Finally, treatment might be improved with the use of clinical 
findings of the above mentioned studies but also based on pathophysiological studies. In AM cases, 
mitochondrial pathology and lipid accumulation have been described especially in type I fibres, and a 
problem in free fatty acids (FFA) metabolism was therefore suspected to occur. A fourth study  
(Study 4) investigated lipid accumulations in affected muscles in order to test this hypothesis. 
Moreover, it is expected that affected horses have acid-base derangements. In order to identify them, 
to understand their origin and to test their prognostic value, a fifth study (Study 5) has further analyzed 
these derangements on hospital admission. 
 
Results 
During the period 2006-2009, 600 potential AM cases were reported from 9 European countries. A 
decisional diagnostic algorithm was developed and with its use 354 cases were categorized as AM 
cases. Thirty-four AM cases could be used to study acid-base imbalances. Sixty-nine of the reported 
cases were categorized as non-AM cases and served as control group for risk analysis. 
Study 1: France, Belgium and Germany were the most severely affected countries. AM 
occurred mostly in the autumn: especially in the autumns of 2006 and 2009. Autumnal outbreaks were 
followed by outbreaks in the next spring although smaller. All ages, but especially young horses were 
represented. Horses and ponies were reported as well as donkeys and zebras. The majority had a 
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normal body condition and was provided with supplementary feed. Few were in current training at the 
time of diagnosis. All cases occurred while at pasture, except for 6 cases that were stabled for up to  
4 days before the onset of clinical signs. Most horses were fulltime out on grass and none were turned 
out for less than 6 hours per day. Previous unexplained sudden deaths and previous cases of AM had 
been noted in several pastures, sometimes in successive years. Pastures where cases occurred were 
typically described as being sparse, sloping, with accumulations of dead leaves, dead wood and 
containing or being surrounded by trees. There was country to country variation in the affected breeds, 
their management and pasture characteristics. Signs with an incidence exceeding 50% at first clinical 
examination were depression, weakness, stiffness, recumbence, trembling, sweating, pigmenturia, 
congested mucous membranes, tachycardia, and normothermia. Previously unreported clinical signs 
including gastrointestinal impactions, diminished rectal tone, mild diarrhoea, penile prolapse, buccal 
necrosis or ulceration and clinical signs consistent with renal dysfunction were reported to occur in 
some cases. The common presenting clinical signs and mortality were largely similar between 
countries. 
Study 2: Variables more frequently encountered in AM compared to non-AM cases 
(indicators of risk factors) were: the presence of trees, dead wood and accumulations of dead leaves at 
pasture, a sloping pasture, normal body condition, and fulltime grazing. Moreover, AM cases more 
frequently exhibited pigmenturia and normothermia, had higher creatine kinase (CK) activities, and 
received more often treatment than non-AM cases. Variables that were more often present in non-AM 
cases compared to AM cases (indicators of protective factors) were: poor body condition, water 
provision from a tank or bath tub, food supplementation, and spending no or limited time at pasture. 
Also, non-AM cases were more frequently found dead without previous clinical signs, and more often 
had cyanotic mucous membranes than AM cases. Pigmenturia had a high sensitivity and positive 
predictive factor (PPV), and normothermia and congested mucous membranes a high PPV for correct 
diagnosis of AM. 
Study 3: Of the 354 AM cases, 88 were survivors (overall survival rate: 26%). Poor prognosis 
was associated with recumbency, sweating, anorexia, dyspnoea, tachypnoea, tachycardia. Only the 
therapeutic category of “vitamins and antioxidants” significantly improved outcome. Clinical signs 
associated with survival were defecation, remaining standing most of the time, normal mucous 
membranes and normothermia. 
Study 4: The amount of total lipids was similar, but affected samples showed less 
triglycerides and more monoglycerides and FFA than controls. Affected muscles had increases in 
C10:0, C16:1, C18:0, C18:1n9, C22:0, C20:4n6, C22:1 FFA and unidentified FFA shorter than C10 
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and longer than C24, however with some differences between cases. C16:1 showed the most 
spectacular increase. 
Study 5: The majority of AM cases had respiratory and/or metabolic acid-base alterations that 
were mainly caused by respiratory alkalosis, lactic acidosis and/or SIDm alkalosis. AM cases had 
significantly lower pH, pCO2, HCO3
-
, BEfw, BEua, [sodium] and [chloride] compared to controls, and 
significantly higher heart and respiratory rates, PCV, BUN, lactate, AG, SIDm and BEcl. The PCV, 
[chloride], BEcl, BUN, heart rate and the presence of respiratory acidosis were suggested to be useful 
variables to predict the likelihood of survival. 
 
Conclusions and Perspectives 
The undertaken studies achieved the initially defined goals: to improve the general knowledge of AM 
and to better understand its pathophysiological mechanisms. The perspectives of these results are a 
better prevention and management of affected cases by improved diagnostic and prognostic criteria 
and an establishment of guidelines for a therapeutic plan. 
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Résumé  
RÉSUMÉ 
L‟objectif général de ce projet était d‟améliorer les connaissances épidémiologiques et 
physiopathologiques de la myopathie atypique (MA) afin d‟amender les mesures de prévention et de 
gestion des cas. 
Les données des cas de MA ont été collectées via le Groupe d‟Alerte de la Myopathie 
Atypique créé par l‟Université de Liège en 2004. Afin de catégoriser les cas rapportés, un arbre 
diagnostique décisionnel a été développé. Les cas « confirmés » pour la MA ou définis comme 
« hautement probables » selon des critères précis ont été utilisés dans nos études. 
Une première étude (Etude 1) a décrit la distribution spatiotemporelle, l‟historique et les 
différentes expressions cliniques de la MA dans les pays Européens afin d‟y extraire de nouvelles 
informations à caractère épidémiologique et clinique. Aussi, une analyse exploratrice des cas 
Européens (Etude 2) a été conduite afin de redéfinir les mesures de prévention. En comparant les cas 
de MA aux cas rapportés comme cas probables mais finalement considérés comme ayant une faible 
probabilité d‟avoir la MA ou pour lesquels un autre diagnostic a pu être établi, les critères 
diagnostiques ont été améliorés. Dans l‟Etude 3, des facteurs pronostiques ont été identifiés en 
comparant le groupe des survivants à celui des chevaux décédés. Une altération de la fonction 
mitochondriale et une accumulation de lipides dans les muscles ont été décrites chez les chevaux 
souffrant de MA. L‟Etude 4 vise à préciser la nature de ces lipides. Une dernière étude (Etude 5) a été 
conduite afin de préciser les déséquilibres acido-basiques et de tester leur valeur pronostique. Les 
résultats de ces études sont essentiels pour améliorer le traitement symptomatique de la MA. 
 
Résultats 
Au cours de la période 2006-2009, 600 cas considérés comme des cas probables de MA ont été 
rapportés par 9 pays Européens. Un algorithme décisionnel diagnostique a été développé. Avec son 
utilisation, 354 cas ont été catégorisés comme souffrant de MA. Pour 34 d‟entre eux, les données 
acido-basiques étaient disponibles. Soixante neuf cas ont été identifiés comme non-cas. 
 Etude 1 - L‟Allemagne, la Belgique et la France ont été les pays où la MA a été le plus 
déclarée. La MA a été observée surtout lors des automnes 2006 et 2009. Des chevaux de tous âges et 
de tous types, mais surtout de jeunes animaux ont été la cible de la MA. La majorité des cas de MA 
avait une condition corporelle normale et recevait des aliments. Les chevaux étaient rarement à 
l‟entraînement. Tous les cas se sont déclarés à la pâture, sauf 6 cas qui étaient en box jusqu‟à quatre 
jours avant l‟apparition des signes cliniques. La plupart des chevaux étaient au pâturage permanent et 
aucun ne pâturait moins de six heures par jour. Antérieurement au cas déclaré, des mortalités 
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soudaines inexpliquées et/ou des cas de MA avaient été observés dans 22% des prairies, parfois au 
cours d‟années successives. Les prairies où les cas ont été rapportés ont été décrites comme étant peu 
fournies, pentues et dans lesquelles des feuilles mortes et/ou du bois mort étaient amassés. Les prairies 
des cas contenaient ou étaient bordées par des arbres. Une comparaison des données des pays les plus 
touchés démontre des différences en ce qui concerne les races atteintes, les caractéristiques des prairies 
et les techniques de gestion tant des équidés que des prairies. Les signes présents avec une incidence 
de plus de 50% au premier examen clinique ont été un psychisme déprimé, de la faiblesse, de la 
raideur, du décubitus, des tremblements, de la sudation, de la pigmenturie, des muqueuses congestives, 
de la tachycardie et une normothermie. Les signes rapportés pour la première fois étaient :  
des impactions gastro-intestinales, un tonus rectal diminué, de la diarrhée (modérée), un prolapsus du 
pénis, de la nécrose et/ou des ulcérations buccales et des signes cliniques d‟un dysfonctionnement 
rénal. La comparaison entre pays a indiqué que le syndrome clinique ainsi que le taux de mortalité 
étaient similaires. 
Etude 2 - Les variables discriminant les cas de MA des non-cas étaient: la présence d‟arbres, 
de bois morts et de feuilles mortes dans les prairies, l‟aspect pentu des pâtures, une condition 
corporelle normale et le pâturage permanent. De plus, les cas de MA présentaient plus fréquemment de 
la pigmenturie, de la normothermie, une activité enzymatique des créatines kinases plus élevée et 
reçoivaient plus fréquemment un traitement que les non-cas. Les variables les plus souvent rencontrées 
chez les non-cas comparées aux cas de MA étaient : une condition corporelle insuffisante,  
un approvisionnement en eau dans un bac, l‟apport de compléments alimentaires, un accès restreint à 
la pâture. Aussi, les non-cas ont été plus fréquemment retrouvés morts sans signe clinique préalable et 
ont présenté plus souvent des muqueuses cyanosées que les cas de MA. En ce qui concerne 
l‟exactitude du diagnostic de MA, l‟étude a montré que la pigmenturie a une sensitivité et une valeur 
prédictive positive élevée tandis que la normothermie et les muqueuses congestives ont une valeur 
prédictive positive élevée. 
Etude 3 - Parmi les 354 cas de MA, 88 survivants ont été recensés (taux de survie 26%).  
Les signes cliniques associés à la survie ont été la défécation, le fait de rester debout la plupart du 
temps, de garder des muqueuses de couleur normale et une température rectale dans les normes. Un 
pronostic défavorable était associé à du décubitus, de la sudation, de l‟anorexie, de la dyspnée, de la 
tachycardie et de la tachypnée. Seule l‟administration de « vitamines et antioxydants » a 
significativement favorisé la survie. 
Etude 4 – Les analyses ont montré un poids de lipides similaire mais les muscles des chevaux 
atteints de MA avaient un taux moins élevé de triglycérides, mais plus élevé de monoglycérides et 
d‟acides gras que les muscles des chevaux contrôles. Avec une certaine variabilité, les muscles des 
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chevaux affectés par la MA contenaient plus d‟acides gras du type C10:0, C16:1, C18:0, C18:1n9, 
C22:0, C20:4n6, C22:1 ainsi que des acides gras non identifiés plus courts que C10 et plus longs que 
C24. En particulier, une élévation importante du C16:1 était observée. 
Etude 5 - L‟analyse sanguine de cas de MA référés dans des cliniques a montré que la 
majorité des chevaux souffrait de déséquilibres acido-basiques ainsi que d‟une augmentation de 
l‟hématocrite et de l‟urée. L‟acidose métabolique résultait essentiellement d‟une acidose lactique et/ou 
d‟une alcalose elle-même issue d‟une différence entre les ions forts (« measured strong-ion 
difference », en anglais). Le taux d‟urée, l‟hématocrite, la chlorémie, l‟excès en base dû au chlorure 
(BEcl), la fréquence cardiaque et le degré d‟acidose respiratoire ont été identifiés comme variables à 
caractère pronostique. 
 
Conclusions et Perspectives 
Les études menées ont atteint les objectifs initialement définis: améliorer notre connaissance de 
l‟épidémiologie de la MA et mieux comprendre ses mécanismes physiopathologiques. Les 
perspectives des résultats de cette recherche sont une meilleure prévention et une meilleur gestion des 
cas grâce à un diagnostic facilité et à l‟établissement d‟un plan thérapeutique basé sur les 
connaissances actualisées. 
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CHAPTER 1: GENERAL INTRODUCTION 
This introduction points out the knowledge about atypical myopathy (AM) at the start of the current 
research project. 
 
ATYPICAL MYOPATHY 
AM has been reported sporadically since the beginning of the 20
th
 century in various parts of the world 
(Votion et al., 2004), but mainly in the United Kingdom (Anonymous, 1985; Hosie et al., 1986; 
Whitwell et al., 1988; Harris and Whitwell, 1990). Since the new millennium, AM has been 
recognised in an increasing number of countries (Delguste et al., 2002; Gerber et al., 2006; van der 
Kolk, 2006; Palencia and Rivero, 2007; Votion et al., 2007b) showing the emerging character of the 
condition throughout Europe. A similar condition, called “seasonal pasture myopathy”, has also been 
recognised in the United States of America (USA; Tritschler and Miles, 1966; Finno et al., 2006). In 
Belgium and France, outbreaks of AM are now encountered at regular intervals  
(Puyalto-Moussu et al., 2004; Votion et al., 2007b). 
This syndrome of a highly fatal, acute myopathy affecting grazing horses was initially named 
“atypical myoglobinuria” (Anonymous, 1985). However, since myoglobinuria is only one of the 
possible clinical signs of the condition, the name atypical myopathy is now preferred  
(Votion et al., 2004). 
 
Epidemiology 
According to a Belgian case-series (Votion et al., 2007b), AM seems to occur in horses being on 
pasture for at least one week. However, horses can still develop the condition in the following days 
after being placed in a box (Votion et al., 2007b). The condition is reported to occur on bare, sloping 
pastures with trees. Most of the grazed pastures where AM declares contain humid areas and are 
crossed or being bordered by a watercourse (Votion et al., 2007b). Affected horses are often young, 
unbroken and in good body condition (Brandt et al., 1997; Puyalto-Moussu et al., 2004; Votion et al., 
2004; Votion et al., 2007b). 
The condition does not seem to be contagious, but it is usually reported as outbreaks since 
particular environmental characteristics and specific weather conditions predispose to AM. The 
climatic conditions favouring AM are little sunshine, cool temperature without heavy frost, heavy 
rainfall or humidity, and strong winds (Hosie et al., 1986; Whitwell et al., 1988; Puyalto-Moussu et 
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al., 2004; Votion et al., 2007b). These particular meteorological conditions lead to seasonal 
occurrence (i.e. the majority of cases are observed in autumn and some in spring; Votion et al., 
2007b). 
 
Aetiology 
For the moment the aetiology of AM remains unknown, but several causes have been considered. 
Toxic products, like ionophores, herbicides, weed killers, nitrates and nitrites have been incriminated. 
However, testing for these products yielded negative results (Whitwell et al., 1988; Brandt et al., 
1997; Delguste et al., 2002). Phytotoxins have also been suspected, but plants known to be toxic for 
horses or other animals were not consistently present in the pastures of affected horses and/or were 
previously identified to cause other clinical signs than rhabdomyolysis (Hosie et al., 1986; Brandt et 
al., 1997; Puyalto-Moussu et al., 2004; Votion et al., 2007b). No evidence of viral infections was 
found in cases with AM (Whitwell et al., 1988; Brandt et al., 1997; Delguste et al., 2002). Mycotoxins 
could be involved as they are known to have potential toxic effects in equines (Osweiler, 2001). This 
hypothesis is supported by the description of a human fatal myopathic condition caused by mycotoxins 
(Bedry et al., 2001). Moreover, fungal growth and mycotoxin production depend on specific climatic 
conditions which are those favouring AM and therefore mycotoxins are a possible cause of AM. Other 
researchers have proposed Clostridial toxins as a cause of AM (Delguste et al., 2002; Gerber et al., 
2006). Unfortunately, until now no result of research was able to confirm neither mycotoxins, nor 
Clostridium spp. as the causative agent. Selenium or vitamin E deficiency can lead to a nutritional 
myopathy, often resembling AM. Antioxidant status of AM cases was variable (Hosie et al., 1986; 
Whitwell et al., 1988; Brandt et al., 1997), and supplementation and treatment with selenium and 
vitamin E rarely improve the condition. However, these important antioxidants may have a protective 
role against a potential oxidative stress encountered in the pathophysiological process of AM. 
 
Pathogenesis 
The myodegenerative process of AM affects more selectively oxidative (i.e. the slow-twitch or type I 
fibres mainly found in postural and respiratory muscles) rather than glycolytic fibres (i.e. the fast 
twitch or type II fibres predominantly found in locomotory muscles) (Brandt et al., 1997; Cassart et 
al., 2007; Palencia and Rivero, 2007). In addition, increased lipid storage is prominent in type I fibres 
(Cassart et al., 2007). These observations alongside with no abnormal glycogen or polysaccharide nor 
calcium salt accumulations suggested an impaired oxidative lipid metabolism and a preserved 
glycolytic pathway. In addition, a central role of the mitochondria in the pathogenesis of AM was 
suggested by the observation of mitochondrial ultrastructural changes (Cassart et al., 2007).  
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Clinical signs 
Clinical studies (Whitwell et al., 1988; Brandt et al., 1997; Delguste et al., 2002; Votion et al., 2007b) 
report that affected horses show a sudden onset of severe general weakness and muscular stiffness and 
often become recumbent within a few hours. They are sometimes even found dead on pasture without 
premonitory signs. The affected horses show increased heart and respiratory rate, often hypothermia 
and congested mucous membranes. Most cases keep a good appetite and continue to pass faeces, 
although some suffer from oesophageal obstruction (Hosie et al., 1986; Whitwell et al., 1988; Brandt 
et al., 1997; Votion et al., 2007b). Dysuria with a distended bladder at rectal examination is frequently 
encountered. A lot of horses demonstrate signs of colic probably due to this bladder distension  
(Hosie et al., 1986; Brandt et al., 1997; Votion et al., 2007b). The urine is dark-brown in the acute 
phase due to the presence of myoglobin in the urine (myoglobinuria; Votion et al., 2007b). 
Subclinical cases have also been described and can be horses that graze on the same premise 
than a clinically affected horse (Delguste et al., 2002; Votion et al., 2007b). They are often recognised 
when blood analyses are performed on co-grazers of the affected horse. These subclinical cases show 
no clinical signs, but have significant increase of serum activities of creatine kinase (CK). They can 
however evolve into clinical cases and so it is important to recognise them and monitor them closely. 
 
Diagnosis 
The clinical diagnosis of AM can be made based on history, clinical signs, blood and urine analysis, 
muscle biopsy and finally on post mortem examination (Cassart et al., 2007; Votion et al., 2007b). 
History is of major importance in the diagnosis. No cases are yet described not being out on 
pasture, probably because the etiologic agent is only found at pasture. Sometimes AM can occur as an 
outbreak and it is known that pastures where the condition has occurred before remain at risk in 
following years (Votion et al., 2009). So knowledge of previous cases on the particular pasture may 
facilitate the diagnosis. Excluding other forms of rhabdomyolysis, for example exercise-induced 
myopathies, is paramount. However, it is speculated that exercise as any other forms of stress can 
predispose for developing AM (Votion et al., 2003). 
The clinical signs are typical for any severe rhabdomyolysis, but not specific at all for AM. It 
is therefore difficult to make a diagnosis just based on clinical signs. 
At blood analysis muscle enzymes are massively increased, confirming severe rhabdomyolysis 
(Hosie et al., 1986; Whitwell et al., 1988; Delguste et al., 2002; Votion et al., 2007b). Often 
hyperglycaemia and hyperlipaemia are present and liver enzymes are increased (Hosie et al., 1986; 
Whitwell et al., 1988; Delguste et al., 2002; Votion et al., 2007b). A hypocalcaemia is almost always 
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found, but no other important electrolyte derangements are reported consistently  
(Votion and Serteyn, 2008). The urine is coloured due to the myoglobinuria, and should be 
differentiated from haematuria or haemoglobinuria. 
The only way to make a more definitive diagnosis of AM is by means of histology performed 
on muscle samples taken by biopsy or at post mortem. Biopsy is best performed in living horses on 
postural muscles (more specifically the shoulder muscles) and at post mortem on the intercostal 
muscles (Cassart et al., 2007). At necropsy, discoloured muscles and myocardium, congestive lungs, 
petechiae and black-reddish gastro-enteric contents may be seen (Cassart et al., 2007). However, 
necropsy may also be disappointing with no specific observation (Cassart et al., 2007). Histology 
shows a multifocal process of Zenker‟s degeneration and necrosis of affected muscles  
(Cassart et al., 2007). Nevertheless this histological feature is not pathognomic for AM and can also 
be encountered in horses that have suffered a long period of recumbency (Votion et al., 2004) or other 
severe forms of rhabdomyolysis such as for example immune-mediated myopathies, polysaccharide 
storage myopathy, nutritional myopathies or post-anaesthetic myopathies. Immunohistochemistry is 
however more specific demonstrating important lipid accumulations in type I muscle fibres  
(Cassart et al., 2007). 
 
Differential diagnosis 
Other severe myopathies described in the horse are sporadic or recurrent exercise-induced myopathies, 
glycogen branching enzyme deficiency in the foal, white muscle disease or nutritional 
myodegeneration, immune-mediated myopathy and post-anaesthetic myopathy. Besides other severe 
myopathies, AM can be confounded with endotoxemia, colic, neurological disorders (e.g. tetanus, 
botulism, bacterial or viral meningitis, spinal cord disease, grass disease), intoxications  
(e.g. ionophores, strychnine, carbamates, organophosphates, cassia occidentalis, acorn, white 
snakeroot), hematuria or hemoglobinuria of any cause (e.g cystitis, calculi, bladder tumours,  
exercise-induced hematuria, urethral defects, renal haemorrhage, systemic haemolysis), or even 
lameness (e.g. iliac thrombosis, laminitis, poly-arthritis, arthritis). Worth mentioning in respect to the 
differential diagnosis of AM is the fact that horses can develop increased muscle enzyme activity due 
to prolonged recumbency. 
In horses with colic, muscle fasciculations can be noted secondary to pain and/or to 
hypocalcaemia. Fasciculations, together with the frequent occurrence of colic in horses and other 
clinical signs of colic (tachycardia, tachypnoea, congestive mucous membranes, recumbency and pain) 
make colic a very important differential diagnosis of AM.  
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Treatment 
Since the aetiology of AM is not known, therapy of AM affected horses is mostly symptomatic and 
based on fluid therapy, muscle relaxants, analgesia, and supporting muscle function and repair with 
vitamins and anti-oxidants. Nevertheless, one of the existing hypotheses about the aetiology includes 
clostridial infections (Delguste et al., 2002; Gerber et al., 2006). Hypothetically, administration of 
metronidazole might therefore be helpful. Administration of botulism type C and D antiserum has also 
been suggested (Gerber et al., 2006). 
Once a horse is recumbent, regular turnings, good thick and clean bedding, and stimulating the 
horse to remain in sternal recumbency instead of lateral can prevent further muscle and pulmonary 
compression as well as the development of important decubital ulcers. Affected horses should be 
exposed to stress (for example exercise, transport) as little as possible, since it might aggravate their 
condition. Nevertheless, treatment is most of the time unsuccessful (Votion and Serteyn, 2008). 
Although sporadic survivors have been described (Puyalto-Moussu et al., 2004; Finno et al., 2006), 
survival of affected horses is questioned (Harris, 2009) amongst others due to the difficulties of 
correctly diagnosing AM. 
 
Prognosis 
The prognosis for most AM cases is not favourable. Finally, most horses die within 3 days  
(Votion et al., 2007b). The mortality rate of AM is estimated at 85% (Puyalto-Moussu et al., 2004; 
Votion et al., 2004) up to 97% (Brandt et al., 1997). Negative prognostic factors recognised in clinical 
studies on fatal cases are dyspnoea with severely lowered arterial partial pressures in oxygen (PaO2) 
levels. Serum activities of CK do not seem to be of prognostic value (Votion et al., 2007b). 
It is important to inform the owner about the risk that his other horses can become affected, 
clinically or sub clinically (Votion et al., 2007b). If possible, horses that are on the same pasture as an 
affected horse should be removed from this pasture and preferably placed in a box. If not enough 
boxes are available for all, young horses should have priority since they seem to be more at risk for 
AM (Votion et al., 2009). Their level of serum CK activities should be checked for several days and 
horses should be monitored closely for any annunciating signs (mainly weakness and stiffness). 
 
Prevention 
A large epidemiological investigation on Belgian confirmed cases enabled the identification of AM 
favouring factors (Votion et al., 2009). In order to prevent AM it may be recommended to regularly 
administrate anthelminthics, to vaccinate, to give supplementary feeding and to provide a salt block all 
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year round. The spreading of manure favours also AM and thus this common practice should be 
prohibited. 
During the at-risk seasons (i.e. autumn and spring), horses should have access only to 
furnished grassland. Particularly humid pastures or pastures where a stream/river flows across and 
with a lot of dead leaves accumulated in autumn, should be assigned for summer pasturing especially 
if this pasture has a history of previous death(s) of horses. Giving water from the distribution network 
has also found to be a protective measure against AM. 
When clinical series of AM declare in neighbouring regions or countries, it may be advised to 
remove horses from pastures, whereas horses maintained at pasture should be supplemented with food. 
It is worth noting that supplementing hay on the ground in a humid environment increases the risk of 
AM. A weather-dependent stabling should be considered with horses returning to pasture when several 
days of heavy frost have been encountered (it is believed that frost would destroy the causal agent). 
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To better understand the pathophysiology of AM, it is necessary to review the pathways of energy 
metabolism of the skeletal muscle cell. 
 
MUSCULAR METABOLISM 
Adenosine triphosphate 
The source of energy used for muscular contraction is adenosine triphosphate (ATP). The phosphate 
linkages of ATP are high-energy bonds. When a phosphate is removed, this energy is released to be 
used for the contractile process. The amount of ATP present in muscles is only sufficient to sustain 
contraction for a couple of seconds. Therefore it is essential that new ATP is regenerated. This ATP 
can be formed by several pathways, being in chronological order the phosphocreatine-creatine system, 
the anaerobic glycogen-lactic acid system and the aerobic system (Lehninger et al., 1993b; Guyton 
and Hall, 2006a; Guyton and Hall, 2006b; Votion et al., 2007c). 
 
Phosphocreatine-creatine system 
Phosphocreatine also contains a high-energy phosphate bond, like ATP, but a bigger amount of energy 
is released by the removal of the phosphate. Therefore it can easily provide enough energy to 
reconstitute the high-energy bond of ATP. This system also is only sufficient to sustain contraction for 
a couple of seconds (Lehninger et al., 1993b; Guyton and Hall, 2006b). 
 
The glycogen-lactic acid system 
Glycolysis begins with glucose-6-phosphate obtained either from blood glucose and phosphorylation 
by the hexokinase or from mobilized stored intracellular glycogen and proceeds through a series of 
steps to produce pyruvate. Up to this stage, two ATP molecules are obtained and two cytosolic 
reduced nicotinamide adenine dinucleotide (NADH) molecules are produced. In the presence of 
oxygen, pyruvate is converted into acetyl-CoA and enters the tricarboxylic acid or Krebs cycle in the 
mitochondria. In absence of oxygen, pyruvate is converted to lactate in the cytoplasm, which diffuses 
out of the muscle cells into the interstitial fluid and blood. The ATP-production of this anaerobic 
system is a rapid energy source, but not an efficient compared to the aerobic system in terms of ATP 
yielded per mole of glucose (Lehninger et al., 1993f; Guyton and Hall, 2006a; Guyton and Hall, 
2006b). 
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The aerobic system 
General 
The aerobic system includes the mitochondrial oxidation of products of glycolysis, fatty acids and 
amino acids to provide energy (Figure 1). These substrates are conversed into acetyl-CoA, and enter 
the Krebs cycle in which electrons are abstracted. These electrons are carried by NADH and reduced 
flavin adenine dinucleotide (FADH2). The reduced coenzymes are reoxidized by the electron transfer 
system (ETS) to provide ATP through oxidative phosphorylation (OXPHOS; Figure 2). In the overall 
reaction catalysed by the mitochondrial respiratory system, electrons move from NADH, succinate 
(via FADH2), or some other primary electron donors through Complex I, Complex II or coenzyme Q 
which is the junction to Complex III. Electrons move from Complex III to cytochrome c and then to 
Complex IV which completes the sequence by transferring electrons from cytochrome c to oxygen 
(thus consuming oxygen). Electron flow through Complexes I, III and IV is accompanied by proton 
flow (H
+
) from the mitochondrial matrix to the intermembrane space. A last enzyme (the ATP 
synthase, sometimes called Complex V) catalyses the formation of ATP from adenosine diphosphate 
(ADP) owing to the energy provided by the “proton-motive” force, i.e. the proton flow back into the 
matrix through a pore associated to the ATP synthase (Figure 2). During the Krebs cycle only a little 
amount of ATP is produced through the production of the high-energy compound guanosine 
triphosphate (GTP), but large amounts are produced during OXPHOS (Lehninger et al., 1993c; 
Guyton and Hall, 2006a). 
Fatty acids 
Since a problem in lipid metabolism is suspected in AM (Cassart et al., 2007), and due to the 
importance of fatty acids for the aerobic metabolism in the skeletal muscle cell (MacLeay, 2004), the 
metabolism of fatty acids will be discussed more in detail. 
The first stage of using lipids for energy is the hydrolysis of triglycerides into free fatty acids 
(FFA) and glycerol, which will be released into the bloodstream to be taken to the muscle cell. When 
glycerol enters the cell, it is immediately changed into glycerol-3-phosphate, entering the glycolytic 
pathway (Lehninger et al., 1993g; Guyton and Hall, 2006d). The enzymes of FFA ß oxidation are 
located in the mitochondrial matrix. Therefore, they must be transported into the mitochondria by the 
carnitine shuttle, which is a rate-limiting step (Lehninger et al., 1993g). The FFA with a chain length 
shorter than 12 carbons can however enter the mitochondria freely (Lehninger et al., 1993g). In the 
mitochondria, the fatty acids undergo ß oxidation: oxidative removal of 2-carbon segments in the form 
of acetyl-CoA (Lehninger et al., 1993g; Guyton and Hall, 2006d). This oxidation requires removal of 
4 hydrogen atoms (two pairs of electrons and four H
+
) per acetyl-CoA. These electrons carried by 
FAD and NAD (i.e. FADH2 or NADH2) enter immediately the ETS of the OXPHOS (Lehninger et al., 
1993g; Figure 3).  
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The ß oxidation of FFA occurs in four steps (Lehninger et al., 1993g; Guyton and Hall, 
2006d). The first process is the dehydrogenation of fatty acyl-CoA with the production of a trans-fatty 
acid (a double bond), catalysed by acyl-CoA deshydrogenases. The acyl-CoA deshydrogenases are 
flavoproteins, which use the coenzyme FAD derived from riboflavin (vitamin B2; Lehninger et al., 
1993g). The electrons removed from the fatty acyl-CoA are transferred to FAD. The produced FADH2 
immediately donates its electron to an electron carrier of the ETS, the electron-transferring 
flavoprotein (ETF), from which they pass to coenzyme Q via the ETF:ubiquinone oxidoreductase 
(ETF:QO; Figure 4). In the second step, water is added to the double bound to form  
ß-hydroxyacyl-CoA. In the third step, ß-hydroxyacyl-CoA is dehydrogenated to form ß-ketoacyl-CoA 
by the ß-hydroxyacyl-CoA dehydrogenase (or 3- hydroxyacyl-CoA dehydrogenase). The liberated 
electrons are transferred to the oxidized form of nicotinamide adenine dinucleotide (NAD
+
)
 
and are 
transported to Complex I of the ETS (Figure 4). In the fourth step, a thiolase catalyses the splitting of 
the ß-ketoacyl-CoA into acetyl-CoA and a thioester. The four steps are repeated to yield acetyl-CoA 
and ATP. The ATP production from fatty acids is much more important than that from glucose  
(131 ATP molecules per molecule of palmitoyl-CoA versus. 38 ATP molecules per glucose molecule; 
Lehninger et al., 1993d). 
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Figure 1 - Aerobic metabolism (catabolism of proteins, fats, and carbohydrates in the three stages of 
cellular respiration). 
 
Legend: Stage 1: oxidation of fatty acids, glucose, and some amino acids yields acetyl-CoA.  
Stage 2: oxidation of acetyl groups in the Krebs (or tricarboxylic acid) cycle includes four steps in 
which electrons are abstracted. Stages 3: electrons carried by reduced nicotinamide adenine 
dinucleotide (NADH) and reduced flavine adenine dinucleotide (FADH2) are funnelled into the 
electron transfer system, providing the energy for ATP synthesis by oxidative phosphorylation 
(OXPHOS). 
Abbreviations: PDH = pyruvate dehydrogenase complex; Cyt C = cytochrome c; Q = coenzyme Q; 
CI, CII, CIII, CIV, and CV = complexes I, II, III, IV and V, respectively. 
Picture adapted from: Principles of Biochemistry, fourth edition, Ed: Lehninger, Nelson and Cox. 
Worth Publishers New York, 2004, pp 602.  
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Figure 2 - The electron transfer system and the oxidative phosphorylation. 
 
Legend: Electrons from reduced nicotinamide adenine dinucleotide (NADH) and other oxidizable 
substrates pass through a chain of carriers arranged asymmetrically in the inner membrane of the 
mitochondria. In this chemiosmotic model, electron flow is accompanied by proton transfer across the 
membrane, producing a chemical gradient (ΔpH) and an electrical gradient (ΔΨ). The inner 
mitochondrial membrane is impermeable to protons; protons can re-enter the matrix only through 
proton specific channels at the level of complex V. 
Abbreviations: IMM = inner mitochondrial membrane; OMM = outer mitochondrial membrane;  
Q = coenzyme Q; Cyt C = cytochrome c; CI, CII, CIII, CIV, and CV = complexes I, II, III, IV and V, 
respectively. 
Picture adapted from: Principles of Biochemistry, fourth edition, Ed: Lehninger, Nelson and Cox. 
Worth Publishers New York, 2004, pp 705.  
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Figure 3 - Lipid metabolism (stages of fatty acid oxidation). 
 
Legend: Stage 1 (ß oxidation): a long chain fatty acid (i.e. palmitate) is oxidized to yield acetyl 
residues in the form of acetyl-CoA. Stage 2 (Krebs cycle): the acetyl groups are oxidised to CO2 via 
the tricarboxylic acid cycle (TCA) or Krebs cycle. Stage 3 (electron transfer system): electrons derived 
from the oxidations of stages 1 and 2 pass to oxygen via the electron transfer system, providing the 
energy for ATP synthesis by oxidative phosphorylation. 
Picture adapted from: Principles of Biochemistry, fourth edition, Ed: Lehninger, Nelson and Cox. 
Worth Publishers New York, 2004, pp 637.  
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Figure 4 - The path of electrons to ubiquinone. 
 
Legend: Electrons from reduced nicotinamide adenine dinucleotide (NADH), succinate, fatty  
acyl-CoA and glycerol 3-phosphate converge to ubiquinone (coenzyme Q).  
Abbreviations: IMM = inner mitochondrial membrane; Q = coenzyme Q; CI = complex I;  
CII = complex II 
Picture adapted from: Principles of Biochemistry, fourth edition, Ed: Lehninger, Nelson and Cox. 
Worth Publishers New York, 2004, pp 697. 
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GENERAL AIMS OF THE RESEARCH PROJECT 
In the autumn of 2000, AM was for the first time identified in Belgium (Delguste et al., 2002). Since 
then this syndrome of acute rhabdomyolysis has been observed in an increasing number of European 
countries (Votion and Serteyn, 2008). Little was known about the condition and clinicians confronted 
to patients felt often powerless. The general aims of this research project were therefore to expand the 
knowledge on epidemiology and pathophysiology of AM in order to improve the prevention and 
management of affected cases. Appropriate management requires an accurate diagnosis and prognosis 
as well as a therapeutic plan. 
Through the Atypical Myopathy Alert Group (AMAG), an informal epidemio-surveillance 
group that was set up by the University of Liege in 2004, data on AM cases can be collected. 
However, in order to correctly categorize reported cases, a decisional diagnostic algorithm needs to be 
developed. Those cases categorized as “confirmed or having a strong suspicion to suffer from AM” 
(AM group) shall be used in the following studies. 
A first study (Study 1) shall describe AM with respect to its spatiotemporal distribution, 
history and clinical data and its different expressions between European countries. Previous studies 
included cases of restricted geographic areas and were largely based on non-survivors (Brandt et al., 
1997; Puyalto-Moussu et al., 2004; Votion et al., 2007b). This study, however, aims at including cases 
from all over Europe and survivors allowing an improved general knowledge on epidemiology of AM. 
Prevention is of major importance because treatment is often ineffective (Votion and Serteyn, 
2008; Harris, 2009). Preventative measures are suggested according 1) the specific conditions under 
which AM occurs, and 2) risk and protective factors. Previously, risk factors were identified but only 
on a limited number of Belgian non-survivors (Votion et al., 2009). Therefore preventative measures 
need to be refined according to the characteristics of European outbreaks. An exploratory analysis of 
European AM cases (Study 2) will be conducted to search for indicators of risk factors by comparing 
AM cases versus horses reported to have AM but finally categorized as “having another final 
diagnosis or a low probability to have AM” (the non-AM group). This comparison of AM versus non-
AM cases can also be used to improve diagnostic criteria, especially since diagnosis is not straight 
forward with clinical signs, blood results and histology not being pathognomic. 
Diagnosis of survivors of AM is often questioned (Harris, 2009). Previously, survival rates 
were estimated at 3% (Brandt et al., 1997) to 15% (Puyalto-Moussu et al., 2004; Votion et al., 2004), 
but possibility of survival remains to be demonstrated. Therefore, data collection of survivors and 
assessment of prognosis was attempted in a third study (Study 3).  
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Finally, diagnosis and treatment might be improved with the use of clinical findings of the 
above mentioned studies but also based on pathophysiological studies. In AM cases, mitochondrial 
alteration and lipid accumulation have been described especially in type I fibres (Cassart et al., 2007; 
Palencia and Rivero, 2007), and a problem in the metabolism of FFA was therefore suspected to 
occur. A fourth study (Study 4) will investigate lipid accumulations in affected muscles in order to test 
this hypothesis. Moreover, it is expected that affected horses have acid-base derangements. In order to 
identify them, to understand their origin and to test their prognostic value, a fifth study (Study 5) will 
further analyze these derangements on hospital admission. 
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CHAPTER 2: SYNOPSIS PRESENTATION OF THE STUDY 
RESULTS 
PART 1: EPIDEMIOLOGICAL ASPECTS 
 
The three studies of this chapter on the epidemiological aspects are published as: 
VAN GALEN G., AMORY H., BUSSCHERS E., CASSART D., DE BRUIJN M., GERBER V.,  
KEEN J., LEFERE L., MARCILLAUD PITEL C., MARR C., MULLER J.-M.V., PINEAU X.,  
SAEGERMAN C., SANDERSEN C., SERTEYN D., TORFS S., UNGER L., VERWILGHEN D.,  
VOTION D.-M. 
European outbreak of atypical myopathy in the fall 2009. 
J. Vet. Emerg. Crit. Care, 2010, 20, 528-532. 
 
VAN GALEN G., MARCILLAUD PITEL C., SAEGERMAN C., PATARIN F., AMORY H.,  
BAILLY J.D., CASSART D., GERBER V., HAHN C.N, HARRIS P., KEEN J.A., KIRSCHVINK N.,  
LEFERE L., McGORUM B., MULLER J.M.V., PICAVET M.T.J.E., PIERCY R., ROSCHER K.,  
SERTEYN D., UNGER L., VAN DER KOLK J.H., VAN LOON G., VERWILGHEN D.,  
WESTERMANN C.M., VOTION D.-M. 
European outbreaks of atypical myopathy in grazing equids (2006 – 2009). Spatiotemporal 
distribution, history and clinical features. 
Equine Vet. J., In press. DOI: 10.1111/j.2042-3306.2012.00556.x 
 
VAN GALEN G., MARCILLAUD PITEL C., SAEGERMAN C., PATARIN F., AMORY H.,  
BAILLY J.D., CASSART D., GERBER V., HAHN C.N, HARRIS P., KEEN J.A., KIRSCHVINK N.,  
LEFERE L., McGORUM B., MULLER J.M.V., PICAVET M.T.J.E., PIERCY R., ROSCHER K.,  
SERTEYN D., UNGER L., VAN DER KOLK J.H., VAN LOON G., VERWILGHEN D.,  
WESTERMANN C.M., VOTION D.-M. 
European outbreaks of atypical myopathy in grazing equids (2006 – 2009). Determination of 
indicators for risk and prognostic factors. 
Equine Vet. J., In press. DOI: 10.1111/j.2042-3306.2012.00555.x  
 22 
 
Chapter 2 : Synopsis Presentation of the Study Results  
They have been presented as: 
- Atypical myopathy in Europe: 2006 – 2009. 
Poster presented at EVECCS congress, Cambridge UK, June 17-20
th
 2010. 
 
- Epidemiological study on European cases of atypical myopathy. 
Poster presented at ECEIM congress, Barcelona, Spain, January 28
th
 2009. 
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STUDY 1: SPATIOTEMPORAL DISTRIBUTION, HISTORY AND CLINICAL FEATURES OF 
ATYPICAL MYOPATHY (2006-2009) 
 
Aims of the study 
Improved understanding of the epidemiology of AM will help to define the environmental factors that 
permit or support the causal agent(s) to exert toxicity. Also a better definition of the clinical features of 
AM will help to optimise diagnosis and management of affected cases. Epidemiological studies have 
already been performed (Votion et al., 2007b; Votion et al., 2009), and various outbreaks described 
(Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 1997; Delguste et al., 2002; Puyalto-Moussu 
et al., 2004; Finno et al., 2006; Palencia and Rivero, 2007), but these have been based on limited 
geographic areas and seasons. There is a possibility that geographical and temporal differences exist 
and that these could explain some of the previously observed differences in the clinical presentation of 
AM (Harris, 2009). This retrospective study describes recent outbreaks of AM in Europe and tests the 
hypothesis that demographic, historical and clinical differences may exist among European AM cases 
and during different outbreaks. 
 
Materials and Methods 
Collection of data 
AMAG is an informal European epidemio-surveillance network consisting of European equine 
veterinarians, national epidemiological networks and universities interested in AM. At the onset of 
outbreaks, AMAG members and Diplomats of the European College of Equine Internal Medicine were 
contacted by email to ask for cooperation in data collection. When cases were reported, details of 
geographic, seasonal, demographic and clinical data (primarily those of the first clinical examination 
by the veterinarian; but for cases that survived for longer periods further clinical information could be 
submitted), horse management and pasture characteristics were obtained as soon as possible. Data 
were collected from 21
st
 September 2006 to 31
st 
January 2010 and were gathered via owners and 
veterinarians, from medical records, from interviews by mail, telephone or via standardized 
questionnaires available on the AMAG website: www.myopathieatypique.be. 
Case definition 
Data from cases reported between Autumn 2006 - Autumn 2009 were analysed and cases were 
categorized following a diagnostic algorithm (Figure 5) by the first and last author only. Only 
confirmed cases or cases with a high probability of having AM were included and together formed the 
study group.  
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Geographical distribution of atypical myopathy over time 
Geographical distribution over time of cases from autumn 2006 until autumn 2009 was visualized by a 
series of geographic maps and histograms using SavGIS
©
 (http://www.savgis.org/en/). These maps 
allow 1) identification of the European countries with the most reported cases and the large outbreaks, 
2) detection of high risk geographic regions in affected countries and 3) description of the pattern of 
outbreaks. 
Signalment, history and clinical course of atypical myopathy 
Signalment and a detailed description of the history and clinical course of AM were obtained based on 
data from a pro-forma questionnaire. Clinical signs that were reported were those of the first clinical 
examination by the veterinarian. For cases that survived for longer periods, further clinical information 
could be recorded. 
Data analysis 
Categorical and continuous data from Confirmed and Highly probable cases were compared. To 
examine geographic differences in the history and clinical features of AM, data from the most severely 
affected countries were compared. To examine if the clinical severity differed over time, the survival 
rates from the large outbreaks were compared. If survival rates differed significantly between these 
outbreaks, clinical parameters of cases were compared. 
The mean of the continuous parameters in each group (Highly probable versus Confirmed 
cases; the countries with the most reported cases; the large outbreaks) with unequal variance was 
compared with a Welch‟s test (Dagnelie, 1998). The categorical parameters were compared using 
Fisher‟s exact tests. A Bonferroni correction was applied for multiple comparisons. Statistical 
significance was defined as P < 0.05/k with k being the number of comparisons made. 
 
Results 
During the study period, 600 potential European cases of AM were notified to AMAG from 9 
European countries (Figure 6-7 and Table I). Of these, 354 met the criteria for confirmed or highly 
probable (Table I). Cases with another final diagnosis (36 cases) or with a low probability of having 
AM (33 cases) were excluded, but in the remaining 177 cases, insufficient data were available in order 
to conclude whether they were AM cases or not. There were no major differences in signalment and 
history between the Highly probable and Confirmed cases but the Confirmed cases had more severe 
clinical signs (more frequently suffering from stiffness, dysphagia, anorexia, dyspnoea, lower rectal 
temperature, and higher serum CK activities) and higher mortality rate compared to the Highly 
probable cases (95% versus 65%).  
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Geographical distribution of atypical myopathy cases over time 
The occurrence of AM cases across Europe is demonstrated in Figure 6 and Table I. France, Belgium 
and Germany together provided 69% of cases. The other affected European countries were: The 
Netherlands, the UK, Ireland, Denmark, Switzerland and Luxembourg. 
The cases were unevenly distributed over affected countries (Figure 7), with clusters occurring 
in specific regions such as south-east Belgium (Walloon region), north-east France, and mid-west 
Germany. Clusters were not identified in other affected countries. 
AM occurred mostly in autumn (93% of cases); however, some cases occurred during spring 
(4%), winter (3%) and summer (0.5%). The majority occurred during autumn 2006 and autumn 2009; 
17% from 25
th
 October to 12
th
 December 2006 and 70% from 9
th
 October to 21
st
 December 
 
2009. 
These two autumns were designated as “large outbreaks”. 
The daily occurrence of cases during outbreaks differed slightly between countries but when 
combined can be described as starting with some sparse cases that a couple of days to one week later 
were followed by more cases occurring more closely to each other. Outbreaks reached either one or 
several incidence peak(s) in the middle followed by a gradual reduction in case numbers (Figure 8a 
and Figure 8b). 
Signalment, history and clinical course of atypical myopathy cases 
Signalment and history 
Signalment and history are shown in Table II and III. All ages were represented, but especially young 
horses (Figure 9). A range of breeds as well as donkeys (3 Highly probable cases) and zebras  
(1 Confirmed and 2 Highly probable cases) were affected and both sexes were equally represented. 
Most affected horses (87%) had normal body condition and 29% were reported to be very muscular. 
The majority (98%) of cases occurred at pasture, except for 6 cases (2%) that had been stabled 
just before the onset of clinical signs (2 horses had been stabled for 1 day, 2 for 2 days, 1 for 3 days 
and 1 for 4 days). The majority of horses (86%) spent 24 hours per day at pasture and none of them 
had been at pasture less than 6 hours a day. One horse survived a first episode of AM, but died from a 
second some years later. Previous unexplained sudden deaths of horses had been noted on 22% of the 
pastures. Previous cases of AM had been noted in several pastures, sometimes in successive years. 
Pasture characteristics that were reported for more than 50% of the cases were: a slope (63%), sparse 
grass (66%; apart from German and UK pastures that were commonly lush), accumulations of dead 
leaves (87%), dead wood (61%) and the presence of trees in or around the pasture (98%). Few horses 
(27%) were in exercise or training at the time of diagnosis: only 4 were trained 5-7 times a week, 
while the others performed no or minimal exercise. The majority of horses received water from the 
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water distribution network (tap water; 56%) out of a tank or bath (51%), and supplementary feeding 
(64%). 
A comparison of the demographic and historical findings in affected horses in Belgium versus 
France versus Germany demonstrated that there is considerable country to country variation in the 
breeds affected, their body condition, the pasture characteristics, and supply of water, feed and salt 
block (Table V). 
Clinical course 
Table IV shows clinical data. Horses were regularly reported to be unusually quiet one to two days 
before the onset of more definitive signs. Signs that occurred in more than 50% of cases at first 
clinical examination were depression, weakness, stiffness, recumbence, trembling, sweating, 
pigmenturia, congested mucous membranes, tachycardia, and normothermia. Some horses were 
dysphagic (25%; with or without oesophageal obstruction), and appetite ranged from anorexic (28%) 
to ravenous (18%). Muscle weakness could become severe and was sometimes evident as a low head 
carriage with severe secondary oedema of the head. Cardiac arrhythmias were detected with cardiac 
auscultation or electrocardiography in 13% of cases. 
Transrectal examination, performed on 38% of horses, revealed impactions of the large and/or 
small colon, and dry and/or mucus covered faeces (35 cases; 10%), mild diarrhoea (5 cases), colon 
displacement (2), perirenal pain (1) and reduced rectal tone (2). Bladder distension was frequently 
palpated (58%) and most of these horses demonstrated dysuria. Other less commonly reported signs 
included: penile prolapse (7), buccal necrosis or ulceration (3) and clinical signs consistent with renal 
dysfunction (i.e. declining urine volume while receiving fluid therapy; 3 cases). Clinical signs 
described in single cases were: ptosis (responsive to the administration of phenylephrine), trismus, 
laminitis, and clinical signs of congestive heart failure due to severe cardiomyopathy with pericardial 
effusion. 
Haematology and biochemistry were performed in 58% of cases. In 7 cases, serum CK 
activities were initially within reference ranges or only slightly increased, but increased markedly in 
the following hours and days. In 92% of the cases medication was administered, consisting mostly of 
intravenous and/or oral fluids (75%), non-steroidal anti-inflammatory drugs (NSAID‟s; 82%), 
corticosteroids (26%), vitamins/antioxidants (including vitamins B, C, E, selenium and carnitine; 
43%) and/or antimicrobials (29%). Survivors recovered after 10.6 ± 5.6 days with a range of 1 to  
30 days. All non-survivors died or were euthanized within 10 days; the majority in the first 72 hours 
(Figure 10). The overall survival rate was 26%, with the highest survival rate of 57% noted in France 
during the outbreak in autumn 2006.  
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Statistical comparison of clinical parameters between Belgian, French and German cases that 
occurred during the autumn of 2009 is shown in Table V. The common presenting clinical signs were 
largely similar and mortality (Belgium: 12%, France: 31%, and Germany: 30%) was not statistically 
different between these countries. However, Belgian cases were more likely to have congested mucous 
membranes, higher serum CK activity, and were more likely to have received metronidazole, muscle 
relaxants, vitamins and anti-oxidants. In addition, they were more likely to have undergone  
post mortem examination compared to French and German cases. The survival rates of the two large 
outbreaks (33% and 24% for autumn 2006 and autumn 2009, respectively) were not statistically 
different (P = 0.13). Therefore no further statistical comparison on clinical parameters was performed 
between outbreaks. 
 
Discussion and Conclusions 
In the past, AM was thought to be a rare disorder, but this study shows that it may be more common 
than previously thought. Most cases occurred during the autumn, suggesting a link with specific 
climatic conditions as previously reported (Votion et al., 2007b). Interestingly when a series of cases 
occurred during an autumn, cases also occurred the following spring, although fewer in number. As 
some horses were stabled for up to 4 days prior to the onset of clinical signs, the „incubation period‟ 
can be estimated to be up to 4 days. 
Although the most frequently reported clinical signs are similar to previous reports (Delguste 
et al., 2002; Puyalto-Moussu et al., 2004; Votion et al., 2004; Votion et al., 2007b), this study 
describes new clinical data, which must be taken into consideration to optimise management of future 
cases. Reporting veterinarians mentioned these new clinical data spontaneously and they were not 
systematically questioned as were the other well-recognized and most frequently reported clinical 
signs of AM. So the true prevalence of these new clinical signs might be underestimated. Moreover, 
this is the first study that describes a significant number of survivors of AM. 
The hypothesis that the clinical signs differed between countries could not be confirmed by 
this study. The most common presenting clinical signs were similar between countries during the 
outbreak of 2009, and mortality rates were not statistically different. The identified differences in 
demographics, management and pastures between these countries might simply reflect differences in 
population and habits without being specific for AM, but they might directly or indirectly influence 
clinical severity or outcome by effects on immunity, contributing or predisposing factors and effects 
on pathogenicity of the causative agent. Moreover, these findings suggest that the populations that are 
affected by AM and the conditions under which AM occurs are not the same everywhere and that 
regional findings should be interpreted with caution.  
 28 
 
Chapter 2 : Synopsis Presentation of the Study Results  
This is the first study of AM to use a European-wide population. Considering that AM is a 
sporadic disease, a large number of cases was recruited onto the study and substantial quantities of 
clinical and historical data were obtained. Nevertheless, this descriptive study has several limitations. 
The described conditions when AM occurred may also be common for that geographic area without 
being specific for AM and thus be coincidental findings. To estimate the importance of some of the 
findings of this and previous studies for the development of AM, case-control studies including  
non-affected control cases and pastures are necessary. The limitations of some of the highly subjective 
data obtained, e.g. pasture slope, should also be recognised and the fact that data were obtained from a 
large number of veterinary surgeons and horse owners/carers with resultant potential biases. 
Alternative methods that could be used in future studies to investigate the spatiotemporal clustering of 
AM cases include k function analysis (French et al., 2005; Abatih et al., 2009), the Biased Sample 
Hospital-based Area Disease Estimation (also called the B-SHADE technique; Wang et al., 2011) and 
the use of SaTScan software (Kulldorff M. and Information Management Services, Inc. SaTScan (TM) 
software for the spatial and space-time scan statistics; Hyder et al., 2011). Despite these limitations, 
this study contains important information for the future management of cases. 
In conclusion, this study describes AM cases in Europe from 2006 – 2009 and includes two 
large outbreaks. New data on signalment, history and clinical course on AM has been described and 
may be helpful for future management of affected cases. 
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Tables and Figures 
Table I. Categorization of cases reported to the Atypical Myopathy Alert Group from various 
European countries. 
 
 
Total Country of origin: 
  Belgium France Germany The 
Netherlands 
United 
Kingdom 
Others* 
Reported cases 
 
600 143 194 108 51 54 50 
Confirmed cases 107 34 38 6 6 15 8 
Highly probable cases 247 47 63 58 33 27 19 
All AM cases 354 81 101 64 39 42 27 
        
Legend: AM = atypical myopathy; * = Ireland, Denmark, Switzerland, and Luxembourg. 
 
Table II. Demographic data from cases with a high probability of, or confirmed as atypical myopathy 
in various European countries. 
 Total 
 
(354 cases) 
Belgium 
 
(81 cases) 
France 
 
(101 cases) 
Germany 
 
(64 cases) 
The 
Netherlands 
(39 cases) 
United 
Kingdom 
(42 cases) 
Others* 
 
(27 cases) 
 n/N 
 
% n/N % n/N % n/N % n/N % n/N % n/N % 
TYPE OF HORSE               
Saddle horse 133/276 48 49/74 66 40/87 46 8/38 21 16/33 48 9/30 30 11/14 79 
Draught horse 42/276 15 9/74 12 23/87 26 6/38 16 2/33 6 0/30 0 2/14 14 
Pony 95/276 34 16/74 22 20/87 23 22/38 58 15/33 45 21/30 70 1/14 7 
Donkey 3/276 1 0/74 0 1/87 1 2/38 5 0/33 0 0/30 0 0/14 0 
Zebra 3/276 1 0/74 0 3/87 3 0/38 0 0/33 0 0/30 0 0/14 0 
               
SEX                
Mare 140/267 52 39/76 51 48/84 57 21/42 50 16/26 62 8/27 30 8/12 67 
Stallion 42/255 16 17/74 23 8/79 10 4/37 11 6/26 23 7/27 26 0/12 0 
Gelding 78/255 31 18/74 24 25/79 32 15/37 41 4/26 15 12/27 44 4/12 33 
               
AGE 
  (years; mean ±SD) 
5.3 ± 6.2 
Range: 0.4 – 
38  
N = 274 
6.1 ± 6.8 
Range: 0.4 – 
38 
N = 75 
6.0 ± 6.4 
Range: 0.4 – 
37 
N = 84 
5.7 ± 7.4 
Range: 0.5 – 
27 
N = 42 
4.2 ± 5.2 
Range: 0.4 – 
26 
N = 28 
3.2 ± 2.7 
Range: 0.4 – 
10 
N = 33 
3.0 ± 2.3 
Range: 0.6 – 
8 
N = 12 
               
BODY CONDITION               
Poor 12/242 5 2/66 3 5/66 8 1/30 3 0/25 0 2/39 5 2/16 13 
Normal 211/242 87 60/66 91 51/66 77 27/30 90 25/25 100 36/39 92 12/16 75 
Obese 19/242 8 4/66 6 10/66 15 2/30 7 0/25 0 1/39 3 2/16 13 
Extremely muscular 51/176 29 12/48 25 6/55 11 23/28 82 2/10 20 1/23 4 7/12 58 
               
Legend: C = confirmed AM cases; HP = cases highly likely to have AM; HPC = cases confirmed or 
highly likely to have AM; SD = standard deviation; N = number of total response for each category;  
n = number of positive response for each category; * = Ireland, Denmark, Switzerland, Luxembourg.  
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Table III. Data on horse management and pasture characteristics of cases with a high probability of, 
or confirmed as a diagnosis of atypical myopathy in the different European countries at the time 
atypical myopathy occurred. 
 Total 
 
(354 cases) 
Belgium 
 
(81 cases) 
France 
 
(101 cases) 
Germany 
 
(64 cases) 
The 
Netherlands 
(39 cases) 
United 
Kingdom 
(42 cases) 
Others* 
 
(27 cases) 
 n/N % n/N % n/N % n/N % n/N % n/N % n/N % 
HORSE 
MANAGMENT  
              
Vaccinated 143/185 77 44/50 88 53/62 85 18/23 78 12/19 63 8/23 35 8/8 100 
Dewormed 174/182 96 48/49 98 58/61 95 23/23 100 14/14 100 21/23 91 10/12 83 
               
Duration of grazing                
< 6h per day 0/195 0 0/56 0 0/62 0 0/25 0 0/17 0 0/23 0 0/12 0 
Only during daytime 21/195 11 5/56 9 4/62 6 4/25 16 2/17 12 0/23 0 6/12 50 
Only at night 2/195 1 0/56 0 0/62 0 0/25 0 0/17 0 2/23 9 0/12 0 
24/24h 177/205 86 49/57 86 58/62 94 27/33 82 16/18 89 21/23 91 6/12 50 
Variable depending on 
the weather 
9/195 5 5/56 9 0/62 0 2/25 8 0/17 0 0/23 0 2/12 17 
               
Nutrition                
Supplementary feed 120/187 64 33/51 65 44/66 67 12/23 52 10/15 67 13/22 59 8/10 80 
               
PASTURE 
CHARACTERISTICS 
 
              
Presence of :                
Shelter 76/179 42 23/52 44 29/57 51 5/21 24 4/13 31 10/24 42 5/12 42 
Trees 194/198 98 50/53 94 55/55 10
0 
29/29 100 19/20 95 27/27 100 14/14 100 
Accumulations of dead 
leaves 
160/184 87 41/52 79 50/55 91 21/21 100 15/20 75 21/24 88 12/12 100 
Dead wood 106/174 61 25/53 47 38/51 75 11/21 52 4/13 31 21/24 88 7/12 58 
Humid zones 78/178 44 29/54 54 17/54 31 6/21 29 6/13 46 11/24 46 9/12 75 
Water course 61/177 34 20/53 38 12/54 22 6/21 29 1/13 8 17/24 71 5/12 45 
Slope 115/182 63 33/53 62 41/55 75 17/25 68 3/13 23 15/24 63 6/12 50 
Lush grass 50/174 29 11/52 21 9/55 16 14/21 67 2/12 17 12/22 55 2/12 17 
Sparse grass 113/171 66 39/52 75 40/54 74 7/21 33 8/10 80 9/22 41 10/12 83 
               
Legend: C = confirmed atypical myopathy (AM) cases; HP = cases highly likely to have AM; HPC = 
cases confirmed or highly likely to have AM; SD = standard deviation; N = number of total response 
for each category; n = number of positive response for each category; *= Ireland, Denmark, 
Switzerland, Luxembourg. 
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Table IV. Clinical data of cases with a high probability of, or confirmed with atypical myopathy in 
various European countries. 
 Total 
 
(354 cases) 
Belgium 
 
(81 cases) 
France 
 
(101 cases) 
Germany 
 
(64 cases) 
The 
Netherlands 
(39 cases) 
United 
Kingdom 
(42 cases) 
Others* 
 
(27 cases) 
 n/N % n/N % n/N % n/N % n/N % n/N % n/N % 
Found dead without 
prodromal signs 
2/327 1 0/78 0 1/97 1 1/60 2 0/33 3 0/41 0 0/18 0 
Survival  88/344 26 13/80 16 32/100 32 19/63 30 7/33 21 13/42 31 4/26 15 
               
GENERAL               
Depression 203/255 80 43/57 75 62/73 85 40/47 85 16/26 62 29/38 76 13/14 93 
Weakness  211/248 85 50/58 86 59/65 91 36/48 75 22/26 85 34/38 89 10/13 77 
Stiffness  210/252 83 47/58 81 59/68 87 37/49 76 24/26 92 33/37 89 10/14 71 
Recumbency  227/290 78 57/72 79 68/82 83 36/54 67 24/28 86 29/39 74 13/15 87 
Trembling  170/250 68 33/55 60 46/69 67 34/48 71 18/27 67 30/38 79 9/13 69 
Sweating  162/253 64 35/52 67 47/73 64 33/50 66 16/26 62 20/37 54 11/15 73 
               
CLINICAL 
EXAMINATION 
              
Rectal temperature  
  (°C; mean±SD) 
  Normal: 37-38.5 
 
37.4 ± 1.0 
Range: 34.5 – 
40.5 
N = 206 
  
37.4 ± 1.2 
Range: 34.6 
– 40.5 
N = 46 
37.1 ± 1.1 
Range: 34.5 – 
39.4  
N =52 
37.5 ± 0.8 
Range: 35 - 
39 
N = 43 
37.5 ± 0.9 
Range: 35.8 – 
39.9 
N = 22 
37.7 ± 1.0 
Range: 35 – 
39.8 
N = 28 
37.3 ± 0.8 
Range: 35 – 
38.5 
N = 15 
Respiratory rate  
  (rpm; mean±SD) 
  Normal: < 15 
 
28 ± 14 
Range: 6 – 72 
N = 158 
34 ± 17 
Range: 8 – 
72  
N = 40 
27 ± 13 
Range: 6 – 50  
N = 29 
27 ± 11 
Range:12 – 
60 
N =33 
26 ± 14 
Range: 14 – 
60  
N = 17 
24 ± 12 
Range: 12 – 
50  
N = 27 
22 ± 10 
Range: 12 – 
50  
N =12 
 
Heart rate  
  (bpm; mean±SD) 
  Normal: < 45 
60 ± 17 
Range: 28 – 
120  
N = 211 
62 ± 19 
Range: 35 – 
112  
N = 47 
58 ± 17 
Range: 28 – 
120  
N = 51 
61 ± 15 
Range: 36 – 
100  
N = 41 
59 ± 23 
Range: 30 – 
120  
N = 24 
59 ± 14 
Range: 32 – 
96  
N = 34 
58 ± 14 
Range: 40 – 
90  
N = 14 
        
Hypothermia 
(<37°C) 
68/238 29 14/51 27 24/69 35 12/49 24 8/23 35 7/31 23 3/15 20 
Normothermia (37-
38.5°C) 
138/229 60 28/51 55 36/64 56 31/45 69 13/23 57 18/31 58 12/15 80 
Hyperthermia 
(>38.5°C) 
25/229 11 9/51 18 5/64 8 3/45 7 2/23 9 6/31 19 0/15 0 
               
Normal mm 86/231 37 9/52 17 21/60 35 16/44 36 14/25 56 19/36 53 7/14 50 
Congested mm 124/232 53 37/52 71 32/61 52 23/44 52 9/25 36 16/36 44 7/14 50 
             
Dyspnoea 110/226 44 34/52 65 28/64 44 19/42 45 3/20 15 12/34 35 4/14 29 
Tachycardia (> 
45bpm) 
185/235 79 44/55 80 52/66 79 34/42 81 16/24 67 28/34 82 11/14 79 
 
OTHERS  
              
Normal defecation  139/205 68 31/45 69 33/51 65 29/41 71 13/22 59 25/35 71 8/11 73 
Pigmenturia 243/260 93 62/65 95 63/70 90 48/52 92 25/25 100 32/35 91 13/13 100 
               
DIAGNOSTICS               
Post mortem 
examination 
108/302 36 40/73 55 20/90 22 14/60 23 7/25 28 16/35 46 11/19 58 
Muscle histology 139/300 46 42/71 59 48/92 52 10/59 17 14/24 58 15/35 43 10/19 53 
Legend: SD = standard deviation; N = number of total response for each category; n = number of 
positive response for each category; mm = mucous membranes; * = Ireland, Denmark, Switzerland, 
Luxembourg.  
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Table V. Demographic, historical and clinical data of atypical myopathy cases that were statistically 
different between Belgium versus France versus Germany. 
Variables  Belgium 
(43 cases) 
France 
(68 cases) 
Germany 
(55 cases) 
Categorical variables 
(Fisher’s exact test with Bonferroni correction;  
P< 0.05/k, k = 3) 
n/N % n/N % n/N % 
DEMOGRAPHIC DATA       
Saddle horses 25/39 64
b
 30/56 54
b
 5/31 16 
Ponies 10/39 26 12/56 21 20/31 65
a,c
 
Normal body condition 34/35 97
a
 44/55 80 20/23 87 
Extremely muscular  7/26 27 6/45 13 21/21 100
a,c
 
       
HORSE MANAGEMENT (when AM occurred)       
Rain water as source of water 6/27 22
a
 1/39 3 8/24 33
c
 
Supplemented with silage 6/19 32
a
 0/33 0 0/10 0 
Supplemented with salt block 12/26 46 28/45 62 19/24 79
c
 
       
PASTURE CHARACTERISTICS 
(when AM occurred) 
      
Dead wood 15/27 44 30/40 75
c
 11/19 58 
Mechanical spreading of faeces 14/26 54
b
 13/44 30
b
 1/19 5 
Lush pasture  4/27 15 8/46 17 12/19 63
a,c
 
Sparse pasture  23/27 85
b
 33/46 72
b
 7/19 37 
       
CLINICAL DATA       
Congestive mm 25/33 76
a,b
 25/52 48 17/37 46 
Treatment with metronidazole 5/28 18
b
 1/47 2 0/33 0 
Treatment with vitamins & antioxidants 19/28 68
b
 21/48 44 12/33 36 
Treatment with myorelaxants 7/27 26
a
 2/47 4 2/33 6 
Post mortem examination  24/41 59
a,b
 14/60 23 10/51 14 
       
Continuous variables 
(Welsh’s test with Bonferroni correction;  
P< 0.05/k, k = 3) 
Mean (SD) N Mean (SD) N Mean (SD) N 
Highest measured CK serum activity  
  (IU/L; normal 50 – 200) 
 
511017 ± 1299047
a,b
 28 171441 ± 237263 36 78852 ± 116411 26 
First measured CK serum activity  
  (IU/L; normal 50 – 200) 
 
298032 ± 810007
a,b
 29 167184 ± 239339 36 76616 ± 117251 26 
Legend: AM = atypical myopathy; 
a
 = statistically more frequent or higher compared to France;  
b
 = statistically more frequent or higher compared to Germany; 
c
 = statistically more frequent or higher 
compared to Belgium; mm = mucous membranes; CK = serum activity of creatine kinase. 
Note: Only cases with a high probability (HP) of having atypical myopathy (AM) and confirmed (C) 
cases that occurred during autumn 2009 are considered in order to limit climatic or temporal 
influences. 
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Figure 5. Diagnostic algorithm used to categorize cases reported to the Atypical Myopathy Alert 
Group. 
 
Legend: AM = atypical myopathy; (*) repeat analysis 24H later; (**) pathognomonic signs;  
C = confirmed case of AM, based on history, clinical expression and histology; HP = case with a high 
probability of having AM; LP = case with a low probability of having AM; OD = case with another 
diagnosis than AM; D = doubtful case; not enough data available. 
Notes: Histology was performed either on muscle biopsies or on post mortem samples. The non-
pathognomic findings for AM on histology are a multifocal process compatible with Zenker‟s 
degeneration and necrosis in fibres of postural and/or respiratory muscles (Cassart et al. 2007). 
Cases that developed signs following anaesthesia or intense exercise were categorized as doubtful. 
If a full post mortem examination was performed and specific findings of another condition were 
found, the case could be categorized OD.  
  
 
Chapter 2 : Synopsis Presentation of the Study Results  
Figure 6. Maps showing the occurrence of the highly probably or confirmed atypical myopathy cases 
from 2006 – 2009. 
 
 
Notes: Only seasons with > 5 cases are represented. Seasons with < 5 cases were: winter 2006-2007  
(3 cases), summer 2007 (1 case), summer 2008 (1 case), autumn 2008 (3 cases), winter 2008-2009  
(1 case). Entire countries are coloured, based on their official borders, but disease occurrence could be 
regional rather than across the entire country e.g. Corsica is coloured as it is part of France but no 
cases have been reported there. 
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Figure 7. Map showing the location of highly probably or confirmed atypical myopathy cases during 
autumn 2006 and autumn 2009, based on addresses or postal codes. 
 
Note: location was established for 28/50 cases in autumn 2006 and 134/248 cases in autumn 2009. 
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Figure 8a. The development of the highly probable or confirmed atypical myopathy cases during the 
outbreaks of autumn 2006. 
 
 
Figure 8b. The development of the highly probable or confirmed atypical myopathy cases during the 
outbreaks of autumn 2009. 
 
Note: Only cases with a known exact date of onset of clinical signs were included.  
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Figure 9. Frequency distribution within age categories of highly probable or confirmed atypical 
myopathy cases. 
 
 
 
Figure 10. The duration of disease for survivors and non-survivors of the highly probable or 
confirmed atypical myopathy cases. 
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STUDY 2: DETERMINATION OF INDICATORS OF RISK FACTORS FOR ATYPICAL 
MYOPATHY 
 
Aims of the study 
Current preventive measures are based on limited pathophysiological knowledge, and risk and 
protective factors as determined by previous epidemiological studies (Votion et al., 2007b; Votion et 
al., 2009). Although extensive epidemiological studies have been performed, statistical analysis has 
been limited to Belgian cases confirmed at post mortem examination (Votion et al., 2007b; Votion et 
al., 2009). By excluding unconfirmed yet highly suspicious cases (including survivors), important 
clinical information may have been lost. 
The aims of the study were to identify clinical and historical data that may increase the 
certainty of a diagnosis of AM and to refine preventive measures both based on identification of risk 
factors using European cases that occurred between autumn 2006 and autumn 2009 and were 
confirmed to have or highly suspected of having AM. 
 
Materials and Methods 
The collection of data and case definition (Figure 5) are similar as in the first study. Confirmed and 
highly probable cases were combined to form the AM group while the non-AM group consisted of 
cases with low probability or another final diagnosis. Doubtful cases were excluded from further 
analysis. 
Data analysis 
The AM and non-AM groups were compared to identify clinical indicators and risk factors for AM. 
Continuous variables were compared using Welch‟s test (Dagnelie, 1998). Categorical variables were 
evaluated by mean of odds ratios (Grenier, 1990). A Bonferroni correction was performed for multiple 
comparisons. Statistical significance was defined as P < 0.05/k with k being the number of 
comparisons made. Sensitivity, specificity and positive and negative predictive values (PPV and NPV) 
were calculated for common clinical signs in AM related to diagnosis (comparing the AM versus the 
non-AM group). Useful clinical signs related to diagnosis were identified based on a high sensitivity 
specificity, PPV or NPV. 
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Results 
During the study period, 600 potential European cases of AM were reported, from which 354 met the 
selection criteria for the AM group, and 69 for the non-AM group. The spatiotemporal, historical and 
clinical features of these cases have been reported in the first study. 
Variables more frequently encountered in AM cases compared to non-AM cases were:  
the presence of trees, dead wood and accumulations of dead leaves at pasture, a sloping pasture, 
normal body condition, and fulltime grazing. Moreover, AM cases more frequently developed 
pigmenturia, exhibited normothermia, had higher serum CK activities, and more frequently received 
supportive treatment than non-AM cases. Variables that were more often present in non-AM cases 
compared to AM cases were: poor body condition, water provision from a tank or bath tub, food 
supplementation, and spending no or limited time at pasture. Also, non-AM cases were more 
frequently found dead without previous clinical signs, and more often had cyanotic mucous 
membranes than AM cases (Table VI). Pigmenturia had a high sensitivity and PPV, and normothermia 
and congested mucous membranes a high PPV for diagnosis of AM (Table VII). 
 
Discussion and Conclusions 
The current study identified factors that permit differentiation between AM and other clinically similar 
diseases. These data will help define diagnostic and preventive measures for AM, while also 
identifying parameters potentially involved in the metabolic imbalance believed to be an integral part 
of AM pathogenesis. 
The clinical signs that were significantly more often encountered in the AM group than in the 
non-AM group and/or had a high sensitivity, specificity, PPV and/or NPV related to diagnosis were: 
pigmenturia, normothermia, congested mucous membranes and high serum CK activity. Nevertheless, 
other pathologies (myopathic or not) may lead to similar clinical signs, and not all AM affected horses 
show these signs. Therefore these distinctive features may be useful to strengthen a clinical suspicion 
of AM, but diagnosis should not solely be based on them. Horses with cyanotic mucous membranes or 
that were found dead without prodromal signs were more often categorized as non-AM. Horses can 
show cyanotic mucous membranes and are sometimes found dead following AM, but other disorders, 
such as acute colic, remain more frequent and a rapid death sometimes hinders correct diagnosis. 
AM horses spent significant time at pasture compared to non-AM cases, which is consistent 
with the causative agent being pasture-associated and prolonged or repetitive contact being required to 
induce disease. The first study, based on the same cases, has even demonstrated that all horses that 
developed the condition had spent more than 6H per day at pasture. Being given supplementary food 
was more common in non-AM cases than AM cases and appears to be protective. On one hand, more 
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energy substrates (especially carbohydrates), vitamins and antioxidants are available if supplementary 
food is given, and on the other, horses might graze less and therefore have less contact with the 
causative agent. Water might also play a role in the development of AM. Previously it was shown that 
providing water from the distribution network was a protective factor (Votion et al., 2009), but the 
current study found water provision from a tank or a bath to be more frequent in non-AM than AM 
cases. Comparison of pasture characteristics showed that several of these (a slope, the presence of 
trees or dead wood, and the accumulation of dead leaves) were more often related to AM cases and 
therefore may be predisposing factors for AM and a diagnostic aid. These features might create an 
ideal microclimate for the causative agent, and/or may contain specific substances, such as flavonoids 
(Hodnick et al., 1994) or mycotoxins, predisposing the horse to AM through metabolic interferences. 
This is the first study of AM to use a European-wide population. Considering that AM is a 
sporadic disease, a very large number of cases with a considerable amount of epidemiological and 
clinical data was included in this study, improving the statistical power of the study. Nevertheless, this 
study has several limitations. Including unconfirmed cases and incomplete files complicated the 
categorization of cases. Confirmation of AM was established by a combination of history, clinical 
signs and histology. A more definitive diagnostic method for AM is muscle histochemistry to show 
selective involvement of type I muscle fibres with marked lipid accumulations (Cassart et al., 2007). 
Unfortunately, this was only used for few cases in the current study. A further limitation is the 
underestimation of the true number of European cases, in part because of the rapid death of AM cases 
(Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 1997; Delguste et al., 2002; Votion et al., 
2007b), and because the authors were dependent on the goodwill of veterinarians and owners to gather 
and communicate data, since AM is not a declarable disease and this may have introduced bias. The 
authors have made efforts to reach and inform veterinarians all over Europe. However, only some 
countries have national epidemiological networks and faculties that are actively involved in collecting 
and communicating data on this disease. Some of the data was very subjective in nature e.g. slope of 
pasture, presence of trees and leaves, body condition and the limitations in confirming the reliability of 
this data should be recognized. Furthermore, there are issues relating to the control group in the 
present study. For this study, non-AM cases were chosen as control group, since they highlight the 
difficulties for correct diagnosis of AM. However, the group is limited in case numbers and some 
cases might have been incorrectly allocated to the non-AM group. 
In conclusion, this risk analysis extends the list of indicators for risk and protective factors for 
development of AM, enabling a refinement of diagnosis and preventive measures. Further research is 
necessary to better understand the aetiopathophysiology of AM. 
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Tables and Figures 
Table VI. Historical and clinical variables that were significantly different between cases with a high 
probability of or confirmed atypical myopathy (AM group) and the cases with a low probability of 
having atypical myopathy or with another diagnosis (non-AM group). 
Variable AM group 
(354 cases) 
non-AM group 
(69 cases) 
     
Categorical variables 
(with Bonferroni 
correction: P < 0.05/k) 
n/N % n/N % ODDS 
ratio 
95% 
Confidence 
Interval 
 P value k 
          
Presence of trees at 
pasture  
194/198 98 31/36 86 7.82 1.99 – 30.73 + 0.003 7 
Accumulation of dead 
leaves at pasture 
160/184 87 12/32 38 11.11 4.82 – 25.59 + <0.001 7 
Dead wood at pasture 106/174 61 11/33 33 3.12 1.42 – 6.84 + 0.005 7 
Water provision in 
tank/bath 
84/164 51 21/26 81 0.25 0.09 – 0.69 - 0.007 7 
Sloping pasture  115/182 63 10/30 33 3.43 1.52 – 7.77 + 0.003 7 
Poor body condition 12/242 5 7/36 19 0.22 0.08 – 0.59 - 0.003 4 
Normal body condition 211/242 87 23/36 64 3.85 1.77 – 8.37 + 0.001 4 
< 6h at pasture/day 0/195 0 8/37 22 0.04 0.01 – 0.19 - <0.001 7 
24h/24h at pasture  177/205 86 21/39 54 5.42 2.57 – 11.42 + <0.001 7 
Not at pasture 6/200 3 6/37 16 0.03 0.00 – 0.22 - 0.001 7 
Supplemented with food  120/187 64 31/34 91 0.17 0.05 – 0.59 - 0.005 7 
Found dead at pasture 
without previous signs 
2/327 1 9/62 15 0.04 0.01 – 0.17 - <0.001 7 
Pigmenturia 243/260 93 12/23 52 13.10 5.04 – 34.03 + <0.001 7 
Normothermia (37-
38.5°C) 
146/229 64 13/36 39 2.59 1.24 – 5.41 + 0.011 3 
Cyanotic mm 18/231 8 8/25 32 0.18 0.07 – 0.47 - 0.001 6 
Received treatment  233/252 92 32/44 73 4.60 2.04 – 10.36 + <0.001 13 
          
Continuous variables 
(with Bonferroni 
correction: P < 0.05/k) 
Mean 
(SD) 
Range N Mean 
(SD) 
Range N    P value  
(Welch’s 
test) 
k 
Survival time  
  (days) 
1.6 ± 1.4 0 – 10  209 1.0 ± 
1.2 
0 – 5  31    0.008 4 
Highest measured CK 
serum activity  
  (IU/L; normal 50-200) 
302443 
±  
751976 
634 –  
7059880 
207 39373 ±  
145282 
203 – 
776000 
28    0.0001 2 
First measured CK 
serum activity   
  (IU/L; normal 50-200) 
239237 
±  
636824 
99 – 
7059880 
207 37677 ±  
145489 
203 – 
776000 
28    0.0001 2 
Legend: AM = atypical myopathy; + = more often present in the AM group compared to the non-AM 
group; - = more often present in the non-AM compared to the AM group; N = number of total 
responses for each category; n = number of positive responses for each category; mm = mucous 
membranes; CK = creatine kinase; SD = standard deviation; k = the number of comparisons made. 
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Table VII. Sensitivity, specificity and positive and negative predictive values of specific clinical signs 
related to a highly probable or confirmed diagnosis atypical myopathy. 
Clinical signs Correct diagnosis of reported cases 
(AM versus non-AM) 
 Sensitivity  Specificity  PPV  NPV  
Depression 0.796 0.325 0.883 0.200 
Weakness 0.851 0.278 0.890 0.213 
Stiffness 0.833 0.333 0.897 0.222 
Recumbency 0.783 0.256 0.876 0.149 
Trembling 0.680 0.467 0.914 0.149 
Sweating 0.640 0.419 0.900 0.125 
Remaining standing most of the time 0.458 0.675 0.910 0.148 
Pigmenturia 0.935* 0.478 0.953* 0.393 
Hypothermia (<37°C) 0.286 0.611 0.829 0.115 
Normothermia (37-38.5°C) 0.605 0.629 0.914* 0.196 
Hyperthermia (>38.5°C) 0.109 0.771 0.758 0.117 
Normal mm 0.372 0.630 0.896 0.105 
Congested mm 0.534 0.704 0.939* 0.150 
Defecation 0.678 0.400 0.921 0.108 
Dyspnoea 0.442 0.591 0.917 0.094 
Tachycardia 0.787 0.261 0.916 0.107 
Legend: AM = atypical myopathy, PPV = positive predictive value; NPV = negative predictive value; 
mm = mucous membranes; * = useful sensitivity, specificity, PPV and/or NPV. 
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STUDY 3: DETERMINATION OF INDICATORS OF PROGNOSTIC FACTORS FOR 
ATYPICAL MYOPATHY 
 
Aims of the study 
Diagnosis of survivors of AM is often questioned (Harris, 2009). Previously, survival rates were 
estimated at 3% (Brandt et al., 1997) to 15% (Puyalto-Moussu et al., 2004; Votion et al., 2004), but 
possibility of survival remains to be demonstrated. Therefore, data collection of survivors and 
assessment of prognosis will be attempted in this third study. 
 
Materials and Methods 
The collection of data and case definition (Figure 5) are similar as in the first and second study. 
Confirmed and Highly probable cases were combined to form the AM group and were divided into 
survivors and non-survivors. 
Data analysis 
The AM survivors were compared to non-survivors to identify factors predicting survival of AM. 
Continuous variables were compared using Welch‟s test (Dagnelie, 1998). Categorical variables were 
evaluated by mean of odds ratios (Grenier, 1990). A Bonferroni correction was performed for multiple 
comparisons. Statistical significance was defined as P < 0.05/k with k being the number of 
comparisons made. Sensitivity, specificity and PPV and NPV were calculated for common clinical 
signs in AM related to outcome (comparing survivors versus non-survivors of the AM group). Useful 
clinical signs related to outcome were identified based on a high sensitivity specificity, PPV or NPV. 
 
Results 
During the study period, 600 potential European cases of AM were reported, from which 354 met the 
selection criteria for the AM group, with 88 survivors and 256 non-survivors (overall survival rate 
26%). The spatiotemporal, historical and clinical features of these cases have been reported in the first 
study. 
Most survivors were Highly probable cases, but five were Confirmed by muscle biopsy. All 
non-survivors died or were euthanized within 10 days; the majority in the first 72 hours. Survivors 
recovered after 10.6 ± 5.6 days with a range of 1 to 30 days (Figure 10). Full recovery was reported for 
survivors of whom a follow-up was available.  
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Positive prognostic factors were defecation and treatment with vitamins and/or antioxidants. 
Negative prognostic factors were recumbency, sweating, anorexia, tachycardia, tachypnoea and 
dyspnoea (Table VIII). Concerning survival, remaining standing and normal mucous membranes had 
both a high specificity, PPV and NPV, and normothermia and defecation had both a high sensitivity 
and NPV (Table IX). 
 
Discussion and Conclusions 
This study describes a significant number of survivors of AM. The difference in survival between 
Confirmed and Highly probable cases can be explained by the reluctance of practitioners and owners 
to perform muscle biopsies in survivors; confirmation is therefore more often achieved in  
non-survivors. Although some clinical cases appeared to recover uneventfully, they have not 
consistently been subjected to follow-up medical examinations in order to exclude signs of subclinical 
disease. Caution is therefore required when discussing the long term prognosis for those animals that 
survive AM, not at least because complications, such as laminitis, renal problems and cardiomyopathy 
were described in some cases in the first study. However, knowledge that affected horses have a 
chance of survival without a major risk of sequelae is very important with respect to diagnosis, 
prognosis and treatment. The overall survival rate (26%) was higher than previously described  
(3 to 15%; Brandt et al., 1997; Puyalto-Moussu et al., 2004; Votion et al., 2004), suggesting an 
attenuation of the disease and/or improved recognition and management of AM over recent years. 
This study is the first extensive comparison of survivors and non-survivors of AM leading to 
the characterisation of clinical signs that are valuable for prognostic assessment. A previous study of 
fatal Belgian cases suggested that normal respiration with normal PaO2 was a positive prognostic 
factor (Votion et al., 2007b). Most cases described in the current study were treated in the field and 
PaO2 levels were not measured. However, dyspnoea was confirmed as a negative prognostic factor and 
non-survivors had a significantly higher respiratory rate than survivors, potentially because respiratory 
muscles are often severely affected in AM. No difference was detected between serum CK activities of 
survivors and non-survivors, confirming previous observations that CK is not a reliable prognostic 
indicator (Votion et al., 2007b). 
Recumbency, a finding that is likely to suggest more severe disease and muscular dysfunction, 
was identified as a negative prognostic factor in the current study. In addition, remaining standing 
most of the time was associated with survival. The tachycardia observed more frequently in  
non-survivors might reflect pain and/or cardiovascular compromise (by hypovolaemia or 
cardiomyopathy) and may contribute to metabolic disturbances. Moreover, normal mucous 
membranes, which indicates no severe cardiovascular compromise, was shown to be related to 
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survival with a high specificity, PPV and NPV. Normothermia was demonstrated to be a useful 
variable to distinguish surviving cases. Muscle cells of severely affected horses can be completely 
carbohydrate depleted (Westermann et al., 2011), limiting energy metabolism even further and causing 
difficulties in maintaining body temperature. Hypothermia occurs in 29% of the cases as demonstrated 
in Study 1. Other possibilities that might lead to hypothermia in severely affected horses are reduced 
rectal tone, the limited ability, through muscle dysfunction, to use shivering as a form of heat 
production, or impaired peripheral circulation in horses with cardiovascular shock. Hyperthermia 
occurred only in 11% of these cases (Study 1) and can be explained by a hypothetical primary 
infection, due to inflammatory/infectious complications or due to reduced heat loss by impaired 
pulmonary ventilation. The anorexia that was more frequently noted in non-surviving cases of AM, 
may aggravate metabolic disturbances and be secondary to other pathophysiological processes such as 
cardiovascular shock, severe hyperlipemia (Votion et al., 2007b) or pharyngeal or oesophageal 
muscular dysfunction. Defecation, also a clinical sign related to gastrointestinal function, had high 
sensitivity and NPV for survival. 
The only treatment shown to offer significant benefits in terms of survival was the 
administration of vitamins and/or anti-oxidants, including vitamin B, C and E, selenium and carnitine, 
which support normal muscular function, antioxidative capacity and aerobic metabolism. Treatment 
with antioxidants, such as selenium, vitamin C and E, has previously been suggested to increase 
survival in horses suffering from AM in the USA by Finno and collaborators (2006). Carnitine might 
be of help considering the suspicion of pathologies in lipid metabolism in affected cases (Cassart et 
al., 2007). 
In conclusion, this epidemiological study is the first to describe a considerable amount of 
survivors of AM and to establish prognostic factors. It is of great importance to know that affected 
horses can survive and when treatment is useful. 
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Tables and Figures 
Table VIII. Historical and clinical variables that were significantly different between the survivors 
and non-survivors of cases with high probability of or confirmed with atypical myopathy. 
Clinical signs Survivors  
(88 cases) 
Non-survivors 
(256 cases) 
   P value k 
Categorical variables  
(with Bonferroni 
correction: P < 0.05/k) 
n/N % n/N % ODDS 
ratio 
95% 
Confidence 
Interval 
   
Recumbency 43/72 60 182/215 85 0.27 0.15 – 0.49 - <0.001 7 
Sweating  28/60 47 134/192 70 0.38 0.21 – 0.69 - 0.001 7 
Anorexia  10/63 16 60/183 33 0.39 0.18 – 0.81 - 0.012 4 
Defecation  45/53 85 94/151 62 3.41 1.50 – 7.75 + 0.003 4 
Dyspnoea  10/53 19 90/172 52 0.21 0.10 – 0.45 - <0.001 6 
Treatment with vitamins 
and antioxidants (i.e. B,C,E, 
selenium, carnitine) 
 
42/66 64 52/155 34 3.47 1.90 – 6.33 + <0.001 13 
Continuous variables  
(with Bonferroni 
correction: P < 0.05/k) 
Mean 
(SD) 
Range N Mean 
(SD) 
Range N    P value  
(Welch’s 
test) 
k 
Duration of disease  
  (days)  
10.6 ± 
5.6 
1 – 30  50 1.6 ± 1.4 0 – 10  207     P < 
0.0001 
4 
Respiratory rate  
  (rpm; reference range < 
20) 
24 ± 
11 
8 – 48 41 29 ± 14 6 – 72 116    P = 0.01 6 
Heart rate  
  (bpm; reference range < 
45) 
53 ± 
13 
28 – 
88  
54 62 ± 18 30 – 
120 
155    P = 0.01 6 
Legend: + = positive prognostic factor and thus more often present in survivors compared to  
non-survivors; - = negative prognostic factor and thus more often present in non-survivors compared 
to survivors; N = number of total responses for each category; n = number of positive responses for 
each category; mm = mucous membranes; SD = standard deviation; k = the number of comparisons 
made. 
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Table IX. Sensitivity, specificity and positive and negative predictive values of specific clinical signs 
of atypical myopathy related to survival. 
Clinical signs Survival of correctly diagnosed cases 
(AM survivors versus non-survivors) 
 Sensitivity  Specificity  PPV  NPV  
Depression 0.700 0.188 0.219 0.659 
Weakness 0.681 0.176 0.215 0.625 
Stiffness 0.782 0.221 0.270 0.733 
Recumbency 0.636 0.135 0.179 0.556 
Trembling 0.488 0.295 0.169 0.662 
Sweating 0.500 0.293 0.165 0.677 
Remaining standing most of the time 0.712 0.687* 0.394* 0.893* 
Pigmenturia 0.750 0.112 0.232 0.556 
Hypothermia (<37°C) 0.051 0.629 0.037 0.704 
Normothermia (37-38.5°C) 0.769* 0.481 0.303 0.877* 
Hyperthermia (>38.5°C) 0.179 0.888 0.318 0.788 
Normal mm 0.600 0.721* 0.409* 0.849* 
Congested mm 0.378 0.447 0.179 0.692 
Defecation 0.902* 0.393 0.333 0.923* 
Dyspnoea 0.205 0.463 0.100 0.667 
Tachycardia 0.692 0.185 0.197 0.676 
Legend: AM = atypical myopathy, PPV = positive predictive value; NPV = negative predictive value; 
mm = mucous membranes; * = useful sensitivity, specificity, PPV and/or NPV. 
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PART 2: PATHOPHYSIOLOGICAL ASPECTS 
 
The two studies of this chapter on the pathophysiological aspects are submitted or prepared for 
publication as: 
VAN GALEN G., DEBY-DUPONT G., SERTEYN D., VOTION D.-M. 
Fat analysis in muscle samples from horses affected with atypical myopathy. 
Submitted to Neuromusc. Dis. 
 
VAN GALEN G., CERRI S., PORTER S., SAEGERMAN C., LEFERE
 
L., ROSCHER K., MARR C.,  
AMORY H., VOTION D.-M. 
Assessment of acid-base and shock variables in horses suffering from atypical myopathy. 
Placed in editorial format for submission to J. Vet. Intern. Med. 
 
They have been presented as: 
- Fat analysis in muscle samples from horses affected with atypical myopathy. 
Poster presented at Equine Health and Nutrition Congress, Waregem Belgium, April 15-16
th
 
2011. 
- Exploratory survey on acid-base derangements on admission in horses suffering from atypical 
myopathy. 
Oral communication at the British Equine Veterinary Association (BEVA) congress, 
Liverpool United Kingdom, September 8-10
th
 2011. 
- Assessment of acid-base imbalances in horses suffering from atypical myopathy. 
Oral communication at the American Association of Equine Practitioners (AAEP) congress, 
Texas USA, November 18-22
th
 2011. 
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STUDY 4: FAT ANALYSIS IN MUSCLE SAMPLES FROM HORSES AFFECTED WITH 
ATYPICAL MYOPATHY 
 
Aims of the study 
The myodegenerative process affects more selectively oxidative (i.e. the “slow-twitch” or type I fibres, 
mainly found in postural and respiratory muscles) rather than glycolytic fibres (i.e. the “fast-twitch” or 
type II fibres, predominantly found in locomotor muscles). In addition, affected muscle fibres show 
excessive intramuscular lipid storage (Cassart et al., 2007; Palencia and Rivero, 2007). Histochemical 
stains for succinate dehydrogenase (SDH; Palencia and Rivero, 2007) and NADH-tetrazolium 
reductase (Cassart et al., 2007) indicated weak oxidative potential and more recently, activities of 
mitochondrial complexes confirmed an impaired oxidative metabolism (Westermann et al., 2011). On 
the other hand, the absence of abnormal accumulation of glycogen or abnormal form of polysaccharide 
in muscle tissue (Cassart et al., 2007; Palencia and Rivero, 2007) suggests a preserved glycolytic 
pathway. 
Hyperlipaemia (Votion et al., 2007b) as well as lipid accumulation in skeletal muscles in the 
form of microvesicular droplets (Cassart et al., 2007; Westermann et al., 2008b) are common findings 
in AM. More detailed information about these lipids is needed to understand the complex disturbances 
in AM affected horses. Therefore, the aims of this study are 1) to analyse the amount of total lipids 
and of the different lipid classes in AM affected muscles, 2) to analyse the profile of FFA and the 
amount of individual FFA in AM affected muscles and 3) to compare those lipid analyses of affected 
muscles to that of normal muscle. 
 
Materials and Methods 
Case selection 
Five horses were included in this study. Two of these horses (AM1 and AM2) were diagnosed with 
AM based on history, clinical signs and presence of a multifocal process compatible with Zenker 
degeneration and necrosis in fibres of postural muscles, respiratory muscles or both on histology. 
Three other horses served as control horses (C1, C2 and C3): they were euthanized for other reasons 
and without any clinical evidence of muscle pathology. From all horses, muscle biopsies of different 
muscles were sampled during general anaesthesia prior to euthanasia. The sampled muscles were 
immediately frozen in liquid nitrogen and then stored at – 80°C until analysis. The muscles that were 
sampled are shown in Table X.  
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Lipid analysis 
The lipid and FFA analysis were performed as previously described in literature (Gorski et al., 1998; 
Nawrocki et al., 1999; Nawrocki and Gorski, 2004). 
Extraction of the lipids 
The muscle samples were thawed, lyophilised and weighted. They were then crushed in 10 ml 
phosphate buffer (0.15 M) at pH 7.4. The crushed samples were added to 8 ml chloroform and stirred 
during 30 minutes. The sample was then centrifuged at 2500 rotations per minute  
(power of centrifuge 1000 g) separating the aqueous phase of the lipid phase. The aqueous phase was 
aspirated and 6 ml of the chloroform lipid phase (75%) were collected in a pre-weighted tube. The 
solvent was evaporated under nitrogen flow and possible traces of water were eliminated by 
lyophilisation. Finally, the tube with its content was weighted. This weight was used to calculate the 
weight of the total extracted lipids (weight of tube with content – weight of empty tube) and finally to 
calculate the weight of lipids in mg per gram muscle. 
Analytical thin layer chromatography 
The extracted lipids were brought in solution by mixing them with 1 ml chloroform. Ten µl of this 
solution were used to perform a thin layer chromatography (TLC) on a silica gel covered plate 
(Merck
©
 KGaA, Darmstadt, Germany) in a solvent mixture of petroleum ether, diethylic ether,  
acetic acid (70; 30; 2). Two control samples (20 µl) were used on every chromatography plate: one 
control sample contained a mix of triolein and cholesterol (S1), and the other control sample contained  
oleic acid and cholesteryl oleate (S2). This TLC permitted a separation of the lipid classes:  
cholesteryl esters, triglycerides, FFA, cholesterol, monoglycerides and phospholipids  
(in migrating order). By vaporisation of a copper acetate solution on the plate followed by a heating of 
the plate at 180°C, the migrated lipids were visualised as brown-black spots. The quantitative 
percentage of every lipid class, their value in µg in the muscle sample and their value per gram of 
muscle were calculated by use of densitometry. 
Preparative thin layer chromatography and isolation of free fatty acids 
A second TLC, identical to the previous one, was performed on 15 µl of the lipid samples with the 
same control solutions and under the same conditions. At the end of this TLC, only S1 and S2 were 
visualised as previously described. The central part of the plate that contains the samples was 
visualised only temporarily by vaporisation of iodine to be able to localise the FFA with precision. 
After iodine evaporation, the plate was vaporised with butylhydroxytoluene dissolved in chloroform to 
prevent lipid peroxidation by oxygen exposure. The zone corresponding with the localisation of the 
FFA was removed with chloroform by the Eluchrom (Camag
©
, Switzerland) at slow velocity  
(1 ml per 10 minutes) and placed in a 1 ml glass tube.  
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Methylation and gas liquid chromatography 
The obtained FFA solution was evaporated under a nitrogen flow and then methylated by 
diazomethane. After methylation, the solution was evaporated and the sample was replaced in solution 
with 10 µl of dichloromethane of which 0.5 µl were injected in the chromatograph. 
The following conditions of gas liquid chromatography (GLC) were used: Chromatograph 
Varian CX 3600 star, equipped with a capillary column Supelco SP
TM
-2380 (cyano-silicone; 30 meter; 
diameter 0.25 mm; thickness of the film 0.2 µm) and a flame ionisation detection. A nitrogen flow was 
used as gas vector (30 ml/min) at 180°C during 6 minutes, followed by an increase of the temperature 
(10°C/min) until 210°C, which was maintained for 40 minutes. The flame was induced by air  
(300 ml/min) and hydrogen (30 ml/min). The column was standardised by a mix of methylated FFA 
(PUFA n°2 from Supelco; Bellefonte, PA, USA) and by individual methylated FFA (purchased from 
Sigma; methylated by diazomethane). The registration of the chromatogram was performed by an 
integrator. The column separated FFA based on their number of carbons and based on their number of 
double bonds. 
The peaks were identified by comparing retention times to the reference FFA (PUFA n°2 or 
the individual FFA). After localizing and identifying the peaks, the total surface of all peaks was 
calculated being equal to 100%. Thereafter the surface of each individual peak was calculated in 
percentage of the specific FFA and converted into μg/g muscle. 
Comparison 
Lipid analyses from AM affected muscle samples and control muscle samples were compared, but due 
to the limited number of cases, no statistic analysis of these data was performed.  
 
Results 
Extraction of the lipids 
The weight of the total lipids (mg/g muscle) was in the same range for AM affected muscle samples as 
for control muscle sample (Table XI). 
Analytical thin layer chromatography 
In contrast to control horses, FFA were clearly visible at TLC in all muscles of AM affected horses 
(Figure 11a and 11b) and the mean muscular FFA in affected horses was higher than that of control 
horses (Table XI). Differences in the other lipid classes were also visible (no quantitative data shown): 
in muscle samples of affected horses less triglycerides were visible than in muscle samples of control 
horses and in some muscles of affected horses monoglycerides were identified. In none of the horses 
cholesteryl esters were visualised at TLC.  
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Gas liquid chromatography 
In AM and control samples, 53.2 ± 6.1% and 53.1 ± 7.6% respectively of GLC peaks could be 
identified by comparison to the reference FFA. In all horses, largely the same FFA were found on the 
chromatograms. In control samples, the major FFA were C16:0 and unidentified FFA with a chain 
length longer than C24:1, and in affected samples the major FFA was C16:1. Samples of horse AM1 
had no FFA below chain length of C10, but showed clearly higher levels of C16:1, C18:0, C22:0 and 
C22:1 compared to control samples, and mild increases were seen for C18:1n9, C20:4n6 and 
unidentified FFA longer than C24:1. Samples of horse AM2 had obvious increases in FFA with a 
shorter chain length than C10, C16:0 and C18:0, and to a lesser extent also increases in C10:0 and 
C22:1 (Table XII). 
 
Discussion and Conclusions 
The present study confirms a problem in muscular lipid metabolism showing a smaller amount of 
triglycerides and a larger amount of monoglycerides and FFA in affected muscles compared to 
controls. Triglycerides consist of FFA bound to glycerol and limited amounts are stored in muscle 
cells as energy source (Lehninger et al., 1993a; MacLeay, 2004). In the light of the important energy 
deficit in affected horses, as suggested by the excretion of AMP metabolites and muscle glycogen 
depletion (Westermann et al., 2011), stored triglycerides probably are degraded into FFA and glycerol 
with monoglycerides as intermediates. 
No difference was demonstrated in the amount of total muscular lipids between the two 
studied groups. The increase in FFA (in μg/gram muscle) was too small to make a significant 
difference on the amount of total lipids (in mg/gram muscle). Still important lipid accumulations are 
visible in affected muscle samples stained by Oil red O in contrast to normal horses  
(Cassart et al., 2007). The affinity for neutral lipids (FFA and their derivatives) and the poor 
coloration of structural fats by the Oil red O staining (Bayliss High and Lake, 1990) may account for 
this phenomenon. Our hypothesis is that due to insolubility, free neutral fat aggregates to lipid droplets 
giving rise to the frequently reported vesicular lipidosis on histology (Cassart et al., 2007; Palencia 
and Rivero, 2007). 
In the current study, findings were variable for short- and medium-chain FFA (shorter or equal 
to C10:0) with one case (AM2) showing increased values compared to the controls and the other 
(AM1) having no short- and medium-chain FFA shorter than C10:0 and with C10:0 levels similar to 
controls. Maybe this can be explained by a less severe dysfunction and/or variation in deficient 
enzymes. The long-chain FFA were increased in affected muscle samples of both AM cases compared 
to the control group: increases were seen for C16:1, C18:0, C18:1n9, C22:0, C20:4n6, C22:1 and 
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unidentified FFA longer than C24, however with some differences between cases. In both cases, the 
most spectacular increase was that in C16:1 (palmitoleic acid). 
Minor differences in FFA profiles between individual horses are probably dependant on 
different feeding practices (Andersson et al., 2002; Perez-Palacios et al., 2007), levels of activity or 
training of horses (Gottlieb et al., 1989), daily fluctuations (Orme et al., 1994; Piccione et al., 2009) 
and/or muscle fibre composition (Vessby, 2000). The current study demonstrates a muscular FFA 
profile with increases in a wide range of FFA including short-, medium- and long-chain FFA. 
Eventhough more data is needed, this FFA analysis on muscle samples might be a promising 
additional diagnostic tool. 
The current study included only a limited amount of cases and did not include a complete set 
of muscle samples of AM affected and control horses. Therefore one should be prudent to interpret 
these findings and further studies are needed to confirm these results. 
In conclusion, the results of this study confirm a problem in lipid metabolism occurring in 
horses suffering from AM, and are therefore supportive for suggestions to favour carbohydrate 
metabolism over lipid metabolism in affected horses (Westermann et al., 2008b). The current study 
demonstrates a characteristic muscular FFA profile with increases in a wide range of FFA including 
short, medium and long-chain FFA. Future studies should further clarify the origin and the impact of 
these FFA. 
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Tables and Figures 
Table X. Sampled muscles on the selected horses. 
Horse m. brachiocephalicus m. longissimus 
dorsi 
m. quadriceps 
femoris 
m. semitendinosis 
AM1 x x x  
AM2 x x x x 
C1 x x x x 
C2  x  x x 
C3 x   x 
Legend: AM = atypical myopathy affected horses; C = control horses. 
 
 
Table XI. Weight of the total lipids and of the free fatty acids in the sampled muscles of the control 
horses and atypical myopathy affected horses. 
Horse Muscle Weight lyophilised 
muscle 
(g) 
Weight total 
lipids 
(mg/g muscle) 
Weight FFA 
(µg/g 
muscle) 
Mean (±SD) 
FFA 
(µg/g muscle) 
Atypical myopathy affected horses   1885.81 ± 
710.02 
AM1 m. brachiocephalicus 0.9030 21.12 2 673.79 1716.58 ± 
915.80  m. longissimus dorsi 1.1898 10.98 848.75 
 m. quadriceps femoris 
 
0.7950 22.60 1 627.20 
AM2 m. brachiocephalicus 1.0900 18.72 2 515.43 2012.74 ± 
631.68  m. longissimus dorsi 1.0642 32.32 2 472.86 
 m. quadriceps femoris 1.2524 61.43 1 898.16 
 m. semitendinosis 
 
1.0142 43.78 1 164.49 
Control horses    487.41 ± 597.44 
C1 m. brachiocephalicus 1.2495 21.45 1 454.31 474.88 ± 653.77 
 m. longissimus dorsi 0.8806 29.37 146.85* 
 m. quadriceps femoris 1.2152 21.81 109.05* 
 m. semitendinosis 
 
0.9438 37.86 189.30* 
C2 m. brachiocephalicus 1.1871 35.94 179.70* 195.15 ± 13.6 
 m. quadriceps femoris 1.2335 41.07 205.35* 
 m. semitendinosis 
 
1.0313 40.08 200.40* 
C3 m. brachiocephalicus 1.1016 45.27 1 616.59 950.87 ± 941.47 
 m. semitendinosis 
 
1.0216 57.03 285.15* 
Legend: AM = atypical myopathy affected horses; C = control horses; SD = standard deviation;  
FFA = free fatty acids; (*) FFA not present or only in traces visible on the thin layer chromatography, 
so < 10 µg or < 0.5 % of the weight of the measured total lipids. To be able to perform the calculations 
for the gas liquid chromatograpy, the quantity of those FFA was arbitrary chosen to be 0.5% of the 
weight of the measured total lipids.  
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Figure 11a. Example of a thin layer chromatography on a muscle sample from a control horse. 
 
 
Legend: A chromatography plate with 5 samples (9E-9K) from a control horse and 2 control samples 
(S1 and S2). The migration of the lipids occurs from ventral to dorsal and the thin layer 
chromatgraphy allows a separation of cholesteryl esters, triglycerides, free fatty acids, cholesterol, 
monoglycerides and phospholipids. After migration, the migrated lipids were visualised under the 
form of brown-black spots. Note the absence of free fatty acids.  
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Figure 11b. Example of a thin layer chromatography on a muscle sample from a horse affected with 
atypical myopathy. 
  
Legend: A chromatography plate with 5 samples (3B-3H) from a horse affected by atypical myopathy 
and 2 control samples (S1 and S2). The migration of the lipids occurs from ventral to dorsal and the 
thin layer chromatgraphy allows a separation of cholesteryl esters, triglycerides, FFA, cholesterol, 
monoglycerides and phospholipids. After migration, the migrated lipids were visualised under the 
form of brown-black spots. Note the presence of free fatty acids.  
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Table XII. The individual free fatty acids in muscle samples of horses affected with atypical myopathy 
and control horses. 
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 µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g 
Affected horses                       
AM1 BC 0.0 75.8 67.9 70.3 118.6 558.4 35.9 75.1 24.5 0.0 0.0 9.4 10.8 0.0 33.9 58.9 21.1 0.0 0.0 43.1 0.0 592.6 
 LD 0.0 45.8 30.6 25.5 37.2 225.6 8.6 17.8 4.3 0.0 0.0 2.0 2.8 0.0 7.8 21.1 11.4 0.0 0.0 18.5 0.0 121.1 
 QF 0.0 93.3 55.6 0.0 0.0 493.4 16.4 249.0 9.9 0.0 0.0 0.0 0.0 0.0 14.4 50.9 26.0 0.0 0.0 44.7 0.0 253.0 
 Mean 0.0 71.6 51.3 31.9 51.9 425.8 20.3 114.0 12.9 0.0 0.0 3.8 4.6 0.0 18.7 43.6 19.5 0.0 0.0 35.4 0.0 322.2 
 SD 0.0 24.1 19.0 35.6 60.7 176.4 14.1 120.4 10.4 0.0 0.0 4.9 5.6 0.0 13.5 19.9 7.4 0.0 0.0 14.7 0.0 243.3 
AM2 BC 549.7 156.4 0.0 0.0 220.5 971.2 42.5 0.0 20.6 0.0 0.0 25.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 46.3 0.0 246.3 
 LD 333.1 168.5 48.5 57.4 328.5 687.3 25.9 9.8 7.2 0.0 0.0 0.0 0.0 0.0 0.0 41.8 14.6 0.0 0.0 44.0 0.0 157.7 
 QF 311.1 100.9 61.2 42.0 52.3 446.4 19.7 3.1 15.7 0.0 0.0 17.7 0.0 0.0 0.0 35.1 13.2 0.0 0.0 31.1 0.0 218.8 
 ST 193.9 56.8 26.6 0.0 42.6 434.0 15.5 0.0 9.9 0.0 0.0 0.0 0.0 0.0 0.0 30.8 0.0 0.0 0.0 25.6 0.0 128.9 
 Mean 346.9 120.7 34.1 24.9 161.0 634.7 25.9 3.2 13.4 0.0 0.0 10.7 0.0 0.0 0.0 26.9 7.0 0.0 0.0 36.8 0.0 187.9 
 SD 148.3 51.7 26.8 29.4 138.4 252.8 11.9 4.6 6.0 0.0 0.0 12.7 0.0 0.0 0.0 18.5 8.1 0.0 0.0 10.0 0.0 54.0 
Control horses                                             
C1 BC 102.1 158.6 0.0 0.0 142.0 202.5 0.0 80.7 43.4 0.0 0.0 37.8 0.0 0.0 0.0 53.0 0.0 0.0 0.0 77.4 59.1 392.9 
 LD 50.1 16.3 0.0 0.0 8.3 17.5 0.0 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.0 2.8 0.0 7.2 5.8 27.8 
 QF 0.0 21.7 0.0 0.0 4.0 11.4 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 7.6 0.0 4.1 12.4 49.3 
 ST 53.9 17.6 0.0 0.0 14.6 23.0 0.0 8.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 5.6 3.5 2.4 0.0 9.0 6.6 39.9 
C2 BC 0.0 15.3 0.0 5.3 43.4 2.2 3.8 4.7 3.8 1.8 2.1 0.0 1.7 1.9 0.0 4.2 2.6 0.0 0.0 0.0 0.0 49.9 
 QF 0.0 21.6 0.0 0.0 90.1 5.4 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 6.0 3.6 1.8 1.5 0.0 0.0 24.0 
 ST 42.6 16.2 0.0 4.8 84.0 1.2 1.4 2.7 0.8 0.8 0.0 0.0 0.0 0.0 0.0 2.2 0.0 3.6 0.0 0.0 0.0 19.7 
C3 BC 268.6 110.5 92.6 33.1 323.5 11.3 0.0 25.7 11.4 0.0 0.0 0.0 0.0 0.0 0.0 20.3 0.0 15.9 0.0 21.6 0.0 134.1 
 ST 62.61 20.9 14.3 13.5 14.1 3.4 0.0 7.6 0.0 0.0 0.0 0.0 3.7 0.0 0.0 5.4 0.0 0.0 0.0 8.4 0.0 59.1 
 Mean 64.4 44.3 11.9 6.3 80.4 30.9 0.6 15.6 6.9 0.5 0.2 4.2 0.6 0.2 0.0 11.7 1.1 3.8 0.2 14.2 9.3 88.5 
 SD 83.9 52.6 30.6 11.0 102.5 64.8 1.3 25.5 14.2 0.7 0.7 12.6 1.3 0.6 0.0 16.4 1.6 5.1 0.5 24.7 19.2 119.1 
Legend: BC = m. brachiocephalicus; LD = m. longissimus dorsi; QF = m. quadriceps femoris;  
ST = m. semitendinosis; SD = standard deviation. 
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STUDY 5: ASSESSMENT OF ACID-BASE AND SHOCK VARIABLES IN HORSES 
SUFFERING FROM ATYPICAL MYOPATHY 
 
Aims of the study 
Theoretically, AM affected horses might develop acid-base imbalances because of muscle dysfunction 
and destruction, cardiovascular and respiratory compromise (Cassart et al., 2007; Votion et al., 2007b; 
Westermann et al., 2008b; Westermann et al., 2011). However, very limited data on acid-base 
variables in AM are available (Votion et al., 2007b). A better understanding of acid-base disturbances 
in AM may assist clinicians with defining supportive therapy. Also, acid-base variables might be good 
candidates as prognostic indicators since they have previously been demonstrated to have prognostic 
value in several equine disorders (Seahorn et al., 1992; Corley and Marr, 1998; Southwood et al., 
2009). 
The objectives of this retrospective study are to: 1) describe the acid-base and cardiovascular 
shock status of horses suffering from AM on admission, and 2) determine if acid-base and shock 
variables on admission can be used as prognostic indicators. 
 
Materials and Methods 
Cases and study design 
Horses suffering from AM during the period 2006-2010, that were reported to AMAG and admitted to 
an equine referral centre where venous blood gas analysis was performed on admission, were included 
in this retrospective multicenter study. Horses were included when they were Confirmed or had a High 
probability of having AM as defined by the decisional algorithm of the first study (Figure 5). Fifteen 
horses, considered healthy based on history and clinical examination, were used as control group. 
Collection of Data and Samples, and Sample Analysis 
Heart and respiratory rates, rectal temperature, venous pH, partial pressure of carbon dioxide  
(pCO2), bicarbonate (HCO3
-
; calculated by the blood gas machine), base excess (BE; calculated by the 
blood gas machine), packed cell volume (PCV), blood nitrogen urea (BUN), serum CK activity, total 
protein (TP), and plasma concentrations of sodium (Na
+
), chloride (Cl
-
), potassium (K
+
), and L-lactate 
on admission, and final survival status were retrieved. A previously reported shock grading system 
(Grulke et al., 2001) was modified such that lactate concentration (for use as independent variable) 
and blood pressure (unavailable) were excluded. The shock variables heart and respiratory rates, PCV 
and BUN recorded on admission were used to attribute a shock grade of I to IV (Table XIII).  
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In all cases, blood had been collected from the jugular vein on admission. Blood gas analysis 
was performed directly by an automated blood gas analyzer 
a,b,c 
on blood collected anaerobically in 
heparinised tubes or syringes. Because of controversy over the need for temperature correction with 
opponents pointing out that there is no logical or scientific basis for the assumption that  
temperature-corrected values are better than values obtained at 37°C (Sharpiro, 1995; Clutton, 2007), 
venous blood gas analyses were not corrected for rectal body temperature. 
Blood collected in EDTA tubes was used for PCV measurements by centrifugation of capillary 
tubes or with automated analyzers 
d,e
. Plasma TP was measured by refractometer or by an automated 
analyzer 
f,g,h
. Automatic analyzers measured plasma lactate concentration 
b,i,j
, BUN 
b,f,g,h
, CK 
f,g,h,k
, and 
[electrolytes] 
a,b,c,h
. 
Calculation of variables and classification of acid-base disturbances 
The acid-base disturbances were classified following three different approaches. First, with use of the 
traditional approach based on the Henderson-Hasselbalch equation (Hasselbalch, 1916) horses were 
diagnosed with the following imbalances: 
- Metabolic acidosis when HCO3
-
 and/or BE were below the reference range 
- Metabolic alkalosis when HCO3
-
 and/or BE were above the reference range 
- Respiratory acidosis when pCO2 level was above the reference range 
- Respiratory alkalosis when pCO2 level was below the reference range. 
To provide more insight in the cause of acid-base imbalances, taking into account effects of 
electrolytes, unidentified anions (including lactate) and non-volatile weak buffers on acid base status, 
the quantitative approach of Stewart‟s strong ion model simplified by Constable was used  
(Constable, 1997). Therefore the following variables were calculated: 
- Measured strong ion difference (SIDm) 
A lot of different equations exist for SIDm, in- or excluding unidentified anions or lactate 
(Constable, 1997), but for this study it was chosen to evaluate lactate separately and to use the 
following formula for SIDm (Constable, 1997): 
SIDm = (Na
+
 + K
+
) – Cl- 
Lactate was evaluated by L-lactate measurements and estimated by calculation of the anion 
gap (AG; Johnson, 1995; Whitehair et al., 1995; Corley and Marr, 1998). 
- AG was calculated with the following formula (Emmett and Narins, 1977): 
AG = (Na
+
 + K
+
) – (Cl- + HCO3
-
) 
- Total plasma concentration of non-volatile weak buffers (Atot) was calculated with the 
following formula (Constable, 1997): 
Atot = 2.24 x TP (g/dL)  
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With use of this quantitative approach, horses were diagnosed with the following acid-base imbalances 
(Constable, 1997): 
- Metabolic acidosis when lactate, AG and/or Atot values were above the reference range, and/or 
SIDm below 
- Metabolic alkalosis when SIDm was above the reference range and/or Atot below 
- Respiratory acidosis when pCO2 level was above the reference range 
- Respiratory alkalosis when pCO2 level was below the reference range 
The reference ranges that were used for the acid-base variables are indicated in Table 3 (Constable, 
1997; Corley and Marr, 1998; Navarro et al., 2005; Viu et al., 2010). 
The agreement on presence or absence of metabolic acid-base derangements between the 
traditional approach and the simplified strong ion model was assessed. 
Thirdly, another quantitative approach, Fencl‟s application of Stewart‟s principles, was used to 
estimate the magnitude of the separate components to metabolic acid-base imbalances as also 
described in equine medicine (Whitehair et al., 1995; Corley and Marr, 1998). 
The following variables were calculated: 
- BE due to free water (BEfw): 
BEfw = 0.3 (Na
+
 measured – Na+ normal) 
(Na
+
 normal = 140 mmol/L) 
- BE due to chloride (BEcl): 
BEcl = Cl
-
 normal – ((Cl- measured x Na+ normal)/Na+ measured) 
(Na
+
 normal = 140mmol/L, Cl
-
 normal = 105) 
- BE due to TP (BEtp): 
BEtp = 0.224 x (TP normal – measured TP measured) 
(TP normal = 67g/L) 
- BE due to unidentified anions (BEua): 
BEua = BEmeasured – (BEfw + BEcl + BEtp) 
Statistical Analysis 
Data are reported as mean ± standard deviation (SD), range and, where appropriate, the number of 
horses out with reference ranges (Constable, 1997; Corley and Marr, 1998; Navarro et al., 2005; Viu 
et al., 2010). Acid-base and shock variables in AM cases were compared to those of control horses 
with a two sample Wilcoxon rank sum (Mann-Whitney) test. 
In AM survivors and non-survivors acid-base and shock variables, rectal temperature and 
serum CK activity were compared with a two sample Wilcoxon rank sum (Mann-Whitney) test. Also, 
a classification and regression tree (CART) analysis, as described in detail by Porter et al. (2011), was 
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performed on AM cases with the survival status as target variable and acid-base and shock variables, 
rectal temperature and serum CK activity as predictor. For all statistical tests P < 0.05 was considered 
significant. 
 
Results 
Thirty-four horses met the inclusion criteria for this study of which four survived AM and 30 died or 
were euthanized (survival rate 12%). Their signalment is presented in Table XIV. 
Acid-base and shock variables are presented in Table XV and XVI, respectively. Cases 
commonly presented with tachycardia, tachypnea, normal to increased PCV and BUN, and severely 
increased serum CK activities on admission. They were hypo- (12 cases), normo- (19 cases) or 
hyperthermic (3 cases) (37.2 ± 1.1°C, range 34.6 – 40.5°C). Ten horses were attributed a shock grade 
I, 19 a grade II, 5 a grade III and none a grade IV. The blood pH was very variable. Electrolyte 
derangements were common, and although mostly mild they lead in the majority of cases to an 
increased SIDm. Of the three considered electrolytes, acid-base status was mostly affected by Cl
-
. 
Only one horse had a combination of hyponatremia, hypochloremia and hyperkalemia. All affected 
horses had a mild to severe increase in AG and the majority an increased plasma lactate concentration 
and decreased BEua. Four horses had mildly elevated AG, but normal lactate concentrations. The 
majority of cases had normal TP concentrations, Atot and BEtp values, and if deviations occurred they 
were mild. When hyperproteinemia occurred, it was always together with high PCV, however not all 
cases with high PCV had increased TP. BUN often, but not always, showed increases parallel with 
PCV. 
Acid-base disturbances classified by the traditional approach and the simplified strong ion 
model are listed in Table XVII. The two cases classified with respiratory acidosis were shortly 
euthanized after arrival. The two classification systems showed poor agreement on the presence of 
acid-base derangements. Nine cases classified as having no derangements according the traditional 
approach, suffered from lactic acidosis (2 cases), lactic acidosis and SIDm alkalosis (5 cases) and 
lactic acidosis, Atot acidosis and SIDm alkalosis (1 case) according the simplified strong ion model. Of 
the ninth case without acid-base abnormality following the traditional approach, not enough data were 
available to perform the full quantitative analysis of the simplified strong ion model. 
The pH, pCO2, HCO3
-
, BEfw, BEua, [Na
+
] and [Cl
-
] were significantly lower in cases 
compared with controls, and heart rate, respiratory rate, PCV, BUN, [lactate], AG, SIDm and BEcl 
significantly higher (Table XV and XVI).  
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Survivors had a significantly lower PCV and BEcl and a significantly higher [Cl
-
] than  
non-survivors (38.3 ± 6.6% versus 47.4 ± 7.4%; 3.0 ± 0.3 versus 8.5 ± 5.4; 102 ± 2.8mmol/L versus 
94 ± 7.7mmol/L, respectively). BEcl, [Cl
-
] and PCV also had strong discriminatory power between 
survivors and non-survivors in the CART analysis, while serum CK activity had almost no 
discriminatory power (Figure 12a). An optimal tree discriminating survival can be suggested by using 
BEcl, BUN and heart rate (Figure 12b). 
 
Discussion and Conclusions 
This study confirms that horses suffering from AM frequently have acid-base derangements on 
admission. They are often mixed and therefore not necessarily resulting in altered blood pH  
(acidemia or alkalemia). Metabolic acidosis is demonstrated to be mainly the result of changes in 
electrolytes (SIDm) and lactate in AM, whereas non-volatile weak buffers (Atot) do not seem to have 
major impact. Massive cell destruction is known to cause electrolyte abnormalities, more specifically 
the combination of hyponatremia, hypochloremia and hyperkalemia (Johnson, 1995; Corley and Marr, 
1998; Polderman, 2004). Eventhough expected to occur in AM cases due to severe rhabdomyolysis, 
this combination was only encountered in a single case in the current study. In a study on acid-base 
and electrolyte derangements in horses with exertional myopathy, hypochloremia was the most 
consistent electrolyte abnormality (Koterba and Carlson, 1982), as was the case in the current study. 
Besides rhabdomyolysis electrolyte derangements in AM cases can theoretically also originate from: 
1) electrolyte losses via excessive sweating and/or via salivation (Corley and Marr, 1998; Guyton and 
Hall, 2006e; Votion et al., 2007b; van Galen et al., 2012b), 2) renal dysfunction (Geor, 2007) and  
3) limited intracellular uptake of potassium by acidemia (Johnson, 1995; Guyton and Hall, 2006c). 
Acidemia and increased BUN were reported in several cases in the current study. False hyponatremia 
and -chloremia can also occur in the face of hyperglycemia and hyperlipemia (Milionis et al., 2002), 
which are regularly encountered in AM (Votion et al., 2007b). 
Lactate concentrations, as well as its estimates AG and BEua, were abnormal in most AM 
cases. Lactate is typically produced in conditions with tissue hypoxia and cell lysis  
(Corley and Marr, 1998), which might occur in AM due to shock, cardiac pathology, hypoventilation 
and inadequate mitochondrial oxygen utilization in muscles. 
Both respiratory acidosis and respiratory alkalosis were documented in the current study. 
Respiratory acidosis can be explained by dyspnoea and hypoventilation that is secondary to the severe 
affection of respiratory muscles as frequently encountered at post mortem (Cassart et al., 2007). 
Unexpectedly, respiratory acidosis only occurred in 2 horses. However, these data were recorded on 
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admission and AM cases often have declining respiratory function, with increasing dyspnoea, 
decreasing PaO2 (Votion et al., 2007b) and increasing arterial pCO2 (personal observation). Both 
horses with respiratory acidosis in this study were euthanized very shortly after arrival, suggesting 
respiratory acidosis as poor prognostic factor. Respiratory alkalosis was more commonly observed in 
this study, and most likely relates to hyperventilation due to pain or distress, and compensation for 
metabolic acidosis and anaerobic metabolism. The respiratory component of acid-base abnormalities, 
pCO2, was measured in this study on venous instead of arterial samples. Abnormal pCO2 values in 
venous samples originate from abnormal pulmonary ventilation, but depend also on tissue CO2 
production, pulmonary perfusion and cardiac output. Therefore venous hypercapnia or hypocapnia 
(classified as respiratory acidosis and alkalosis, respectively, in the current study) may not be solely 
respiratory in origin. Nevertheless, there is acceptable agreement in human medicine between arterial 
and venous values of pCO2, suggesting that venous blood gas analysis is a good substitute for arterial 
blood gas analysis (Malatesha et al., 2007). In addition, venous pCO2 values are commonly used in 
equine studies to classify respiratory acidosis or alkalosis (Navarro et al., 2005; Viu et al., 2010). 
A previous much larger epidemiological study on AM (Study 3) identified prognostic factors 
from clinical signs. Complementary to this, the current study allowed identification of PCV, BEcl,  
[Cl
-
] and respiratory acidosis as variables that are useful for prognostic assessment, and an optimal tree 
was suggested with BEcl, BUN and heart rate to discriminate survival status on admission. Only a 
limited number of clinical and blood variables were included in this study, nevertheless these are 
commonly used and/or measured in equine medicine or can easily be calculated from commonly used 
variables. However, as the case numbers were limited, with very few survivors, this prognostic 
assessment has limited statistical power. 
Previous reports on several equine conditions have demonstrated that quantitative acid-base 
analysis provides more insight in acid-base pathophysiology and allows diagnosis of mixed metabolic 
disturbances (Whitehair et al., 1995; Navarro et al., 2005; Viu et al., 2010). The current study points 
out the importance of using quantitative acid-base analysis over the traditional approach in AM 
affected horses. 
This study is limited by restricted availability of blood biochemistry due to its retrospective 
nature, the small number of cases and few survivors. Although AM has been more common in Europe 
in the past years (van Galen et al., 2012b), it remains a rare condition and thus difficult to generate 
large and complete data sets. Nevertheless, these data remain important for a better understanding of 
the condition and help clinicians to assess prognosis and adapt therapy for horses suffering from AM. 
A further limitation is that samples were analyzed in different clinics with different techniques. Small 
disagreements between data from different clinics might therefore have occurred.  
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In conclusion, this study shows that the majority of horses suffering from AM have respiratory 
and/or metabolic acid-base alterations and that they are better recognized by quantitative than 
traditional acid-base analysis. In AM patients, alterations are mainly the result of respiratory alkalosis, 
lactic acidosis and/or SIDm alkalosis. Several shock and acid-base variables are suggested to be useful 
to predict the likelihood of survival. This study provides better insight in pathophysiology of AM and 
improves prognostic assessment in affected cases. 
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Tables and Figures 
Table XIII. The shock grading system adapted from Grulke et al. (2001) that was used to attribute a 
shock grade to each individual horse with atypical myopathy. 
Shock variables Shock grade 
I II III IV 
Heart rate (bpm) < 60 60-80 80-100 >100 
Respiratory rate (rpm) < 25 25-35 35-45 >45 
PCV (%) < 45 45-55 55-65 >65 
BUN (mmol/L) < 14 14-20 20-25 >25 
Legend: PCV = packed cell volume; BUN = blood urea nitrogen. 
 
 
 
Table XIV. Signalment of horses suffering from atypical myopathy and of control horses. 
 AM horses 
(n = 34) 
Control horses 
(n = 15) 
Female 22 10 
Gelding 7 3 
Stallion 5 2 
Pony 7 0 
Saddle horse 24 15 
Draught horse 3 0 
Age (years; mean ± SD) 4.6 ± 4.7 
range 1.5 months – 17 year 
12.5 ± 6.8 
range 2 – 25 years 
Legend: AM = atypical myopathy; SD = standard deviation; n = number of horses. 
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Table XV. Acid-base variables from horses with atypical myopathy on admission and from healthy 
control horses. 
ACID 
BASE 
VARIABLE 
Reference 
value 
Cases 
(n=34) 
 Controls  
(n=15) 
Comparison 
AM versus 
control 
  Mean ± 
SD 
Range  n n > rr  n < rr  Mean ± 
SD 
Range  P value 
pH 7.31 – 7.45 7.36 ± 0.09 7.14 – 7.56 34 3 7  7.40 ± 0.02 7.38 – 7.44 0.092 
pCO2 
(mmHg) 
41 – 53 40.6 ± 7.9 28.3 – 62.0 34 2 17  46.1 ± 2.3 42.2 – 50.2 <0.001 
HCO3
- 
(mmol/L) 
24 – 30 22.0 ± 4.4 9.5 – 29.9 34 0 22  28.2 ± 0.98 26.1 – 30 <0.001 
BE total -6 – +6 -3.1 ± 4.7 -16.7 – 3.9 34 0 9  2.8 ± 1.1 0.6 – 4.5 <0.001 
Na
+
 
(mmol/L) 
134 – 144 136.5 ± 6.0 124 – 148 32 3 9  142.3 ± 2.7 136 – 147 <0.001 
BEfw X -1.1 ± 1.8 -4.8 – 2.4 32 X X  0.7 ± 0.8 -1.2 – 2.1 <0.001 
Cl
-
 
(mmol/L) 
100 – 110 94.7 ± 7.7 76 – 105 27 0 19  106 ± 2.4 100 – 110 <0.001 
BEcl X 8.1 ± 5.4 0.3 – 27.3 27 X X  0.7 ± 2.3 -3.1 – 4.2 <0.001 
K
+ 
(mmol/L) 
2.5 – 4.5 4.0 ± 0.5 2.8 – 5.1 32 3 0  3.8 ± 0.5 2.8 – 4.6 0.235 
SIDm 38 – 44 46.0 ± 45.0 38.4 – 65.5 27 18 0  40.1 ± 2.8 34.9 – 44.2 <0.001 
PT (g/L) 60 – 75 65.6 ± 7.5 43 – 78 31 3 4  67.6 ± 4.3 60 – 72 0.878 
BEpt  X 0.3 ± 1.7 -2.5 – 5.4 31 X X  -0.1 ± 1.0 -1.1 – 1.6 0.878 
Atot 13 – 17 14.7 ± 1.7 9.6 – 17.5 31 1 3  15.1 ± 1.0 13.4 – 16.1 0.878 
BEua X -10.8 ± 6.1 -23.4 – -2.6 26 X X  1.5 ± 2.8 -4.2 – 5.2 <0.001 
AG 6 – 15 24.2 ± 6.1 15.1 – 38.3 27 27 0  12.0 ± 2.8 6.6 – 17.3 <0.001 
lactate 
(mmol/L) 
< 2 6.7 ± 4.4 0.8 – 18.7 23 19 0  0.8 ± 0.6 LOW – 2.2 <0.001 
Legend: SD = standard deviation; n = number of horses; rr = reference range; pCO2 = partial pressure 
of venous carbon dioxide; HCO3
-
 = bicarbonate; BE = base excess; Na
+
 = sodium; BEfw = BE due to 
free water; Cl
-
 = chloride; BEcl = BE due to chloride; K
+
 = potassium; SIDm = measured strong ion 
difference; TP = total protein; BEtp = BE due to total protein; Atot = total plasma concentration of  
non-volatile weak buffers; BEua = BE due to unidentified anions; AG = anion gap.  
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Table XVI. Shock variables and shock grades from horses with atypical myopathy on admission and 
from healthy control horses. 
SHOCK 
VARIABLE 
Referen
ce value 
Cases 
(n=34) 
 Controls  
(n=15) 
Comparison 
AM versus 
control 
  Mean ± SD Range  n n > 
rr  
n < 
rr 
 Mean ± 
SD 
Range  P value 
HR (bpm) 
 
< 45 65 ± 18.5 
 
36 – 112  34 30 X  36  ± 6.1 28 – 44  <0.001 
RR (rpm) 
 
< 15 29.6 ± 12.7 
 
8 – 62  32 28 X  19.5 ± 4.0 16 – 24  <0.001 
PCV (%) 
 
30 – 45  46.3 ± 7.8 
 
30 – 62  34 22 0  35.1 ± 2.3 31 – 38  <0.001 
BUN 
(mmol/L) 
 
2 – 8 8.9 ± 3.8 1.9 – 18.7  27 15 1  4.8 ± 1.1 3.2 – 6.8  <0.001 
Shock grade 1 1.9 ± 0.7 1 – 3 34 24 0  1 ± 0 1 <0.001 
Legend: SD = standard deviation; n = number of horses; rr = reference range; HR = heart rate; 
RR = respiratory rate; PCV = packed cell volume; BUN = blood urea nitrogen. 
 
 
Table XVII. Acid-base imbalances identified in 34 horses affected by atypical myopathy classified 
with the traditional approach and the simplified strong ion model. 
 Acid-base imbalance n N % 
Traditional 
approach 
No imbalance 9 34 26 
Metabolic acidosis 6 34 18 
Metabolic alkalosis 0 34 0 
Respiratory acidosis 0 34 0 
Respiratory alkalosis 3 34 9 
Metabolic acidosis + respiratory alkalosis 14 34 41 
Metabolic acidosis + respiratory acidosis 2 34 6 
Simplified 
strong ion 
model 
No complete data for this quantitative approach 8 34 24 
No imbalance 0 26 0 
Lactic acidosis 4 26 15 
Lactic acidosis + SIDm alkalosis 8 26 31 
Lactic acidosis + SIDm alkalosis + Atot alkalosis 1 26 4 
Lactic acidosis + SIDm alkalosis + Atot alkalosis + respiratory alkalosis 1 26 4 
Lactic acidosis + SIDm alkalosis + respiratory alkalosis 4 26 15 
Lactic acidosis + SIDm alkalosis + respiratory acidosis 2 26 8 
Lactic acidosis + SIDm alkalosis + Atot acidosis 1 26 4 
Lactic acidosis + Atot alkalosis 1 26 4 
Lactic acidosis + respiratory alkalosis 4 26 15 
Legend: N = number of total response for each category; n = number of positive response for each 
category; SIDm = measured strong ion difference; Atot = total plasma concentration of non-volatile 
weak buffers.  
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Figure 12a. Classification and regression tree analysis on 34 atypical myopathy cases with survivor 
status as target variable and acid-base and shock parameters as predictors: the discriminatory power 
of variables. 
 
Variable Discriminatory power (score max. = 100) 
BEcl  100.00 |||||||||||||||||||||||||||||||||||||||||| 
Cl
-
  91.81 |||||||||||||||||||||||||||||||||||||| 
PCV  46.69 ||||||||||||||||||| 
SIDm  37.93 ||||||||||||||| 
BUN  36.26 ||||||||||||||| 
BEfw  27.76 ||||||||||| 
K
+
  27.76 ||||||||||| 
Na
+
  27.76 ||||||||||| 
Heart rate 23.43 ||||||||| 
BEtp  20.08 |||||||| 
Atot  20.08 |||||||| 
TP  20.08 |||||||| 
HCO3
-
  14.96 ||||| 
pCO2  8.41 ||| 
BE  4.24 | 
CK  1.70  
 
Legend: pCO2 = partial pressure of venous carbon dioxide; HCO3
-
 = bicarbonate; BE = base excess;  
Na
+
 = sodium; BEfw = BE due to free water; Cl
-
 = chloride; BEcl = BE due to chloride;  
K
+
 = potassium; SIDm = measured strong ion difference; TP = total protein; BEtp = BE due to total 
protein; Atot = total plasma concentration of non-volatile weak buffers; CK = creatine kinase;  
BUN = blood urea nitrogen; PCV = packed cell volume. 
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Figure 12b. Classification and regression tree analysis on 34 atypical myopathy cases with survivor 
status as target variable and acid-base and shock parameters as predictors: the optimal tree with a 
sensitivity of 84% and a specificity of 93%. 
 
Legend: N = number of horses; HR = heart rate; BUN = blood urea nitrogen; BEcl = base excess due 
to chloride. 
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CHAPTER 3: GENERAL DISCUSSION AND CONCLUSIONS 
The undertaken studies have achieved the initially defined goals: to improve the general knowledge of 
AM and to better understand its pathophysiological mechanisms. The perspectives of these results are 
a better prevention and management of affected cases by improved diagnostic and prognostic criteria 
and an establishment of guidelines for a therapeutic plan. 
 
GENERAL DISCUSSION, CONCLUSIONS AND PERSPECTIVES RESULTING FROM AN 
IMPROVED PATHOPHYSIOLOGICAL KNOWLEDGE  
The muscular lipid analysis of Study 4 confirmed a problem in FFA metabolism. During the current 
research project, a biochemical defect in AM was described by Westermann et al. as “multiple  
acyl-CoA dehydrogenase deficiency” (MADD), with defects in intramitochondrial dehydrogenation of 
fatty acyl-CoA‟s and and other intermediates in branched-chain amino acid metabolism. Therefore 
MADD also leads to dysfunction of the most efficient way for energy generation by the mitochondria, 
i.e. the OXPHOS. The recognition of this “MADD” - like disorder in AM affected horses was based 
on 1) characteristic profiles of organic acids in urine, 2) significant increases in short- and medium-
chain acylcarnitines in urine and plasma, and 3) the finding of deficiencies of short- and medium-chain 
acyl-CoA dehydrogenases and isovaleryl dehydrogenase in muscle tissue (Westermann et al., 2008b). 
Opposite to the study of Westermann et al. (2008b), Study 4 of the current project 
demonstrates the effect on all lipid classes and measured FFA instead of acylcarnitines. But 
chloroform dissolves lipids, broke lipid-proteins connections, and caused acylcarnitines to join the 
measured FFA. Therefore, eventhough they are very different groups, there is a close link between 
acylcarnitines and FFA in this study. In addition, lipids were studied in muscular tissue. Abnormalities 
in lipids are namely expected to occur first at the location of the deficiencies, which is the muscle, and 
it was suggested that plasma acylcarnitines and FFA profiles in exercising horses reflect muscle 
metabolism (Westermann et al., 2008a). In addition, blood analysis is not always reliable as diagnostic 
tool for human disorders of fatty acid oxidation and therefore additional testing of intermediates has 
also been performed in tissues, such as fresh muscle or post mortem tissues, showing characteristic 
profiles for the disorder (Boles et al., 1998; Onkenhout et al., 2001; Tyni et al., 2002). 
The study of Westermann et al. demonstrated no significant increase in plasma and muscular 
long-chain acylcarnitines in affected horses, and they only tested the muscle activity of short- and 
medium-chain acyl-CoA dehydrogenases, not of long-chain acyl-CoA dehydrogenases  
(Westermann et al., 2008b). However, in the human MADD syndrome, a general accumulation of 
plasmatic acylcarnitines or FFA and tissular (hepatic and muscular) FFA is observed from C4 to C18, 
thus including long-chain acylcarnitines and long-chain FFA (Onkenhout et al., 1995; Costa et al., 
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1998; Onkenhout et al., 2001; Nyhan et al., 2005). Individual results can however be variable 
dependant on the severity of human disease (Costa et al., 1998; Nyhan et al., 2005). In accordance to 
human MADD and in contrast to the study of Westermann et al., the current study demonstrates a 
characteristic muscular FFA profile with increases in a wide range of FFA corresponding to short-, 
medium- and long-chain acyl-CoA dehydrogenases deficiencies. Eventhough more data is needed, this 
FFA analysis on muscle samples might also be a promising additional diagnostic tool, especially for 
cases with no urine or blood samples available (for example due to a rapid death) or with inconclusive 
results of urine or plasmatic acylcarnitines profiles. 
Besides an increase in FFA, the AM affected muscle samples in Study 4 demonstrated also an 
increase in monoglycerides and a decrease in triglycerides. Interestingly, in human MADD the amount 
of muscular triglycerides is increased and abnormal fatty acids are contained in this lipid group and 
not in the FFA group (Onkenhout et al., 2001). It is currently unknown why this difference occurs 
between humans and horses. The chronicity of the condition does not seem to play a role since in 
human neonates the condition is acute as well and still the abnormal fatty acids are found in the 
muscular triglyceride and not in the FFA group (Onkenhout et al., 2001). In future studies, it would be 
interesting to study the muscular content of the triglycerides in affected horses. 
In general, FFA accumulations suggest a dysbalance between their uptake or delivery and the 
following steps of their metabolism. Currently the origin of muscular FFA increase in AM is 
unknown. At the level of the muscle they could accumulate following hydrolyzation of triglycerides 
(as suggested by the decrease in muscular triglycerides and increase in monoglycerides) and/or the 
catabolism of structural lipids. Also, the frequently encountered hyperlipaemia in affected horses 
(Votion et al., 2007b) might be a source of FFA since the possibility of rapid uptake of FFA by 
muscles from hyperlipeamic blood has been demonstrated in humans (Bachmann et al., 2001). 
Moreover, rats and persons with dyslipaemia and obesity show consistently an increase in plasmatic 
levels of C16:1 (Zak et al., 2000; Fukuchi et al., 2004; Mozaffarian et al., 2010) as do fasting ponies 
(Bauer and Ransone, 1983). C16:1 could theoretically also increase in muscular tissue after 
desaturation of the very common C16:0 (Robb et al., 1972; Luther et al., 1981; Orme et al., 1994; 
Westermann et al., 2008a). Interestingly, stearoyl-CoA desaturase, which catalyses the synthesis of 
C16:1, is recognized as an important component in the regulation of oxidative muscle metabolism 
(Dobrzyn and Dobrzyn, 2006; Flowers and Ntambi, 2008). In this perspective, it should also be 
mentioned that a FAD-dependent dysfunction was hypothesised in AM because of the decreased 
activity of several dehydrogenases that all use FAD as a coenzyme (Westermann et al., 2008b). If 
C16:1 would originate from desaturation of C16:0, it can be suggested that a FAD-dependant enzyme 
(Lehninger et al., 1993e) functions correctly, thus challenging the hypothesis of a FAD-dependent 
dysfunction. Several of the increased FFA are unsaturated, and therefore they require the action of two 
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auxiliary enzymes (i.e. an isomerase and a reductase) before undergoing the classical pathway of  
ß oxidation (Lehninger et al., 1993g). In humans, disorders of fatty acid ß oxidation relate mainly to 
saturated precursors, but it may not be excluded that the cause of AM alters the specific pathway of 
unsaturated fatty acid oxidation (Roe et al., 1990; Miinalainen et al., 2009). Finally, partial ß oxidation 
of precursors of the increased FFA, as is suggested in humans with MADD (Onkenhout et al., 2001) 
or complete blockage of lipid metabolism of accumulated FFA may be responsible for their increase in 
muscle. Severe problems have indeed been detected in enzymes involved in the oxidation, ETS and 
OXPHOS in AM (Westermann et al., 2008b; Westermann et al., 2011) and could support these last 
two possibilities. 
Multiple scientific studies on humans and rats have shown that accumulations of long-chain 
FFA have effects on glucose metabolism and insulin sensitivity of muscle cells, but these effects have 
been various and sometimes in opposite directions going from positive to cytotoxic or “lipotoxic” 
(Vessby, 2000; Kusunoki et al., 2006; Hirabara et al., 2007; Mozaffarian et al., 2010). Moreover the 
effects depend on the FFA chain length and saturation (Hommelberg et al., 2009). In contrast to other 
long-chain FFA, C16:1 seems merely to have a positive effect on insulin sensitivity (Dimopoulos et 
al., 2006; Stefan et al., 2010; Yang et al., 2011). If this effect is similar in horses it would be 
beneficial in AM, because it would enhance carbohydrate metabolism. Nevertheless, it can be 
suggested that some horses suffering from AM have a certain degree of insulin resistance because, as 
opposed to human MADD, hyperglycaemia often occurs in AM (Votion et al., 2007b; Westermann et 
al., 2008b) and that in the face of severe energetic problems with mitochondrial lipid metabolism, and 
intrasarcoplasmatic active glycolysis and glycogen depletion (Westermann et al., 2008b; Westermann 
et al., 2011). 
As already mentioned above, the severe energetic problems in AM are demonstrated by  
1) increased uric acid excretion in urine due to AMP degradation, 2) muscle glycogen depletion, and 
3) increase of glycolytic enzymes, except a very low activity of the enzyme phosphoglycerate mutase 
(PGAM) in one horse (believed to be partially due to cell leakage and partially due to a mutation in the 
affected patient). These observations can probably be attributed to the occurrence of the  
“MADD” – like defect, but also to the low activity of mitochondrial complexes of the ETS including 
the severely decreased ATP-synthase (Complex V) activity (Westermann et al., 2011). The amount of 
mitochondria has not changed (Westermann et al., 2011), although the overall oxidative capacity of 
myofibers is weaker as demonstrated in other studies by immunohistochemical stainings with NADH 
tetrazolium reductase (Cassart et al., 2007) and SDH (Palencia and Rivero, 2007). Results of the 
staining with NADH tetrazolium reductase are related to the mitochondrial Complex I and/or 
mitochondrial alterations, whereas weak staining with SDH suggests biochemical defects associated 
with the mitochondrial Complex II and/or mitochondrial alterations. In addition, with electronic 
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microscopy also ultrastructural changes of the mitochondria have been visualised (Cassart et al., 2007; 
Unger-Torroledo et al., 2010). It is not clear if the low activity of mitochondrial complexes in AM 
affected muscles is primary or secondary. In addition, in vitro studies show that accumulation of short- 
and medium-chain acyl-CoA‟s has inhibitory effects on pyruvate dehydrogenase complex, alpha-
ketoglutarate dehydrogenase complex and Complex III (Sauer et al., 2008). Also exposure to long-
chain FFA in skeletal muscle can lead to mitochondrial uncoupling (Hirabara et al., 2007), although 
this is mainly caused by saturated and not by unsaturated FFA (Hirabara et al., 2010). It is currently 
unknown if these secondary effects of intrasarcoplasmatic accumulations of FFA and other 
intermediate products can be extrapolated to the equine species and more importantly to AM. An 
ongoing study with the use of high resolution respirometry on muscle cells with functional 
mitochondria (Lemieux et al., 2007; Votion et al., 2007a; Votion et al., 2012) should provide more 
information about mitochondrial respiration in horses affected with AM. Preliminary results show 
indeed a severely decreased mitochondrial respiration compared to normal horses (van Galen, 2008). 
Due to this abnormal mitochondrial aerobic energy metabolism, anaerobic metabolism will be 
promoted and leads to increased lactate levels as demonstrated by Study 5 of this research project. In 
four horses, a mildly elevated AG was identified but with normal lactate concentrations. This 
difference might indicate hyperproteinemia (Whitehair et al., 1995) or increases in other unidentified 
anions than lactate. Since TP was noted to be normal in these four cases it can be suggested to be 
related to increases in ketone bodies, acyl-carnitines, glycine conjugates and organic acids in plasma 
that occur due to MADD. Organic acids in plasma, contrary to those in urine, were, however, not 
consistently elevated in AM (Westermann et al., 2008b). 
Lactic acidosis, SIDm alkalosis and respiratory abnormalities (alkalosis or acidosis) were 
commonly recognised acid-base derangements in affected horses. Changes in acid-base parameters 
could theoretically result from cardiovascular and/or respiratory compromise and muscle dysfunction 
or destruction (Corley and Marr 1998). Rhabdomyolysis is also known to liberate myoglobine, with 
the potential to induce nephropathy (Polderman, 2004). The current studies demonstrated that BUN 
was frequently increased on admission and some cases suffered from clinical renal dysfunction. These 
findings and the consistent presence of renal casts on histology (Cassart, Baise et al. 2007) highlight 
the need for renal monitoring in AM. However, increased BUN might also be a consequence of 
dehydration (prerenal dysfunction), protein catabolism for gluconeogenesis or deamination of 
adenosine monoposphate (AMP; purine catabolism). Indeed, the current study shows that PCV was 
frequently increased (hemoconcentration) and that it was positively correlated to BUN. The possibility 
of protein catabolism is supported by the finding that a reduced amount of muscle protein was found 
in two AM patients; increased uric acid excretion in urine suggests that deamination of AMP occurs 
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(Westermann et al., 2011). It is however unclear if these two mechanisms of BUN production would 
lead to significant rises in serum BUN levels. 
Also, during the current research project an association was postulated between AM and 
Clostridium sordellii‟s lethal toxin, based on the positive immunohistochemical reaction of muscle 
samples from three horses with AM to sera from other affected horses and to lethal toxin-specific 
antibodies (Unger-Torroledo et al., 2010). This toxin is known to interfere with mitochondrial 
haemostasis (Petit et al., 2003). However, the study of Unger-Torroledo et al. was performed on a 
very limited number of horses, and necrotised muscle fibres tend to react aspecifically to various 
antibodies (personal communication, Dr Richard Piercy, RCV, London, UK). In addition, Clostridium 
sordellli is known as a normal habitant of animal and human gastro-intestinal tract (Rorbye et al., 
2000) and as a cadaver contaminant (Voth et al., 2006). Therefore the results of this study need to be 
interpreted very carefully and further research is needed before it can be concluded that this clostridial 
toxin is the cause of AM. 
 
GENERAL DISCUSSION, CONCLUSIONS AND PERSPECTIVES RESULTING FROM AN 
IMPROVED EPIDEMIOLOGICAL KNOWLEDGE 
The current epidemiological studies included data from a large number of European cases, including 
survivors. In summary, these studies have confirmed the key features of the history and the clinical 
syndrome and have recognized new features. Moreover, the list of risk factors for AM has been 
refined, clinical signs valuable for differential diagnosis have been identified, and prognostic factors 
have been determined in the face of an overall survival rate of 26%. Also, differences concerning 
affected population, management and pastures were demonstrated between countries. These 
geographic differences might simply reflect different populations and habits without being specific for 
AM, but they might directly or indirectly influence clinical severity or outcome by effects on 
immunity, contributing or predisposing factors and effects on pathogenicity of the causative agent. 
Moreover, these findings suggest that the affected populations and the conditions under which AM 
occurs are not everywhere the same and that local findings should thus be interpreted with caution. 
Case-control studies might be an interesting tool to show the true impact of these differences. 
The epidemiological findings will be discussed in the following chapters together with the 
suggestion of guidelines for future prevention and case management.  
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DISCUSSION AND SUGGESTION OF GUIDELINES IN PREVENTION AND 
MANAGEMENT OF CASES SUFFERING FROM ATYPICAL MYOPATHY 
The results of this research project, both epidemiological and pathophysiological data, have allowed a 
significant improvement of prevention of AM and case management of affected horses. 
Prevention 
Since supportive therapy is often unsuccessful, prevention of this severe condition is of major 
importance (Votion and Serteyn, 2008; Harris, 2009). Preventive measures are based on descriptive 
data, but also on risk and protective factors. Descriptive data about AM are largely available in 
scientific literature from case reports or descriptions of outbreaks and from aetiopathogenic research. 
Risk and protective factors were determined by statistical analysis of data of affected horses compared 
to those of a control group. The determination of risk and protective factors, however, is a statistical 
risk analysis, which means that the risk for a horse to develop AM increases, but is not certain, when 
risk factors are present or protective factors are absent, and that the risk decreases, but is not zero, 
when protective factors are present or risk factors are absent. Therefore AM still can occur in absence 
of risk factors or in the presence of protective factors. 
A first risk analysis was performed on 57 Belgian non-surviving cases from 2000-2005. They 
were compared to clinically healthy co-grazers and to healthy grazing control horses that were 
matched for the region where AM broke out (Votion et al., 2007b; Votion et al., 2009). The second 
study of the current research project was a second risk analysis performed on AM cases. Table XVIII 
summarizes the risk and protective factors drawn from both studies. 
The following preventive measures are based on the above mentioned risk analyses: 
A summary of preventive measures is given in Table XIX. Whenever possible, preventive measures 
should be applied to all horses, but if a choice should be made between horses due to limitations of 
infrastructure or management, horses at greater risk should be favoured. Young horses have been 
demonstrated to be at risk to develop AM. Young horses spend more time at pasture and are less 
frequently submitted to intensive training compared to older horses. Not being intensively trained 
seems to be a necessity for the development of AM. Moreover, a hypothetical protective immunity 
against the condition might not yet be optimally developed in young horses. Besides age, also body 
condition seems to influence the development of AM, which might be explained by the capability or 
incapability to compensate for the occurring energetic imbalance with the aid of body reserves. 
Training is considered a protective factor, and most affected horses were in no or only limited 
training at the time of diagnosis. Training influences muscle metabolism (MacLeay, 2004) and horses 
with intense training schedules often receive supplementary feedings and spend less time at pasture. 
Moreover, horses are only used intensively for training from a certain age. To reduce the risk for AM, 
 54 
 
Chapter 3 : General Discussion and Conclusions  
it can be advised to regularly exercise grazing horses and to favour non-exercised horses for other 
preventive measures. However, if the horse suffers already from subclinical disease it is probably 
contra-indicated to exercise the horse. 
Since it is thought that horses get in contact with the causative agent while being at pasture, 
preventive measures limiting pasturing are of major importance to prevent AM. During high risk 
seasons and/or during outbreaks it is advised to stable horses and avoid pasture. If stabling is however 
difficult or impossible or if stabling is considered no good practice for horse welfare, pasturing should 
be limited. Less than 6H a day or weather dependant pasturing are considered protective and are 
valuable alternatives. 
Even though is it unexpected that the causative agent directly originates from the drinking 
water, water might have an indirect influence on the development of AM. It has been shown that 
providing water from the distribution network and in a tank or a bath are protective factors. This might 
avoid that horses go to and drink from water courses and streams and that they spend time in humid 
zones. Humidity at pasture has been determined as a risk factor and might provide the causative agent 
with good conditions to exert its toxicity. 
Providing supplementary feeding and a salt block were determined as protective factors. They 
should be provided all year round, but especially during high risk periods. Due to supplementary 
feeding and a salt block horses are probably less prone to eat substances that they would normally not 
consume when sufficient nutrients are available, they might be more selective in grazing, and/or graze 
less. Moreover, it provides the horse with protective antioxidants, vitamins and minerals that might 
counteract on the metabolic imbalance and support muscle function. Supplementary feeding can 
consist of silage, straw, complete mix, corn or oats. However, one must be careful with giving hay in 
the autumn (Votion et al., 2009). Hay is often given from the ground and thus possibly stimulates 
contact with soil or grass and the causative agent 
Pastures with a history of previous dead horses, regardless the cause and year, were found to 
be a risk factor for AM and should be avoided whenever possible. In addition, pastures where AM has 
declared in the past remain a danger for horses grazing on it, as pastures have been described to 
declare AM in successive years (Votion et al., 2007b). Pastures that are lush during the winter season 
were found to be a risk factor for AM. These data should be interpreted with caution, because a 
discrepancy between observations by scientists and horse owners was noted. Owners often described 
their pastures as having lush grass, but regularly scientists found them to be bare (Votion et al., 2009). 
Sloping pastures, especially those with a steep slope, should be avoided. This can be a confounding 
effect with the geographic area where AM regularly occurs, but it might in one way or the other also 
play a role in creating an optimal microclimate for the causative agent. Horses grazing on sloping 
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pastures probably also use their postural muscles more intensively and this might add to the energetic 
imbalance of affected muscles. Pastures that contain dead leaves and dead wood form a risk and 
therefore it is suggested to remove and burn dead leaves and wood. Pastures surrounded by or 
containing trees were also determined to be a risk factor, and almost for all described cases in the 
studies of Votion (2009) and van Galen (2012a) trees were present at their pasture. Trees, dead leaves 
and dead wood might contain the causative agent, favour its development, and/or contribute to its 
toxicity or act in synergy with it. 
The following preventive measures are based on descriptive data on AM: 
A summary of preventive measures is given in Table XIX. Most of western European countries have 
had cases suffering from AM, but Belgium (especially the Walloon region), France (especially the 
north east regions) and Germany (especially the mid west regions) have had multiple large outbreaks 
as demonstrated by the current and previous (Brandt et al., 1997; Delguste et al., 2002; Puyalto-
Moussu et al., 2004; Votion et al., 2007b) studies. These countries or areas probably share a similar 
landscape, flora and management of pastures and horses that combine multiple risk factors during high 
risk periods. 
High risk seasons are defined as autumn and spring, but cases do not declare every year. 
Winter cases are mostly cases occurring during early winter just following autumn, or late winter just 
before spring. After an outbreak in autumn, some cases can be expected to occur in the following 
spring. 
Specific climatic conditions have been related to the occurrence of AM, such as a lack of solar 
radiation, strong wind, rain, thunderstorms and a cool temperature without heavy frost (Hosie et al., 
1986; Whitwell et al., 1988; Finno et al., 2006; Votion et al., 2007b). Development of new cases 
during an outbreak ceases after heavy frost and/or snow (Votion et al., 2007b; personal observation), 
which suggests that extreme cold may destroy or de-activate the causative agent. Nevertheless, the 
occurrence of AM remains unpredictable and one should not solely rely on weather forecasts to decide 
whether horses should be submitted to preventive measures for AM. 
Even though that some horses are more at risk than others as discussed above, all equids (all 
horse breeds, as well as donkeys and zebras, both sexes, all ages, and thin, normal and obese horses) 
can be affected by AM, so preventive measures should whenever possible be applied to all equids. 
Since AM severely affects the horse‟s lipid metabolism, it can be suggested as a preventive 
measure to fraction feedings and to favour a carbohydrate rich diet (concentrates, good quality of 
fibres) over a diet rich in fat in order to optimally support the energy and nutrient supply. Limiting 
pasturing has been defined as a protective factor, but above this AM has not been described in horses 
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spending less than 6 hours at pasture. This demonstrates that contact time with the pasture is of major 
importance to develop the disease. Moreover, while previously horses were described to become ill 
after being stabled 1 day (Votion et al., 2007b), the latency period can now be estimated at 4-5 days. 
Often AM declares often on natural and untreated pastures (Votion et al., 2009). A general 
aspecific treatment of pastures can therefore be suggested. Ploughing, sowing, mowing and fertilizing 
for example influence the soil and plant cover and might interfere with the causative agent and/or 
predisposing factors. 
Although the presence of trees was a risk factor for the development of AM, tree species have 
not been evaluated by statistical risk analysis in the current studies. Nevertheless, one tree in particular 
has been mentioned repeatedly in relation to AM: Acer pseudoplatanus, better known as the maple 
tree (Votion et al., 2007b; van der Kolk et al., 2010). It is unknown for the time being if this common 
European tree or its fungus Rhytisma acerinum (tar spot) plays a role in the pathogenesis of AM. It is 
strongly advised to avoid using pastures surrounded by or containing trees during risk seasons, and 
this measure counts especially for the maple tree. Nevertheless, cutting down trees can for the moment 
not be supported by scientific data and should be discouraged. It is considered sufficient to remove 
and burn organic waste originating from trees. 
 
Diagnosis 
Diagnosis of AM is not straight forward, but has been facilitated by the current studies. 
A diagnosis of AM should always be based on the combination of history, clinical signs, and 
laboratory findings and histological examination (Hosie et al., 1986; Whitwell et al., 1988; Brandt et 
al., 1997; Delguste et al., 2002; Votion et al., 2007b). Taking this principle into account, a decisional 
algorithm was developed for the present studies in order to categorize cases that were reported to the 
AMAG as having AM or not (Figure 5). This algorithm can be of diagnostic help to clinicians as well. 
However, eventhough that history, clinical signs, laboratory findings and histological examination can 
be highly indicative, they are not pathognomic for AM. Therefore this algorithm should in the future 
probably best be used as a first screening of suspected cases. It would be interesting to test this 
algorithm against more definitive diagnostic means that are available now (see later). 
The descriptive parts of these studies are highly valuable with respect to recognizing the 
typical features of AM. They confirmed the previously described typical history (the sudden onset of 
clinical signs consistent with an acute, not exercise-related myopathic process in horses at pasture) 
and the typical clinical features and have identified further details. Clinical signs with an incidence 
exceeding 50% were similar as in previous studies (Puyalto-Moussu et al., 2004; Votion et al., 
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2007b): depression, weakness, stiffness, recumbence, trembling, sweating, pigmenturia, congested 
mucous membranes, tachycardia, and normothermia. Serum CK activities are high, but as they may 
only be slightly increased when measured shortly after the onset of clinical signs, repeated analysis 
can be recommended. Acid-base imbalances (mainly lactic acidosis, mSID alkalosis, and respiratory 
disturbances) and increased PCV and BUN are common. Unfortunately, data collection on blood 
calcium, glucose and triglyceride levels was insufficient, but hypocalcemia, hyperglycaemia and 
hyperlipaemia have been previously reported (Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 
1997; Delguste et al., 2002; Votion et al., 2007b; Westermann et al., 2008b). 
The risk analysis (Study 2) identified variables concerning history and clinical signs that were 
significantly different between AM affected horses than in the non-AM control group and are 
therefore helpful for diagnosis. The variables concerning history that were significantly more often 
encountered in AM cases compared with non-AM cases were as follows: the presence of trees, dead 
wood and accumulations of dead leaves at pasture, a sloping pasture, normal body condition and  
full-time grazing. Variables that were more often present in non-AM cases compared with AM cases 
were: poor body condition, water provision from a tank or bath tub, food supplementation, and 
spending no time or limited time at pasture. Clinical signs that occurred more often in AM cases were: 
pigmenturia, normothermia, congested mucous membranes and high serum CK values. These clinical 
signs may be useful to strengthen a clinical suspicion of AM, but other conditions may also lead to 
these signs, whereas not all AM affected horses show them. Horses with cyanotic mucous membranes 
or sudden death without observation of previous clinical signs, were more often categorized in the 
non-AM group. Other disorders, such as acute colic, remain probably a more frequent cause of sudden 
death and cyanosis. Although being found dead on pasture without prodromal signs is often associated 
to AM, this clinical presentation was only reported in 3/57 (Votion et al., 2007b) and 2/327 horses 
diagnosed with AM in the current study, and it should therefore probably not be categorized as being a 
typical feature of AM. 
Also sensitivity, specificity, positive, PPV and NPV of common clinical signs were calculated 
related to diagnosis. Pigmenturia had a high sensitivity and PPV in this study, which means that the 
proportion of AM cases with pigmenturia on all AM cases was high (only few AM cases had no 
pigmenturia) and that the proportion of AM cases with pigmenturia on all horses with pigmenturia in 
the study was high (only few cases with pigmenturia had another disease than AM). Normothermia 
and congested mucous membranes had a high PPV for diagnosis of AM, meaning that the proportion 
of AM cases with these signs on all horses with these signs in the study was high. However in relation 
to these results it should be mentioned that PPV and NPV are related to the prevalence of the condition 
in the studied population, which is not the case for sensitivity and specificity (Morley et al., 2007). 
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Since history, clinical exam, blood and urine analysis and muscle biopsy and histology are not 
pathognomic for AM, in the future more definitive diagnostic means should be used such as analysis 
of acylcarnitines, organic acids and glycine conjugates in urine or blood to identify the “MADD” -like 
defect (Westermann, Dorland et al. 2008) and/or muscle immunohistochemistry to identify important 
lipid accumulations in mainly type I myofibres (Cassart, Baise et al. 2007). Table XX gives examples 
of laboratories that perform immunohistochemistry on equine muscle samples on a regular basis. 
Table XXI shows the reference range for acylcarnitines in urine or blood in healthy horses, and 
indicates those acylcarnitines (short- and medium-chain acylcarnitines) that were reported to be 
significantly increased in the case of AM (Westermann et al., 2008b). However, as mentioned above, 
the lipid analysis in muscle samples (Study 4) demonstrates that also long-chain FFA are implicated in 
the condition, and ongoing studies are currently investigating their role, especially with regards to their 
impact on acylcarnitine or FFA profiling in blood and urine. It is important for diagnostic and 
pathophysiologic means that we can specify if only short- and medium-chain acylcarnitines are 
increased or long-chain acylcarnitines as well. Moreover, the diagnostic method of acylcarnitine 
profiling in blood and/or urine needs further validation, especially since increases in acylcarnitines can 
be encountered in myopathies other than AM (Westermann et al., 2007; Westermann et al., 2008b). 
Based on the results of the lipid analysis of Study 4, it was also suggested that FFA analysis on muscle 
samples could be a promising additional diagnostic tool demonstrating characteristic increases in a 
wide range of FFA, especially for cases without urine or blood samples available (for example due to a 
rapid death) or with inconclusive results of urine or plasmatic acylcarnitines profiles. 
For a complete description on diagnosing AM, the reader is referred to the review article in 
Chapter 4: 
“Review of atypical myopathy with emphasis on prevention and management based on the current 
scientific knowledge.” 
 
Prognosis 
Advances on prognostic evaluation of patients have been made. For the first time, a significant group 
of survivors of AM was described. The overall survival rate during the study period (26%) was higher 
than previously thought (Brandt et al., 1997; Puyalto-Moussu et al., 2004; Votion et al., 2004). Most 
non-survivors died or were euthanized within 3 days of onset of clinical signs, however some 
remained alive up to 10 days. Survival was associated with defecation, remaining standing most of the 
time, normal mucous membranes and normothermia. Poor prognosis was associated with recumbence, 
sweating, anorexia, dyspnoea, tachypnea and/or tachycardia, a high PCV, low [Cl
-
], high BEcl, low 
PaO2 (Votion et al., 2007b) and respiratory acidosis. If the horse has none or only few of these poor 
prognostic parameters or if the horse corrects these abnormalities following treatment, continued 
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treatment is probably justified. Moreover, an optimal tree with BEcl, BUN and heart rate can help to 
identify survivors. Eventhough serum CK activity can be highly interesting to monitor ongoing muscle 
damage, serum CK activity was found not to be higher in more severe cases. This probably reflects 
laboratory limits and/or the kinetics of serum CK and may depend on the time of sampling. It is likely 
that both the peak and the duration of CK release in serum are important to signify muscle 
compromise and the clinical importance of muscle compromise depends on the affected muscle. 
Moreover, other problems besides massive muscle destruction might contribute to death in AM cases. 
Eventhough we have been able to identify certain clinical signs and blood parameters on 
admission or at first clinical examination as being prognostic indicators, it still remains difficult to 
recognise those horses that might survive a clinical episode of AM. Therefore it would be most helpful 
if other more objective prognostic measures could be identified or developed in the future. Since 
energy metabolism plays such a crucial role in AM (Westermann et al., 2008b; Westermann et al., 
2011), our hypothesis is that blood parameters reflecting the patient‟s energetic state such as blood 
glucose or triglyceride levels have a prognostic value. Also the severity of mitochondrial dysfunction 
and/or acylcarnitine profile abnormalities might have an impact on prognosis and therefore 
acylcarnitine profiles or high resolution respirometry should be investigated as potential monitoring 
tools of patients. 
 
Treatment 
Based on the current studies, the following therapeutic options can be suggested: 
In order to limit energetic demands and respiratory alkalosis, physical effort and stress should be 
avoided. Individually adapted fluid therapy is recommended in order to restore circulating volume, 
promote myoglobin excretion, and correct acid-base and electrolyte imbalances. Digestive, respiratory, 
cardiac, and urinary function warrant close monitoring and support. The pathophysiological data of the 
current studies, demonstrating lactic acidosis, respiratory alkalosis and accumulation of FFA, suggests 
that support of aerobic mitochondrial metabolism and favouring carbohydrate metabolism over lipid 
metabolism is reasonable. This can be done by restoring circulatory volume, providing a fractioned 
carbohydrate-rich diet, glucose, vitamins, antioxidants and carnitine. Moreover, these suggestions are 
also supported by the studies of Westermann et al. (2008b; 2011). Also the authors of the USA case 
series (Finno et al., 2006; Finno and Spier, 2008) suggested anti-oxidant therapy (vitamin C, vitamin E 
and selenium). Vitamins, antioxidants and carnitine were the only therapeutic group that appeared to 
be beneficial for outcome. This highlights the importance of these compounds, but it does not mean 
that other therapies are not useful.  
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All above mentioned treatments are only based on suggestions, and no or only limited direct 
scientific proof of true efficacy of these treatments, drugs or supplements is available and therefore 
further investigated is necessary. 
For other suggestions on monitoring and treatment of AM patients, the reader is referred to the 
review articles in Chapter 4: 
“Management of cases suffering from atypical myopathy based on interpretation of the current 
descriptive, epidemiological and pathophysiological knowledge. Part 1: First aid, cardiovascular, 
nutritional and digestive care.” 
“Management of cases suffering from atypical myopathy based on interpretation of the current 
descriptive, epidemiological and pathophysiological knowledge. Part 2: Muscular, urinary, 
respiratory and hepatic care and inflammatory/infectious status.” 
 
Management of co-grazers 
When AM declares on a pasture, it is strongly advised to check the seemingly healthy co-grazers of 
the affected horse. These co-grazers most likely have also been in contact with the causative agent and 
are often submitted to the same predisposing and/or contributing factors as their sick friend. They are 
thus at risk to develop the disease in the following hours or days, or suffer already from subclinical 
disease (Delguste et al., 2002; Votion et al., 2007b). Therefore they merit special attention. 
Without creating stress for these co-grazers, the same preventive measures as discussed before 
should be applied to them, even if this might sound like “last minute” prevention. More specifically, 
co-grazers should be removed from the pasture; ideally they should be stabled full time, at least during 
the risk period. Stress, such as transport, anaesthesia or exercise, probably should be avoided as much 
as possible to limit muscular energetic deficits that might favour the onset of clinical disease. Without 
excess, supplementary food, by preference carbohydrate rich food, such as concentrates, might be 
considered. 
It is prudent to place these co-grazers under close clinical surveillance and to measure serum 
CK activity regularly, since they can develop clinical AM in the following hours and days with up to  
4 days after being stabled. As soon as serum CK activity is increased or if clinical signs are noted, the 
horse should receive supportive treatment to limit any further muscle damage. Vitamin B, C and E, 
selenium and carnitine can already be administered as preventive therapy to support muscle 
mitochondrial metabolism, moreover since this was the only therapeutic category that had a positive 
effect on outcome in clinical AM cases.  
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GENERAL CONCLUSION AND FUTURE RESEARCH PROJECTS 
The development of AM is probably multi factorial with several endogenous and exogenous factors 
leading to biochemical defects amongst which MADD and decreased activity of OXPHOS complexes. 
On one side, certain factors cause and aggravate biochemical defects: the yet unknown aetiological 
agent, risk factors, triggering factors (stress, nutritional deficiencies), and possible complications 
(renal dysfunction, cardio-respiratory compromise, insulin resistance, hyperlipaemia and acid-base and 
electrolyte disturbances). On the other side, other factors may avoid or limit the development or reduce 
the impact of these biochemical defects: physiological compensatory mechanisms, protective factors, 
treatment and possible development of immunity. Contact time (> 6H/day), dosage and pathogenicity 
of the aetiological agent might influence development and severity of disease. 
The current research project has achieved its initially set goals and has allowed improving 
overall management and knowledge of AM. However, still a lot is unknown about this highly fatal 
syndrome of acute rhabdomyolysis and further research is indispensable. For future research,  
case-control studies would be interesting to further identify the value of the geographically related 
differences and descriptive findings. The mitochondrial respiration should be further examined on 
affected muscle cells with functional mitochondria, and it needs to be investigated if energetic 
problems have a prognostic implication. Also, more information is needed on diagnostic tools, 
especially in FFA and/or acylcarnitine profiling in urine, blood and muscle samples. Of course further 
investigations on the causative agent of AM and its mechanisms of inducing disease are indispensable. 
The future goal is to further improve prevention, to facilitate diagnosis and to develop effective 
treatment in case of disease. 
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Tables and annexes 
Table XVIII. Risk and protective factors for the development of atypical myopathy according to the 
studies of Votion et al. (2009) and van Galen et al. (2012a). 
Parameters Risk factors Protective factors 
Demographic data 
Age  Young horses (< 3 years)  
Sex*  Colts 
 Stallions 
 Geldings 
Body condition  Thin 
 Normal weight 
 Thin 
 Overweight 
Management practices at the horse level 
Deworming   Frequent deworming 
Vaccination   Regular vaccination 
Occupation   Training 
Pasturing  Full time pasturing (all year round)  Not at pasture 
 <6H per day at pasture 
 Weather dependant pasturing in spring 
and in autumn 
Food and water 
 Supplementary feeds  Hay in autumn  Supplementary feeds in autumn (except 
hay), in particular silage and complete 
mix 
 Supplementary feeds in winter, in 
particular straw, silage, complete mix 
and corn 
 Supplementary feeds in spring 
 Supplementary feeds in summer 
 Salt block (all year round) 
 Water supply   Distribution network 
 In tank or bath tub 
Pasture characteristics 
 History  Dead horses on the pasture in the past  
 Grass land  Lush pasture in winter  
 Incline  Sloping pasture 
 Steep slope 
 Gentle slope 
 Trees  Surrounded by or containing trees 
 Presence of dead leaves 
 Presence of dead wood 
 
 Humidity  Humid pasture 
 Pasture surrounded by or containing a 
stream/river 
 
 
Management of the pastures 
  Spreading of manure  
(*) Age was identified as a confounding variable regarding the risk factors associated with the 
animal‟s sex. Sex is linked to age, as “gelding” is a status that follows castration, a procedure usually 
performed in males >18 months old (i.e. the most risky age for AM). Because females are more 
frequently kept at pasture than males, a higher percentage of AM cases are females.  
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Table XIX. Summary of preventive measures for the development of atypical myopathy. 
 
WHERE? 
All over Europe, but especially in Belgium, France and Germany 
WHEN? 
High risk seasons (mainly autumn and spring) 
Spring after an autumnal outbreak 
During outbreaks 
DURING WHICH WEATHER CONDITIONS? 
Lack of solar radiation 
Strong wind 
Rain and thunderstorms 
Cool temperature without heavy frost 
FOR HOW LONG? 
Until important frost or snow covering the pasture 
FOR ALL GRAZING EQUIDS, but horses particularly at risk are: 
Young horses 
Horses with normal body condition 
Untrained horses 
HORSE MANAGEMENT 
Regular deworming and vaccination 
Provide supplementary feeding 
Do not feed hay from the ground 
Provide water from the distribution network and in a tank or a bath 
Regular exercise 
Stable horses or limit pasturing during the risky seasons(< 6H a day or weather dependant pasturing) 
Provide a salt block 
PASTURE MANAGEMENT 
Avoid spreading of manure on the pasture; prefer manual removal of faeces 
Avoid pastures where previous deaths have occurred 
Dead leaves and wood should be removed from the pasture and be burned 
Ensure rotation of pastures and avoid (during the risky seasons) (1) sloping pastures, especially those 
with a steep slope, (2) bare pastures, (3) humid pastures or pastures surrounded by or containing a 
stream or river, (4) pastures surrounded by or containing trees, especially the tree species Acer 
pseudoplatanus 
Provide general aspecific pasture treatment such as ploughing, sowing, mowing, fertilizing 
 
  
 
Chapter 3 : General Discussion and Conclusions  
Table XX. Examples of laboratories that perform immunohistochemistry on equine muscle samples on 
a regular basis. 
Laboratory University Responsible 
person 
Address Telephone number Email Website 
Veterinary 
Neuromuscular 
Diagnostic 
Laboratory  
 
Minnesota Stephanie Valberg 
Jim Mickelson 
Molly McCue 
1333 Gortner Avenue 
St. Paul 
MN 55108-1098 
USA 
ph: (612) 625-8787 
toll free: (800) 605-8787 
fax: (612) 624-8707 
nmdl@umn.edu http://www.cvm.umn.edu/
umec/lab/home.html 
Neuromuscular 
Disease 
Laboratory 
Edinburgh Caroline Hahn Easter Bush, 
Midlothian 
EH25 9RG 
UK 
 
+44 (0) 131 650 6403 
Fax: +44 (0) 131 445 5770 
vetneurolab@ed.ac.uk http://neurolab.vet.ed.ac.uk
/Default.htm 
Comparative 
Neuromuscular 
Diseases 
Laboratory 
RVC, London Richard Piercy Hawkhead Lane 
North Mymms 
Hatfield, Herts 
AL9 7TA 
UK 
+44 (0) 1707 666848 neuromuscular@rvc.ac.
uk 
http://www.rvc.ac.uk/Neur
oLab/Index.cfm 
 
Packing and Shipping the muscle sample:·Enclose a completed submission form (available on the 
websites) for each animal.·Do not squeeze, squish, or otherwise disturb the muscle sample, as that can 
damage cells. 
Fresh muscle should be wrapped in dry gauze, sealed in plastic container for protection, and 
shipped on ice packs in an insulated container. The samples should be processed in the laboratory 
within 24H (Stanly et al., 2009).·If circumstances are such that a biopsy cannot be submitted that day 
(e.g. death of animal on a weekend), samples can be placed in a freezer and submitted on Monday on 
ice packs. This is not ideal and should be avoided if at all possible. 
Formalin fixed samples - If samples larger than TruCuts are submitted, they should sit in the 
air for five minutes before they are placed in formalin to prevent contraction bands from forming. 
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Table XXI. Reference range for acylcarnitines based on measurements of 12 healthy horses as 
determined by Westermann et al. (2008b). 
 Urine  Plasma  
 Substantial 
elevation above 
cut-off value in 
AM 
Upper limit of 
reference range, P95 
Substantial elevation 
above cut-off value in 
AM 
Upper limit of 
reference range, P95  
  (mmol/mol 
creatinine) 
 (µmol/L) 
Free carnitine Y 12.5 P 44 
C2-carnitine Y 1 Y 5.6 
C3-carnitine Y 0.1 P 0.95 
C4-carnitine Y 1 Y 0.7 
C5:1-carnitine  0.01  0.02 
C5-carnitine Y 0.1 Y 0.5 
C4:3-carnitine  0  0.03 
C6-carnitine Y 0.02 Y 0.02 
C5-OH-carnitine  0.1  0.04 
C8:1-carnitine Y 0.01 Y 0.02 
C8-carnitine Y 0.03 P 0.02 
C10:2-carnitine Y 0.02 Y 0.02 
C10:1-carnitine Y 0.01 Y 0.02 
C10-carnitine  0.02  0.03 
C4DC-carnitine  0.4  0.05 
C5DC-carnitine  0.5  0.06 
C12:1-carnitine  0.01  0.02 
C12-carnitine  0.04  0.02 
C6DC-carnitine  0.1  0.02 
C14:2-carnitine  0  0.02 
C14:1-carnitine  0.01  0.03 
C14-carnitine  0.03  0.02 
C8DC-carnitine  0.05  0.02 
C14:OH-carnitine  0.01  0.01 
C16:1-carnitine  0  0.02 
C16-carnitine  0.02  0.02 
C10DC-carnitine  0.02  0.01 
C16:1-OH-carnitine  0  0.01 
C16-OH-carnitine  0.01  0.01 
C18:2-carnitine  0  0.01 
C18:1-carnitine  0  0.02 
C18-carnitine  0  0.01 
C18:2-OH-carnitine  0  0.01 
C18:1-OH-carnitine  0  0.01 
C16DC-carnitine  0  0.01 
C18:1DC-carnitine  0  0.01 
Legend: Y = yes, increased in all the studied cases; P = increased in part of the studied cases. 
Note: horses with myopathies of another origin than AM have been demonstrated to have elevated 
blood free carnitine, C2-, C3-, and C4-carnitine (Westermann et al., 2008b) or even a “MADD”- like 
acylcarnitine profile as in AM (Westermann et al., 2007). 
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CHAPTER 4: PUBLICATIONS 
ORIGINAL ARTICLES 
EUROPEAN OUTBREAK OF ATYPICAL MYOPATHY IN THE FALL 2009 
 
VAN GALEN G., AMORY H., BUSSCHERS E., CASSART D., DE BRUIJN M., GERBER V.,  
KEEN J., LEFERE L., MARCILLAUD PITEL C., MARR C., MULLER J.-M.V., PINEAU X.,  
SAEGERMAN C., SANDERSEN C., SERTEYN D., TORFS S., UNGER L., VERWILGHEN D.,  
VOTION D.-M. 
J. Vet. Emerg. Crit. Care, 2010, 20, 528-532. 
 
 
Abstract 
Background: Atypical myopathy (AM) is an acute, severe rhabdomyolysis occurring in grazing 
horses. In the beginning of October 2009, a new outbreak started in several European countries. 
Geographic, demographic and clinical data of the reported cases in the month October 2009 are 
described. 
Key Findings: The survival rate over the month October 2009 was 25%. The most frequently 
observed clinical signs were congested mucous membranes, dyspnea, tachycardia, depression, 
weakness, stiffness, recumbency, trembling, sweating, and myoglobinuria. Non-survivors were 
significantly more likely to be recumbent than survivors. Prognostic factors, symptomatic treatment 
and preventive measures are discussed. 
Significance: Differences were encountered during the described outbreak of AM in October 2009 
compared to previous studies. Equine practitioners should be aware that previous epidemiological 
studies have shown that after a high prevalence this autumn, new cases are likely to occur in the spring 
2010. 
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Introduction 
Atypical myopathy (AM) is an acute, highly fatal myopathy in grazing horses that has been reported 
sporadically throughout the 20
th
 century (Hosie et al., 1986). Since 2000, outbreaks have been 
described in Europe (Puyalto-Moussu et al., 2004; Votion et al., 2007b; van Galen, 2008). The disease 
does not appear to be contagious, but certain environmental factors and weather conditions are 
believed to increase the prevalence of AM (Votion et al., 2007b). The etiology remains unclear, 
however, there may be an association between the disease and Clostridium spp (Gerber et al., 2006). 
In 2000, the University of Liege established an informal European epidemio-surveillance network: the 
atypical myopathy alert group (AMAG). This network consists of European equine veterinarians, 
national epidemiological networks and Universities, and whose purpose is to exchange information 
about the occurrence of outbreaks of this disease. During the autumn of 2009, an increased frequency 
of clinical reports suggested that a large outbreak of AM occurred in Europe. 
The objectives of this brief communication are 1) to describe the clinical manifestations of 
AM during October 2009, 2) to alert the equine community of possible new cases in the upcoming 
spring and 3) to review prognostic factors and therapeutic and preventive measures based on the 
current knowledge of the condition. 
 
Methods 
Collection of data 
AMAG members and Diplomates of the European College of Equine Internal Medicine were 
contacted by email within a week of the suspected outbreak to request their cooperation in data 
collection. Geographic and demographic data, details pertaining to medical management of the horses, 
and clinical data were obtained from medical records, and via interviews with veterinarians and 
owners. Data was collected via mail, telephone interviews or via a standardized questionnaire 
available on the AMAG website 
a
. 
Selection of cases 
All cases reported during October 2009 were included in the study and allocated to 5 categories: 
confirmed cases (C), cases with a high probability (HP) of being affected, cases with a low probability 
(LP) of being affected, or doubtful (D) cases in which it was not possible to determine whether they 
had AM. 
HP cases had to fulfill the following criteria to be included into the study: being out at pasture 
at the onset of clinical signs or at least within 3 days preceding clinical signs (van Galen, 2008), and 
have overt signs of acute myopathy (i.e., increased serum activity of creatine kinase (CK) or presence 
of myoglobinuria; Votion et al., 2007b). Cases showing clinical signs and grazing at the same pasture 
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as a HP or C case and occurring in the same period were also considered to belong to the HP group 
without further clinicopathological evidence of AM. C cases had to meet the criteria for the HP group 
and also have evidence of a multifocal process compatible with Zenker degeneration and necrosis in 
fibers of postural or respiratory muscles on histology of post mortem samples or muscle biopsies 
(Cassart et al., 2007). Cases were defined as OD cases when post mortem or histology of muscle 
biopsy samples did not confirm AM. Cases were allocated to the LP group when clinical signs typical 
for conditions other than AM where present or when cases did not fulfill the HP criteria. Cases were 
defined as doubtful (D) when there were insufficient clinical data or histological findings submitted to 
either confirm or exclude AM as a diagnosis. Only the data from the C and HP cases (the C/HP group) 
were included in this report. Survival was defined as the horse being alive at the latest report before or 
on 1
st
 December 2009. 
Statistical analysis 
Demographic and clinical data from survivors and non-survivors were compared using unpaired 
Student‟s t-tests for continuous data and Fisher‟s exact tests for categorical data. Significance was 
defined at P < 0.05. 
 
Results 
During the month October 2009, 120 potential cases were reported to the AMAG. Distribution of 
cases and geographic location are listed in Table 1. The final diagnoses encountered in the LP and  
OD group were undetermined in 4 cases; colic in 2 cases and an interstitial pneumonia combined with 
hepatitis and nephritis in 1 case. There were 71 cases in the HP/C group and these were evaluated 
further. 
Demographic data are shown in Table 2. Three mares were pregnant. All horses were grazing 
when clinical signs developed, except for 3 that had been stabled for 1 day before showing clinical 
signs. None of the affected horses were known to be exercised more than once or twice a week, except 
for a recently broken horse which was being trained several days a week. The course of disease is 
described in Table 3. 
The most frequently observed clinical signs included congested mucous membranes, dyspnea, 
tachycardia, depression, weakness (often demonstrated by low head carriage), stiffness, recumbency, 
trembling, sweating, and myoglobinuria (Table 4). Several cases were dysphagic, with or without 
signs of esophageal obstruction. Appetite varied from ravenous to to absent. Some C/HP horses were 
hypothermic, but both normothermia and hyperthermia were also observed. A distended bladder was 
often palpated on trans-rectal examination. Some affected horses showed signs of delayed intestinal 
transit (e.g., dry fecal matter, impaction in the large intestine) or slight diarrhea. All horses had 
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increased serum activity of CK demonstrating significant muscle damage. In some cases, initial serum 
CK activities were only slightly increased, but these concentrations usually increased severely in the 
following hours and days. 
A variety of treatments were instituted, consisting mostly of intravenous or oral fluids,  
anti-inflammatory drugs (steroidal and non-steroidal), vitamins and antimicrobials. Eighteen horses 
(25%) survived the condition. Non-survivors were significantly more likely to be recumbent compared 
to survivors. No other statistical differences were noted in clinical data between survivors and  
non-survivors. 
 
Discussion 
The described outbreak in the current study was less severe than outbreaks reported in recent years. In 
this outbreak sudden death, weakness, recumbency, colic signs and dyspnoeawere still observed 
although less frequently and with a greater number of survivors (25% versus 15%; Votion et al., 2009, 
and 3%; Brandt et al., 1997). The survival time for their non-surviving group was also longer when 
compared with the present study (5 versus 3 days; Votion et al., 2007b). This is the first report to note 
slight diarrhea in some horses and that AM was confirmed in aged horses. Less severe European 
outbreaks with a survival rate of 28% were documented during the 2006-2008 period  
(van Galen, 2008).
 
Survivors of the outbreak of 2006 went on to make full recoveries and did not seem 
to suffer from any long-term sequelae (van Galen, 2008). It is important that equine practitioners 
recognize that although fatalities are common, horses can recover from AM and if they do, long term 
prognosis is good. 
Prognostic factors 
Previously reported favorable prognostic factors included normal mucous membranes, remaining 
standing most of the time and normal respiration patterns with adequate PaO2 concentrations (Votion 
et al., 2007b; van Galen, 2008). Non survivors are more likely to be recumbent than survivors 
although some recumbent horses did survive. Most non-survivors died during the first 2 days of the 
disease, and horses that survived for 5 days had a good chance for recovery. Taken together, these 
findings suggest that continuing with treatment in horses with AM in order to maintain normal mucous 
membranes, normal respiration with a normal PaO2 concentration may be worthwhile. Not being 
recumbent, or being able to rapidly correct abnormalities during treatment are also positive prognostic 
factors. Nevertheless, some horses can be extremely painful and euthanasia is recommended 
irrespective of their current metabolic status. It is important to note that serum activity of CK does not 
appear to be a useful prognostic factor (Votion et al., 2007b; van Galen, 2008). This may be because 
the reported CK activity does not reflect its peak activity and because data had been collected by 
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numerous laboratories and in some settings, the value exceeded the upper limits of detection of the 
equipment. 
Treatment 
Both survivors and non-survivors were treated intensively with a range of different treatments, but no 
specific measure appears to influence outcome (Hosie et al., 1986; Brandt et al., 1997; van Galen, 
2008). As the cause of AM remains unknown, treatment is mostly symptomatic. 
Treatments options currently considered to reflect best practice include provision of general 
supportive care with fluid therapy to correct dehydration and acid-base or electrolyte derangements, 
anti-inflammatory drugs, vitamins and antioxidants (e.g., vitamin E, selenium, carnitine) to stimulate 
muscular regeneration, myorelaxants (for example acepromazine, diazepam, midazolam or 
methocarbamol), avoiding muscular efforts and placing the horse in a well bedded stall. 
Recent research implicates a severe problem in lipid metabolism of muscular mitochondria, 
but with appropriate carbohydrate metabolism (Cassart et al., 2007; Palencia and Rivero, 2007; van 
Galen, 2008; Westermann et al., 2008b). In addition, the biochemical defect has been recently 
described as multiple acetyl-CoA dehydrogenase deficiency (Westermann et al., 2008b). Hyperlipemia 
is often encountered in such cases as well (Votion et al., 2007b). Based on these findings it might be 
beneficial to provide carbohydrates (e.g., grass, hay, grains, molasses, sugar water, carrots) ideally in 
frequent small quantities, and to add glucose and insulin therapy as necessary. Supplementation with 
carnitine, vitamin B1 and B2 is thought to support mitochondrial metabolism. Miscellaneous therapies 
based on previous clinical reports include bladder catherization to relieve abdominal discomfort, and 
intra-nasal oxygen insufflation to correct hypoxemia (Votion et al., 2007b). 
Possible therapeutic options but without clear evidence to support them yet include:  
1) dimethyl sulfoxide as a free-radical scavenger, 2) paraffin or active charcoal per os and 
metronidazole or penicillin to eliminate a possible clostridial infection, and 3) metformin in the case of 
possible insulin resistance. 
Preventive measures 
Data from epidemiological studies show that outbreaks in autumn are often followed by smaller 
outbreaks in the following spring (Votion et al., 2007b; van Galen, 2008), thus highlighting the 
importance for preventive measures for the upcoming spring. Preventive measures based on 
previously recognized risk and preventive factors include (Votion et al., 2009): nutritional 
supplementation, providing water supply from distribution network, regular vaccination and 
deworming, avoiding spreading of manure over pasture and stabling during predisposing climatic 
conditions (autumn and spring). Young (Votion et al., 2009) and aged horses, particularly those not in 
training are at the highest risk group (Votion et al., 2009), and should be given priority for stabling. 
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When cases arise, monitoring serum activities of CK in co-grazers of affected horses is highly 
recommended to detect subclinical or early muscle damage (Votion et al., 2007b). 
The current study has several limitations. The number of cases described in this report is likely 
to be an underestimation of the real number of cases in Europe as not all cases are reported to the 
AMAG and many cases died suddenly without a diagnosis being established (Hosie et al., 1986; 
Brandt et al., 1997; Delguste et al., 2002; Votion et al., 2007b). Numerous submitted questionnaires 
were incomplete leading to missing data. Larger case numbers are necessary to detect other statistical 
differences between survivors and non-survivors. 
In conclusion, some differences were encountered during the described outbreak of AM in 
October 2009 compared to previous studies; notably an improved survival rate is reported compared to 
earlier reports and recumbency appears to be a poor prognostic factor for survival. Clinicians should 
be aware that new cases or outbreaks can be expected to occur next spring, as has previously occurred 
following severe autumnal outbreaks, and to take preventive measures to minimize risks for AM. 
 
Footnotes 
a
 www.myopathieatypique.be 
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Tables 
Table 1. Classification and geographic distribution of the cases reported to the Atypical Myopathy 
Alert Group during the month October 2009. 
 
Legend: C = confirmed atypical myopathy (AM) cases; HP = cases with a high probability of having 
AM ; LP = cases with a low probability of having AM; OD = cases with another diagnosis;  
D = doubtful cases where not enough information is available neither to exclude nor to confirm AM. 
 
Table 2. Demographic data from horses confirmed or highly likely to have atypical myopathy reported 
during the month October 2009. 
 HP/C  S  NS 
 n N %  n N %  n N % 
Gender: 
Female 
 
28 
 
51 
 
55 
  
7 
 
13 
 
54 
  
21 
 
38 
 
55 
Male 23 51 45  6 13 46  17 38 45 
Stallion  6 42 14  1 10 10  5 32 16 
Gelding 
Breed: 
13 42 31  3 10 30  10 32 31 
Saddle horse 26 45 58  4 12 33  22 33 67 
Draft horse 3 45 7  1 12 8  2 33 6 
Pony 16 45 36  7 12 58  9 33 27 
Donkey 
Body condition: 
0 45 0  0 12 0  0 33 0 
Thin 3 44 7  0 10 0  3 34 9 
Normal 38 44 86  8 10 80  30 34 88 
Overweight 3 44 7  2 10 20  1 34 3 
Age(years, range; mean ± SD) 0.5 – 18 
4.3 ± 4.0 
N = 43 
 0.7 – 15  
4.9 ± 3.95 
N = 15 
 0.5 – 18 
4.1 ± 4.1 
N = 38 
Legend: HP/C = cases confirmed or highly likely to have atypical myopathy (AM); S = surviving 
cases of the HP/C group; NS = non-surviving cases of the HP/C group; Number of total (N) or positive 
(n) response for each category. 
*Denotes significant difference between survivors and non-survivors with p < 0.05.  
 Europe Belgium France Germany 
The 
Netherlands 
Swiss 
United 
Kingdom 
Total 120 33 7 35 9 29 7 
HP/C 71 20 6 14 8 16 7 
LP 4 3 0 0 1 0 0 
OD 3 2 0 0 0 1 0 
D 42 8 1 21 0 12 0 
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Table 3. Survival rate, and duration of the condition in horses confirmed or highly likely to have 
atypical myopathy reported during the month October 2009. 
Group Duration of disease 
in days 
(range) 
Duration of disease 
in days 
(Mean ± SD) 
Duration of disease 
in days 
(Median) 
Duration of disease in 
days 
(Confidence interval:  
lower 95% limit – upper 
95% limit) 
 
S 
n = 18 
(25%) 
 
4 – 18 
N = 7 
 
10.3 ± 5.4 
 
 
10.0 
 
5.3 – 15.3 
NS 
n = 53 
(75%) 
0.2 – 5 
N = 41 
1.6 ± 1.3 
 
1.0 1.2 – 1.9 
 
Legend: Surviving (S) and non-surviving (NS) cases confirmed or highly likely to have AM.  
Number of total (N) or positive (n) response for each category. 
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Table 4. Clinical signs and serum activities of creatine kinase from horses confirmed or highly likely 
to have atypical myopathy reported during the month October 2009. 
Clinical signs HP/C  S  NS 
 n N %  n N %  n N % 
Depressed mental status 29 42 69  7 11 64  22 31 71 
Weakness 34 42 81  7 11 64  27 31 87 
Stiffness 40 46 87  12 12 100  28 34 82 
Recumbency 44 55 80  8 14 57  36 41 88* 
Remaining standing most of the time 21 55 38  8 14 57  13 41 32 
Trembling 28 37 76  8 10 80  20 27 74 
Sweating  30 40 75  7 9 78  23 31 74 
Distended bladder at rectal palpation 19 28 68  4 7 57  15 21 71 
Myoglobinuria1 43 44 98  10 11 91  33 33 100 
Signs of colic 12 44 27  4 12 33  8 32 25 
Hypothermia  (< 37°C) 9 42 21  1 10 10  8 32 25 
Hyperthermia (> 38.5°C) 2 38 5  1 10 10  1 28 4 
Dysphagia 10 37 27  2 11 18  8 26 31 
Anorexia 15 44 34  2 12 17  13 32 41 
Normal mucous membranes 16 42 38  5 10 50  11 32 34 
Tachycardia (> 45bpm) 28 39 72  6 10 60  22 29 76 
Dyspnea 11 39 28  1 10 10  10 29 34 
Increased CK activity   59 59 100  14 14 100  45 45 100 
 
CK activity (IU/L)2 
 
Range :  
2 036 – 793 000 
(mean ± SD:  
246 056  ± 240 093) 
N = 39 
  
Range:  
2 036 – 443 169 
(mean ± SD:  
138 670 ± 164 824) 
N = 11 
  
Range:  
2 036 – 793 000  
(mean ± SD:  
288 243 ± 254 016) 
N = 28 
Legend: HP/C = cases confirmed or highly likely to have atypical myopathy (AM); S = surviving 
cases of the HP/C group; NS = non-surviving cases of the HP/C group; Number of total (N) or positive 
(n) response for each category; CK = creatine kinase. 
1
 Myoglobinuria was observed after spontaneous urination or after urine collection. 
2
 CK activities were analyzed by a variety of different laboratories. Exact values were not always 
known, because upper limits of certain assays were reached. 
* Denotes significant difference between survivors and non-survivors with P < 0.05. 
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EUROPEAN OUTBREAKS OF ATYPICAL MYOPATHY IN GRAZING EQUIDS (2006 – 
2009). SPATIOTEMPORAL DISTRIBUTION, HISTORY AND CLINICAL FEATURES 
 
VAN GALEN G., MARCILLAUD PITEL C., SAEGERMAN C., PATARIN F., AMORY H.,  
BAILLY J.D., CASSART D., GERBER V., HAHN C.N, HARRIS P., KEEN J.A., KIRSCHVINK N.,  
LEFERE L., McGORUM B., MULLER J.M.V., PICAVET M.T.J.E., PIERCY R., ROSCHER K.,  
SERTEYN D., UNGER L., VAN DER KOLK J.H., VAN LOON G., VERWILGHEN D.,  
WESTERMANN C.M., VOTION D.-M. 
Equine Vet. J., In press. DOI: 10.1111/j.2042-3306.2012.00556.x 
 
Abstract 
Reasons for performing study: Improved understanding of the epidemiology of atypical myopathy 
(AM) will help to define the environmental factors that permit or support the causal agent(s) to exert 
toxicity. 
Objectives: This European survey of AM aimed to describe spatiotemporal distribution, survival, 
clinical signs, circumstances in which AM develops and its different expressions between countries 
and over time. 
Methods: The spatiotemporal distribution, history and clinical features of AM cases reported to the 
Atypical Myopathy Alert Group from 2006 – 2009 were described. Comparisons of data from the 
most severely affected countries and from the large outbreaks were made with Fisher‟s exact and 
Welch‟s test with Bonferroni correction. 
Results: Of 600 suspected cases, 354 met the diagnostic criteria for confirmed or highly probable AM. 
The largest outbreaks occurred during the autumns of 2006 and 2009 in Belgium, France and 
Germany. For the first time, donkeys, zebras and old horses were affected, as were clinical signs such 
as gastrointestinal impaction, diarrhoea, penile prolapse, buccal ulceration and renal dysfunction. 
Affected horses almost always spent more than 6H/day on pastures that contained or were surrounded 
by trees. The latency period was estimated at up to 5 days. Overall survival rate was 26%. Although 
differences between countries in affected breeds, body condition, horse management and pasture 
characteristics were recognised, the common presenting clinical signs and mortality were similar 
between countries. 
Conclusions and potential relevance: This study describes new data on signalment, history and 
clinical course on AM that is of preventive, diagnostic and therapeutic value. However, the true impact 
of the findings of this study on the development of or severity of AM should be tested with case-
control studies.  
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Introduction 
Atypical myopathy (AM) is a severe form of rhabdomyolysis that occurs in grazing horses  
(Votion et al., 2007b). Several recent studies have contributed to a better understanding of its potential 
aetiopathogenesis. Ultrastructural changes in affected muscle suggest a role for altered mitochondrial 
function (Cassart et al., 2007; Palencia and Rivero, 2007) in the development of AM. Defects in fatty 
acid oxidation (multiple acyl-CoA dehydrogenase deficiency or MADD) were then demonstrated 
(Westermann et al., 2008b) and more recently, the lethal toxin of Clostridium sordellii has been 
reported in myofibres of horses with AM (Unger-Torroledo et al., 2010). However, it is not currently 
known whether C. sordellii is the primary or sole cause of AM or if its toxin acts in synergy with other 
toxins and/or metabolic imbalances. 
Improved understanding of the epidemiology of AM will help to define the environmental 
factors that permit or support the causal agent(s) to exert toxicity. A better definition of the clinical 
features of AM will help to optimise disease diagnosis and management of affected cases. 
Epidemiological studies have already been performed (Votion et al., 2007b; Votion et al., 2009), and 
various outbreaks described (Hosie et al., 1986; Brandt et al., 1997; Delguste et al., 2002; Puyalto-
Moussu et al., 2004; Finno et al., 2006; Palencia and Rivero, 2007), but these have been based on 
limited geographic areas and seasons. There is a potential that geographical and temporal differences 
exist and that these could explain some previously observed differences in the clinical presentation of 
AM (Harris, 2009). This retrospective study describes recent outbreaks of AM in Europe and tests the 
hypothesis that demographic, historical and clinical differences may exist among European AM cases 
and during different outbreaks. 
 
Materials and methods 
Collection of data 
The “Atypical Myopathy Alert Group” (AMAG) is an informal European epidemio-surveillance 
network consisting of European equine veterinarians, national epidemiological networks and 
universities interested in AM. At the onset of outbreaks, AMAG members and Diplomats of the 
European College of Equine Internal Medicine (ECEIM) were contacted by email to ask for 
cooperation in data collection. When cases were reported, details of geographic, seasonal, 
demographic and clinical data, horse management and pasture characteristics were obtained as soon as 
possible. Data were collected from 21
st
 September 2006 to 31
st 
January 2010 and were gathered via 
owners and veterinarians, from medical records, from interviews by mail, telephone or via 
standardized questionnaires available on the AMAG website: www.myopathieatypique.be. 
  
 70 
 
Chapter 4 : Publications  
Case definition 
Data from cases reported between Autumn 2006 - Autumn 2009 were analysed and cases were 
categorized following a diagnostic algorithm (Fig 1) by the first and last author only. Only confirmed 
cases or cases with a high probability of having AM were included and together formed the study 
group. 
Geographical distribution of atypical myopathy over time 
Geographical distribution over time of cases from autumn 2006 until autumn 2009 was visualized by a 
series of geographic maps and histograms using SavGIS
©
 (http://www.savgis.org/en/). These maps 
allow 1) identification of the European countries with the most reported cases and the large outbreaks, 
2) detection of high risk geographic regions in affected countries and 3) description of the pattern of 
outbreaks. 
Signalment, history and clinical course of atypical myopathy 
Signalment and a detailed description of the history and clinical course of AM were obtained based on 
data from a pro-forma questionnaire. Clinical signs that were reported were those of the first clinical 
examination by the veterinarian. For cases that survived for longer periods, further clinical information 
could be recorded. 
Data analysis 
Categorical and continuous data from Confirmed and Highly probable cases were compared. To 
examine geographic differences in the history and clinical features of AM, data from the most severely 
affected countries were compared. To examine if the clinical severity differed over time, the survival 
rates from the large outbreaks were compared. If survival rates differed significantly between these 
outbreaks, clinical parameters of cases were compared. 
The mean of the continuous parameters in each group (Highly probable versus Confirmed 
cases; the countries with the most reported cases; the large outbreaks) with unequal variance was 
compared with a Welch‟s test (Dagnelie, 1998). The categorical parameters were compared using 
Fisher‟s exact tests. A Bonferroni correction was applied for multiple comparisons. Statistical 
significance was defined as P < 0.05/k with k being the number of comparisons made. 
 
Results 
During the study period, 600 potential European cases of AM were notified to AMAG from 9 
European countries (Fig 2-3, Supporting item 1 and 2, Table 1). Of these, 354 met the criteria for 
Confirmed or Highly probable (Table 1). Cases with another final diagnosis (36 cases) or with a low 
probability of having AM (33 cases) were excluded, but in the remaining 177 cases, insufficient data 
were available in order to conclude whether they were AM cases or not. There were no major 
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differences in signalment and history between the Highly probable and Confirmed cases but the 
Confirmed cases had more severe clinical signs (more frequently suffering from stiffness, dysphagia, 
anorexia, dyspnoea, lower rectal temperature, and higher serum creatine kinase (CK) activities) and 
higher mortality rate compared to the Highly probable cases (95% versus 65%). 
Geographical distribution of atypical myopathy cases over time 
The occurrence of AM cases across Europe is demonstrated in Figure 2 and Table 1. France, Belgium 
and Germany together provided 69% of cases. The other affected European countries were: The 
Netherlands, the UK, Ireland, Denmark, Switzerland and Luxembourg. 
The cases were unevenly distributed over affected countries (Fig 3), with clusters occurring in 
specific regions such as south-east Belgium (Walloon region), north-east France, and mid-west 
Germany. Clusters were not identified in other affected countries. 
AM occurred mostly in autumn (93% of cases); however, some cases occurred during spring 
(4%), winter (3%) and summer (0.5%). The majority occurred during autumn 2006 and autumn 2009; 
17% from 25
th
 October to 12
th
 December 2006 and 70% from 9
th
 October to 21
st
 December 
 
2009. 
These two autumns were designated as “large outbreaks”. 
The daily occurrence of cases during outbreaks differed slightly between countries but when 
combined can be described as starting with some sparse cases that a couple of days to one week later 
were followed by more cases occurring more closely to each other. Outbreaks reached either one or 
several incidence peak(s) in the middle followed by a gradual reduction in case numbers (Supporting 
Items 1 and 2). 
Signalment, history and clinical course of atypical myopathy cases 
Signalment and history 
Signalment and history are shown in Supporting Items 3 and 4. All ages were represented, but 
especially young horses (Supporting Item 5). A range of breeds as well as donkeys (3 Highly probable 
cases) and zebras (1 Confirmed and 2 Highly probable cases) were affected. and both sexes were 
equally represented. Most affected horses (87%) had normal body condition and 29% were reported to 
be very muscular. 
The majority (98%) of cases occurred at pasture, except for 6 cases (2%) that had been stabled 
just before the onset of clinical signs (2 horses had been stabled for 1 day, 2 for 2 days, 1 for 3 days 
and 1 for 4 days). The majority of horses (86%) spent 24 hours per day at pasture and none of them 
had been at pasture less than 6 hours a day. One horse survived a first episode of AM, but died from a 
second some years later. Previous unexplained sudden deaths of horses had been noted on 22% of the 
pastures. Previous cases of AM had been noted in several pastures, sometimes in successive years. 
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Pasture characteristics that were reported for more than 50% of the cases were: a slope (63%), sparse 
grass (66%; apart from German and UK pastures that were commonly lush), accumulations of dead 
leaves (87%), dead wood (61%) and the presence of trees in or around the pasture (98%). Few horses 
(27%) were in exercise or training at the time of diagnosis: only 4 were trained 5-7 times a week, 
while the others performed no or minimal exercise. The majority of horses received water from the 
water distribution network (tap water; 56%) out of a tank or bath (51%), and supplementary feeding 
(64%). 
A comparison of the demographic and historical findings in affected horses in Belgium versus 
France versus Germany demonstrated that there is considerable country to country variation in the 
breeds affected, their body condition, the pasture characteristics, and supply of water, feed and salt 
block (Supporting items 4 and 6). 
Clinical course 
Table 2 shows clinical data. Horses were regularly reported to be unusually quiet one to two days 
before the onset of more definitive signs. Signs that occurred in more than 50% of cases at first 
clinical examination were depression, weakness, stiffness, recumbence, trembling, sweating, 
pigmenturia, congested mucous membranes, tachycardia, and normothermia. Some horses were 
dysphagic (25%; with or without oesophageal obstruction), and appetite ranged from anorexic (28%) 
to ravenous (18%). Muscle weakness could become severe and was sometimes evident as a low head 
carriage with severe secondary oedema of the head. Cardiac arrhythmias were detected with cardiac 
auscultation or electrocardiography in 13% of cases. 
Transrectal examination, performed on 38% of horses, revealed impactions of the large and/or 
small colon, and dry and/or mucus covered faeces (35 cases; 10%), mild diarrhoea (5 cases), colon 
displacement (2), perirenal pain (1) and reduced rectal tone (2). Bladder distension was frequently 
palpated (58%) and most of these horses demonstrated dysuria. Other less commonly reported signs 
included: penile prolapse (7), buccal necrosis or ulceration (3) and clinical signs consistent with renal 
dysfunction (i.e. declining urine volume while receiving fluid therapy; 3 cases). Clinical signs 
described in single cases were: ptosis (responsive to the administration of phenylephrine), trismus, 
laminitis, and clinical signs of congestive heart failure due to severe cardiomyopathy with pericardial 
effusion. 
Haematology and biochemistry were performed in 58% of cases. In 7 cases, serum CK 
activities were initially within reference ranges or only slightly increased, but increased markedly in 
the following hours and days. In 92% of the cases medication was administered, consisting mostly of 
intravenous and/or oral fluids (75%), non steroidal anti-inflammatory drugs (82%), corticosteroids 
(26%), vitamins/antioxidants (including vitamins B, C, E, selenium and carnitine; 43%) and/or 
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antimicrobials (29%). Survivors recovered after 10.6 ± 5.6 days with a range of 1 to 30 days. All  
non-survivors died or were euthanized within 10 days; the majority in the first 72 hours 
(Supplementary item 7). The overall survival rate was 26%, with the highest survival rate of 57% 
noted in France during the outbreak in autumn 2006. 
Statistical comparison of clinical parameters between Belgian, French and German cases that 
occurred during the autumn of 2009 is shown Supporting item 6. The common presenting clinical 
signs were largely similar and mortality (Belgium: 12%, France: 31%, and Germany: 30%) was not 
statistically different between these countries. However, Belgian cases were more likely to have 
congested mucous membranes, higher serum CK activity, and were more likely to have received 
metronidazole, muscle relaxants, vitamins and anti-oxidants. In addition, they were more likely to 
have undergone post mortem examination compared to  French and German cases. The survival rates 
of the two large outbreaks (33% and 24% for autumn 2006 and autumn 2009, respectively) were not 
statistically different (P = 0.13). Therefore no further statistical comparison on clinical parameters was 
performed between outbreaks. 
 
Discussion 
In the past, AM was thought to be a rare disorder, but this study shows that it may be more common 
than previously thought. Most cases occurred during the autumn, suggesting a link with specific 
climatic conditions as previously reported (Votion et al., 2007b). Interestingly when a series of cases 
occurred during an autumn, cases also occurred the following spring, although fewer in number. 
Previously, specific weather conditions have been linked with AM: lack of solar radiation  
(Votion et al., 2007b), stormy winds (Hosie et al., 1986; Harris and Whitwell, 1990; Votion et al., 
2007b) and rain and thunderstorms (Finno et al., 2006). Moreover, a previous study  
(Votion et al., 2007b) reported that cases ceased after heavy frost, suggesting that extreme cold may 
destroy the causative agent. Following this observation and as some horses were stabled for up to  
4 days prior to the onset of clinical signs, the „incubation period‟ can be estimated to be up to 4-5 days. 
Horses can thus be considered at low risk after stabling for at least 5 days. 
AM has been reported to affect mostly young horses (Hosie et al., 1986; Whitwell et al., 1988; 
Brandt et al., 1997; Palencia and Rivero, 2007; Votion et al., 2007b; Votion et al., 2009), but in the 
current study population all age groups were represented, apart from young foals. There is however a 
predominance of young animals. This finding might be explained by acquisition of immunity to an 
unidentified causative agent or the greater likelihood of young horses to be on pasture. This is the first 
time that clinically affected donkeys and zebra‟s are described, however to date, there is no evidence 
that AM affects other species than equids.  
 74 
 
Chapter 4 : Publications  
Pastures where cases occur were typically described as being sparse, sloping and containing or 
being surrounded by trees, and containing accumulations of dead leaves, and dead wood. Some 
pastures not resembling this description have, however, also had clinical cases. The most consistent 
pasture characteristic was the presence of trees (98%). The presence Acer pseudopalatanus on pastures 
of Belgian confirmed cases has been reported in the past (Votion et al., 2007b) and recently, it has 
been suggested that this tree species, particularly when affected with European tar spot  
(Rhytisma acerinum), might be related to AM (van der Kolk et al., 2010). This possibly reflects its 
common occurrence in Europe rather than a direct association with the disease. Pastures were not 
systematically visited nor were data on tree species collected in this study. 
Although the most frequently reported clinical signs are similar to previous reports  
(Votion et al., 2007b), this study describes new clinical data, which must be taken into consideration 
to optimise management of future cases. Previously unreported clinical signs including gastrointestinal 
impactions, diminished rectal tone, mild diarrhoea, penile prolapse, buccal necrosis or ulceration and 
clinical signs consistent with renal dysfunction were reported to occur in some cases. These findings 
highlight the importance of monitoring and supporting gastrointestinal and urinary function. Other 
previously unreported clinical signs were encountered in single and mostly unconfirmed, but highly 
probable cases, so caution is warranted before linking them with AM. 
This is the first study that describes a significant number of survivors of AM. Most survivors 
were Highly probable cases, but five were Confirmed by muscle biopsy. The difference in survival 
between Confirmed and Highly probable cases can be explained by the reluctance of practitioners and 
owners to perform muscle biopsies in survivors; confirmation is therefore more often achieved in  
non-survivors. Although some clinical cases appeared to recover uneventfully, they have not 
consistently been subjected to follow-up medical examinations in order to exclude signs of subclinical 
disease. Caution is therefore required when discussing the long term prognosis for those animals that 
survive AM, not at least because complications, such as laminitis, renal problems and cardiomyopathy 
were described in some cases. However, knowledge that affected horses have a chance of survival 
without a major risk of sequelae is very important with respect to diagnosis, prognosis and treatment. 
The overall survival rate (26%) was higher than previously described (3%, Brandt et al., 1997; to 15%, 
Puyalto-Moussu et al., 2004; Votion et al., 2004), suggesting an attenuation of the disease and/or 
improved recognition and management of AM over recent years. Despite this, no statistical difference 
in survival rates was noted between the two outbreaks described in this study. 
The hypothesis that the clinical signs differed between countries could not be confirmed by 
this study. The most common presenting clinical signs were similar between countries during the 
outbreak of 2009, but nevertheless Belgian cases seemed to be more severely affected than French and 
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German cases. Fewer Belgian horses presented with normal mucous membranes and they had higher 
serum CK activity. Moreover, Belgian cases were treated considerably more often with therapies such 
as metronidazole, muscle relaxants (e.g. acepromazine, diazepam), vitamins and antioxidants (B, C 
and E vitamins, selenium and carnitine). Despite this their survival rate remained low (12%) and 
mortality rates were not statistically different from France and Germany. The identified differences in 
demographics, management and pastures between these countries might simply reflect differences in 
population and habits without being specific for AM, but they might directly or indirectly influence 
clinical severity or outcome by effects on immunity, contributing or predisposing factors and effects 
on pathogenicity of the causative agent. Moreover, these findings suggest that the populations that are 
affected by AM and the conditions under which AM occurs are not the same everywhere and that 
regional findings should be interpreted with caution. 
This is the first study of AM to use a European-wide population. Considering that AM is a 
sporadic disease, a large number of cases was recruited onto the study and substantial quantities of 
clinical and historical data were obtained. Nevertheless, this descriptive study has several limitations. 
The described conditions when AM occurred may also be common for that geographic area without 
being specific for AM and thus be coincidental findings. To estimate the importance of some of the 
findings of this and previous studies for the development of AM, case-control studies including non-
affected control cases and pastures are necessary. The limitations of some of the highly subjective data 
obtained, e.g. pasture slope, should also be recognised and the fact that data were obtained from a 
large number of veterinary surgeons and horse owners/carers with resultant potential biases. 
Alternative methods that could be used in future studies to investigate the spatiotemporal clustering of 
AM cases include k function analysis (French et al., 2005; Abatih et al., 2009), the Biased Sample 
Hospital-based Area Disease Estimation (also called the B-SHADE technique; Wang et al., 2011) and 
the use of SaTScan software (Kulldorff M. and Information Management Services, Inc. SaTScan (TM) 
software for the spatial and space-time scan statistics; Hyder et al., 2011). Despite these limitations, 
this study contains important information for the future management of cases. 
In conclusion, this study describes AM cases in Europe from 2006 – 2009 and includes two 
large outbreaks. With a 26% survival rate, these outbreaks were less devastating than previously 
reported; nevertheless severity was not different between the two outbreaks. New data on signalment, 
history and clinical course on AM has been described and may be helpful for future management of 
affected cases. 
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Tables and Figures 
Table 1. Categorization of cases reported to the Atypical Myopathy Alert Group from various 
European Countries. 
 
 
Total Country of origin: 
  Belgium France Germany The 
Netherlands 
United 
Kingdom 
Others* 
Reported cases 
 
600 143 194 108 51 54 50 
Confirmed cases 107 34 38 6 6 15 8 
Highly probable 
cases 
247 47 63 58 33 27 19 
All AM cases 354 81 101 64 39 42 27 
        
Legend: AM = atypical myopathy; * = Ireland, Denmark, Switzerland, Luxembourg.  
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Table 2. Clinical data of cases with a high probability of, or confirmed with atypical myopathy in 
various European countries. 
 Total 
 
(354 cases) 
Belgium 
 
(81 cases) 
France 
 
(101 cases) 
Germany 
 
(64 cases) 
The 
Netherlands 
(39 cases) 
United 
Kingdom 
(42 cases) 
Others* 
 
(27 cases) 
 n/N % n/N % n/N % n/N % n/N % n/N % n/N % 
Found dead without 
prodromal signs 
2/327 1 0/78 0 1/97 1 1/60 2 0/33 3 0/41 0 0/18 0 
Survival  88/344 26 13/80 16 32/100 32 19/63 30 7/33 21 13/42 31 4/26 15 
               
GENERAL                
Depression 203/255 80 43/57 75 62/73 85 40/47 85 16/26 62 29/38 76 13/14 93 
Weakness  211/248 85 50/58 86 59/65 91 36/48 75 22/26 85 34/38 89 10/13 77 
Stiffness  210/252 83 47/58 81 59/68 87 37/49 76 24/26 92 33/37 89 10/14 71 
Recumbency  227/290 78 57/72 79 68/82 83 36/54 67 24/28 86 29/39 74 13/15 87 
Trembling  170/250 68 33/55 60 46/69 67 34/48 71 18/27 67 30/38 79 9/13 69 
Sweating  162/253 64 35/52 67 47/73 64 33/50 66 16/26 62 20/37 54 11/15 73 
               
CLINICAL 
EXAMINATION 
              
Rectal temperature  
  (°C; mean±SD) 
  Normal: 37-38.5 
 
37.4 ± 1.0 
Range: 34.5 – 
40.5 
N = 206 
  
37.4 ± 1.2 
Range: 34.6 
– 40.5 
N = 46 
37.1 ± 1.1 
Range: 34.5 – 
39.4  
N =52 
37.5 ± 0.8 
Range: 35 - 
39 
N = 43 
37.5 ± 0.9 
Range: 35.8 – 
39.9 
N = 22 
37.7 ± 1.0 
Range: 35 – 
39.8 
N = 28 
37.3 ± 0.8 
Range: 35 – 
38.5 
N = 15 
Respiratory rate  
  (rpm; mean±SD) 
  Normal: < 15 
 
28 ± 14 
Range: 6 – 72 
N = 158 
34 ± 17 
Range: 8 – 
72  
N = 40 
27 ± 13 
Range: 6 – 50  
N = 29 
27 ± 11 
Range:12 – 
60 
N =33 
26 ± 14 
Range: 14 – 
60  
N = 17 
24 ± 12 
Range: 12 – 
50  
N = 27 
22 ± 10 
Range: 12 – 
50  
N =12 
 
Heart rate  
  (bpm; mean±SD) 
  Normal: < 45 
60 ± 17 
Range: 28 – 
120  
N = 211 
62 ± 19 
Range: 35 – 
112  
N = 47 
58 ± 17 
Range: 28 – 
120  
N = 51 
61 ± 15 
Range: 36 – 
100  
N = 41 
59 ± 23 
Range: 30 – 
120  
N = 24 
59 ± 14 
Range: 32 – 
96  
N = 34 
58 ± 14 
Range: 40 – 
90  
N = 14 
        
Hypothermia 
(<37°C) 
68/238 29 14/51 27 24/69 35 12/49 24 8/23 35 7/31 23 3/15 20 
Normothermia (37-
38.5°C) 
138/229 60 28/51 55 36/64 56 31/45 69 13/23 57 18/31 58 12/15 80 
Hyperthermia 
(>38.5°C) 
25/229 11 9/51 18 5/64 8 3/45 7 2/23 9 6/31 19 0/15 0 
               
Normal mm 86/231 37 9/52 17 21/60 35 16/44 36 14/25 56 19/36 53 7/14 50 
Congested mm 124/232 53 37/52 71 32/61 52 23/44 52 9/25 36 16/36 44 7/14 50 
             
Dyspnoea 110/226 44 34/52 65 28/64 44 19/42 45 3/20 15 12/34 35 4/14 29 
Tachycardia (> 
45bpm) 
185/235 79 44/55 80 52/66 79 34/42 81 16/24 67 28/34 82 11/14 79 
 
OTHERS  
              
Normal defecation  139/205 68 31/45 69 33/51 65 29/41 71 13/22 59 25/35 71 8/11 73 
Pigmenturia 243/260 93 62/65 95 63/70 90 48/52 92 25/25 100 32/35 91 13/13 100 
               
DIAGNOSTICS               
Post mortem 
examination 
108/302 36 40/73 55 20/90 22 14/60 23 7/25 28 16/35 46 11/19 58 
Muscle histology 139/300 46 42/71 59 48/92 52 10/59 17 14/24 58 15/35 43 10/19 53 
Legend: SD = standard deviation; N = number of total response for each category; n = number of 
positive response for each category; mm = mucous membranes; * = Ireland, Denmark, Switzerland, 
Luxembourg.  
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Figure 1. Diagnostic algorithm used to categorize cases reported to the Atypical Myopathy Alert 
Group. 
 
Legend: AM = atypical myopathy; (*) repeat analysis 24H later; (**) pathognomonic signs;  
C = confirmed case of AM, based on history, clinical expression and histology; HP = case with a high 
probability of having AM; LP = case with a low probability of having AM; OD = case with another 
diagnosis than AM; D = doubtful case; not enough data available. 
Notes: Histology was performed either on muscle biopsies or on post mortem samples. The  
non-pathognomic findings for AM on histology are a multifocal process compatible with Zenker‟s 
degeneration and necrosis in fibres of postural and/or respiratory muscles (Cassart et al. 2007). 
Cases that developed signs following anaesthesia or intense exercise were categorized as doubtful. 
If a full post mortem examination was performed and specific findings of another condition were 
found, the case could be categorized OD.  
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Figure 2. Maps showing the occurrence of the highly probably or confirmed atypical myopathy cases 
from 2006 – 2009. 
 
 
Notes: Only seasons with > 5 cases are represented. Seasons with < 5 cases were: winter 2006-2007  
(3 cases), summer 2007 (1 case), summer 2008 (1 case), autumn 2008 (3 cases), winter 2008-2009  
(1 case). 
Entire countries are coloured, based on their official borders, but disease occurrence could be regional 
rather than across the entire country e.g. Corsica is coloured as it is part of France but no cases have 
been reported there.  
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Figure 3. Map showing the location of highly probably or confirmed atypical myopathy cases during 
autumn 2006 and autumn 2009, based on addresses or postal codes. 
 
Note: location was established for 28/50 cases in autumn 2006 and 134/248 cases in autumn 2009. 
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Supporting items 
Item 1: The development of the highly probable or confirmed atypical myopathy cases during the 
outbreaks of autumn 2006. 
 
 
Item 2: The development of the highly probable or confirmed atypical myopathy cases during the 
outbreaks of autumn 2009. 
 
Note: Only cases with a known exact date of onset of clinical signs were included.  
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Item 3: Demographic data from cases with a high probability of, or confirmed as atypical myopathy 
in various European countries. 
 Total 
 
(354 cases) 
Belgium 
 
(81 cases) 
France 
 
(101 cases) 
Germany 
 
(64 cases) 
The 
Netherlands 
(39 cases) 
United 
Kingdom 
(42 cases) 
Others* 
 
(27 cases) 
 n/N 
 
% n/N % n/N % n/N % n/N % n/N % n/N % 
TYPE OF HORSE               
Saddle horse 133/276 48 49/74 66 40/87 46 8/38 21 16/33 48 9/30 30 11/14 79 
Draught horse 42/276 15 9/74 12 23/87 26 6/38 16 2/33 6 0/30 0 2/14 14 
Pony 95/276 34 16/74 22 20/87 23 22/38 58 15/33 45 21/30 70 1/14 7 
Donkey 3/276 1 0/74 0 1/87 1 2/38 5 0/33 0 0/30 0 0/14 0 
Zebra 3/276 1 0/74 0 3/87 3 0/38 0 0/33 0 0/30 0 0/14 0 
               
SEX                
Mare 140/267 52 39/76 51 48/84 57 21/42 50 16/26 62 8/27 30 8/12 67 
Stallion 42/255 16 17/74 23 8/79 10 4/37 11 6/26 23 7/27 26 0/12 0 
Gelding 78/255 31 18/74 24 25/79 32 15/37 41 4/26 15 12/27 44 4/12 33 
               
AGE 
  (years; mean ±SD) 
5.3 ± 6.2 
Range: 0.4 – 
38  
N = 274 
6.1 ± 6.8 
Range: 0.4 – 
38 
N = 75 
6.0 ± 6.4 
Range: 0.4 – 
37 
N = 84 
5.7 ± 7.4 
Range: 0.5 – 
27 
N = 42 
4.2 ± 5.2 
Range: 0.4 – 
26 
N = 28 
3.2 ± 2.7 
Range: 0.4 – 
10 
N = 33 
3.0 ± 2.3 
Range: 0.6 – 
8 
N = 12 
               
BODY CONDITION               
Poor 12/242 5 2/66 3 5/66 8 1/30 3 0/25 0 2/39 5 2/16 13 
Normal 211/242 87 60/66 91 51/66 77 27/30 90 25/25 100 36/39 92 12/16 75 
Obese 19/242 8 4/66 6 10/66 15 2/30 7 0/25 0 1/39 3 2/16 13 
Extremely muscular 51/176 29 12/48 25 6/55 11 23/28 82 2/10 20 1/23 4 7/12 58 
               
Legend: C = confirmed AM cases; HP = cases highly likely to have AM; HPC = cases confirmed or 
highly likely to have AM; SD = standard deviation; N = number of total response for each category;  
n = number of positive response for each category; * = Ireland, Denmark, Switzerland, Luxembourg. 
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Item 4: Data on horse management and pasture characteristics from cases with a high probability of, 
or confirmed with atypical myopathy in various European countries. 
 Total 
 
(354 cases) 
Belgium 
 
(81 cases) 
France 
 
(101 cases) 
Germany 
 
(64 cases) 
The 
Netherlands 
(39 cases) 
United 
Kingdom 
(42 cases) 
Others* 
 
(27 cases) 
 n/N % n/N % n/N % n/N % n/N % n/N % n/N % 
HORSE 
MANAGMENT  
              
Vaccinated 143/185 77 44/50 88 53/62 85 18/23 78 12/19 63 8/23 35 8/8 100 
Dewormed 174/182 96 48/49 98 58/61 95 23/23 100 14/14 100 21/23 91 10/12 83 
               
Duration of grazing                
< 6h per day 0/195 0 0/56 0 0/62 0 0/25 0 0/17 0 0/23 0 0/12 0 
Only during daytime 21/195 11 5/56 9 4/62 6 4/25 16 2/17 12 0/23 0 6/12 50 
Only at night 2/195 1 0/56 0 0/62 0 0/25 0 0/17 0 2/23 9 0/12 0 
24/24h 177/205 86 49/57 86 58/62 94 27/33 82 16/18 89 21/23 91 6/12 50 
Variable depending on 
the weather 
9/195 5 5/56 9 0/62 0 2/25 8 0/17 0 0/23 0 2/12 17 
               
Nutrition                
Supplementary feed 120/187 64 33/51 65 44/66 67 12/23 52 10/15 67 13/22 59 8/10 80 
               
PASTURE 
CHARACTERISTICS 
 
              
Presence of :                
Shelter 76/179 42 23/52 44 29/57 51 5/21 24 4/13 31 10/24 42 5/12 42 
Trees 194/198 98 50/53 94 55/55 10
0 
29/29 100 19/20 95 27/27 100 14/14 100 
Accumulations of dead 
leaves 
160/184 87 41/52 79 50/55 91 21/21 100 15/20 75 21/24 88 12/12 100 
Dead wood 106/174 61 25/53 47 38/51 75 11/21 52 4/13 31 21/24 88 7/12 58 
Humid zones 78/178 44 29/54 54 17/54 31 6/21 29 6/13 46 11/24 46 9/12 75 
Water course 61/177 34 20/53 38 12/54 22 6/21 29 1/13 8 17/24 71 5/12 45 
Slope 115/182 63 33/53 62 41/55 75 17/25 68 3/13 23 15/24 63 6/12 50 
Lush grass 50/174 29 11/52 21 9/55 16 14/21 67 2/12 17 12/22 55 2/12 17 
Sparse grass 113/171 66 39/52 75 40/54 74 7/21 33 8/10 80 9/22 41 10/12 83 
               
Legend: C = confirmed atypical myopathy (AM) cases; HP = cases highly likely to have AM;  
HPC = cases confirmed or highly likely to have AM; SD = standard deviation; N = number of total 
response for each category; n = number of positive response for each category; *= Ireland, Denmark, 
Switzerland, Luxembourg. 
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Item 5: Frequency distribution within age categories of highly probable or confirmed atypical 
myopathy cases. 
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Item 6: Comparision of demographic, historical and clinical data from cases with a high probability 
of, or confirmed as atypical myopathy in Belgium, France, Germany. Only those categories and 
variable that were statistically different are listed. 
Variables  Belgium 
(43 cases) 
France 
(68 cases) 
Germany 
(55 cases) 
Categorical variables 
(Fisher’s exact test with Bonferroni correction;  
P< 0.05/k, k = 3) 
n/N % n/N % n/N % 
DEMOGRAPHIC DATA       
Saddle horses 25/39 64
b
 30/56 54
b
 5/31 16 
Ponies 10/39 26 12/56 21 20/31 65
a,c
 
Normal body condition 34/35 97
a
 44/55 80 20/23 87 
Extremely muscular  7/26 27 6/45 13 21/21 100
a,c
 
       
HORSE MANAGEMENT (when AM occurred)       
Rain water as source of water 6/27 22
a
 1/39 3 8/24 33
c
 
Supplemented with silage 6/19 32
a
 0/33 0 0/10 0 
Supplemented with salt block 12/26 46 28/45 62 19/24 79
c
 
       
PASTURE CHARACTERISTICS 
(when AM occurred) 
      
Dead wood 15/27 44 30/40 75
c
 11/19 58 
Mechanical spreading of faeces 14/26 54
b
 13/44 30
b
 1/19 5 
Lush pasture  4/27 15 8/46 17 12/19 63
a,c
 
Sparse pasture  23/27 85
b
 33/46 72
b
 7/19 37 
       
CLINICAL DATA       
Congestive mm 25/33 76
a,b
 25/52 48 17/37 46 
Treatment with metronidazole 5/28 18
b
 1/47 2 0/33 0 
Treatment with vitamins & antioxidants 19/28 68
b
 21/48 44 12/33 36 
Treatment with myorelaxants 7/27 26
a
 2/47 4 2/33 6 
Post mortem examination  24/41 59
a,b
 14/60 23 10/51 14 
       
Continuous variables 
(Welsh’s test with Bonferroni correction;  
P< 0.05/k, k = 3) 
Mean (SD) N Mean (SD) N Mean (SD) N 
Highest measured CK serum activity  
  (IU/L; normal 50 – 200) 
 
511017 ± 1299047
a,b
 28 171441 ± 237263 36 78852 ± 116411 26 
First measured CK serum activity  
  (IU/L; normal 50 – 200) 
 
298032 ± 810007
a,b
 29 167184 ± 239339 36 76616 ± 117251 26 
Legend: 
a
 = statistically more frequent or higher compared to France; 
b
 = statistically more frequent or 
higher compared to Germany; 
c
 = statistically more frequent or higher compared to Belgium;  
mm = mucous membranes; CK = serum activity of creatine kinase. 
Note: Only cases with a high probability (HP) of having atypical myopathy (AM) and confirmed (C) 
cases that occurred during autumn 2009 are considered in order to limit climatic or temporal 
influences. 
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Item 7: The duration of disease for survivors and non-survivors of the highly probable or confirmed 
atypical myopathy cases. 
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EUROPEAN OUTBREAKS OF ATYPICAL MYOPATHY IN GRAZING EQUIDS (2006 – 
2009). DETERMINATION OF INDICATORS FOR RISK AND PROGNOSTIC FACTORS 
 
VAN GALEN G., MARCILLAUD PITEL C., SAEGERMAN C., PATARIN F., AMORY H.,  
BAILLY J.D., CASSART D., GERBER V., HAHN C.N, HARRIS P., KEEN J.A., KIRSCHVINK N.,  
LEFERE L., McGORUM B., MULLER J.M.V., PICAVET M.T.J.E., PIERCY R., ROSCHER K.,  
SERTEYN D., UNGER L., VAN DER KOLK J.H., VAN LOON G., VERWILGHEN D.,  
WESTERMANN C.M., VOTION D.-M. 
Equine Vet. J., In press. DOI: 10.1111/j.2042-3306.2012.00555.x 
 
Abstract 
Reasons for performing study: Appropriate management of atypical myopathy (AM) requires 
establishing an accurate diagnosis and prognosis. Furthermore, preventive measures to avoid AM need 
to be refined. 
Objectives: The aims of the study were to 1) improve the diagnosis of AM, 2) identify prognostic 
predictors and 3) refine recommended preventive measures based on indicators of risk factors. 
Methods: An exploratory analysis of cases in Europe between 2006 and 2009 reported to the Atypical 
Myopathy Alert Group was conducted. Based on clinical data, reported cases were allocated into  
2 groups: confirmed or highly probable AM (AM group; further divided into survivors and  
non-survivors); and cases with a low probability of having AM or with another final diagnosis  
(non-AM group). Using a Welch‟s test and odds ratios corrected for multiple comparisons the AM 
versus non-AM groups were compared to identify indicators for diagnosis and risk factors, and 
survivors versus non-survivors in the AM group were compared to identify prognostic factors. 
Sensitivity, specificity and positive and negative predictive values were calculated for specific clinical 
signs related to final diagnosis and outcome. 
Results: From 600 reported cases, 354 AM cases (survival rate of 26%) and 69 non-AM cases were 
identified, while there was insufficient data to categorize the remainder. Variables valuable for 
diagnosing AM compared to similar diseases were: presence of dead leaves and wood, and/or trees on 
pastures, sloping pastures, full time pasture access, no food supplementation, normal body condition, 
pigmenturia, normothermia and congested mucous membranes. Non-survival was associated with 
recumbency, sweating, anorexia, dyspnoea, tachypnoea, and/or tachycardia. Survival was associated 
with remaining standing most of the time, normothermia, normal mucous membranes, defaecation and 
vitamin and antioxidant therapy. 
Conclusions and potential relevance: This study refines the list of risk factors for AM. Clinical signs 
valuable for diagnosis and prognosis have been identified enabling clinicians to improve management 
of AM cases.  
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Introduction 
Atypical myopathy (AM) is an acute and severe non-exercise related rhabdomyolysis with a high 
mortality rate that is being increasingly recognised in Europe (van Galen et al., 2012b). Despite 
several risk factors being identified in single case reports, outbreaks or single countries (Hosie et al., 
1986; Brandt et al., 1997; Delguste et al., 2002; Votion et al., 2007b; Votion et al., 2009), to date no 
large scale epidemiological study has identified key factors that may predispose to the development of 
AM and predict likelihood of survival from this disorder. 
The pathogenesis of AM is unclear, but involves a metabolic defect defined as multiple  
acyl-CoA dehydrogenase deficiency, which blocks mitochondrial fatty acid energy metabolism. 
Affected horses therefore depend largely on carbohydrate metabolism for their energy supply 
(Westermann et al., 2008b; Westermann et al., 2011). The development of AM is probably 
multifactorial with several endogenous and exogenous factors. AM has been associated with 
Clostridium sordellii lethal toxin (Unger-Torroledo et al., 2010) and contact time, dosage and 
pathogenicity of this toxin may all influence the severity of disease. Expression of clinical disease may 
depend on the balance between those factors. In horses with subclinical AM (Delguste et al., 2002; 
Votion et al., 2007b), the energy balance is probably more or less maintained. But if the horse‟s 
metabolism is imbalanced because it is too severely affected by the causative agent or is further 
disturbed by other interfering factors, severe disease may follow and death can occur. Defining risk 
and prognostic factors may aid recognition of some of the key factors involved in this balance-
imbalance situation. 
There are limited available strategies to prevent AM and treatment is often unsuccessful 
(Votion and Serteyn, 2008; Harris, 2009). Current therapeutic and preventive measures are based on: 
1) limited pathophysiological knowledge, 2) symptomatic treatment of clinical signs, and 3) risk and 
protective factors as determined by previous epidemiological studies (Votion et al., 2007b; Votion et 
al., 2009). Although extensive epidemiological studies have been performed, statistical analysis has 
been limited to cases confirmed at post mortem examination (Votion et al., 2007b; Votion et al., 
2009). By excluding unconfirmed yet highly suspicious cases (including survivors), important clinical 
information may have been lost. Moreover clinical factors associated with survival have not been 
established. 
The aims of the study were to identify clinical and historical data that may increase the 
certainty of a diagnosis of AM, to refine preventive measures based on identified risk factors and to 
identify prognostic predictors using European cases that occurred between autumn 2006 and autumn 
2009 and were confirmed to have or highly suspected of having AM, including survivors.  
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Materials and methods 
Collection of data 
The “Atypical Myopathy Alert Group” (AMAG) is an informal European epidemio-surveillance 
network consisting of European equine veterinarians, national epidemiological networks and 
universities with an interest in AM. At the onset of outbreaks, AMAG members and Diplomats of the 
European College of Equine Internal Medicine were contacted by email to ask for cooperation in data 
collection. Details of geographic, seasonal, demographic and clinical data (primarily those of the first 
clinical examination by the veterinarian; but for cases that survived for longer periods further clinical 
information could be submitted), horse management and pasture characteristics were obtained as soon 
as possible. Data were collected from 21
st
 September 2006 to 31
st 
January 2010 and were gathered via 
owners and veterinarians, from medical records, from interviews by mail, telephone or via 
standardized questionnaires available on the AMAG website: www.myopathieatypique.be. 
Case definition 
Following data analysis of all reported cases from autumn 2006 until autumn 2009 by the first and last 
author only, cases were allocated to the following categories following a previously described 
decisional algorithm (van Galen et al., 2012b): confirmed cases; cases with a high probability of 
having AM, cases with a low probability of having AM; cases with another final diagnosis; or 
doubtful cases in which it was impossible to determine whether they had AM due to lack of data. 
Confirmed and highly probable cases were combined to form the AM group while and the non-AM 
group consisted of cases with low probability or an alternative diagnosis. The AM group was further 
divided into survivors and non-survivors and doubtful cases were excluded from further analysis. 
Data analysis 
The AM and non-AM groups were compared to identify clinical indicators and risk factors for AM 
while AM survivors were compared to non-survivors to identify factors predicting survival of AM. 
Continuous variables were compared using Welch‟s test (Dagnelie, 1998). Categorical 
variables were evaluated by mean of odds ratios (Grenier, 1990). A Bonferroni correction was 
performed for multiple comparisons. Statistical significance was defined as P < 0.05/k with k being the 
number of comparisons made. 
Sensitivity, specificity and positive and negative predictive values (PPV and NPV) were 
calculated for common clinical signs in AM; they were related to diagnosis (comparing the AM versus 
the non-AM group) and to outcome (comparing survivors versus non-survivors of the AM group). 
Useful clinical signs related to these calculations were identified based on a high sensitivity 
specificity, PPV or NPV.  
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Results 
During the study period, 600 potential European cases of AM were reported, from which 354 met the 
selection criteria for the AM group, with a survival rate of 26%, and 69 for the non-AM group. The 
spatiotemporal, historical and clinical features of these cases have been reported in a concurrent study 
(van Galen et al., 2012b). 
Features of Atypical Myopathy 
Variables more frequently encountered in AM cases compared to non-AM cases were: the presence of 
trees, dead wood and accumulations of dead leaves at pasture, a sloping pasture, normal body 
condition, and fulltime grazing. Moreover, AM cases more frequently developed pigmenturia, 
exhibited normothermia, had higher serum CK activities, and more frequently received supportive 
treatment than non-AM cases. Variables that were more often present in non-AM cases compared to 
AM cases were: poor body condition, water provision from a tank or bath tub, food supplementation, 
and spending no or limited time at pasture. Also, non-AM cases were more frequently found dead 
without previous clinical signs, and more often had cyanotic mucous membranes than AM cases 
(Table 1). Pigmenturia had a high sensitivity and PPV, and normothermia and congested mucous 
membranes a high PPV for diagnosis of AM (Table 2). 
Prediction of survival versus non-survival 
Positive prognostic factors were defecation and treatment with vitamins and/or antioxidants. Negative 
prognostic factors were recumbency, sweating, anorexia, tachycardia, tachypnoea and dyspnoea 
(Table 3). Concerning survival, remaining standing and normal mucous membranes had both a high 
specificity, PPV and NPV, and normothermia and defecation had both a high sensitivity and NPV 
(Table 2). 
 
Discussion 
The current study identified factors that permit differentiation between AM and other clinically similar 
diseases as well as prognostic factors for AM. These data will help define diagnostic, prognostic, 
preventive and therapeutic measures for AM, while also identifying parameters potentially involved in 
the metabolic imbalance believed to be an integral part of AM pathogenesis. 
In previous studies, risk and protective factors were also described, but statistical analysis was 
restricted to demographic data, horse management and pasture characteristics, and a comparison was 
made between confirmed cases versus co-grazers (Votion et al., 2007b) or confirmed cases versus  
co-grazers and control horses from the same region (Votion et al., 2007b; Votion et al., 2009). The 
present study compared highly probable or confirmed cases of AM to cases presenting with similar 
clinical signs but which were unlikely to be suffering from AM. The clinical signs that were 
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significantly more often encountered in the AM group than in the non-AM group and/or had 
sensitivity, specificity, PPV and/or NPV related to diagnosis were pigmenturia, normothermia, 
congested mucous membranes and high serum CK activity. Nevertheless, other pathologies 
(myopathic or not) may lead to similar clinical signs, and not all AM affected horses show these signs. 
Therefore these distinctive features may be useful to strengthen a clinical suspicion of AM, but 
diagnosis should not solely be based on them. Horses with cyanotic mucous membranes or that were 
found dead without prodromal signs were more often categorized as non-AM. Horses can show 
cyanotic mucous membranes and are sometimes found dead following AM, but other disorders, such 
as acute colic, remain more frequent and a rapid death sometimes hinders correct diagnosis. 
This study is the first extensive comparison of survivors and non-survivors of AM leading to 
the characterisation of clinical signs that are valuable for prognostic assessment. A previous study of 
fatal Belgian cases suggested that normal respiration with normal arterial partial pressure of oxygen 
(PaO2) was a positive prognostic factor (Votion et al., 2007b). Most cases described in the current 
study were treated in the field and PaO2 levels were not measured. However, dyspnoea was confirmed 
as a negative prognostic factor and non-survivors had a significantly higher respiratory rate than 
survivors, potentially because respiratory muscles are often severely affected in AM. No difference 
was detected between serum CK activities of survivors and non-survivors, confirming previous 
observations that CK is not a reliable prognostic indicator (Votion et al., 2007b; van Galen et al., 
2010). This probably reflects laboratory limits and/or the kinetics of serum CK and may depend on the 
time of sampling. It is likely that both the peak and the duration of CK release in serum are important 
to signify muscle compromise and the clinical importance of muscle compromise depends on the 
affected muscle. Moreover, other problems besides massive muscle destruction might contribute to 
death in AM cases. Recumbency, a finding that is likely to suggest more severe disease and muscular 
dysfunction, was identified as a negative prognostic factor in the current and a previous study  
(van Galen et al., 2010). In addition, remaining standing most of the time was associated with 
survival. The tachycardia observed more frequently in non-survivors might reflect pain and/or 
cardiovascular compromise (by hypovolaemia or cardiomyopathy) and may contribute to metabolic 
disturbances. Moreover, normal mucous membranes, which indicates no severe cardiovascular 
compromise, was shown to be related to survival with a high specificity, PPV and NPV. 
Normothermia was demonstrated to be a useful variable to distinguish surviving cases. Muscle cells of 
severely affected horses can be completely carbohydrate depleted (Westermann et al., 2011), limiting 
energy metabolism even further and causing difficulties in maintaining body temperature. 
Hypothermia occurs in 29% of the cases (van Galen et al., 2012b). Other possibilities that might lead 
to hypothermia in severely affected horses are reduced rectal tone (van Galen et al., 2012b), the 
limited ability, through muscle dysfunction, to use shivering as a form of heat production, or impaired 
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peripheral circulation in horses with cardiovascular shock. Hyperthermia occured only in 11% of these 
cases (van Galen et al., 2012b) and can be explained by a hypothetical primary infection, due to 
inflammatory/infectious complications or due to reduced heat loss by impaired pulmonary ventilation. 
The anorexia that was more frequently noted in non surviving cases of AM, may aggravate metabolic 
disturbances and be secondary to other pathophysiological processes such as cardiovascular shock, 
severe hyperlipemia (Votion et al., 2007b) or pharyngeal or oesophageal muscular dysfunction. 
Defecation, also a clinical sign related to gastrointestinal function, had high sensitivity, and NPV for 
survival. 
The only treatment shown to offer significant benefits in terms of survival was the 
administration of vitamins and/or anti-oxidants, including vitamin B, C and E, selenium and carnitine, 
which support normal muscular function, antioxidative capacity and aerobic metabolism. Treatment 
with antioxidants, such as selenium, vitamin C and E, has previously been suggested to increase 
survival in horses suffering from AM in the USA by Finno and collaborators (2006). Carnitine and  
B vitamins are suggested as a treatment for AM following the finding that affected horses suffer from 
multiple acyl-CoA dehydrogenase deficiency and therefore have a dysfunctional mitochondrial lipid 
metabolism (Westermann et al., 2008b). 
Comparison of demographic data identified no prognostic factors, only factors that facilitate 
differential diagnosis between AM and other similarly presenting disorders (indicators for 
risk/protective factors; Table 1). In a previous case control study on Belgian cases  
(Votion et al., 2009), poor and normal body condition were identified as a risk factor for AM. In this 
study, horses with poor body condition were not more likely to have AM nor seemed to be more prone 
to die when affected. 
AM horses spent significant time at pasture compared to non-AM cases, which is consistent 
with the causative agent being pasture-associated and prolonged or repetitive contact being required to 
induce disease. A concurrent study utilising the same data has even demonstrated that all horses that 
developed the condition had spent more than 6H per day at pasture (van Galen et al., 2012b). Being 
given supplementary food was more common in non-AM cases than AM cases and appears to be 
protective. On one hand, more energy substrates (especially carbohydrates), vitamins and antioxidants 
are available if supplementary food is given, and on the other, horses might graze less and therefore 
have less contact with the causative agent. Water might also play a role in the development of AM. 
Previously it was shown that providing water from the distribution network was a protective factor 
(Votion et al., 2009) but the current study found water provision from a tank or a bath to be more 
frequent in non-AM than AM cases. Comparison of pasture characteristics showed that several of 
these (a slope, the presence of trees or dead wood, and the accumulation of dead leaves) were more 
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often related to AM cases and therefore may be predisposing factors for AM and a diagnostic aid. 
These features might create an ideal microclimate for the causative agent, and/or may contain specific 
substances, such as flavonoids (Hodnick et al., 1994) or mycotoxins, predisposing the horse to AM 
through metabolic interferences. 
This is the first study of AM to use a European-wide population and to include survivors. 
Considering that AM is a sporadic disease, a very large number of cases with a considerable amount of 
epidemiological and clinical data was included in this study, improving the statistical power of the 
study. Nevertheless, this study has several limitations. Including unconfirmed cases and incomplete 
files complicated the categorization of cases. Confirmation of AM was established by a combination 
of history, clinical signs and histology. More definitive diagnostic methods for AM include analysis of 
organic acids, glycine conjugates, and acylcarnitines in urine and/or blood (Westermann et al., 2008b) 
and muscle histochemistry to show selective involvement of type I muscle fibres with marked lipid 
accumulations (Cassart et al., 2007). Unfortunately, these diagnostic tests were only used for few 
cases in the current study. A further limitation is the underestimation of the true number of European 
cases, in part because of the rapid death of AM cases (Hosie et al., 1986; Whitwell et al., 1988; Brandt 
et al., 1997; Delguste et al., 2002; Votion et al., 2007b), and because the authors were dependent on 
the goodwill of veterinarians and owners to gather and communicate data, since AM is not a 
declarable disease and this may have introduced bias. The authors have made efforts to reach and 
inform veterinarians all over Europe. However, only some countries have national epidemiological 
networks and faculties that are actively involved in collecting and communicating data on this disease. 
Some of the data was very subjective in nature e.g. slope of pasture, presence of trees and leaves, body 
condition and the limitations in confirming the reliability of this data should be recognized. 
Furthermore, there are issues relating to the control group in the present study. For this study, non-AM 
cases were chosen as control group, since they highlight the difficulties for correct diagnosis of AM. 
However, the group is limited in case numbers and some cases might have been incorrectly allocated 
to the non-AM group. 
In conclusion, based on the results of this and a concurrent study (van Galen et al., 2012b), 
advice for owners and veterinarians handling affected cases can be summarised as follows: 
1) Preventive measures: stable horses (prioritise young horses) or limit grazing during high risk 
periods (autumn, spring following autumnal outbreaks); remove dead leaves and dead wood; 
use non-sloping pastures without trees and supplement horses with food during high risk 
periods. Horses can be considered safe once stabled for at least 5 days. 
2) Diagnosis: Clinical signs that are useful for diagnosing AM compared to similar diseases are: 
pigmenturia, normothermia and congested mucous membranes. Horses with cyanotic mucous 
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membranes or that have been found dead without previous signs are more likely to have a 
condition other than AM. Serum CK activities are high in AM cases but as they may only be 
slightly increased when measured shortly after the onset of clinical signs, repeated analysis is 
recommended. 
3) Prognosis: Clinical signs useful to predict survival in AM cases are: remaining standing most 
of the time, normothermia, normal mucous membranes and defecation. Prognosis is poor 
when horses are recumbent, or show sweating, anorexia, dyspnoea, tachypnoea and/or 
tachycardia. If the horse has none or only a few of these parameters or if the horse corrects 
these abnormalities following treatment, continued treatment is probably justified. The 
survival rate during the study period was 26%, and all non-survivors died or were euthanized 
within 10 days of onset of clinical signs. 
4) Therapeutic measures: Vitamins and antioxidants may be beneficial. 
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Tables 
Table 1. Historical and clinical variables that were significantly different between cases with a high 
probability of or confirmed atypical myopathy (AM group) and the cases with a low probability of 
having atypical myopathy or with another diagnosis (non-AM group). 
Variable AM group 
(354 cases) 
non-AM group 
(69 cases) 
     
Categorical variables 
(with Bonferroni 
correction: P < 0.05/k) 
n/N % n/N % ODDS 
ratio 
95% 
Confidence 
Interval 
 P value k 
          
Presence of trees at 
pasture  
194/198 98 31/36 86 7.82 1.99 – 30.73 + 0.003 7 
Accumulation of dead 
leaves at pasture 
160/184 87 12/32 38 11.11 4.82 – 25.59 + <0.001 7 
Dead wood at pasture 106/174 61 11/33 33 3.12 1.42 – 6.84 + 0.005 7 
Water provision in 
tank/bath 
84/164 51 21/26 81 0.25 0.09 – 0.69 - 0.007 7 
Sloping pasture  115/182 63 10/30 33 3.43 1.52 – 7.77 + 0.003 7 
Poor body condition 12/242 5 7/36 19 0.22 0.08 – 0.59 - 0.003 4 
Normal body condition 211/242 87 23/36 64 3.85 1.77 – 8.37 + 0.001 4 
< 6h at pasture/day 0/195 0 8/37 22 0.04 0.01 – 0.19 - <0.001 7 
24h/24h at pasture  177/205 86 21/39 54 5.42 2.57 – 11.42 + <0.001 7 
Not at pasture 6/200 3 6/37 16 0.03 0.00 – 0.22 - 0.001 7 
Supplemented with food  120/187 64 31/34 91 0.17 0.05 – 0.59 - 0.005 7 
Found dead at pasture 
without previous signs 
2/327 1 9/62 15 0.04 0.01 – 0.17 - <0.001 7 
Pigmenturia 243/260 93 12/23 52 13.10 5.04 – 34.03 + <0.001 7 
Normothermia (37-
38.5°C) 
146/229 64 13/36 39 2.59 1.24 – 5.41 + 0.011 3 
Cyanotic mm 18/231 8 8/25 32 0.18 0.07 – 0.47 - 0.001 6 
Received treatment  233/252 92 32/44 73 4.60 2.04 – 10.36 + <0.001 13 
          
Continuous variables 
(with Bonferroni 
correction: P < 0.05/k) 
Mean 
(SD) 
Range N Mean 
(SD) 
Range N    P value  
(Welch’s 
test) 
k 
Survival time  
  (days) 
1.6 ± 1.4 0 – 10  209 1.0 ± 
1.2 
0 – 5  31    0.008 4 
Highest measured CK 
serum activity  
  (IU/L; normal 50-200) 
302443 
±  
751976 
634 –  
7059880 
207 39373 ±  
145282 
203 – 
776000 
28    0.0001 2 
First measured CK 
serum activity   
  (IU/L; normal 50-200) 
239237 
±  
636824 
99 – 
7059880  
207 37677 ±  
145489 
203 – 
776000 
28    0.0001 2 
Legend: AM = atypical myopathy; + = more often present in the AM group compared to the non-AM 
group; - = more often present in the non-AM compared to the AM group; N = number of total 
responses for each category; n = number of positive responses for each category; mm = mucous 
membranes; CK = creatine kinase; SD = standard deviation; k = the number of comparisons made. 
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Table 2. Sensitivity, specificity and positive and negative predictive values of specific clinical signs 
related to the highly probable or confirmed diagnosis atypical myopathy and related to survival. 
Clinical signs Correct diagnosis of reported cases 
(AM versus non-AM) 
Survival of correctly diagnosed cases 
(AM survivors versus non-survivors) 
 Sensitivity  Specificity  PPV  NPV  Sensitivity  Specificity  PPV  NPV  
Depression 0.796 0.325 0.883 0.200 0.700 0.188 0.219 0.659 
Weakness 0.851 0.278 0.890 0.213 0.681 0.176 0.215 0.625 
Stiffness 0.833 0.333 0.897 0.222 0.782 0.221 0.270 0.733 
Recumbency 0.783 0.256 0.876 0.149 0.636 0.135 0.179 0.556 
Trembling 0.680 0.467 0.914 0.149 0.488 0.295 0.169 0.662 
Sweating 0.640 0.419 0.900 0.125 0.500 0.293 0.165 0.677 
Remaining 
standing most of 
the time 
0.458 0.675 0.910 0.148 0.712 0.687* 0.394* 0.893* 
Pigmenturia 0.935* 0.478 0.953* 0.393 0.750 0.112 0.232 0.556 
Hypothermia 
(<37°C) 
0.286 0.611 0.829 0.115 0.051 0.629 0.037 0.704 
Normothermia 
(37-38.5°C) 
0.605 0.629 0.914* 0.196 0.769* 0.481 0.303 0.877* 
Hyperthermia 
(>38.5°C) 
0.109 0.771 0.758 0.117 0.179 0.888 0.318 0.788 
Normal mm 0.372 0.630 0.896 0.105 0.600 0.721* 0.409* 0.849* 
Congested mm 0.534 0.704 0.939* 0.150 0.378 0.447 0.179 0.692 
Defecation 0.678 0.400 0.921 0.108 0.902* 0.393 0.333 0.923* 
Dyspnoea 0.442 0.591 0.917 0.094 0.205 0.463 0.100 0.667 
Tachycardia 0.787 0.261 0.916 0.107 0.692 0.185 0.197 0.676 
Legend: AM = atypical myopathy, PPV = positive predictive value; NPV = negative predictive value; 
mm = mucous membranes; * = useful sensitivity, specificity, PPV and/or NPV. 
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Table 3. Historical and clinical variables that were significantly different between the survivors and 
non-survivors of cases with high probability of or confirmed with atypical myopathy. 
Clinical signs Survivors  
(88 cases) 
Non-survivors 
(256 cases) 
   P value k 
Categorical variables (with 
Bonferroni correction:  
P < 0.05/k) 
n/N % n/N % ODDS 
ratio 
95% 
Confidence 
Interval 
   
Recumbency 43/72 60 182/215 85 0.27 0.15 – 0.49 - <0.001 7 
Sweating  28/60 47 134/192 70 0.38 0.21 – 0.69 - 0.001 7 
Anorexia  10/63 16 60/183 33 0.39 0.18 – 0.81 - 0.012 4 
Defecation  45/53 85 94/151 62 3.41 1.50 – 7.75 + 0.003 4 
Dyspnoea  10/53 19 90/172 52 0.21 0.10 – 0.45 - <0.001 6 
Treatment with vitamins 
and antioxidants (i.e. B,C,E, 
selenium, carnitine) 
 
42/66 64 52/155 34 3.47 1.90 – 6.33 + <0.001 13 
Continuous variables (with 
Bonferroni correction:  
P < 0.05/k) 
Mean 
(SD) 
Range N Mean 
(SD) 
Range N    P value  
(Welch’s 
test) 
k 
Duration of disease  
  (days)  
10.6 ± 
5.6 
1 – 30  50 1.6 ± 1.4 0 – 10  207    P < 0.001 4 
Respiratory rate  
  (rpm; reference range < 
20) 
24 ± 
11 
8 – 48 41 29 ± 14 6 – 72 116    P = 0.01 6 
Heart rate  
  (bpm; reference range < 
45) 
53 ± 
13 
28 – 
88  
54 62 ± 18 30 – 
120 
155    P = 0.01 6 
Legend: + = positive prognostic factor and thus more often present in survivors compared to  
non-survivors; - = negative prognostic factor and thus more often present in non-survivors compared 
to survivors; N = number of total responses for each category; n = number of positive responses for 
each category; mm = mucous membranes; SD = standard deviation ; k = the number of comparisons 
made. 
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FAT ANALYSIS IN MUSCLE SAMPLES FROM HORSES AFFECTED WITH ATYPICAL 
MYOPATHY: PRELIMINARY RESULTS 
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Abstract 
Previously lipid accumulations were demonstrated in atypical myopathy affected muscles. The 
objectives are to further describe this accumulation by comparing lipid content of atypical myopathy 
affected versus control muscles. The muscle content of lipids, lipid classes and free fatty acid profiles 
were determined. The amount of total lipids was similar, but affected samples showed less 
triglycerides and more monoglycerides and free fatty acids than controls. Affected muscles had 
increases in C10:0, C16:1, C18:0, C18:1n9, C22:0, C20:4n6, C22:1 free fatty acids and unidentified 
free fatty acids shorter than C10 and longer than C24, however with some differences between cases. 
C16:1 showed the most spectacular increase. Previously problems with short- and medium-chain free 
fatty acids were described, but these data suggest long-chain free fatty acids to be involved in atypical 
myopathy as well. The results strengthen previously made suggestions to favour carbohydrate 
metabolism over lipid metabolism as supportive therapy in these critically ill patients. 
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Introduction 
Atypical myopathy (AM) is a severe rhabdomyolysis occurring in grazing horses. The 
myodegenerative process affects more selectively oxidative type I fibres (mainly found in postural and 
respiratory muscles) rather than glycolytic type II fibres. Histochemical stains for succinate 
dehydrogenase (SDH; Palencia and Rivero, 2007) and NADH-tetrazolium reductase  
(Cassart et al., 2007) indicated weak oxidative potential and more recently, decreased activities of 
mitochondrial complexes confirmed an impaired oxidative metabolism (Westermann et al., 2011). In 
addition, affected muscle fibres show excessive intramuscular lipid storage (Cassart et al., 2007; 
Palencia and Rivero, 2007), and the biochemical defect associated to AM induces a “multiple  
acyl-CoA dehydrogenase deficiency (MADD)” -like disorder (Westermann et al., 2008b) with defects 
in intramitochondrial dehydrogenation of fatty acyl-CoA‟s and and other intermediates in branched-
chain amino acid metabolism with functional impairment of the mitochondrial electron transfer (ETS) 
system. Therefore MADD also leads to dysfunction of the most efficient way for energy generation by 
the mitochondria, i.e. the oxidative phosphorylation (OXPHOS). This defect among other things 
causes an accumulation of specific acylcarnitines in plasma and urinary excretion of metabolites 
derived from the accumulated acyl-CoA ester intermediates (Gregersen, 1985) as found in  
AM-affected horses (Westermann et al., 2008b). On the other hand, the absence of abnormal 
accumulation of glycogen or abnormal form of polysaccharide in affected muscle tissue (Cassart et al. 
2007; Palencia and Rivero 2007) suggests a preserved glycolytic pathway. 
Hyperlipaemia (Votion et al., 2007b) as well as lipid accumulation in skeletal muscles in the 
form of microvesicular droplets (Cassart et al., 2007; Westermann et al., 2008b) are common findings 
in AM. More detailed information about these lipids is needed to understand the complex disturbances 
in AM affected horses. Previously lipid disorders in AM have been mainly studied by plasma and 
urine acylcarnitine profiles (Westermann et al., 2008b). It was previously suggested that plasma 
acylcarnitines and FFA profiles in exercising horses reflect muscle metabolism  
(Westermann et al., 2008a). However, it would be interesting to investigate lipid classes, with a main 
emphasis on free fatty acids (FFA), in muscular tissue, because abnormalities in lipids are expected to 
occur first at the location of the deficiencies. In addition, blood analysis is not always reliable as 
diagnostic tool for human disorders of fatty acid oxidation and therefore additional testing of 
intermediates has also been performed in tissues such as fresh muscle or post mortem tissues, showing 
characteristic profiles for the disorder (Boles et al., 1998; Onkenhout et al., 2001; Tyni et al., 2002). 
The aims of this study are 1) to analyse the amount of total lipids and of the different lipid 
classes in AM affected muscles, 2) to analyse the profile of FFA and the amount of individual FFA in 
AM affected muscles and 3) to compare those analyses of affected muscles to that of normal muscle.  
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Materials and methods 
Case selection 
Five horses were included in this study. Two of these horses (AM1 and AM2) were diagnosed with 
AM based on history, clinical signs, presence of a multifocal process compatible with Zenker 
degeneration and necrosis in fibres of postural muscles, respiratory muscles or both on histology and 
confirmation of MADD by determination of acylcarnitines profile in serum. Three other horses served 
as control horses (C1, C2 and C3): they were euthanized for other reasons and without any clinical 
evidence of muscle pathology. From all horses, muscle biopsies of different muscles were sampled 
during general anaesthesia prior to euthanasia. The sampled muscles were immediately frozen in 
liquid nitrogen and then stored at – 80°C until analysis. The muscles that were sampled are shown in 
Table 1. 
Lipid analysis 
The lipid and FFA analysis were performed as previously described in literature (Gorski et al., 1998; 
Nawrocki et al., 1999; Nawrocki and Gorski, 2004). 
Extraction of the lipids 
The muscle samples were thawed, lyophilised and weighted. They were then crushed in 10 ml 
phosphate buffer (0.15 M) at pH 7.4. The crushed samples were added to 8 ml chloroform and stirred 
during 30 minutes. The sample was then centrifuged at 2500 rotations per minute  
(power of centrifuge 1000 g) separating the aqueous phase of the lipid phase. The aqueous phase was 
aspirated and 6 ml of the chloroform lipid phase (75%) were collected in a pre-weighted tube. The 
solvent was evaporated under nitrogen flow and possible traces of water were eliminated by 
lyophilisation. Finally, the tube with its content was weighted. This weight was used to calculate the 
weight of the total extracted lipids (weight of tube with content – weight of empty tube) and finally to 
calculate the weight of lipids in mg per gram muscle. 
Analytical thin layer chromatography 
The extracted lipids were brought in solution by mixing them with 1 ml chloroform. Ten µl of this 
solution were used to perform thin layer chromatography (TLC) on a silica gel covered plate  
(Merck
©
 KGaA, Darmstadt, Germany) in a solvent mixture of petroleum ether, diethylic ether,  
acetic acid (70; 30; 2). Two control samples (20 µl) were used on every chromatography plate:  
one control sample contained a mix of triolein and cholesterol (S1), and the other control sample 
contained oleic acid and cholesteryl oleate (S2). This TLC permitted a separation of the lipid classes: 
cholesteryl esters, triglycerides, FFA, cholesterol, monoglycerides and phospholipids  
(in migrating order). By vaporisation of a copper acetate solution on the plate followed by a heating of 
the plate at 180°C, the migrated lipids were visualised as brown-black spots. The quantitative 
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percentage of every lipid class, their value in µg in the muscle sample and their value per gram of 
muscle were calculated by use of densitometry. 
Preparative thin layer chromatography and isolation of FFA 
A second TLC, identical to the previous one, was performed on 15 µl of the lipid samples with the 
same control solutions and under the same conditions. At the end of this TLC, only S1 and S2 were 
visualised as previously described. The central part of the plate that contains the samples was 
visualised only temporarily by vaporisation of iodine to be able to localise the FFA with precision. 
After iodine evaporation, the plate was vaporised with butylhydroxytoluene dissolved in chloroform to 
prevent lipid peroxidation by oxygen exposure. The zone corresponding with the localisation of the 
FFA was removed with chloroform by the Eluchrom (Camag
©
, Switzerland) at slow velocity  
(1 ml per 10 minutes) and placed in a 1 ml glass tube. 
Methylation and gas liquid chromatography 
The obtained FFA solution was evaporated under a nitrogen flow and then methylated by 
diazomethane. After methylation, the solution was evaporated and the sample was replaced in solution 
with 10 µl of dichloromethane of which 0.5 µl were injected in the chromatograph. 
The following conditions of gas liquid chromatography (GLC) were used: Chromatograph 
Varian CX 3600 star, equipped with a capillary column Supelco SP
TM
-2380 (cyano-silicone; 30 meter; 
diameter 0.25 mm; thickness of the film 0.2 µm) and a flame ionisation detection. A nitrogen flow was 
used as gas vector (30 ml/min) at 180°C during 6 minutes, followed by an increase of the temperature 
(10°C/min) until 210°C, which was maintained for 40 minutes. The flame was induced by air  
(300 ml/min) and hydrogen (30 ml/min). The column was standardised by a mix of methylated FFA 
(PUFA n°2 from Supelco; Bellefonte, PA, USA) and by individual methylated FFA (purchased from 
Sigma; methylated by diazomethane). The registration of the chromatogram was performed by an 
integrator. The column separated FFA based on their number of carbons and based on their number of 
double bonds. 
The peaks were identified by comparing retention times to the reference FFA (PUFA n°2 or 
the individual FFA). After localizing and identifying the peaks, the total surface of all peaks was 
calculated being equal to 100%. Thereafter the surface of each individual peak was calculated in 
percentage of the specific FFA and converted into μg/g muscle. 
Comparison 
Lipid analyses from AM affected muscle samples and control muscle samples were compared, but due 
to the limited number of cases, no statistic analysis of these data was performed. 
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Results 
Extraction of the lipids 
The weight of the total lipids (mg/g muscle) was in the same range for AM affected muscle samples as 
for control muscle sample (Table 2). 
Analytical thin layer chromatography 
In contrast to control horses, FFA were clearly visible at TLC in all muscles of AM affected horses 
(Figure 1a and 1b) and the mean muscular FFA in affected horses was higher than that of control 
horses (Table 2). Differences in the other lipid classes were also visible (no quantitative data shown): 
in muscle samples of affected horses less triglycerides were visible than in muscle samples of control 
horses and in some muscles of affected horses monoglycerides were identified. In none of the horses 
cholesteryl esters were visualised at TLC. 
Gas liquid chromatography 
In AM and control samples, 53.2 ± 6.1% and 53.1 ± 7.6% respectively of GLC peaks could be 
identified by comparison to the reference FFA. In all horses, largely the same FFA were found on the 
chromatograms. In control samples the major FFA were C16:0 and unidentified FFA with a chain 
length longer than C24:1, and in affected samples the major FFA was C16:1. Samples of horse AM1 
had no FFA below chain length of C10, but showed clearly higher levels of C16:1, C18:0, C22:0 and 
C22:1 compared to control samples, and mild increases were seen for C18:1n9, C20:4n6 and 
unidentified FFA longer than C24:1. Samples of horse AM2 had obvious increases in FFA with a 
shorter chain length than C:10, C16:0 and C18:0, and to a lesser extent also increases in C10:0 and 
C22:1 (Table 3). 
 
Discussion 
The present study confirms a problem in muscular lipid metabolism showing a smaller amount of 
triglycerides and a larger amount of monoglycerides and FFA in affected muscles compared to 
controls. Triglycerides consist of FFA bound to glycerol and limited amounts are stored in muscle 
cells as energy source (Lehninger et al., 1993a; MacLeay, 2004). In the light of the important energy 
deficit in affected horses, as suggested by the excretion of AMP metabolites and muscle glycogen 
depletion (Westermann et al., 2011), stored triglycerides probably are degraded into FFA and glycerol 
with monoglycerides as intermediates. Interestingly, in human MADD the amount of muscular 
triglycerides is increased and abnormal fatty acids are contained in this lipid group and not in the FFA 
group (Onkenhout et al., 2001). It is currently unknown why this difference occurs between humans 
and horses in accumulation of abnormal fatty acids. The chronicity of the condition does not seem to 
play a role since in human neonates the condition is acute as well and still the abnormal fatty acids are 
found in the muscular triglyceride and not in the FFA group (Onkenhout et al., 2001). In future 
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studies, it would be interesting to study the triglyceride group in affected horses. No difference was 
demonstrated in the amount of total muscular lipids between the two studied groups. The increase in 
FFA (in μg/gram muscle) was too small to make a significant difference on the amount of total lipids 
(in mg/gram muscle). Still important lipid accumulations are visible in affected muscle samples 
stained by Oil red O in contrast to normal horses (Cassart et al., 2007). The affinity for neutral lipids 
(FFA and their derivatives) and the poor coloration of structural fats by the Oil red O staining  
(Bayliss High and Lake, 1990) may account for this phenomenon. Our hypothesis is that due to 
insolubility, free neutral fat aggregates to lipid droplets giving rise to the frequently reported vesicular 
lipidosis on histology (Cassart et al., 2007; Palencia and Rivero, 2007). 
Opposite to the study of Westermann et al. (2008b), the current study demonstrates the effect 
on all lipid classes and measured FFA instead of acylcarnitines. But chloroform dissolves lipids, broke 
lipid-proteins connections, and caused acylcarnitines to join the measured FFA. Therefore, eventhough 
they are very different groups, there is a close link between acylcarnitines and FFA in this study. In the 
two cases of the current study, diagnosis of AM was confirmed with the use of plasma acylcarnitine 
profiles that showed increases of plasma short-, medium- and long-chain acylcarnitines in both. It 
could thus be expected that this would be joined by an increase in muscular short-, medium- and long-
chain FFA. Findings were, however, variable for short- and medium-chain FFA (shorter or equal to 
C10:0) with one case (AM2) showing increased values compared to the controls and the other (AM1) 
having no short- and medium-chain FFA shorter than C10:0 and with C10:0 levels similar to controls. 
Interestingly, affected horse AM1 also had a lower total FFA muscular concentration and lower plasma 
levels of acylcarnitines and organic acids compared to AM2. Maybe this can be explained by a less 
severe dysfunction and/or variation in the deficient enzymes. Another explanation is that the amount 
of acylcarnitines was not large enough to lead to an increase in FFA. 
In the current study, mostly the long-chain FFA were increased in affected muscle samples 
compared to the control group: increases were seen for C16:1, C18:0, C18:1n9, C22:0, C20:4n6, 
C22:1 and unidentified FFA longer than C24, however with some differences between cases. In both 
cases, the most spectacular increase was that in C16:1 (palmitoleic acid). The study of Westermann et 
al. demonstrated no significant increase in plasma and muscular long-chain acylcarnitines in affected 
horses, and they only tested the muscle activity of short- and medium-chain acyl-CoA 
dehydrogenases, not of long-chain acyl-CoA dehydrogenases (Westermann et al., 2008b). However in 
the human MADD syndrome, a general accumulation of plasmatic acylcarnitines or FFA and tissular 
(hepatic and muscular) FFA is observed from C4 to C18, thus including long-chain acylcarnitines and 
long-chain FFA (Onkenhout et al., 1995; Costa et al., 1998; Onkenhout et al., 2001; Nyhan et al., 
2005). As in our study, individual results can however be variable dependant on the severity of human 
disease (Costa et al., 1998; Nyhan et al., 2005). Minor differences in FFA profiles between individual 
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horses are probably also dependant on different feeding practices (Andersson et al., 2002; Perez-
Palacios et al., 2007), levels of activity or training of horses (Gottlieb et al., 1989), daily fluctuations 
(Orme et al., 1994; Piccione et al., 2009) and/or muscle fibre composition (Vessby, 2000). In 
accordance to human MADD, the current study demonstrates a characteristic muscular FFA profile 
with increases in a wide range of FFA corresponding to short-, medium- and long-chain acyl-CoA 
dehydrogenases deficiencies. Eventhough more data is needed, this FFA analysis on muscle samples 
might therefore be a promising additional diagnostic tool, especially for cases without urine or blood 
samples available (for example due to a rapid death) or with inconclusive results of urine or plasmatic 
acylcarnitines profiles. 
In general, FFA accumulations suggest a dysbalance between their uptake or delivery and the 
following steps of their metabolism. Currently the origin of muscular FFA increase in AM is 
unknown. At the level of the muscle they could accumulate following hydrolyzation of triglycerides 
(as suggested by this study by the decrease in muscular triglycerides and increase in monoglycerides) 
and/or the catabolism of structural lipids. Also, the frequently encountered hyperlipaemia in affected 
horses (Votion et al., 2007b) might be a source of FFA since the possibility of rapid uptake of FFA by 
muscles from hyperlipeamic blood has been demonstrated in humans (Bachmann et al., 2001). 
Moreover, rats and persons with dyslipaemia and obesity show consistently an increase in plasmatic 
levels of C16:1 (Zak et al., 2000; Fukuchi et al., 2004; Mozaffarian et al., 2010) as do fasting ponies 
(Bauer and Ransone, 1983). However, in this study plasma levels of C16:1-carnitine were only 
increased in one of the two cases compared to the reference values. C16:1 could theoretically also 
increase in muscular tissue after desaturation of the very common C16:0 (Robb et al., 1972; Luther et 
al., 1981; Orme et al., 1994; Westermann et al., 2008a). Interestingly, stearoyl-CoA desaturase, which 
catalyses the synthesis of C16:1, is recognized as an important component in the regulation of 
oxidative muscle metabolism (Dobrzyn and Dobrzyn, 2006; Flowers and Ntambi, 2008). In this 
perspective, it should also be mentioned that a flavin adenine dinucleotide (FAD)-dependent 
dysfunction was hypothesised in AM because of the decreased activity of several dehydrogenases that 
all use FAD as a coenzyme (Westermann et al., 2008b). If C16:1 would originate from desaturation of 
C16:0, it can be suggested that a FAD dependant enzyme (Lehninger et al., 1993e) functions correctly, 
thus challenging the hypothesis of a FAD-dependent dysfunction. Several of the increased FFA are 
unsaturated, and therefore they require the action of two auxiliary enzymes (i.e. an isomerase and a 
reductase) before undergoing the classical pathway of ß oxidation (Lehninger et al., 1993g). In 
humans, disorders of fatty acid ß oxidation relate mainly to saturated precursors, but it may not be 
excluded that the cause of AM alters the specific pathway of unsaturated fatty acid oxidation  
(Roe et al., 1990; Miinalainen et al., 2009). Finally, partial ß oxidation of precursors of the increased 
FFA, as is suggested in humans with MADD (Onkenhout et al., 2001) or complete blockage of lipid 
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metabolism of accumulated FFA may be responsible for their increase in muscle. Severe problems 
have indeed been detected in enzymes involved in the ß oxidation, ETS and OXPHOS in AM 
(Westermann et al., 2008b; Westermann et al., 2011) and could support these last two possibilities. 
Multiple scientific studies on humans and rats have shown that accumulations of long-chain 
FFA have effects on glucose metabolism and insulin sensitivity of muscle cells, but these effects have 
been various and sometimes in opposite directions going from positive to cytotoxic or “lipotoxic” 
(Vessby, 2000; Kusunoki et al., 2006; Hirabara et al., 2007; Mozaffarian et al., 2010). Moreover the 
effects depend on the FFA chain length and saturation (Hommelberg et al., 2009). In contrast to other 
long-chain FFA, C16:1 seems merely to have a positive effect on insulin sensitivity (Dimopoulos et 
al., 2006; Stefan et al., 2010; Yang et al., 2011). If this effect is similar in horses it would be 
beneficial in AM, because it would enhance carbohydrate metabolism. Nevertheless, it can be 
suggested that some horses suffering from AM have a certain degree of insulin resistance because, as 
opposed to human MADD, hyperglycaemia often occurs in AM (Votion et al., 2007b; Westermann et 
al., 2008b) and that in the face of severe energetic problems with mitochondrial lipid metabolism, and 
intrasarcoplasmatic active glycolysis and glycogen depletion (Westermann et al., 2008b; Westermann 
et al., 2011). Another effect of exposure to long-chain FFA in skeletal muscle is that it can lead to 
mitochondrial uncoupling (Hirabara et al., 2007), although this is mainly caused by saturated and not 
by unsaturated FFA (Hirabara et al., 2010). Indeed in AM decreased activities in mitochondrial 
respiration complexes have been described (Westermann et al., 2011), but it is not clear whether they 
are primary or secondary. In addition, in vitro studies show that accumulation of short- and  
medium-chain acyl-CoA‟s has inhibitory effects on pyruvate dehydrogenase complex, alpha-
ketoglutarate dehydrogenase complex and Complex III (Sauer et al., 2008). It is currently unknown if 
these secondary effects of intrasarcoplasmatic accumulations of FFA and other intermediate products 
can be extrapolated to the equine species and more importantly to AM. 
The current study included only a limited amount of cases and did not include a complete set 
of muscle samples of AM affected and control horses. Therefore one should be prudent to interpret 
these findings and further studies are needed to confirm these results. Testing of insulin resistance was 
not performed in these cases, because fasting is recommended for insulin resistance testing but 
believed to be harmful in AM cases regarding the energetic pathologies. As a matter effect, in human 
MADD it is generally known that fasting can induce clinical disease (Costa et al., 1998; Nyhan et al., 
2005) and moreover, results of a previous study on clinical prognostic factors in AM indicated 
anorexia as a negative prognostic factor (van Galen et al., 2012a). 
In conclusion, the results of this study confirm a problem in lipid metabolism occurring in 
horses suffering from AM, and are therefore supportive for previously made suggestions to favour 
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carbohydrate metabolism over lipid metabolism in affected horses (Westermann et al., 2008b). In 
accordance to human MADD, the current study demonstrates a characteristic “MADD”- like muscular 
FFA profile with increases in a wide range of FFA and including long-chain FFA. The implication of 
long-chain FFA in the metabolic disturbances of AM has not been described previously and future 
studies should further clarify their impact. 
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Tables and Figures 
Table 1. Sampled muscles on the selected horses. 
Horse m. brachiocephalicus m. longissimus 
dorsi 
m. quadriceps 
femoris 
m. semitendinosis 
AM1 x x x  
AM2 x x x x 
C1 x x x x 
C2  x  x x 
C3 x   x 
Legend: AM = atypical myopathy affected horses; C = control horses. 
 
 
Table 2. Weight of the total lipids and of the free fatty acids in the sampled muscles of the control 
horses and atypical myopathy affected horses. 
Horse Muscle Weight lyophilised 
muscle 
(g) 
Weight total 
lipids 
(mg/g muscle) 
Weight FFA 
(µg/g 
muscle) 
Mean (±SD) 
FFA 
(µg/g muscle) 
Atypical myopathy affected horses   1885.81 ± 
710.02 
AM1 m. brachiocephalicus 0.9030 21.12 2 673.79 1716.58 ± 
915.80  m. longissimus dorsi 1.1898 10.98 848.75 
 m. quadriceps femoris 
 
0.7950 22.60 1 627.20 
AM2 m. brachiocephalicus 1.0900 18.72 2 515.43 2012.74 ± 
631.68  m. longissimus dorsi 1.0642 32.32 2 472.86 
 m. quadriceps femoris 1.2524 61.43 1 898.16 
 m. semitendinosis 
 
1.0142 43.78 1 164.49 
Control horses    487.41 ± 597.44 
C1 m. brachiocephalicus 1.2495 21.45 1 454.31 474.88 ± 653.77 
 m. longissimus dorsi 0.8806 29.37 146.85* 
 m. quadriceps femoris 1.2152 21.81 109.05* 
 m. semitendinosis 
 
0.9438 37.86 189.30* 
C2 m. brachiocephalicus 1.1871 35.94 179.70* 195.15 ± 13.6 
 m. quadriceps femoris 1.2335 41.07 205.35* 
 m. semitendinosis 
 
1.0313 40.08 200.40* 
C3 m. brachiocephalicus 1.1016 45.27 1 616.59 950.87 ± 941.47 
 m. semitendinosis 
 
1.0216 57.03 285.15* 
Legend: AM = atypical myopathy affected horses; C = control horses; SD = standard deviation;  
FFA = free fatty acids; (*) FFA not present or only in traces visible on the thin layer chromatography, 
so < 10 µg or < 0.5 % of the weight of the measured total lipids. To be able to perform the calculations 
for the gas liquid chromatograpy, the quantity of those FFA was arbitrary chosen to be 0.5% of the 
weight of the measured total lipids.  
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Figure 1a. Example of a thin layer chromatography on a muscle sample from a control horse. 
 
 
Legend: A chromatography plate with 5 samples (9E-9K) from a control horse and 2 control samples 
(S1 and S2). The migration of the lipids occurs from ventral to dorsal and the TLC permits a 
separation of cholesteryl esters, triglycerides, free fatty acids, cholesterol, monoglycerides and 
phospholipids. After migration, the migrated lipids were visualised under the form of brown-black 
spots. Note the absence of free fatty acids.  
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Figure 1b. Example of a thin layer chromatography on a muscle sample from a horse affected with 
atypical myopathy. 
  
Legend: A chromatography plate with 5 samples (3B-3H) from a horse affected by atypical myopathy 
and 2 control samples (S1 and S2). The migration of the lipids occurs from ventral to dorsal and the 
TLC permits a separation of cholesteryl esters, triglycerides, FFA, cholesterol, monoglycerides and 
phospholipids. After migration, the migrated lipids were visualised under the form of brown-black 
spots. Note the presence of free fatty acids.  
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Table 3. The individual free fatty acids in muscle samples of horses affected with atypical myopathy 
and control horses. 
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 µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g 
Affected horses                       
AM1 BC 0.0 75.8 67.9 70.3 118.6 558.4 35.9 75.1 24.5 0.0 0.0 9.4 10.8 0.0 33.9 58.9 21.1 0.0 0.0 43.1 0.0 592.6 
 LD 0.0 45.8 30.6 25.5 37.2 225.6 8.6 17.8 4.3 0.0 0.0 2.0 2.8 0.0 7.8 21.1 11.4 0.0 0.0 18.5 0.0 121.1 
 QF 0.0 93.3 55.6 0.0 0.0 493.4 16.4 249.0 9.9 0.0 0.0 0.0 0.0 0.0 14.4 50.9 26.0 0.0 0.0 44.7 0.0 253.0 
 Mean 0.0 71.6 51.3 31.9 51.9 425.8 20.3 114.0 12.9 0.0 0.0 3.8 4.6 0.0 18.7 43.6 19.5 0.0 0.0 35.4 0.0 322.2 
 SD 0.0 24.1 19.0 35.6 60.7 176.4 14.1 120.4 10.4 0.0 0.0 4.9 5.6 0.0 13.5 19.9 7.4 0.0 0.0 14.7 0.0 243.3 
AM2 BC 549.7 156.4 0.0 0.0 220.5 971.2 42.5 0.0 20.6 0.0 0.0 25.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 46.3 0.0 246.3 
 LD 333.1 168.5 48.5 57.4 328.5 687.3 25.9 9.8 7.2 0.0 0.0 0.0 0.0 0.0 0.0 41.8 14.6 0.0 0.0 44.0 0.0 157.7 
 QF 311.1 100.9 61.2 42.0 52.3 446.4 19.7 3.1 15.7 0.0 0.0 17.7 0.0 0.0 0.0 35.1 13.2 0.0 0.0 31.1 0.0 218.8 
 ST 193.9 56.8 26.6 0.0 42.6 434.0 15.5 0.0 9.9 0.0 0.0 0.0 0.0 0.0 0.0 30.8 0.0 0.0 0.0 25.6 0.0 128.9 
 Mean 346.9 120.7 34.1 24.9 161.0 634.7 25.9 3.2 13.4 0.0 0.0 10.7 0.0 0.0 0.0 26.9 7.0 0.0 0.0 36.8 0.0 187.9 
 SD 148.3 51.7 26.8 29.4 138.4 252.8 11.9 4.6 6.0 0.0 0.0 12.7 0.0 0.0 0.0 18.5 8.1 0.0 0.0 10.0 0.0 54.0 
Control horses                                             
C1 BC 102.1 158.6 0.0 0.0 142.0 202.5 0.0 80.7 43.4 0.0 0.0 37.8 0.0 0.0 0.0 53.0 0.0 0.0 0.0 77.4 59.1 392.9 
 LD 50.1 16.3 0.0 0.0 8.3 17.5 0.0 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.0 2.8 0.0 7.2 5.8 27.8 
 QF 0.0 21.7 0.0 0.0 4.0 11.4 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 7.6 0.0 4.1 12.4 49.3 
 ST 53.9 17.6 0.0 0.0 14.6 23.0 0.0 8.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 5.6 3.5 2.4 0.0 9.0 6.6 39.9 
C2 BC 0.0 15.3 0.0 5.3 43.4 2.2 3.8 4.7 3.8 1.8 2.1 0.0 1.7 1.9 0.0 4.2 2.6 0.0 0.0 0.0 0.0 49.9 
 QF 0.0 21.6 0.0 0.0 90.1 5.4 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 6.0 3.6 1.8 1.5 0.0 0.0 24.0 
 ST 42.6 16.2 0.0 4.8 84.0 1.2 1.4 2.7 0.8 0.8 0.0 0.0 0.0 0.0 0.0 2.2 0.0 3.6 0.0 0.0 0.0 19.7 
C3 BC 268.6 110.5 92.6 33.1 323.5 11.3 0.0 25.7 11.4 0.0 0.0 0.0 0.0 0.0 0.0 20.3 0.0 15.9 0.0 21.6 0.0 134.1 
 ST 62.61 20.9 14.3 13.5 14.1 3.4 0.0 7.6 0.0 0.0 0.0 0.0 3.7 0.0 0.0 5.4 0.0 0.0 0.0 8.4 0.0 59.1 
 Mean 64.4 44.3 11.9 6.3 80.4 30.9 0.6 15.6 6.9 0.5 0.2 4.2 0.6 0.2 0.0 11.7 1.1 3.8 0.2 14.2 9.3 88.5 
 SD 83.9 52.6 30.6 11.0 102.5 64.8 1.3 25.5 14.2 0.7 0.7 12.6 1.3 0.6 0.0 16.4 1.6 5.1 0.5 24.7 19.2 119.1 
Legend: BC = m. brachiocephalicus; LD = m. longissimus dorsi; QF = m. quadriceps femoris;  
ST = m. semitendinosis; SD = standard deviation. 
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ASSESSMENT OF ACID-BASE IMBALANCES IN HORSES SUFFERING FROM ATYPICAL 
MYOPATHY 
 
VAN GALEN G., CERRI S., PORTER S., SAEGERMAN C., LEFERE
 
L., ROSCHER K., MARR C.,  
AMORY H., VOTION D.-M. 
Placed in editorial format for submission to J. Vet. Intern. Med. 
 
Abstract 
Background - Descriptions on acid-base disturbances in atypical myopathy (AM) are limited. 
Hypothesis/Objectives - 1) Describe acid-base and cardiovascular shock status in AM cases on 
admission, 2) identify prognostic indicators amongst acid-base and shock variables. 
Animals - 34 AM cases and 15 healthy controls 
Methods - Records were searched for venous blood gas analysis, electrolytes, total protein, lactate, 
PCV, BUN, CK, rectal temperature and heart and respiratory rate on admission and final survival 
status. Base excess (BE) of free water (BEfw), chloride (BEcl), total protein (BEtp), and unidentified 
anions (BEua), anion gap (AG), measured strong ion difference (SIDm) and total non-volatile weak 
acids (Atot) were calculated. Acid-base classifications and shock grades were attributed. Statistical 
analysis compared variables in AM cases versus control horses and AM survivors versus AM  
non-survivors. 
Results - The majority of AM cases had respiratory and/or metabolic acid-base alterations that were 
mainly caused by respiratory alkalosis, lactic acidosis and/or SIDm alkalosis. AM cases had 
significantly lower pH, pCO2, HCO3
-
, BEfw, BEua, [Na
+
] and [Cl
-
] compared to controls, and 
significantly higher heart and respiratory rates, PCV, BUN, lactate, AG, SIDm and BEcl. The PCV, 
[Cl
-
], BEcl, BUN and heart rate are suggested to be useful variables to predict the likelihood of 
survival. 
Conclusions and clinical importance – This study has lead to the recognition of derangements in 
acid-base and shock status in horses affected by AM, to insight about the origin of acid-base 
derangements, and to improvement of prognostic assessment of patients.  
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Introduction 
Atypical myopathy (AM) is an acute myopathy occurring in grazing horses, considered an emerging 
condition in Europe (van Galen et al., 2012b), but also described in the USA (Finno et al., 2006). AM 
has a guarded prognosis and prognostic indicators based on clinical signs have recently been identified 
(van Galen et al., 2012a). It remains, however, difficult to assess prognosis and further prognostic 
indicators are needed. Serum creatine kinase (CK) activity had no prognostic value in AM (Votion et 
al., 2007b; van Galen et al., 2012a). Acid-base and cardiovascular shock variables are good candidates 
since they have previously been demonstrated to have prognostic value in several equine disorders 
(Seahorn et al., 1992; Corley and Marr, 1998; Southwood et al., 2009). Moreover, theoretically AM 
affected horses might develop acid-base imbalances because of muscle dysfunction (a “multiple acyl 
dehydrogenase deficiency or MADD” – like defect, Westermann et al., 2008b; and decreased 
activities of mitochondrial complexes, Westermann et al., 2011) and muscle destruction, 
cardiovascular and respiratory compromise (Votion et al., 2007b; van Galen et al., 2012b). In addition 
to their prognostic value, a better understanding of acid-base disturbances in AM may assist clinicians 
with supportive therapy. However, limited data on acid-base variables in AM are available  
(Votion et al., 2007b). 
The objectives of this retrospective study are to: 1) describe the acid-base and cardiovascular 
shock status of horses suffering from AM on admission, and 2) determine if acid-base and shock 
variables on admission can be used as prognostic indicators. 
 
Materials and methods 
Cases and study design 
Horses suffering from AM during the period 2006-2010, admitted to an equine referral centre where 
venous blood gas analysis was performed on admission were included in this retrospective multicenter 
study. Horses were included when they were confirmed (C cases) or strongly suspected of having AM 
(highly probable - HP cases) as defined in previous studies by the following algorithm (Figure 1;  
van Galen et al., 2010; van Galen et al., 2012b; van Galen et al., 2012a). If stored serum was 
available, retrospective analysis of acylcarnitines was performed allowing more definitive diagnosis of 
AM by detecting a MADD-like biochemical defect (Westermann et al., 2008b). Fifteen research 
horses, considered healthy based on history and clinical examination, were used as control group. 
Collection of Data and Samples, and Sample Analysis 
Heart and respiratory rates, rectal temperature, venous pH, partial pressure of carbon dioxide (pCO2), 
bicarbonate (HCO3
-
; calculated by the blood gas machine), base excess (BE; calculated by the blood 
gas machine), packed cell volume (PCV), blood nitrogen urea (BUN), serum CK activity, total protein 
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(TP), and plasma concentrations of sodium (Na
+
), chloride (Cl
-
), potassium (K
+
), and L-lactate on 
admission, and final survival status were retrieved. A previously reported shock grading system 
(Grulke et al., 2001) was modified such that lactate concentration (for use as independent variable) 
and blood pressure (unavailable) were excluded. The shock variables heart and respiratory rates, PCV 
and BUN recorded on admission were used to attribute a shock grade of I to IV (Table 1). 
In all cases, blood had been collected from the jugular vein on admission. Blood gas analysis 
was performed directly by an automated blood gas analyzer 
a,b,c 
on blood collected anaerobically in 
heparinised tubes or syringes. Because of controversy over the need for temperature correction with 
opponents pointing out that there is no logical or scientific basis for the assumption that temperature-
corrected values are better than values obtained at 37°C (Sharpiro, 1995; Clutton, 2007), venous blood 
gas analyses were not corrected for rectal body temperature. 
Blood collected in EDTA tubes was used for PCV measurements by centrifugation of capillary 
tubes or with automated analyzers 
d,e
. Plasma TP was measured by refractometer or by an automated 
analyzer 
f,g,h
. Automatic analyzers measured plasma lactate concentration 
b,i,j
, BUN 
b,f,g,h
, CK 
f,g,h,k
, and 
[electrolytes] 
a,b,c,h
. 
Calculation of variables and classification of acid-base disturbances 
The acid-base disturbances were classified following three different approaches. First, with use of the 
traditional approach based on the Henderson-Hasselbalch equation (Hasselbalch, 1916) horses were 
diagnosed with the following imbalances: 
- Metabolic acidosis when HCO3
- 
and/or BE were below the reference range 
- Metabolic alkalosis when HCO3
-
 and/or BE were above the reference range 
- Respiratory acidosis when pCO2 level was above the reference range 
- Respiratory alkalosis when pCO2 level was below the reference range. 
To provide more insight in the cause of acid-base imbalances, taking into account effects of 
electrolytes, unidentified anions (including lactate) and non-volatile weak buffers on acid base status, 
the quantitative approach of Stewart‟s strong ion model simplified by Constable was used  
(Constable, 1997). Therefore the following variables were calculated: 
- Measured strong ion difference (SIDm) 
A lot of different equations exist for SIDm, in- or excluding unidentified anions or lactate 
(Constable, 1997), but for this study it was chosen to evaluate lactate separately and to use the 
following formula for SIDm (Constable, 1997): 
SIDm = (Na
+
 + K
+
) – Cl-  
Lactate was evaluated by L-lactate measurements and estimated by calculation of the anion 
gap (AG; Johnson, 1995; Whitehair et al., 1995; Corley and Marr, 1998). 
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- AG was calculated with the following formula (Emmett and Narins, 1977): 
AG = (Na
+
 + K
+
) – (Cl- + HCO3
-
) 
- Total plasma concentration of non-volatile weak buffers (Atot) was calculated with the 
following formula (Constable, 1997): 
Atot = 2.24 x TP (g/dL) 
With use of this quantitative approach, horses were diagnosed with the following acid-base imbalances 
(Constable, 1997): 
- Metabolic acidosis when lactate, AG and/or Atot values were above the reference range, and/or 
SIDm below 
- Metabolic alkalosis when SIDm was above the reference range and/or Atot below 
- Respiratory acidosis when pCO2 level was above the reference range 
- Respiratory alkalosis when pCO2 level was below the reference range 
The reference ranges that were used for the acid-base variables are indicated in Table 3 (Constable, 
1997; Corley and Marr, 1998; Navarro et al., 2005; Viu et al., 2010). 
The agreement on presence or absence of metabolic acid-base derangements between the 
traditional approach and the simplified strong ion model was assessed. 
Thirdly, another quantitative approach, Fencl‟s application of Stewart‟s principles, was used to 
estimate the magnitude of the separate components to metabolic acid-base imbalances as also 
described in equine medicine (Whitehair et al., 1995; Corley and Marr, 1998). 
The following variables were calculated: 
- BE due to free water (BEfw): 
BEfw = 0.3 (Na
+
 measured – Na+ normal) 
(Na
+
 normal = 140 mmol/L) 
- BE due to chloride (BEcl): 
BEcl = Cl
-
 normal – ((Cl- measured x Na+ normal)/Na+ measured) 
(Na
+
 normal = 140mmol/L, Cl
-
 normal = 105) 
- BE due to TP (BEtp): 
BEtp = 0.224 x (TP normal – measured TP measured) 
(TP normal = 67g/L) 
- BE due to unidentified anions (BEua): 
BEua = BEmeasured – (BEfw + BEcl + BEtp) 
Statistical Analysis 
Data are reported as mean ± standard deviation (SD), range and, where appropriate, the number of 
horses out with reference ranges (Constable, 1997; Corley and Marr, 1998; Navarro et al., 2005; Viu 
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et al., 2010). Acid-base and shock variables in AM cases were compared to those of control horses 
with a two sample Wilcoxon rank sum (Mann-Whitney) test. 
In AM survivors and non-survivors acid-base and shock variables, rectal temperature and 
serum CK activity were compared with a two sample Wilcoxon rank sum (Mann-Whitney) test. Also, 
a classification and regression tree (CART) analysis, as described in detail by Porter et al. (2011), was 
performed on AM cases with the survival status as target variable and acid-base and shock variables, 
rectal temperature and serum CK activity as predictor. For all statistical tests P < 0.05 was considered 
significant. 
 
Results 
Thirty-four horses met the inclusion criteria for this study of which four survived AM and 30 died or 
were euthanized (survival rate 12%). Their signalment is presented in Table 2. Of three horses, frozen 
serum was available and retrospective acylcarnitine analysis allowed identification of a MADD-like 
biochemical defect. 
Acid-base and shock variables are presented in Table 3 and 4, respectively. Cases commonly 
presented with tachycardia, tachypnea, normal to increased PCV and BUN, and severely increased 
serum CK activities on admission. They were hypo- (12 cases), normo- (19 cases) or hyperthermic  
(3 cases) (37.2 ± 1.1°C, range 34.6 – 40.5°C). Ten horses were attributed a shock grade I, 19 a grade 
II, 5 a grade III and none a grade IV. The blood pH was very variable. Electrolyte derangements were 
common, and although mostly mild they lead in the majority of cases to an increased SIDm. Of the 
three considered electrolytes, acid-base status was mostly affected by Cl
-
. Only one horse had a 
combination of hyponatremia, hypochloremia and hyperkalemia. All affected horses had a mild to 
severe increase in AG and the majority an increased plasma lactate concentration and decreased BEua. 
Four horses had mildly elevated AG, but normal lactate concentrations. The majority of cases had 
normal TP concentrations, Atot and BEtp values, and if deviations occurred they were mild. When 
hyperproteinemia occurred, it was always together with high PCV, however not all cases with high 
PCV had increased TP. BUN often, but not always, showed increases parallel with PCV. 
Acid-base disturbances classified by the traditional approach and the simplified strong ion 
model are listed in Table 5. The two cases classified with respiratory acidosis were shortly euthanized 
after arrival. The two classification systems showed poor agreement on the presence of acid-base 
derangements. Nine cases classified as having no derangements according the traditional approach, 
suffered from lactic acidosis (2 cases), lactic acidosis and SIDm alkalosis (5 cases) and lactic acidosis, 
Atot acidosis and SIDm alkalosis (1 case) according the simplified strong ion model. Of the ninth case 
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without acid-base abnormality following the traditional approach, not enough data were available to 
perform the full quantitative analysis of the simplified strong ion model. 
The pH, pCO2, HCO3
-
, BEfw, BEua, [Na
+
] and [Cl
-
] were significantly lower in cases 
compared with controls, and heart rate, respiratory rate, PCV, BUN, [lactate], AG, SIDm and BEcl 
significantly higher (Table 3 and 4). 
Survivors had a significantly lower PCV and BEcl and a significantly higher [Cl
-
] than  
non-survivors (38.3 ± 6.6% versus 47.4 ± 7.4%; 3.0 ± 0.3 versus 8.5 ± 5.4; 102 ± 2.8mmol/L versus 
94 ± 7.7mmol/L, respectively). BEcl, [Cl
-
] and PCV also had strong discriminatory power between 
survivors and non-survivors in the CART analysis, while serum CK activity had almost no 
discriminatory power (Figure 2a). An optimal tree discriminating survival can be suggested by using 
BEcl, BUN and heart rate (Figure 2b). 
 
Discussion 
This study confirms that horses suffering from AM frequently have acid-base derangements on 
admission. They are often mixed and therefore not necessarily resulting in altered blood pH (acidemia 
or alkalemia). Metabolic acidosis is demonstrated to be mainly the result of changes in electrolytes 
(SIDm) and lactate in AM, whereas non-volatile weak buffers (Atot) do not seem to have major impact. 
Massive cell destruction is known to cause electrolyte abnormalities, more specifically the 
combination of hyponatremia, hypochloremia and hyperkalemia (Johnson, 1995; Corley and Marr, 
1998; Polderman, 2004). Eventhough expected to occur in AM cases due to severe rhabdomyolysis, 
this combination was only encountered in a single case in the current study. In a study on acid-base 
and electrolyte derangements in horses with exertional myopathy, hypochloremia was the most 
consistent electrolyte abnormality (Koterba and Carlson, 1982), as was the case in the current study. 
Besides rhabdomyolysis electrolyte derangements in AM cases can theoretically also originate from: 
1) electrolyte losses via excessive sweating and/or via salivation (Corley and Marr, 1998; Guyton and 
Hall, 2006e; Votion et al., 2007b; van Galen et al., 2012b), 2) renal dysfunction (Geor, 2007) and  
3) limited intracellular uptake of potassium by acidemia (Johnson, 1995; Guyton and Hall, 2006c). 
Acidemia and increased BUN were reported in several cases in the current study. False hyponatremia 
and -chloremia can also occur in the face of hyperglycemia and hyperlipemia (Milionis et al., 2002), 
which are regularly encountered in AM (Votion et al., 2007b). 
Lactate concentrations, as well as its estimates AG and BEua, were abnormal in most  
AM cases. Lactate is typically produced in conditions with tissue hypoxia and cell lysis  
(Corley and Marr, 1998), which might occur in AM due to shock, cardiac pathology, hypoventilation 
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and inadequate mitochondrial oxygen utilization in muscles related to MADD and lowered activity of 
mitochondrial complexes(Westermann et al., 2008b; Westermann et al., 2011). However, in four 
horses mildly elevated AG was identified with normal lactate concentrations. This difference might 
indicate hyperproteinemia (Whitehair et al., 1995) or increases in other unidentified anions than 
lactate. Since TP was noted to be normal in these four cases it might relate to increases in  
acyl-carnitines, glycine conjugates and organic acids in plasma. Organic acids in plasma are, however, 
not consistently elevated in AM (Westermann et al., 2008b). 
TP, BEtp and Atot were demonstrated by the current study to have few effects on acid-base 
status in AM. Unfortunately data on albumin, globulin and phosphate were unavailable in this 
retrospective study, and therefore a less accurate formula for Atot was used than when albumin, 
globulin and phosphate values would be taken into account. Nevertheless, when those values are not 
markedly abnormal, the used formula is believed to be accurate enough (Constable, 1997). 
Eventhough previously no to only mild abnormalities in these values have been reported (Delguste et 
al., 2002; Votion et al., 2007b), the results of the current study (not identifying more severe alterations 
in protein levels in horses affected with AM) were somewhat unexpected, since hemoconcentration 
and myoglobinemia are well known features of AM. However, these results make significant errors in 
estimating Atot less probable. The authors recognize that TP measurement by refractometer, as used on 
some of the studied horses, is less precise than the use of automatic analysers and refractometric 
results might be influenced by hyperglycemia and hyperlipemia (Hayes et al., 2011). 
Both respiratory acidosis and respiratory alkalosis were documented in the current study. 
Respiratory acidosis can be explained by dyspnoea and hypoventilation that is secondary to the severe 
affection of respiratory muscles as frequently encountered at post mortem (Cassart et al., 2007). 
Unexpectedly, respiratory acidosis only occurred in 2 horses. However, these data were recorded on 
admission and AM cases often have declining respiratory function, with increasing dyspnoea, 
decreasing arterial oxygen concentrations (Votion et al., 2007b) and increasing arterial pCO2 
concentrations (personal observation). Both horses with respiratory acidosis in this study were 
euthanized very shortly after arrival, suggesting respiratory acidosis as poor prognostic factor. 
Respiratory alkalosis was more commonly observed in this study, and most likely relates to 
hyperventilation due to pain or distress, and compensation for metabolic acidosis and anaerobic 
metabolism. The respiratory component of acid-base abnormalities, pCO2, was measured in this study 
on venous instead of arterial samples. Abnormal pCO2 values in venous samples originate from 
abnormal pulmonary ventilation, but depend also on tissue CO2 production, pulmonary perfusion and 
cardiac output. Therefore venous hypercapnia or hypocapnia (classified as respiratory acidosis and 
alkalosis, respectively, in the current study) may not be solely respiratory in origin. Nevertheless, there 
is acceptable agreement in human medicine between arterial and venous values of pCO2, suggesting 
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that venous blood gas analysis is a good substitute for arterial blood gas analysis  
(Malatesha et al., 2007). In addition, venous pCO2 values are commonly used in equine studies to 
classify respiratory acidosis or alkalosis (Navarro et al., 2005; Viu et al., 2010). 
A previous much larger epidemiological study on AM identified prognostic factors from 
clinical signs (van Galen et al., 2012a). Complementary to this, the current study allowed 
identification of PCV, BEcl, [Cl
-
] as variables that are useful for prognostic assessment, and an 
optimal tree was suggested with BEcl, BUN and heart rate to discriminate survival status on 
admission. Only a limited number of clinical and blood variables were included in this study, 
nevertheless these are commonly used and/or measured in equine medicine or can easily be calculated 
from commonly used variables. However, as the case numbers were limited, with very few survivors, 
this prognostic assessment has limited statistical power. 
The current study confirmed, in accordance with previous studies (Votion et al., 2007b; van 
Galen et al., 2010; van Galen et al., 2012a), that CK activity has no prognostic value. This can be 
explained by absence of maximum CK values. In addition, CK activity is linked to the weight of 
damaged muscle (Volfinger et al., 1994), but the clinical impact of muscle destruction differs with the 
muscle that is affected. 
The current study demonstrated that BUN was frequently increased on admission in 
accordance to previous studies (Delguste et al., 2002; Puyalto-Moussu et al., 2004; Votion et al., 
2007b). Also the presence of renal casts on histology is consistent in AM (Cassart et al., 2007). 
Eventhough only few cases suffer from clinical renal dysfunction (van Galen et al., 2012b), these 
findings highlight the need for renal monitoring and support in AM patients. It can be suggested that 
BUN increases as a result of renal damage due to myoglobinuria (Arighi et al., 1984; Polderman, 
2004). However, increased BUN might also be a consequence of dehydration (prerenal azotemia), 
protein catabolism for gluconeogenesis or deamination of adenosine monoposphate (AMP). Indeed, 
the current study shows that PCV was frequently increased (hemoconcentration). The possibility of 
protein catabolism is supported by the finding that a reduced amount of muscle protein was found in 
another study on AM (Westermann et al., 2011); increased uric acid excretion in urine suggests that 
deamination of AMP (purine catabolism) occurs (Westermann et al., 2011). It is however unclear if 
these two mechanisms of BUN production would lead to significant rises in serum BUN levels. Other 
indicators for renal dysfunction such as creatinine and urine analysis would be needed to evaluate the 
significance of elevated BUN, but were unfortunately unavailable in this retrospective study for the 
majority of the cases. 
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Previous reports on several equine conditions have demonstrated that quantitative acid-base 
analysis provides more insight in acid-base pathophysiology and allows diagnosis of mixed metabolic 
disturbances (Whitehair et al., 1995; Navarro et al., 2005; Viu et al., 2010). The current study points 
out the importance of using quantitative acid-base analysis over the traditional approach in AM 
affected horses. 
This study is limited by restricted availability of blood biochemistry due to its retrospective 
nature, the small number of cases and few survivors. Although AM has been more common in Europe 
in the past years (van Galen et al., 2012b), it remains a rare condition and thus difficult to generate 
large and complete data sets. Nevertheless, these data remain important for a better understanding of 
the condition and help clinicians to assess prognosis and adapt therapy for horses suffering from AM. 
A further limitation is that samples were analyzed in different clinics with different techniques. Small 
disagreements between data from different clinics might therefore have occurred. 
In conclusion, this study shows that the majority of horses suffering from AM have respiratory 
and/or metabolic acid-base alterations and that they are better recognized by quantitative than 
traditional acid-base analysis. In AM patients, alterations are mainly the result of respiratory alkalosis, 
lactic acidosis and/or SIDm alkalosis. Several shock and acid-base variables are suggested to be useful 
to predict the likelihood of survival. This study provides better insight in pathophysiology of AM and 
improves prognostic assessment in affected cases. 
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Tables 
Table 1. The shock grading system adapted from Grulke et al. (2001) that was used to attribute a 
shock grade to each individual horse with atypical myopathy. 
Shock variables Shock grade 
I II III IV 
Heart rate (bpm) < 60 60-80 80-100 >100 
Respiratory rate (rpm) < 25 25-35 35-45 >45 
PCV (%) < 45 45-55 55-65 >65 
BUN (mmol/L) < 14 14-20 20-25 >25 
Legend: PCV = packed cell volume; BUN = blood urea nitrogen. 
 
 
 
Tabel 2. Signalment of horses suffering from atypical myopathy and of control horses. 
 AM horses 
(n = 34) 
Control horses 
(n = 15) 
Female 22 10 
Gelding 7 3 
Stallion 5 2 
Pony 7 0 
Saddle horse 24 15 
Draught horse 3 0 
Age (years; mean ± SD) 4.6 ± 4.7 
range 1.5 months – 17 year 
12.5 ± 6.8 
range 2 – 25 years 
Legend: AM = atypical myopathy; SD = standard deviation; n = number of horses. 
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Table 3. Acid-base variables from horses with atypical myopathy on admission and from healthy 
control horses. 
ACID 
BASE 
VARIABLE 
Reference 
value 
Cases 
(n=34) 
 Controls  
(n=15) 
Comparison 
AM versus 
control 
  Mean ± 
SD 
Range  n n > rr  n < rr  Mean ± 
SD 
Range  P value 
pH 7.31 – 7.45 7.36 ± 0.09 7.14 – 7.56 34 3 7  7.40 ± 0.02 7.38 – 7.44 0.092 
pCO2 
(mmHg) 
41 – 53 40.6 ± 7.9 28.3 – 62.0 34 2 17  46.1 ± 2.3 42.2 – 50.2 <0.001 
HCO3
- 
(mmol/L) 
24 – 30 22.0 ± 4.4 9.5 – 29.9 34 0 22  28.2 ± 0.98 26.1 – 30 <0.001 
BE total -6 – +6 -3.1 ± 4.7 -16.7 – 3.9 34 0 9  2.8 ± 1.1 0.6 – 4.5 <0.001 
Na
+
 
(mmol/L) 
134 – 144 136.5 ± 6.0 124 – 148 32 3 9  142.3 ± 2.7 136 – 147 <0.001 
BEfw X -1.1 ± 1.8 -4.8 – 2.4 32 X X  0.7 ± 0.8 -1.2 – 2.1 <0.001 
Cl
-
 
(mmol/L) 
100 – 110 94.7 ± 7.7 76 – 105 27 0 19  106 ± 2.4 100 – 110 <0.001 
BEcl X 8.1 ± 5.4 0.3 – 27.3 27 X X  0.7 ± 2.3 -3.1 – 4.2 <0.001 
K
+ 
(mmol/L) 
2.5 – 4.5 4.0 ± 0.5 2.8 – 5.1 32 3 0  3.8 ± 0.5 2.8 – 4.6 0.235 
SIDm 38 – 44 46.0 ± 45.0 38.4 – 65.5 27 18 0  40.1 ± 2.8 34.9 – 44.2 <0.001 
PT (g/L) 60 – 75 65.6 ± 7.5 43 – 78 31 3 4  67.6 ± 4.3 60 – 72 0.878 
BEpt  X 0.3 ± 1.7 -2.5 – 5.4 31 X X  -0.1 ± 1.0 -1.1 – 1.6 0.878 
Atot 13 – 17 14.7 ± 1.7 9.6 – 17.5 31 1 3  15.1 ± 1.0 13.4 – 16.1 0.878 
BEua X -10.8 ± 6.1 -23.4 – -2.6 26 X X  1.5 ± 2.8 -4.2 – 5.2 <0.001 
AG 6 – 15 24.2 ± 6.1 15.1 – 38.3 27 27 0  12.0 ± 2.8 6.6 – 17.3 <0.001 
lactate 
(mmol/L) 
< 2 6.7 ± 4.4 0.8 – 18.7 23 19 0  0.8 ± 0.6 LOW – 2.2 <0.001 
Legend: SD = standard deviation; n = number of horses; rr = reference range; pCO2 = partial pressure 
of venous carbon dioxide; HCO3
-
 = bicarbonate; BE = base excess; Na
+
 = sodium; BEfw = BE due to 
free water; Cl
-
 = chloride; BEcl = BE due to chloride; K
+
 = potassium; SIDm = measured strong ion 
difference; TP = total protein; BEtp = BE due to total protein; Atot = total plasma concentration of  
non-volatile weak buffers; BEua = BE due to unidentified anions; AG = anion gap.  
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Table 4. Shock variables and shock grades from horses with atypical myopathy on admission and from 
healthy control horses. 
SHOCK 
VARIABLE 
Referen
ce value 
Cases 
(n=34) 
 Controls  
(n=15) 
Comparison 
AM versus 
control 
  Mean ± SD Range  n n > 
rr  
n < 
rr 
 Mean ± 
SD 
Range  P value 
HR (bpm) 
 
< 45 65 ± 18.5 
 
36 – 112  34 30 X  36  ± 6.1 28 – 44  <0.001 
RR (rpm) 
 
< 15 29.6 ± 12.7 
 
8 – 62  32 28 X  19.5 ± 4.0 16 – 24  <0.001 
PCV (%) 
 
30 – 45  46.3 ± 7.8 
 
30 – 62  34 22 0  35.1 ± 2.3 31 – 38  <0.001 
BUN 
(mmol/L) 
 
2 – 8 8.9 ± 3.8 1.9 – 18.7  27 15 1  4.8 ± 1.1 3.2 – 6.8  <0.001 
Shock grade 1 1.9 ± 0.7 1 – 3 34 24 0  1 ± 0 1 <0.001 
Legend: SD = standard deviation; n = number of horses; rr = reference range; HR = heart rate; 
RR = respiratory rate; PCV = packed cell volume; BUN = blood urea nitrogen. 
 
 
 
Table 5. Acid-base imbalances identified in 34 horses affected by atypical myopathy (AM) classified 
with the traditional approach and the simplified strong ion model. 
 Acid-base imbalance n N % 
Traditional 
approach 
No imbalance 9 34 26 
Metabolic acidosis 6 34 18 
Metabolic alkalosis 0 34 0 
Respiratory acidosis 0 34 0 
Respiratory alkalosis 3 34 9 
Metabolic acidosis + respiratory alkalosis 14 34 41 
Metabolic acidosis + respiratory acidosis 2 34 6 
Simplified 
strong ion 
model 
No complete data for this quantitative approach 8 34 24 
No imbalance 0 26 0 
Lactic acidosis 4 26 15 
Lactic acidosis + SIDm alkalosis 8 26 31 
Lactic acidosis + SIDm alkalosis + Atot alkalosis 1 26 4 
Lactic acidosis + SIDm alkalosis + Atot alkalosis + respiratory alkalosis 1 26 4 
Lactic acidosis + SIDm alkalosis + respiratory alkalosis 4 26 15 
Lactic acidosis + SIDm alkalosis + respiratory acidosis 2 26 8 
Lactic acidosis + SIDm alkalosis + Atot acidosis 1 26 4 
Lactic acidosis + Atot alkalosis 1 26 4 
Lactic acidosis + respiratory alkalosis 4 26 15 
Legend: N = number of total response for each category; n = number of positive response for each 
category; SIDm = measured strong ion difference; Atot = total plasma concentration of non-volatile 
weak buffers. 
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Figure 1. Diagnostic algorithm that was followed to categorize cases with a tentative diagnosis of 
atypical myopathy. With permission from van Galen et al 2012, EVJ. 
 
 
Legend: AM = atypical myopathy ; (*) repeat analysis 24H later ; (**) pathognomonic signs ;  
C = confirmed case of AM, based on history, clinical expression and histology ; HP = case with a high 
probability of having AM ; LP = case with a low probability of having AM ; OD = case with another 
diagnosis than AM ; D = doubtful case; not enough data available or complementary testing would be 
needed for categorization. 
Notes: Histology can be performed on muscle biopsies sampled from a living horse or at post mortem. 
The non-pathognomic findings for AM on histology are a multifocal process compatible with Zenker‟s 
degeneration and necrosis in fibres of postural and/or respiratory muscles (Cassart et al. 2007). 
Not included in the diagram: Disease following anesthesia or intense exercise  D.  
If a full post mortem examination was performed and specific findings of another condition were 
found, the case could be categorized OD.  
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Figure 2a. Classification and regression tree analysis on 34 atypical myopathy cases with survivor 
status as target variable and acid-base and shock parameters as predictors: the discriminatory power 
of variables. 
 
Variable Discriminatory power (score max. = 100) 
BEcl  100.00 |||||||||||||||||||||||||||||||||||||||||| 
Cl
-
  91.81 |||||||||||||||||||||||||||||||||||||| 
PCV  46.69 ||||||||||||||||||| 
SIDm  37.93 ||||||||||||||| 
BUN  36.26 ||||||||||||||| 
BEfw  27.76 ||||||||||| 
K
+
  27.76 ||||||||||| 
Na
+
  27.76 ||||||||||| 
Heart rate 23.43 ||||||||| 
BEtp  20.08 |||||||| 
Atot  20.08 |||||||| 
TP  20.08 |||||||| 
HCO3
-
  14.96 ||||| 
pCO2  8.41 ||| 
BE  4.24 | 
CK  1.70  
 
Legend: pCO2 = partial pressure of venous carbon dioxide; HCO3
-
 = bicarbonate; BE = base excess;  
Na
+
 = sodium; BEfw = BE due to free water; Cl
-
 = chloride; BEcl = BE due to chloride;  
K
+
 = potassium; SIDm = measured strong ion difference; TP = total protein; BEtp = BE due to total 
protein; Atot = total plasma concentration of non-volatile weak buffers; CK = creatine kinase;  
BUN = blood urea nitrogen; PCV = packed cell volume. 
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Figure 2b. Classification and regression tree analysis on 34 atypical myopathy cases with survivor 
status as target variable and acid-base and shock parameters as predictors: the optimal tree with a 
sensitivity of 84.2% and a specificity of 93.33%. 
 
Legend: N = number of horses; HR = heart rate; BUN = blood urea nitrogen; BEcl = base excess due 
to chloride. 
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REVIEW ARTICLES 
 
ATYPICAL MYOPATHY: NEW INSIGHTS INTO THE PATHOPHYSIOLOGY, PREVENTION 
AND MANAGEMENT OF THE CONDITION 
 
VAN GALEN G., SERTEYN D., AMORY H., VOTION D.-M. 
Equine Veterinary Education, 2008, 20, 234-238. 
 
 
Short summary 
Atypical myopathy (AM) is frequently fatal seasonal pasture myopathy that emerges in several 
European Countries in recent years. Currently, the aetiology of AM is unknown but recent surveys of 
confirmed cases have lead to new insights into the pathophysiology, prevention and management of 
the condition. 
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Introduction 
Sherlock and Mair (Sherlock and Mair, 2008) described a filly affected with atypical myoglobinuria. 
This syndrome of a highly fatal, acute myopathy affecting grazing horses was initially named 
“atypical myoglobinuria” (Anonymous, 1985). However, since myoglobinuria is only one of the 
possible clinical signs of the condition, the name atypical myopathy (AM) is now preferred  
(Votion et al., 2004). 
AM has been reported sporadically since the beginning of the 20
th
 century in various parts of 
the world (Votion et al., 2004), but mainly in the UK. Since the new millennium, AM has been 
recognised in a increasing number of countries (Delguste et al., 2002; Gerber et al., 2006; van der 
Kolk, 2006; Palencia and Rivero, 2007) showing the emerging character of the condition. A similar 
condition has also been recognised in the United States of America (Finno et al., 2006). In Belgium 
and France, large outbreaks of AM are now encountered at regular intervals (Puyalto-Moussu et al., 
2004; Votion et al., 2007b). 
 
Epidemiology 
According to a large case report (Votion et al., 2007b), AM seems to occur in horses being on pasture 
for at least 1 week.  However, horses can still develop the condition in the following days after being 
placed in a box (van Galen et al. unpublished data). 
The condition is reported to occur on bare, sloping pastures with trees. Most of the grazed 
pastures where AM declares contains humid areas and are crossed or being bordered by a watercourse 
(Votion et al., 2007b). 
Affected horses are often young, unbroken and in good body condition, however older horses 
have been affected also (Brandt et al., 1997; Puyalto-Moussu et al., 2004; Votion et al., 2004; Votion 
et al., 2007b). Recently, even a donkey and a zebra were highly suspected to suffer from AM (reported 
cases via the “Atypical Myopathy Alert Group”; AMAG). 
The condition does not seem to be contagious, but it is usually reported as outbreaks since 
particular environmental characteristics and specific weather conditions predispose to AM. The 
climatic conditions favouring AM are little sunshine, cool temperature without heavy frost, heavy 
rainfall or humidity, and strong winds (Hosie et al., 1986; Whitwell et al., 1988; Votion et al., 2007b). 
These particular meteorological conditions lead to seasonal occurrence (i.e. the majority of cases are 
observed in autumn and some in spring; Votion et al., 2007b). It is postulated that the observed 
climate changes of the last years contribute to the increasing number of cases recorded. 
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Aetiology 
For the moment the aetiology of AM remains unknown, but several causes have been considered. 
Toxic products, like ionophores, herbicides, weed killers, nitrates and nitrites have been incriminated. 
However, testing for these products yielded negative results (Whitwell et al., 1988; Brandt et al., 
1997). Phytotoxins have also been suspected, but plants known to be toxic for horses or other animals 
were not consistently present in the pastures of affected horses and/or were previously identified to 
cause other clinical signs than rhabdomyolysis (Hosie et al., 1986; Brandt et al., 1997; Puyalto-
Moussu et al., 2004; Votion et al., 2007b). No evidence of viral infections was found in cases with 
AM (Whitwell et al., 1988; Brandt et al., 1997; Delguste et al., 2002). Mycotoxins could be involved 
as they are known to have potential toxic effects in equines (Osweiler, 2001). The recently described 
human fatal myopathic condition caused by mycotoxins supports this hypothesis (Bedry et al., 2001). 
Moreover, fungal growth and mycotoxin production depends on specific climatic conditions which are 
those favouring AM and therefore mycotoxins are a possible cause of AM. Other researchers have 
proposed clostridial toxins as a cause of AM (Delguste et al., 2002; Gerber et al., 2006). 
Unfortunately, until now no result of research was able to confirm neither mycotoxins, nor 
Clostridium spp. as the causative agent. Selenium or vitamin E deficiency can lead to a nutritional 
myopathy, often resembling AM. Antioxidant status of AM cases was variable (Hosie et al., 1986; 
Whitwell et al., 1988; Brandt et al., 1997), but nutritional myopathy is not thought to be the cause of 
AM since supplementation and treatment with selenium and vitamin E rarely improve the condition. 
However, these important antioxidants may have a protective role against a potential oxidative stress 
encountered in the pathophysiological process of AM. 
 
Pathogenesis 
The myodegenerative process of AM affects more selectively oxidative (i.e. the slow-twitch or type I 
fibres mainly found in postural and respiratory muscles) rather than glycolytic fibres (i.e. the fast 
twitch or type II fibres predominantly found in locomotory muscles; Brandt et al., 1997; Cassart et al., 
2007; Palencia and Rivero, 2007). In addition, increased lipid storage is prominent in type I fibres 
(Cassart et al., 2007). These observations alongside with no abnormal glycogen or polysaccharide 
accumulation suggested an impaired oxidative metabolism and a preserved glycolytic pathway 
(Cassart et al., 2007). In addition, a central role of the mitochondria in the pathogenesis of AM was 
suggested by the observation of mitochondrial ultrastructural changes (Cassart et al., 2007). 
This hypothesis has been recently supported by the description of the biochemical defect 
occurring in AM (Westermann et al., 2008b). A Multiple Acyl-CoA Dehydrogenase Deficiency 
(MADD) was found in confirmed cases of AM. Dehydrogenase enzymes catalyse key events in fatty 
acids metabolism. They catalyse oxidation-reduction reactions using a coenzyme derived from the 
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riboflavin (vitamin B2) thus suggesting that AM might result from a riboflavin deficiency or blockage. 
This MADD leads to dysfunction of the most efficient way for generating energy by the mitochondria, 
i.e. oxidative phosphorylation from lipid substrates therefore resulting in severe rhabdomyolysis, 
especially in postural and respiratory muscles. Identification of this metabolic defect is of paramount 
importance since it will contribute to improve the medical management of AM and will guide the 
search for the etiological agent towards toxins that reproduce the identified defect. 
 
Clinical signs 
Clinical studies (Whitwell et al., 1988; Brandt et al., 1997; Votion et al., 2007b) report that affected 
horses show a sudden onset of severe general weakness and muscular stiffness and, often become 
recumbent within a few hours. They are sometimes even found dead on pasture without premonitory 
signs. Some are reluctant to move, others are so weak that they have difficulty keeping their head up 
(personal observation). 
The affected horses show increased heart and respiratory rate, often hypothermia and 
congestive mucous membranes. Most cases keep a good appetite and continue to pass faeces, although 
some suffer from oesophageal obstruction (Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 
1997; Votion et al., 2007b). 
Dysuria with a distended bladder at rectal examination is frequently encountered. A lot of 
horses demonstrate signs of colic probably due to this bladder distension (Hosie et al., 1986; Brandt et 
al., 1997; Votion et al., 2007b), but rarely intestinal causes for these colic signs are found, as they are 
described in the case report of Sherlock and Mair (2008). The urine is dark-brown in the acute phase 
due to the presence of myoglobin in the urine (myoglobinuria; Hosie et al., 1986; Votion et al., 
2007b). 
Subclinical cases have also been described and can be horses that graze on the same premise 
than a clinically affected horse. They are often recognised when blood analyses are performed on  
co-grazers of the affected horse. These subclinical cases show no clinical signs, but have significant 
increase of serum activities of CK (Delguste et al., 2002; Votion et al., 2007b). They can however 
evolve into clinical cases and so it is important to recognise and monitor them closely. It is thought 
that they are in balance with the causative agent, but a sudden imbalance may occur due to a trigger or 
a stress factor resulting in the clinical development of AM. These stress factors are suggested to be 
cold weather, exercise (Votion et al., 2003), transport (personal observation), or anaesthesia as 
described in the case report of Sherlock and Mair (2008) where overt signs of AM were observed after 
the recovery.  
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Diagnosis 
The clinical diagnosis of AM can be made based on history, clinical signs, blood and urine analysis, 
muscle biopsy and finally on post mortem examination (Delguste et al., 2002; Cassart et al., 2007; 
Votion et al., 2007b). 
History is of major importance in the diagnosis. No cases are yet described not being out on 
pasture, probably because the etiologic agent is only found at pasture. Sometimes AM can occur as an 
outbreak and it is known that pastures where the condition has occurred before remain at risk in 
following years (Votion et al., 2007b). So knowledge of previous cases on the particular pasture may 
facilitate the diagnosis. Excluding other forms of rhabdomyolysis, for example exercise-induced 
myopathies, is paramount. However, as mentioned earlier, it is speculated that exercise as any other 
forms of stress can predispose for developing AM (Votion et al., 2003) most probably because the 
metabolic defect recently described (Westermann et al., 2008b) induces a metabolic imbalance that 
precludes to any additional energetic demand. 
The clinical signs are typical for any severe rhabdomyolysis, but not specific at all for AM. It 
is therefore difficult to make a diagnosis just based on clinical signs. However, the frequently apparent 
absence of pain in AM is surprising as regard to the suffering that usually accompanies other form of 
severe rhabdomyolysis, especially exercised-induced myopathies. 
At blood analysis muscle enzymes are massively increased, confirming the severe 
rhabdomyolysis (Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 1997; Votion et al., 2007b). If 
CK levels remain below 10,000 UI/L, diagnosis of AM is challenging since one should be aware that 
the first blood analysis does not always demonstrates the highest CK levels (unpublished data). Often 
hyperglycaemia and hyperlipaemia are present and liver enzymes are increased (Hosie et al., 1986; 
Whitwell et al., 1988; Votion et al., 2007b). A hypocalcaemia is almost always found, but no other 
important electrolyte derangements are reported consistently. The urine is coloured due to the 
myoglobinuria, and should be differentiated from haematuria or haemoglobinuria. 
The only way to make a definitive diagnosis of AM is by means of histology performed on a 
muscle samples taken by biopsy or post mortem. Biopsy is best performed in living horses on postural 
muscles and in post mortem, on the intercostal muscles (Cassart et al., 2007). At necropsy, discoloured 
muscles and myocardium, congestive lungs, petechiae and black-reddish gastro-enteric contents may 
be seen (Cassart et al., 2007). However, necropsy may also be disappointing with no specific 
observation. The most specific microscopic feature of AM is the important lipid accumulations in type 
I muscle fibres that undergoes Zenker necrosis/degeneration (Cassart et al., 2007). 
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Differential diagnosis 
Other severe myopathies described in the horse are sporadic or recurrent exercise-induced myopathies, 
glycogen branching enzyme deficiency (GBED) in the foal, white muscle disease or nutritional 
myodegeneration, Streptococcal myopathy, post-anesthethic myopathy, etc. Besides other severe 
myopathies, AM can be confounded with endotoxemia, colic, neurological disorders (e.g. tetanus, 
botulism, tick paralysis, rabies, meningitis, spinal cord disease,…), intoxications (e.g. ionophores, 
strychnine, carbamates, organophosphates, cassia occidentalis, acorn, white snakeroot….), hematuria 
or hemoglobinuria of any cause (e.g cystitis, exercise-induced hematuria, urethral defects…), or even 
lameness (e.g. iliac thrombosis, laminitis, polyarthritis, arthritis,…). Worth mentioning in respect to 
the differential diagnosis of AM is the fact that horses can develop increased muscle enzyme activity 
due to prolonged recumbency as described in the clinical report of Sherlock and Mair (2008). 
In horses with colic, muscle fasciculations are often noted secondary to pain and/or to 
hypocalcaemia. These fasciculations, together with the frequent occurrence of colic in horses and other 
clinical signs of colic (tachycardia, tachypnoea, congestive mucous membranes, recumbency and pain) 
make colic a very important differential diagnosis of AM. As shown in the case report of Sherlock and 
Mair (2008), they can even occur together. 
 
Treatment 
Since the aetiology of AM is not known, therapy of AM affected horses is mostly symptomatic. 
Nevertheless, one of the existing hypotheses about the aetiology includes Clostridial infections 
(Delguste et al., 2002; Gerber et al., 2006). Administration of metronidazole (15mg/kg bwt q8H PO) 
might therefore be hypothetically helpful. Administration of botulism type C and D antiserum has also 
been proposed (Gerber et al., 2006). 
It is of great importance to administer fluid therapy to horses with an acute myopathy to avoid 
acute tubular necrosis due to myoglobinuria. Together with fluid therapy, electrolyte and acid-base 
balance should be maintained. Since AM cases seem prone to the development of hypocalcemia, 
special attention should be carried out for calcium imbalances administrating slow intravenous 
calcium borogluconate (100 – 300 ml calcium borogluconate 20% until correction). Moreover, 
outcome of colic horses has recently been reported to be favoured by correction of their 
hypocalcaemia (Delesalle et al., 2005). 
Histology of affected horses (Cassart et al., 2007) and metabolic studies  
(Westermann et al., 2008b) have shown defects in the mitochondrial lipid metabolism of the muscle 
cell, but not in carbohydrate metabolism. This corroborates with the presence of hyperglycaemia and 
hyperlipaemia in blood analysis of affected horses (Brandt et al., 1997; Votion et al., 2007b). Thus 
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carbohydrate metabolism should be enhanced by intravenous administration of 5% glucose  
(2ml/kg bwt/H), or oral administration of glucose (100gram 2x/day). Glucose also supports the 
affected hepatic metabolism, by decreasing the need for hepatic gluconeogenesis. Insulin  
(15-30 UI SC) and heparin (40-250 UI/kg bwt SC 2x/day) can be administrated to further control the 
hyperlipaemia and hyperglycemia. Supplementing affected horses with chromium (5 mg SID PO) will 
improve their insulin sensitivity (Anderson, 2008), and will probably enhance their 
intersarcoplasmatic glucose-uptake. Most horses keep a good appetite; some of them are even craving 
for food (Votion et al., 2007b). Seen the suspected defect in lipid metabolism and not in carbohydrate 
metabolism (Cassart et al., 2007; Westermann et al., 2008b), it is proposed that concentrates with a 
high quantity of carbohydrates might be beneficial. This increase in carbohydrate content is 
contradictory to nutritional advice for several other equine myopathies, proposing a decrease of 
carbohydrate content and an increase of lipid content. The MADD found in AM affected horses is 
possibly due to a riboflavin deficiency or blocking and thus a supplementation of affected horses with 
this vitamin B2 (via B-complex
 
vitamin supplementation) might also be interesting  
(Westermann et al., 2008b). Support for muscular function and repair should be offered to these horses 
by vitamins and anti-oxidants, like selenium, vitamin C and vitamin E. 
A lot of affected horses have difficulties urinating and should be relieved by regular or 
continuous bladder catherization. In general, horses fully regain their capacity to urinate once the 
myoglobinuria has disappeared (unpublished data). 
Although not all horses seem to suffer intensively (Votion et al., 2007b) analgesia can be 
provided if necessary by non steroidal anti-inflammatory drugs (NSAID‟s), morphine or morphine-
derivatives. It should be noted that NSAID‟s are a cause of renal toxicity, and especially with 
enormous amounts of myoglobin passing through the kidneys warrant is justified with their 
administration. 
Due to the progressively affected respiratory muscles a severe hypoxia can develop (Delguste 
et al., 2002; Votion et al., 2007b), and respiratory support in the form of nasal oxygen can be 
considered. For foals artificial ventilation might even be envisaged. 
Dantrolene sodium (2-2.5 mg/kg in saline by slow IV administration) is proposed for limiting 
rhabdomyolyis in other myopathies. This drug limits the rate of calcium release from the 
sarcoplasmatic reticulum. 
Once a horse is recumbent, regular turnings, good thick and clean bedding, and stimulating the 
horse to remain in sternal recumbency instead of lateral can prevent further muscle and pulmonary 
compression as well as the development of important decubital ulcers. Affected horses should be 
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exposed to stress (for example exercise, transport) as little as possible, since it might aggravate their 
condition. 
 
Prognosis 
The prognosis for most AM cases is not favourable. Finally most horses die within 3 days  
(Votion et al., 2007b), although some non-survivors remain alive for a longer period up to 10 days 
(unpublished data). The mortality rate of AM is estimated at 85% (Votion et al., 2004; Votion et al., 
2007b), but the outbreak occurring in the 2006 autumn was less devastating with a mortality rate of 
65% (unpublished data). Fewer horses were found dead without premonitory signs and fewer horses 
were being recumbent. It is of great importance for equine practitioners to know that AM-affected 
horses have a chance to survive. Prognostic factors recognised in clinical studies are normal 
respiration with normal arterial partial pressures in oxygen (PaO2) levels and the absence of permanent 
recumbence. Serum activities of CK have not shown to be of prognostic value  
(Votion et al., 2007b). The survivors of the autumn 2006 had an uneventful recovery and surprisingly 
only showed minimal muscle wastage (unpublished data). 
It is important to inform the owner about the risk that his other horses can become affected, 
clinically or sub clinically. If possible, horses that are on the same pasture as an affected horse should 
be removed from this pasture and preferably placed in a box. If not enough boxes are available for all, 
young horses should have priority since they seem to be more at risk for AM (Votion et al., 2007b). 
Their level of CK activities should be checked for several days and horses should be monitored closely 
for any annunciating signs (mainly weakness and stiffness). 
 
Prevention 
A large epidemiological investigation on Belgian confirmed cases enabled the identification of AM 
favouring factors (Votion et al., 2009). In order to prevent AM it may be recommended to regularly 
administrate anthelminthics, to vaccinate, to give supplementary feeding and to provide a salt block all 
year round. The mechanical harrowing of pasture (i.e. the spreading of manures) favours also AM and 
thus this common practice should be prohibited. 
During the at-risk seasons (i.e. autumn and spring), horses should have access only to 
furnished grassland.  Particularly humid pastures or pastures where a stream/river flows across and 
with a lot of dead leaves accumulated in autumn, should be assigned for summer pasturing especially 
if this pasture has a history of previous death(s) of horses. Giving water from the distribution network 
has also found to be a protective measure against AM. 
 110 
 
Chapter 4 : Publications  
When clinical series of AM declare in neighbouring regions or countries, it may be advised to 
remove young and old horses from pastures, whereas horses maintained at pasture should be 
supplemented with concentrates rich in carbohydrates. It is worth noting that supplementing hay on 
the ground in a humid environment increases the risk of AM. A weather-dependent stabling should be 
considered with horses returning to pasture when several days of heavy frost have been encountered  
(it is thought that frost would destroy the causal agent). 
 
Conclusions 
By gathering information about cases all over Europe and continuing research by the partners of the 
AMAG (Atypical Myopathy Alert Group) on different aspects on the condition, the knowledge about 
AM enlarges year by year.  On behalf of the AMAG, we are very grateful for the information received 
from veterinary surgeons and owners of affected horses. On the website of the AMAG, cases reporting 
will continue, and can be performed by veterinarians as well as owners. 
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PREVENTING ATYPICAL MYOPATHY IN GRAZING HORSES WITH RATIONAL 
MANAGEMENT OF PASTURES AND HORSES DRAWN ON THE BASIS OF THE 
IDENTIFICATION OF RISK FACTORS FOR DISEASE 
 
VAN GALEN G., PATARIN F., VOTION D.-M. 
In: Agricultural Research Updates. Volume 1, B.P. Hendriks (Ed), Nova publication; 2011,  
pp 147-163.  
 https://www.novapublishers.com/catalog/product_info.php?products_id=23577 
 http://hdl.handle.net/2268/98754 
 
Abstract 
Atypical myopathy (AM) is a specific disease of horses kept at pastures most of the day. The condition 
is distinguished by the acute and unpredictable nature of its appearance, its high fatality rate and its 
rapid evolution. Indeed, over 75% of affected horses die within 72 hours after presenting clinical signs 
resulting from the severe degeneration of different muscle groups involved in breathing, posture, or 
the heart muscle. Less than ten years ago, this disease was unknown from the veterinary and 
equestrian field. More than a dozen European countries are now concerned by this specific disease of 
equines. Recently, AM has also been recognised in the USA. AM does not show characteristics of a 
contagious disease but its occurrence is linked to specific environmental conditions and thus, it 
emerges in the form of an epizooty: several grazing horses are hit by the disease at the same time and 
in different regions or even in different European countries. The clinical outbreaks are reported mainly 
in autumn and spring. Occurrence of the clinical syndrome in a horse implies that appropriate 
circumstances to the onset of the AM were present in the host and/or in its environment. Large 
European epidemiological investigations have identified those circumstances, thus defining risk 
factors. These factors are related to the host (e.g. host susceptibility due to age), timing (e.g. season), 
location (e.g. local geological and ecological factors) and other miscellaneous features (e.g. type of 
feed, climatic conditions, the use of the horse). This review describes management practices at the 
horse and pasture level in order to reduce the incidence of AM in grazing horses. 
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Introduction 
Epidemiology 
Atypical myopathy (AM) is an acute and severe muscle pathology that can lead to the death of 
affected horses in a few days. In the past, AM was only sporadically encountered, but since the last 
years it has been recognized as an emergent disease (Votion and Serteyn, 2008; van Galen et al., 
2012b). Several large outbreaks have taken place in Belgium (Delguste et al., 2002; Votion et al., 
2007b), Germany (Brandt et al., 1997) and France (Puyalto-Moussu et al., 2004) and the disease has 
now been recognized in a dozen of European countries (Palencia and Rivero, 2007; Votion and 
Serteyn, 2008; Votion et al., 2009; van Galen et al., 2010; van Galen et al., 2012b). Sporadic cases 
have also been described in the USA, New Zealand and Australia (Finno et al., 2006; reported to 
AMAG). 
Horses of all races, as well as donkeys and zebra‟s, suffer from the disease. However, no other 
species has been described to be affected. Most cases are unexercised, young horses in normal body 
condition, but horses of all ages can be affected. AM occurs in horses that spend significant time out 
on pasture: most are full time pasturing and always more than 6H per day (Votion et al., 2007b; 
Votion et al., 2009; van Galen et al., 2012b). 
Pastures on which the disease occurs are typically described as being sparse, sloping and 
containing or being surrounded by trees, dead leaves and wood and humid zones. Clinical cases have, 
however, also occurred on pastures not resembling this description. Pastures can give rise to AM cases 
for successive years (Votion et al., 2007b; Votion et al., 2009; van Galen et al., 2012b). 
AM has a strong seasonal appearance with the majority of cases declaring in autumn and a 
limited amount of cases in spring and winter. Autumnal outbreaks are often followed by a smaller one 
in spring (van Galen et al., 2012b). Although the condition is not contagious, cases often occur as 
outbreaks probably because horses are submitted to the same environmental and climatic factors that 
play a role in the aetiopathogenesis of AM. Cases have been shown to occur during autumns that are 
warmer than usual (van Galen et al., 2012b), and during periods with lack of solar radiation, low 
temperature but without frost (Votion et al., 2007b), stormy winds (Hosie et al., 1986; Harris and 
Whitwell, 1990) and rain and thunderstorms (Finno et al., 2006). 
Aetiopathogenesis 
The metabolic defect occurring in AM affected horses is a multiple acyl-CoA dehydrogenase 
deficiency (MADD), which blocks mitochondrial fatty acid energy metabolism. Affected horses 
depend therefore largely on carbohydrate metabolism for their energy supply (van Galen, 2008; 
Westermann et al., 2008b).  
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The aetiological agent of AM, however, is unknown up to now. Several aetiological 
hypotheses have been refuted (Votion et al., 2004; Votion and Serteyn, 2008), whereas others such as 
a clostridial toxin, a phytotoxin or a mycotoxin remain possible. Recently, an association between AM 
and Clostridium sordelli‟s lethal toxin has been demonstrated (Unger-Torroledo et al., 2010), but 
further proof should be provided before assuming that this is the cause, or the solely cause, of AM.  
It has also been noted that cases very frequently occur in the presence of Acer pseudopalatanus  
(maple tree; Votion et al., 2007b; van der Kolk et al., 2010). Even though this common European tree 
has no proven toxic potential, it might contain yet undiscovered phytotoxins. Moreover, this tree is 
often covered with tar spot (i.e. Rhytisma acerinum; van der Kolk et al., 2010). As any tree it 
contributes to organic waste on the ground and as such might favour mould formation and mycotoxin 
production. 
The development of AM is probably multifactorial with several endogenous and exogenous 
factors leading to MADD. On one side, certain factors cause and aggravate MADD and thus an 
imbalance in energy metabolism: the aetiological agent, risk factors, and other predisposing and/or 
triggering factors such as stress (e.g. inclement weather, exercise and transport), nutritional 
deficiencies and possible environmental substrates. Contact time, dosage and pathogenicity of the 
aetiological agent probably influence the severity of disease. On the other side, other factors may limit 
the development or reduce the impact of the MADD: physiological compensatory mechanisms, 
protective factors and a possible development of immunity. In subclinical affected horses (Delguste et 
al., 2002; Votion et al., 2007b), the energetic balance is probably more or less maintained. But if the 
horse‟s metabolism gets out of balance because it is too severely affected by the aetiological agent or 
is further disturbed by other interfering factors, severe disease follows and death can occur. 
Clinical description 
AM is distinguished by the acute and unpredictable nature of its appearance. Most affected horses die 
within 72 hours after presenting the first clinical signs (Votion et al., 2007b; van Galen et al., 2012b). 
The disease has a high fatality rate, which was at first estimated at 85-100% (Puyalto-Moussu et al., 
2004; Votion et al., 2004), but it has recently been demonstrated to be 74% (van Galen et al., 2012b). 
The presented clinical signs are due to the acute and severe destruction of postural, respiratory 
and cardiac muscles. More than 50% of affected horses suffers from depression, weakness, stiffness, 
recumbence, trembling, sweating, myoglobinuria, congestive mucous membranes, tachycardia, and 
normothermia, and horses can develop respiratory, cardiac, renal and digestive complications  
(Votion et al., 2007b; van Galen et al., 2012b). Subclinical disease has been described and is 
sometimes encountered in seemingly healthy cograzers of clinically affected horses  
(Delguste et al., 2002; Votion et al., 2007b).  
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Diagnosis 
Diagnosis of AM can be challenging, amongst others due to the rapid clinical evolution of cases. The 
history of the horse is important for the diagnosis of AM. A prerequisite is that the horse has to be at 
pasture at the onset of clinical signs, or at least within several days preceding. The diagnosis of AM 
becomes more likely if the case occurs during autumn and during an outbreak. A diagnosis of AM 
should be questioned when severe rhabdomyolysis develops following general anaesthesia or intensive 
exercise (suspicion of post-anaesthetic myopathy or exertional myopathy, respectively). 
A suspicion of AM can be further strengthened based on clinical signs, blood and urine 
analysis (explosive increase of serum levels of CK and presence of myoglobinuria; Votion et al., 
2007b; van Galen et al., 2012b), histology on muscle samples, and in fatal cases a full post mortem 
examination (Cassart et al., 2007). 
Treatment and prognosis 
Unfortunately, treatment of affected horses is often unrewarding. Specific therapies directed against 
the hypothetical causative agents are unavailable, and thus practitioners rely solely on supportive care. 
Nevertheless 24% of affected horses survive AM (van Galen et al., 2012b; van Galen et al., 2012a) 
and supportive therapy should be tempted when horses have none or only a few of negative prognostic 
factors or if the horse improves following treatment. Negative prognostic factors were described to be 
recumbence, sweating, myoglobinuria, hypothermia, anorexia, congestive or cyanotic mucous 
membranes, dyspnoea, tachypnoea and/or tachycardia (van Galen et al., 2012a). 
 
Prevention of atypical myopathy 
General 
Since no specific treatment exists against AM, and supportive therapy is often unsuccessful, 
prevention of this severe condition is of major importance (Harris, 2009). Preventive measures are 
based on descriptive data, but also on risk and protective factors. Descriptive data about AM are 
largely available in scientific literature from case reports or descriptions of outbreaks and from 
aetiopathogenic research. Risk and protective factors were determined by statistical analysis of data of 
affected horses compared to those of a control group. If a certain parameter occurs more frequently in 
the group of affected horses compared to the control group this parameter is determined a risk factor 
for AM. The opposite, a parameter occurring more frequently in the control group versus the affected 
group, is considered a protective factor for AM. The determination of risk and protective factors is a 
statistical risk analysis, which means that the risk for a horse to develop AM increases but is not 
certain when risk factors are present or protective factors are absents, and that the risk decreases but is 
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not zero when protective factors are present or risk factors are absent. Therefore AM still can occur in 
absence of risk factors or in the presence of protective factors. 
Preventive measures based on risk and protective factors 
Since 2004, the University of Liege has founded the Atypical Myopathy Alert Group (AMAG) to 
collect as much as possible geographic, climatic, demographic, clinical and management data on AM 
cases and their pastures. Data were collected with the help of horse owners and their veterinarians by 
means of standardised questionnaires available on the website www.myopathieatypique.be. A first 
analysis was performed on 57 Belgian cases from 2000-2005 that were confirmed to suffer from AM 
based on post mortem and histology results. They were compared to clinically healthy co-grazers and 
to healthy grazing control horses that were matched for the region where AM predominantly broke out 
(Votion et al., 2007b; Votion et al., 2009). A second analysis was performed on 354 European cases 
that were suspected or confirmed to suffer from AM from 2006-2009, including survivors. They were 
compared to cases that were reported to suffer from AM, but finally had another diagnosis or had a 
low probability to suffer from AM. Since they are compared to a control group of diseased horses, risk 
factors determined in this second study can be considered to help in the diagnosis of the condition  
(van Galen et al., 2012b; van Galen et al., 2012a). The above-mentioned studies help narrowing the 
search for the causative agent and predisposing or interfering factors. Table 1 summarizes the risk and 
protective factors drawn from these large epidemiological studies. 
Preventive measures based on risk and protective factors: demographic data 
Whenever possible, preventive measures should be applied to all horses, but if a choice should be 
made between some horses due to limitations of infrastructure or management, horses at risk should be 
favoured. 
Young horses are at risk to develop AM. Young horses spend more time at pasture than horses 
of middle age, which increases the contact time with the causative agent. At the same time they also 
are less frequently submitted to intensive training and the non-use for work seems to be a necessity for 
the development of AM (van Galen et al., 2012b). Moreover, a hypothetical protective immunity 
against the condition might not yet be optimally developed in young horses. 
Horses with a normal body condition are at risk and should thus be favoured for preventive 
measures (Votion et al., 2007b; Votion et al., 2009; van Galen et al., 2012a). Overweight horses seem 
to be protected against AM and better withstand the condition, which might be explained by 
compensation in the occurring muscle energetic imbalance (Votion et al., 2009). 
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Preventive measures based on risk and protective factors: horse management  
Regular deworming and vaccination were found to be protective factors without having a confounding 
effect with age (Votion et al., 2009). Regular deworming and vaccination are recommended to prevent 
AM and form a part of the general basic care of horses. 
Training is considered a protective factor (Votion et al., 2009), and most affected horses 
performed no or only limited exercise at the time of diagnosis (van Galen et al., 2012b). Training 
influences muscle metabolism and intensively exercised horses often receive supplementary feeding 
and spend less time at pasture. Moreover, horses are only used intensively for training from a certain 
age depending on the discipline, mostly starting at the age of 4 years. To reduce the risk for AM, it can 
be advised to regularly exercise grazing horses and to favour non-exercised horses for other preventive 
measures. However, if the horse suffers already from subclinical disease it is probably contra-indicated 
to work the horse. 
Since it is suspected that horses get in contact with the causative agent while being at pasture, 
preventive measures limiting pasturing are of major importance to prevent AM. During high risk 
seasons (spring and autumn) and/or during outbreaks it should be advised to stable horses and avoid 
the pasture as much as possible (van Galen et al., 2012a). If stabling is however difficult or impossible 
or if stabling is considered no good practice for horse welfare, pasturing should be limited. Full time 
pasturing, during all seasons but especially during risk seasons, is clearly a risk factor (Votion et al., 
2009; van Galen et al., 2012a) and owners should be convinced to not full time turn their horses out on 
pasture. Less than 6H a day (van Galen et al., 2012a) or weather dependant pasturing, especially 
during spring and autumn, (Votion et al., 2009; van Galen et al., 2012a) are protective factors and are 
valuable alternatives if full time stabling is not an option. 
Even though is it not suspected that the causative agent directly originates from the drinking 
water, water might have an indirect influence on the development of AM. It has been shown that 
providing water from the distribution network and in a tank or a bath are protective factors  
(Votion et al., 2009). This might avoid that horses go to and drink from water courses and streams and 
that they spend time in humid zones. Humidity at pasture has also been determined as a risk factor and 
might provide the causative agent with good conditions to exert its toxicity. 
Providing supplementary feeding and a salt block determined as protective factors  
(Votion et al., 2009). They should be provided all year round, but especially during high risk periods. 
Due to supplementary feeding and a salt block horses are less prone to eat substances that they would 
normally not consume when sufficient nutrients are available, they might be more selective in grazing, 
and/or graze less. Moreover, it provides the horse with protective antioxidants, vitamins and minerals 
that might counteract on the metabolic imbalance created by AM and support muscle function. 
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Supplementary feeding can consist of silage, straw, complete mix, corn or oats. However, one must be 
careful with giving hay in the autumn (Votion et al., 2009). Hay is often given from the ground and 
thus possibly stimulates contact with soil and the causative agent. Hay can also be a source of bacteria 
and fungal spores exerting potential toxicity especially in humid environment. 
Preventive measures based on risk and protective factors: pasture characteristics 
and management 
A history of previous dead horses on the pasture, regardless the cause and date, was found to be a risk 
factor for AM (Votion et al., 2009) and should be avoided whenever possible. Pastures where AM has 
declared in the past remain a danger for horses grazing on it, as pastures have been described to 
declare AM in successive years (Votion et al., 2007b; van Galen et al., 2012b). The etiological agent 
probably remains present at the pasture and it can exert its toxicity during specific seasons and 
environmental and climatic conditions. 
Pastures that are lush during the winter season were found to be a risk factor for AM. These 
data should be interpreted with caution, because a discrepancy between observations by scientists and 
horse owners was noted. Owners often described their pastures as having lush grass, but regularly 
scientists found them to be bare (Votion et al., 2009). An additional study (van Galen et al., 2012b) 
strengthened the observation that the majority of pastures was bare (66%) and only a minority were 
pastures with lush grass (29%). 
Sloping pastures, especially those with a steep slope, should be avoided to prevent AM 
(Votion et al., 2009; van Galen et al., 2012a). This can be a confounding effect with the geographic 
area where AM regularly occurs, but it might in one way or the other also play a role in creating an 
optimal microclimate for the causative agent to cause AM. Horses grazing on sloping pastures 
probably also use their postural muscles more intensively and this might add to the energetic 
imbalance when muscles are affected by AM. 
Pastures that contain dead leaves and dead wood form a risk (Votion et al., 2009; van Galen et 
al., 2012a) and therefore dead leaves and wood should be removed from the pasture and be burned. 
Pastures surrounded by or containing trees were also determined to be a risk factor, and almost for all 
described cases trees were present at their pasture (34/35 pastures; Votion et al., 2009, and 194/198 
pastures; van Galen et al., 2012b). Trees, dead leaves and dead wood might contain the causative 
agent (for example a phytotoxin or a mycotoxin), favour its development, and/or contribute to its 
toxicity or act in synergy with it via the growth of other saprophytic and toxigenic moulds or micro-
organisms. Growths of moulds should be removed from the pasture. 
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Humid pastures or pastures surrounded by or containing a stream or river should be avoided 
and pastures should be drained. Humidity and water favour the growth of mould, and production of 
mycotoxins. Specific soil conditions and plant cover also favour the emergence of soil-borne 
clostridial diseases (Seifert et al., 1996). 
Spreading of manure on the pasture should be avoided, since it results in faecal contamination 
of the soil with microbial contaminants such as spores of Clostridia spp and this pasture management 
practice has been identified at risk (Votion et al., 2009). Faeces should be removed manually from the 
pasture. 
Preventive measures based on descriptive data on atypical myopathy 
Preventive measures based on descriptive data: Geographic zones 
Most of western European countries have had cases suffering from AM, but Belgium (especially the 
Walloon region), France (especially the north east regions) and Germany (especially the mid west 
regions) have known multiple large outbreaks (Brandt et al., 1997; Delguste et al., 2002; Puyalto-
Moussu et al., 2004; Votion et al., 2007b; van Galen et al., 2012b). These countries probably share a 
similar landscape, flora and management of pastures and horses that combine multiple risk factors 
during high risk periods. 
Preventive measures based on descriptive data: Season 
High risk seasons are defined as autumn and spring. Winter cases are mostly cases occurring during 
early winter just following autumn, or late winter just before spring. However, cases do not declare 
every year. Large case series occur especially during autumns that are significantly warmer than usual 
(van Galen et al., 2012b). After an outbreak in autumn, some cases can be expected to occur in the 
following spring (van Galen et al., 2012b). Special attention is of course warranted during outbreaks 
regarding climatic conditions (see further). 
Preventive measures based on descriptive data: Climatic conditions 
Specific climatic conditions have been related to the occurrence of AM, such as a lack of solar 
radiation, strong wind, rain, thunderstorms and a cool temperature without heavy frost (Hosie et al., 
1986; Whitwell et al., 1988; Finno et al., 2006; Votion et al., 2007b; van Galen et al., 2012b). 
Development of new cases during an outbreak ceases after 4-5 days of heavy frost and/or snow 
(Votion et al., 2007b; van Galen et al., 2012b), which suggests that extreme cold may destroy the 
causative agent. Nevertheless, the occurrence of AM remains unpredictable and one should not solely 
rely on weather forecasts to decide whether horses should be submitted to preventive measures for 
AM. 
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Preventive measures based on descriptive data: Demographic data 
Even though that some horses are more at risk than others as discussed in previous chapter, all equids 
(all horse breeds, as well as donkeys and zebras, both sexes, all ages, and thin, normal and obese 
horses (van Galen et al., 2012b) can be affected by AM so preventive measures should ideally be 
applied to all equids. 
Preventive measures based on descriptive data: Horse management 
Since AM affects severely the horse‟s energy metabolism, it can be suggested to fraction feedings and 
to supply a high carbohydrate diet (concentrates, good quality of fibres) in order to support optimally 
the energy and nutrient supply. Limiting pasturing has been defined as a protective factor, but above 
this AM has not been described in horses spending less than 6 hours at pasture  
(van Galen et al., 2012b). This demonstrates that contact time with the causative agent is of major 
importance to develop the disease and that limiting pasturing is indeed of interest. 
Preventive measures based on descriptive data: Pastures 
Often AM declares on natural and untreated pastures (Votion et al., 2009). A general aspecific 
treatment of pastures can therefore be suggested. Ploughing, sowing, mowing and fertilizing for 
example influence the soil and plant cover and might interfere with the causative agent and/or 
predisposing factors. 
Although the presence of trees was a risk factor for the development of AM, tree species have 
not been evaluated by statistical risk analysis. Nevertheless, one tree in particular has been mentioned 
repeatedly in relation to AM: Acer pseudoplatanus (maple tree; Votion et al., 2007b; van der Kolk et 
al., 2010; van Galen et al., 2012b). It is unknown for the time being if this common European tree 
plays a direct role in the pathogenesis of AM. It is however often infected by tar spot and its presence 
results unavoidably to organic waste on the ground. It is strongly advised to avoid using pastures 
surrounded by or containing trees, and this measure counts especially for the maple tree. 
 
Management of cograzers at pasture with a case of atypical myopathy 
When AM declares on a pasture, it is strongly advised to check the seemingly healthy co-grazers of 
the affected horse. These co-grazers most likely have also been in contact with the causative agent and 
are often submitted to the same predisposing and/or contributing factors. They are thus at risk to 
develop the disease in the following hours or days, or already suffer from subclinical disease (Delguste 
et al., 2002; Votion et al., 2007b). They merit special attention concerning prevention. 
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Without creating stress for these co-grazers, the same preventive measures as discussed before 
should be applied as good as possible to them, even if this might sound like “last minute” prevention. 
More specifically, co-grazers should be removed from the pasture where AM declared; ideally they 
should be stabled full time, at least during the risk period. After a couple of days of heavy frost, horses 
can be turned out again. Placing them on another parcel and limiting pasturing (< 6H per day or 
weather dependant) can also be an option. Stress, such as transport, anaesthesia or exercise, should be 
avoided as much as possible to limit energetic deficits that favour clinical disease in subclinical 
affected animals. Without excess, they should receive supplementary food, by preference carbohydrate 
rich food, such as concentrates. 
These co-grazers should also be placed under close clinical surveillance and serum levels of 
CK should regularly be measured since these horses can develop clinical AM in the following hours 
and days with a maximum up to 4 days after being stabled (van Galen et al., 2012b). As soon as the 
serum levels of CK are increased or if clinical signs are noted, the horse should receive supportive 
treatment to limit any further muscle damage. Vitamin B, C and E, selenium and carnitine can be 
already administered as preventive therapy to support muscle mitochondrial metabolism, moreover 
since this was the only treatment category that increased survival in clinical AM cases  
(van Galen et al., 2012a). 
 
Conclusion 
Prevention of AM is primordial since no specific therapy is available against AM and supportive 
treatment often is unrewarding. Preventive measures are determined based on descriptive data and on 
risk and protective factors identified by statistical risk analysis. Specific countries, seasons and 
climatic conditions are at risk for AM and parameters concerning the signalement, horse management 
and pasture characteristics were previously determined as risk or protective factor. Co-grazers of AM 
affected horses are severely at risk to develop the condition (clinical or subclinical) and thus demand 
special attention concerning prevention. 
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Tables 
Table 1. Risk and protective factors for the development of atypical myopathy. 
Parameters Risk factors Protective factors 
Demographic data 
Age  Young horses (< 3 years) 
 Old horses (> 20 years) 
 
Sex*  Colts 
 Stallions 
 Geldings  
Body condition  Normal weight  Overweight 
Management practices at the horse level 
Deworming   Frequent deworming 
Vaccination   Regular vaccination 
Occupation  No work at all  Use for work 
Pasturing  Full time pasturing all the year round  Weather dependant pasturing in spring 
and in autumn 
Food and water 
 Supplementary feeds  Hay in autumn  Supplementary feeds in autumn (except 
hay), in particular silage, complete mix 
 Supplementary feeds in winter, in 
particular straw, complete mix and corn 
 Supplementary feeds in spring 
 Supplementary feeds in summer 
 Salt block all year round 
 Nature of the water   Distribution network 
Pasture characteristics 
 History  Dead horses on the pasture in the past  
 Grassland  Lush pasture in winter  
 Incline  Sloping pasture 
 Steep slope 
 Gentle slope 
 Trees  Surrounded by or containing trees 
 Access to dead leaves piles up in autumn 
 
 Humidity  Humid pasture 
 Pasture surrounded by or containing a 
stream/river 
 
 
Management of the pastures 
  Spreading of manure  
(*) Age was identified as a confounding variable regarding the risk factors associated with the 
animal‟s sex. Sex is linked to age, as “gelding” is a status that follows castration, a procedure usually 
performed in males >18 months old (i.e. the most risky age for AM). Because females are more 
frequently kept at pasture than males, a higher percentage of AM cases are females.  
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Table 2. Summary of preventive measures for the development of atypical myopathy. 
 
WHERE? 
All over Europe, but especially in Belgium, France and Germany. 
WHEN (in general)? 
High risk seasons (mainly autumn and spring) 
Especially autumns that are warmer than usual 
Spring after an autumnal outbreak 
During outbreaks 
WHEN (in particular, i.e. during high risk seasons)? 
Lack of solar radiation 
Strong wind 
Rain and thunderstorms 
Cool temperature without heavy frost 
FOR HOW LONG? 
Until 4-5 days of important frost or snow covering the pasture 
FOR ALL GRAZING EQUIDS, but horses particularly at risk are: 
Young horses 
Horses with normal body condition  
Untrained horses 
HORSE MANAGEMENT TO REDUCE THE RISK 
Regular deworming and vaccination 
Provide supplementary feeding (by preference carbohydrate rich food) 
Do not feed hay from the ground or in conditions that favour mould formation 
Provide water from the distribution network and in a tank or a bath 
Regular exercise 
Stable horses or limit pasturing during the risky seasons(< 6H a day or weather dependant pasturing) 
Provide a salt block 
PASTURE MANAGEMENT TO REDUCE THE RISK 
Avoid spreading of manure on the pasture; prefer manual removal of faeces 
Avoid pastures (mainly in autumn and spring) where previous deaths have occurred 
Dead leaves and wood should be removed from the pasture and be burned 
Remove mould formations from the pasture 
Ensure rotation of pastures and avoid (during the risky seasons) (1) sloping pastures, especially those 
with a steep slope, (2) bare pastures, (3) humid pastures or pastures surrounded by or containing a 
stream or river, (4) pastures surrounded by or containing trees, especially the tree species Acer 
pseudoplatanus 
Provide general aspecific pasture treatment such as ploughing, sowing, mowing, fertilizing 
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REVIEW OF ATYPICAL MYOPATHY WITH EMPHASIS ON PREVENTION AND 
MANAGEMENT BASED ON THE CURRENT SCIENTIFIC KNOWLEDGE 
 
VAN GALEN G., PATARIN F., VOTION D.-M. 
Placed in editorial format for submission to: J. Vet. Intern. Med. 
 
Abstract 
Atypical myopathy (AM) outbreaks are of an acute and unexpected nature and it can be difficult and 
frustrating to handle suspected cases. Diagnosis is based on the combination of history, clinical signs, 
laboratory findings (including serum creatine kinase (CK) activity and acylcarnitine profiles) and 
histology. The possibility of survival of affected cases was often questioned but has been 
demonstrated, and prognosis can be assessed with the combination of clinical signs and blood 
parameteres that were recently identified as prognostic indicators. Treatment plans can be extrapolated 
from the described clinical signs and metabolic problems, but they remain only supportive until the 
causative agent has been identified. Since treatment is still unsuccessfull in the majority of cases, the 
main emphasis is currently still on prevention. 
This review aims at being a practical support for equine clinicians dealing with AM and is based on 
discussion and comparison of the available scientific data. 
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Introduction 
Atypical myopathy (AM) is an acute rhabdomyolysis syndrome occurring sporadically in grazing 
horses. Since the new millennium, this highly fatal pasture myopathy appears to emerge in Europe. Up 
to a dozen of European countries have had cases or outbreaks with this condition (Votion and Serteyn, 
2008). Also several cases of non exertional pasture-associated rhabdomyolysis in the midwestern 
United States were described; likely to be AM as well (Finno et al., 2006). During the last decade, 
more than one thousand potential AM cases throughout Europe have been communicated to the 
Atypical Myopathy Alert Group (AMAG), an informal group of veterinarians and researchers that are 
interested in AM. Epidemiological and clinical data from outbreaks gathered through AMAG  
(Votion et al., 2007b; Votion et al., 2009; van Galen et al., 2012b; van Galen et al., 2012a) have 
improved our knowledge concerning its epidemiology, clinical signs, diagnostics, clinical 
management and prevention of the condition. Although several hypotheses have been suggested about 
the cause of this acute rhabdomyolysis, such as Clostridium sordelli‟s lethal toxin and maple leaves 
(Acer pseudoplatanus) covered with Rhytisma acerinum (Unger-Torroledo et al., 2010; van der Kolk 
et al., 2010), none of these have consistently been proven to be associated with AM. However, 
pathological and laboratory investigations (Cassart et al., 2007; Westermann et al., 2008b; van Galen 
et al., 2011; Westermann et al., 2011) have allowed an improved knowledge of the AM-associated 
pathogenesis, which is of help to suggest specific supportive treatment of the condition. 
AM outbreaks are of an acute and unexpected nature and the information given in this review 
aims at helping equine practitioners in the recognition and handling of a suspected case. This review 
describes and discusses (1) diagnostic tools for AM, (2) the possibility of survival together with 
prognostic assessment, (3) suggestions for symptomatic treatment and management of clinical and 
subclinical cases, and (4) preventive measures. 
 
Diagnosis of atypical myopathy 
Diagnosis of AM is not straight forward, and AM can easily mimic other acute equine diseases.  
A diagnosis of AM should always be based on the combination of history, clinical signs, and 
laboratory findings and histological examination (Hosie et al., 1986; Whitwell et al., 1988; Brandt et 
al., 1997; Delguste et al., 2002; Votion et al., 2007b). Taking this principle into account van Galen et 
al (2012b) developed a decisional algorithm in order to categorize cases that were reported to the 
AMAG as having AM or not (Figure 2). This algorithm can be of diagnostic help to clinicians. 
However, eventhough that history, clinical signs, laboratory findings and histological examination can 
be indicative, they are not pathognomic for AM. Therefore this algorithm should in the future 
probably best be used as a first screening of suspected cases. As described in the following chapter, 
more definitive diagnosis can be obtained by immunohistochemistry (Cassart et al., 2007; Palencia 
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and Rivero, 2007) or acylcarnitine and organic acid profiles (Westermann et al., 2008b). The 
suggested algorithm, as well as the two latter diagnostic means, need further validation in the future. 
The following chapter will discuss the typical features of history, clinical signs, laboratory 
findings and histological examination according to the available scientific data that are helpful for 
establishing a diagnosis. 
History 
The most remarkable feature of the disease is the sudden onset of clinical signs consistent with an 
acute, not exercise-related myopathic process in horses at pasture (Hosie et al., 1986; Whitwell et al., 
1988; Delguste et al., 2002; Votion et al., 2007b; van Galen et al., 2012b). If a rhabdomyolsis 
syndrome is recurrent, and/or related to exercise, anaesthesia, previous infectious diseases or ingestion 
of ionophores or toxic plants, diagnosis of AM should be questioned, and one should consider the 
possibility of recurrent exercise-induced rhabdomyolysis (RER), polysaccharide storage myopathy 
(PSSM), post-anaesthetic myopathy, immune-mediated myopathy or toxic myopathy, respectively. 
European outbreaks have mostly been observed in the fall and in the spring (Votion and Serteyn, 
2008; van Galen et al., 2012b). Most cases are not or minimally exercised, young horses in normal 
body condition, but horses of all ages, breeds and body condition can be affected. Pastures on which 
AM occurs are typically described as having a slope and containing dead leaves, dead wood and 
humid zones, and containing or being surrounded by trees. Clinical cases have, however, also occurred 
on pastures not resembling this description. All cases occurred while grazing more than 6H per day, 
except some horses that are stabled for up to 4 days (Votion et al., 2007b; van Galen et al., 2012b). 
A recent European risk analysis (van Galen et al., 2012a) compared AM affected horses to 
horses that were reported to AMAG as being suspected for AM, but finally categorized as having a 
low likelihood of having AM or diagnosed with another condition (non-AM group). Because this 
comparison points out the difficulties of correctly diagnosing AM, differences between groups are not 
only indicators of risk factors, but are also diagnostic aids. Variables concerning the history of cases 
that were significantly more often encountered in AM cases compared with non-AM cases in this 
study were as follows: the presence of trees, dead wood and accumulations of dead leaves at pasture, a 
sloping pasture, normal body condition and full-time grazing. Variables that were more often present 
in non-AM cases compared with AM cases were as follows: poor body condition, water provision 
from a tank or bath tub, food supplementation, and spending no time or limited time at pasture. 
Clinical signs 
Many of the clinical signs of AM are the consequence of degeneration of postural and respiratory 
muscles, which are the primary targets of the disease (Cassart et al., 2007). The clinical syndrome is 
characterized by the sudden onset of pronounced muscular weakness and stiffness and can rapidly 
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progress: horses often develop respiratory difficulties and recumbency and the majority dies within  
72 hours of the onset of signs (Delguste et al., 2002; Puyalto-Moussu et al., 2004; Votion et al., 
2007b; van Galen et al., 2012b). The emission of dark coloured urine due to myoglobinuria is an 
indicative clinical sign, however, since it is a consequence of severe rhabdomyolysis, it can occur in 
other severe rhabdomyolyis syndromes. Moreover, absence of myoglobinuria does not exclude AM. 
Dependant on the moment of examination of the patient according the onset of clinical signs and the 
severity of rhabdomyolysis, myoglobinuria can be missed and/or be less pronounced (Hosie et al., 
1986; Harris and Whitwell, 1990; Votion et al., 2007b; van Galen et al., 2012b). Affected horses can 
be anorexic or dysphagic, but more often they have a normal to even ravenous appetite. They can 
display hypothermia or have a rectal temperature within the normal range, while some are even 
hyperthermic. Tachycardia and congested mucous membranes are often encountered (Hosie et al., 
1986; Whitwell et al., 1988; Brandt et al., 1997; Delguste et al., 2002; Puyalto-Moussu et al., 2004; 
Finno et al., 2006; Votion et al., 2007b; van Galen et al., 2012b). When rectal palpation is performed, 
frequently a distended bladder (Hosie et al., 1986; Brandt et al., 1997; Votion et al., 2007b) and 
sometimes dry, mucous covered faeces or colon impactions (van Galen et al., 2012b) are encountered. 
These findings can lead to colic signs or discomfort in cases (Puyalto-Moussu et al., 2004; Votion et 
al., 2007b). In general, pain is reported to be variable and mostly mild to moderate, although pain can 
be absent or on the contrary severe in some cases (Whitwell et al., 1988; Brandt et al., 1997; Votion et 
al., 2007b; van Galen, 2008; van Galen et al., 2008). Less common clinical signs that have been 
reported in AM are: icterus, paddling, hemorrhagic diathesis, oedema at the head, absence of 
consciousness, cardiac arrhythmias, mild diarrhoea, colon displacement, perirenal pain, reduced rectal 
tone, penile prolapse, buccal necrosis or ulceration, ptosis, trismus, laminitis and clinical signs 
consistent with renal dysfunction or congestive heart failure (Brandt et al., 1997; Votion et al., 2007b; 
van Galen et al., 2012b). Table 1 shows the frequency of the main clinical features of AM. 
The above mentioned European risk analysis (van Galen et al., 2012a) compared not only 
historical but also clinical variables that can be of diagnostic aid. The clinical signs that were 
significantly more often encountered in AM affected horses than in the non-AM control group in this 
study were: pigmenturia, normothermia, congested mucous membranes and high serum CK values. 
These clinical signs may be useful to strengthen a clinical suspicion of AM, but other conditions may 
also lead to these signs, whereas not all AM affected horses show them. Horses with cyanotic mucous 
membranes or sudden death without observation of previous clinical signs, were more often 
categorized in the non-AM group. Other disorders, such as acute colic, remain probably a more 
frequent cause of sudden death and cyanosis. Although being found dead on pasture without 
prodromal signs is often associated to AM, this clinical presentation was only reported in 3/57  
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(Votion et al., 2007b) and 2/327 (van Galen et al., 2012b) horses diagnosed with AM, and it should 
therefore probably not be categorized as being a typical feature of AM. 
Based on the same European AM cases and non-AM cases sensitivity, specificity, positive and 
negative predictive factors (PPV and NPV, respectively) of common clinical signs were calculated 
related to diagnosis (van Galen et al., 2012a). Pigmenturia had a high sensitivity and PPV in this 
study, which means that the proportion of AM cases with pigmenturia on all AM cases was high (only 
few AM cases had no pigmenturia) and that the proportion of AM cases with pigmenturia on all horses 
with pigmenturia in the study was high (only few cases with pigmenturia had another disease than 
AM). Normothermia and congested mucous membranes had a high PPV for diagnosis of AM, 
meaning that the proportion of AM cases with these signs on all horses with these signs in the study 
was high. However in relation to these results it should be mentioned that PPV and NPV are related to 
the prevalence of the condition in the studied population, which is not the case for sensitivity and 
specificity (Morley et al., 2007). 
Laboratory findings 
Standard blood and urine analysis 
The most helpful laboratory test to screen for AM is probably the determination of the serum activities 
of muscle enzymes and the presence of myoglobin in urine samples. A massive acute rhabdomyolysis 
can be confirmed when serum activities of CK, aspartate aminotransferase (AST) and lactate 
dehydrogenase (LDH) are highly increased. In most cases, CK values attain hundreds of thousands or 
even exceed the million of international units per litre (Hosie et al., 1986; Whitwell et al., 1988; 
Brandt et al., 1997; Delguste et al., 2002; Puyalto-Moussu et al., 2004; Finno et al., 2006; Votion et 
al., 2007b; Westermann et al., 2008b; van Galen et al., 2012b). However in some cases, they may only 
be slightly increased when measured shortly after the onset of clinical signs, and therefore repeated 
analysis can be recommended (van Galen et al., 2012b). 
Acid-base imbalances (mainly lactic acidosis, measured strong ion difference [mSID] 
alkalosis, and respiratory disorders) are common in horses suffering from AM (van Galen et al., 
2011). Also electrolyte derangements, such as hypocalcaemia and hypochloraemia, are often reported, 
and occasionally mild hyponatremia, mild hypernatremia and mild hyperkalemia occur (Delguste et 
al., 2002; Puyalto-Moussu et al., 2004; Finno et al., 2006; Votion et al., 2007b; van Galen et al., 
2011). 
Other common laboratory findings are: leucocytosis due to neutrophilia, hyperglycemia, 
hyperlipemia, and increased troponin, haptoglobin, PCV, urea, creatinine and liver enzyme activities 
(Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 1997; Delguste et al., 2002; Votion et al., 
 126 
 
Chapter 4 : Publications  
2007b; Westermann et al., 2008b; van Galen et al., 2011). The selenium status varies from normal to 
severely deficient (Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 1997; Delguste et al., 2002). 
 
Acylcarnitine profile 
Analysis of acylcarnitines in urine or blood allows identification of the characteristic “multiple  
acyl-CoA dehydrogenase deficiency (MADD)” - like defect (Westermann et al., 2008b). Especially on 
urine samples, the additional dosage of organic acids and glycine conjugates can be helpful as well. 
These laboratory tests can be performed at most human laboratories. Affected horses have been 
demonstrated to have significant increases in urinary lactic acid, ethylmalonic acid, 2-methylsuccinic 
acid, butyrylglycine, (iso)valerylglycine, hexanoylglycine, free carnitine, C2-, C3-, C4-, C5-, C6-, C8-, 
C8:1-, C10:1- and C10:2-carnitine. In plasma they showed significant increases in lactic acid, C2-,  
C4-, C5-, C6-, C8:1-, C10:1- and C10:2-carnitine. Plasmatic free carnitine and C3- and C8-carnitine 
were increased in most, but not all cases. In the same study by Westermann et al. (2008b), horses 
suffering from other acute myopathies were also examined and two out of three were shown to have 
increased plasmatic free carnitine, C2-, C3-, and C4-carnitine. In addition, two other horses with a 
myopathy other then AM have been described to have a MADD-like defect (Westermann et al., 2007). 
So eventhough acylcarnitine profiling can be considered a highly valuable diagnostic tool with regards 
to AM, it needs further validation and one should not blindly attribute a diagnosis of AM to a patient 
with increased acylcarnitines. It should be used as another piece in the puzzle in combination with 
history, clinical signs, other laboratory findings and histological examination. 
Histology 
Macroscopic findings 
At necropsy, the most consistent feature is the presence of dark brown urine in the bladder  
(Cassart et al., 2007). Macroscopically visible muscular lesions are aspecific and consist of 
discolorations in postural and respiratory muscles, particularly intercostals, diaphragm and muscles of 
the neck and shoulder. Pale areas may also be seen in the myocardium. However in some cases, there 
is no lesion in either skeletal or cardiac muscles (Hosie et al., 1986; Whitwell et al., 1988; Brandt et 
al., 1997; Finno et al., 2006; Cassart et al., 2007; Palencia and Rivero, 2007). 
Histological findings 
Muscle biopsy for histological examination is best performed in living horses on postural muscles 
(more specifically the shoulder muscles) and at post mortem examination on the intercostal muscles 
(Cassart et al., 2007). 
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On histological examination of AM affected muscles, severe lesions of Zenker‟s degeneration 
are visualised, which is characterized by loss of cross-striations, fibre swelling, hypereosinophilia of 
the sarcoplasm, hyaline degeneration and necrosis. These lesions are multifocal, meaning that on the 
same slide affected and unaffected myofibers are visible. Lesions are severe in postural and respiratory 
muscles (i.e. rich in slow oxidative type I fibres) and may be absent or minimal in the locomotor 
muscles (i.e. rich in the glycolytic type II fibres; Cassart et al., 2007; Palencia and Rivero, 2007). 
There is no or minimal cellular response with infiltration by macrophages or more rarely neutrophils 
(Hosie et al., 1986; Whitwell et al., 1988; Delguste et al., 2002; Finno et al., 2006; Cassart et al., 
2007). Neither glycogen not calcium salt accumulations are present in affected muscles, but a severe 
accumulation of neutral lipids is demonstrated by Oil Red O stainings (Finno et al., 2006; Cassart et 
al., 2007; Palencia and Rivero, 2007). 
Differential diagnosis 
Differential diagnosis of AM includes other severe rhabdomyolysis syndromes amongst which:  
RER, PSSM, post-anaesthetic myopathy, immune-mediated myopathy, clostridial myonecrosis, toxic 
myopathy due to ingestion of ionophores or toxic plants (for example white snake root and  
Cassia occidentalis), nutritional myopathy, hyperkalemic periodic paralysis, malignant hyperthermia. 
Other conditions with endotoxemic or hypovolemic shock must be considered (especially colic), as 
well as conditions leading to abnormal gait or recumbency (for example laminitis, neurological 
disease, hypocalcemia, pleuropneumonia). Myoglobinuria must be differentiated from hematuria and 
hemoglobinuria. Worth mentioning in this respect is the fact that recumbent horses, independent of the 
cause, often show mild to moderate increased muscle enzyme activity. 
 
Assessment of prognosis 
Survival 
Survival rate was previously estimated at 3% (Brandt et al., 1997) to 15% (Puyalto-Moussu et al., 
2004; Votion et al., 2004), but the possibility of survival was questioned (Harris, 2009). During more 
recent European outbreaks (2006-2009) the overall survival rate was reported to be 26%  
(88/356 cases), and reached a maximum of 57% in France in 2006 (van Galen et al., 2012b). The 
survivors in this study were mostly cases with a high suspicion of AM based on history, clinical signs, 
increase of serum CK activities, presence of myoglobinuria. Nevertheless, eventhough people are 
often reluctant to perform muscle biopsy in living horses, some of them were confirmed by means of 
muscle histology (van Galen et al., 2012b). As explained in the section above, this is still not 
waterproof confirmation and can be questioned. However in the meantime, the authors have had 
surviving cases that were diagnosed based on the typical history, clinical signs, CK increase, 
 128 
 
Chapter 4 : Publications  
myoglobinuria and with the aid of acylcarnitine profiling (personal observation), and one surviving 
case was confirmed by the same methods was described by Westermann et al. (2008b). 
Most non-survivors died or were euthanized within 3 days of onset of clinical signs, however 
some remained alive up to 10 days (Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 1997; 
Delguste et al., 2002; Puyalto-Moussu et al., 2004; Votion et al., 2007b; van Galen et al., 2012b). 
Surviving cases recovered after 10.6 - 5.6 days with a range of 1 - 30 days. Those where a follow up 
was available appeared to recover uneventfully (Finno et al., 2006; van Galen et al., 2012b), however 
not all have consistently been subjected to follow-up medical examinations in order to exclude signs 
of subclinical disease. Caution is therefore required when discussing the long-term prognosis after a 
clinical episode of AM. Moreover, horses probably do not seem to develop protective immunity since 
they can get the disease another time (van Galen et al., 2012b). 
Prognostic factors 
Indicators of prognostic factors have been recently identified by statistical comparison of variables of 
survivors versus those of non-survivors, by the calculation of sensitivity, specificity PPV and NPV of 
clinical signs regarding survival status, and by classification and regression tree (CART) analysis 
discriminating survival (van Galen et al., 2011; van Galen et al., 2012a). All methods indicate a risk of 
survival or non-survival associated with certain variables, but this doesn‟t mean that survival  
(or mortality) is certain once a specific variable is present (or absent). Therefore to applicate these 
prognostic indicators in a clinical setting, it is advised to evaluate the patient thoroughly, to make a 
prognostic assessment based on several variables and never on one solely, and to take into account the 
clinical evolution. 
Clinical signs 
Non-survivors showed significantly more often recumbency, sweating, anorexia, tachycardia, 
tachypnoea and dyspnoea compared to survivors, whereas defecation was significantly more often 
encountered in survivors. Remaining standing and normal mucous membranes had both a high 
specificity, PPV and NPV, and normothermia and defecation had both a high sensitivity and NPV 
when they were used to predict survival (van Galen et al., 2012a). Regarding to the high specificity, 
PPV, NPV and sensitivity this means respectively that : 
- the proportion of non-surviving AM cases without « remaining standing » or « normal mucous 
membranes » on the total of non-surviving AM cases is high (few non-survivors have these signs) ; 
- the proportion of AM survivors with « remaining standing » or « normal mucous membranes » on 
the total of AM horses with these signs is high (few AM affected horses with these signs are non-
survivors) ; 
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- the proportion of AM non-survivors without « remaining standing » or « normal mucous 
membranes » or « normothermia » or « defecation » on the total of AM horses without these signs is 
high (few AM affected horses without these signs are survivors) ; 
- the proportion of AM survivors with « normothermia » or « defecation » on the total of AM 
survivors is high (most survivors show these signs). 
As mentioned above, it should be pointed out that PPV and NPV are related to the prevalence of the 
condition in the studied population (Morley et al., 2007). 
Blood analysis 
Eventhough serum CK activity can be highly interesting to monitor ongoing muscle damage, serum 
CK activity (at first examination and/or the highest recorded value) was repeatedly found not to be 
higher in worse cases (Votion et al., 2007b; van Galen et al., 2011; van Galen et al., 2012a). 
Other blood parameters were, however, found to have prognostic value by a study on  
34 hospitalised cases on admission (van Galen et al., 2011). This study has limited statistical strength 
due to low case numbers and therefore results should be interpreted carefully. Nevertheless, these 
results can be of aid to clinicians when combined with the above mentioned clinical prognostic 
indicators. Non-survivors were shown to have a significantly higher packed cell volume (PCV) and 
base excess based on plasma chloride concentrations (BEcl) and significantly lower plasma chloride 
concentrations compared to survivors. In addition, a CART analysis also demonstrated that the BEcl, 
plasma chloride concentrations and PCV had strong discriminatory power between survivors and  
non-survivors. The variable BEcl was calculated in this study by the following equation:  
BEcl = Cl
-
 normal – ((Cl- measured x Na+ normal)/Na+ measured) 
(Na
+
 normal = 140mmol/L, Cl
-
 normal = 105) 
Moreover, the same CART analysis allowed development of an optimal tree to identify  
non-survivors based on BEcl, urea and heart rate with a sensitivity and specificity of 84% and 93%, 
respectively. It concludes that cases with the following three criteria were likely to end as  
non-survivor : BEcl of higher than 3.32, a urea higher than 5.26mmol/L and a heart rate of higher than 
40bpm. 
Respiratory distress and/or failure often develops in affected cases and can be demonstrated by 
a low partial pressure of arterial oxygen (PaO2), and venous hypercapnia (venous partial pressure of 
carbon dioxide > 53mmHg; respiratory acidosis). Based on clinical evolution of non-survivors, the 
occurrence of hypoxemia (PaO2 < 60mmHg) and hypercapnia were suggested to be associated with 
mortality (Votion et al., 2007b; van Galen et al., 2011). 
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Eventhough certain clinical signs and blood parameters were identified as having prognostic 
value, it still remains difficult to recognise horses that might survive a clinical episode of AM. 
Moreover, the clinical status of AM patients can deteriorate, but also improve rapidly (personal 
observation). 
 
Treatment and management of affected horses 
As long as the causative agent is not identified, treatment remains symptomatic and supportive. It can 
be extrapolated from and based on described clinical signs and current pathophysiological knowledge 
of the condition. During the last years important pathophysiological advances have been made and 
severe problems have been identified in mitochondrial metabolism in affected muscles, more 
specifically a MADD-like defect (Westermann et al., 2008b) and decreased activity of respiratory 
chain complexes (Cassart et al., 2007; Palencia and Rivero, 2007; Westermann et al., 2011). They 
limit mitochondrial aerobic metabolism, especially based on lipid substrates, and cause an energetic 
imbalance. Flavin adenine dinucleotide (FAD) is cofactor of the deficient mitochondrial 
dehydrogenases and riboflavin is a precursor of FAD. Therefore a riboflavin problem was put forward 
by Westermann et al. (2008b). Plasma riboflavin concentrations were however not different from 
control horses, excluding a deficiency but leaving the possibility of a competition or blockage by a yet 
unidentified toxin (Westermann et al., 2008b). The occurrence of lactic acidosis and respiratory 
alkalosis in affected horses (van Galen et al., 2011) is possibly also directly related to anaerobic 
metabolism. 
The following actions and treatments can be considered for horses that suffer from AM: 
Horses should be stabled as soon as possible before recumbency and hypothermia occur  
(Brandt et al., 1997; Delguste et al., 2002; Votion et al., 2007b; van Galen et al., 2012b), and to avoid 
further contact with the pasture. In order to decrease energetic demands and respiratory alkalosis, it is 
probably indicated to avoid physical effort and stress as much as possible. Horses should be kept as 
comfortable and quiet as possible with the aid of muscle relaxants and if needed non-steroidal anti-
inflammatory drugs or other analgesics. Individually adapted fluid therapy is recommended in order to 
restore circulating volume, promote myoglobin excretion, and correct acid-base and electrolyte 
imbalances and should be individually tailored. Digestive, respiratory, cardiac, and urinary function 
warrant close monitoring and support (van Galen et al., 2012b). Considering the metabolic problems, 
support of aerobic mitochondrial metabolism and favouring carbohydrate metabolism over lipid 
metabolism seems reasonable (Finno and Spier, 2008; Westermann et al., 2008b). This can be done by 
restoring circulatory volume, providing further cardio-respiratory support, feeding a fractioned 
carbohydrate-rich diet and giving intravenous glucose solutions. Vitamin B‟s, including riboflavin, are 
important for aerobic metabolism. And although they are usually sufficiently provided in good quality 
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roughage (Rooney, 2004), it might be that affected horses are in need of bigger amounts and 
supplementation could avoid them from becoming a limiting step. Carnitine supplementation can be 
considered because it might improve lipid metabolism, eventhough free carnitine levels were shown to 
be already increased in blood in affected horses (Westermann et al., 2008b). The therapeutic group 
consisting of vitamins, antioxidants (vitamins B, C, E and selenium) and carnitine were the only 
therapeutic group that appeared to be more often used in survivors compared to non-survivors and can 
thus be considered beneficial for outcome (van Galen et al., 2012a). Also the authors of the American 
case series suggested anti-oxidant therapy (vitamin C, vitamin E and selenium; Finno et al., 2006; 
Finno and Spier, 2008). These findings highlights the importance of these compounds, but it does not 
mean that other therapies are not useful. 
Dantrolene is probably not indicated for AM affected horses since important accumulations of 
calcium have not been visualised in affected muscle samples (Cassart et al., 2007), and more 
importantly dantrolene has an inhibitory effect on complex I of the respiratory chain  
(Mehta et al., 2008). 
All above mentioned treatments are only based on suggestions, and no or only limited direct 
scientific proof of true efficacy of these treatments, drugs or supplements on AM is available and 
therefore further investigated is necessary. 
 
Management of pasture companions 
When AM declares on a pasture, it is strongly advised to check the seemingly healthy pasture 
companions of the affected horse. These pasture companions most likely have also been in contact 
with the causative agent and are often submitted to the same predisposing and/or contributing factors 
as their sick friend. They are thus at risk to develop the disease in the following hours or days, or 
suffer already from subclinical disease (Delguste et al., 2002; Votion et al., 2007b). 
Without creating stress for these pasture companions, preventive measures as discussed in the 
following chapter should be applied to them, even if this might sound like “last minute” prevention. 
More specifically, pasture companions should be removed from the pasture; ideally they should be 
stabled full time, at least during the risk period. Stress, such as transport, anaesthesia or exercise, 
should probably be avoided as much as possible to limit muscular energetic deficits that favour 
clinical disease. Without excess, supplementary food, by preference carbohydrate rich food, can be 
considered. 
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These pasture companions need also close clinical surveillance and serum CK activity should 
regularly be measured (van Galen et al., 2012b). As soon as serum CK activity is increased or if 
clinical signs are noted, the horse supportive treatment to limit any further muscle damage can be 
considered. Vitamins and anti-oxidants might be already administered as preventive therapy to support 
muscle mitochondrial metabolism, moreover since they seem to have a positive effect on outcome in 
clinical cases (van Galen et al., 2012a). 
 
Prevention of atypical myopathy 
Since supportive therapy is still often unsuccessful, prevention of this severe condition is of major 
importance (Harris, 2009). Preventive measures are based on descriptive data, but also on risk and 
protective factors. Risk and protective factors were determined by statistical analysis of data of 
affected horses compared to those of a control group. If a certain parameter occurs more frequently in 
the group of affected horses compared to a control group this parameter is determined a risk factor for 
AM. The opposite, a parameter occurring more frequently in a control group versus the affected group, 
is considered a protective factor for AM. The determination of risk and protective factors is a 
statistical risk analysis, which means that the risk for a horse to develop AM increases, but is not 
certain, when risk factors are present or protective factors are absent, and that the risk decreases, but is 
not zero, when protective factors are present or risk factors are absent. Therefore AM still can occur in 
absence of risk factors or in the presence of protective factors. 
Preventive measures based on risk and protective factors 
A first risk analysis was performed on 57 Belgian non-surviving cases from 2000-2005. They were 
compared to clinically healthy co-grazers and to healthy grazing control horses that were matched for 
the region where AM broke out (Votion et al., 2007b; Votion et al., 2009). A second analysis was 
performed on 354 European cases that were highly suspicious or confirmed to have AM from  
2006-2009, including survivors. They were compared to cases that were reported to suffer from AM, 
but finally had another diagnosis or had a low probability to suffer from AM. Table 2 summarizes the 
risk and protective factors drawn from these studies and Table 3 lists the preventive measures that can 
be concluded from these risk factors and descriptive data. 
Demographic data 
Whenever possible, preventive measures should be applied to all horses, but if a choice should be 
made between horses due to limitations of infrastructure or management, horses at greater risk should 
be favoured. Young horses have been demonstrated to be at risk to develop AM. Young horses spend 
probably more time at pasture and are less frequently submitted to intensive training compared to 
older horses. Not being intensively trained seems to be a necessity for the development of AM. 
Moreover, a hypothetical protective immunity against the condition might not yet be optimally 
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developed in young horses. In addition, in a group of unexercised Standardbred mares at pasture, 
young horses have been demonstrated to have significantly more type I myofibers compared to old 
horses (Lehnhard et al., 2004), therefore having a more important amount of target myofibers for the 
causative agent of AM. Besides age, also body condition seems to influence the development of AM, 
which might be explained by the capability or incapability to compensate for the occurring energetic 
imbalance with the aid of body reserves. 
 
Horse management 
Training is considered a protective factor, and most affected horses were in no or only limited training 
at the time of diagnosis (Hosie et al., 1986; Whitwell et al., 1988; Votion et al., 2007b; van Galen et 
al., 2012b). Training increases oxidative capacity (MacLeay, 2004; Kim et al., 2005; Rietbroek et al., 
2007) and horses with intense training schedules often receive supplementary feedings and spend less 
time at pasture. Moreover, horses are only used intensively for training from a certain age. To reduce 
the risk for AM, it can be advised to regularly exercise grazing horses and to favour non-exercised 
horses for other preventive measures. However, if the horse suffers already from (sub)clinical disease 
it is probably contra-indicated to work the horse. 
Since it is thought that horses get in contact with the causative agent while being at pasture, 
preventive measures limiting pasturing are of major importance to prevent AM. During high risk 
seasons and/or during outbreaks it is advised to stable horses and avoid pasture. If stabling is however 
difficult or impossible or if stabling is considered no good practice for horse welfare, pasturing should 
be limited. Less than 6H a day or weather dependant pasturing are considered protective and are 
suggested as valuable alternatives. 
Even though is it unexpected that the causative agent directly originates from the drinking 
water, water might have an indirect influence on the development of AM. It has been shown that 
providing water from the distribution network and in a tank or a bath are protective factors. This might 
avoid that horses go to and drink from water courses and streams and that they spend time in humid 
zones. Humidity at pasture has been determined as a risk factor and might provide the causative agent 
with good conditions to exert its toxicity. 
Providing supplementary feeding and a salt block were determined as protective factors. They 
should be provided all year round, but especially during high risk periods. Due to supplementary 
feeding and a salt block horses are probably less prone to eat substances that they would normally not 
consume when sufficient nutrients are available, they might be more selective in grazing, and/or graze 
less. Moreover, it provides the horse with protective antioxidants, vitamins and minerals that might 
counteract on the metabolic imbalance and support muscle function. Supplementary feeding can 
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consist of silage, straw, complete mix, corn or oats. However, one must be careful with giving hay in 
the autumn (Votion et al., 2009). Hay is often given from the ground and thus possibly stimulates 
contact with soil or grass and the causative agent. 
Pasture characteristics and management 
Pastures with a history of previous dead horses, regardless the cause and year, were found to be a risk 
factor for AM and should be avoided whenever possible. In addition, pastures where AM has declared 
in the past remain a danger for horses grazing on it, as pastures have been described to declare AM in 
successive years (Votion et al., 2007b; van Galen et al., 2012b). 
Pastures that are lush during the winter season were found to be a risk factor for AM. These 
data should be interpreted with caution, because a discrepancy between observations by scientists and 
horse owners was noted. Owners often described their pastures as having lush grass, but regularly 
scientists found them to be bare (Votion et al., 2009). 
Sloping pastures, especially those with a steep slope, should be avoided. This can be a 
confounding effect with the geographic area where AM regularly occurs, but it might in one way or 
the other also play a role in creating an optimal microclimate for the causative agent. Horses grazing 
on sloping pastures probably also use their postural muscles more intensively and this might add to the 
energetic imbalance when muscles are affected. 
Pastures that contain dead leaves and dead wood form a risk and therefore it is advised to 
remove dead leaves and wood from the pasture and burn them. Pastures surrounded by or containing 
trees were also determined to be a risk factor, and almost for all described cases in the studies of 
Votion et al. and van Galen et al. (97 and 98%, respectively) trees were present at pasture. Trees, dead 
leaves and dead wood might contain the causative agent, favour its development, and/or contribute to 
its toxicity or act in synergy with it. 
Preventive measures based on descriptive data on AM 
Geographic zones 
Most of western European countries have had cases suffering from AM, but Belgium (especially the 
Walloon region), France (especially the north east regions) and Germany (especially the mid west 
regions) are known to have had multiple large outbreaks (Brandt et al., 1997; Delguste et al., 2002; 
Puyalto-Moussu et al., 2004; Votion et al., 2007b; van Galen et al., 2012b). These countries or areas 
probably share a similar landscape, flora and/or management of pastures and horses that combine 
multiple risk factors during high risk periods. 
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Season 
High risk seasons are defined as autumn and spring, but cases do not declare every year. Winter cases 
are mostly cases occurring during early winter just following autumn, or late winter just before spring. 
After an outbreak in autumn, some cases can be expected to occur in the following spring  
(van Galen et al., 2012b). 
Climatic conditions 
Specific climatic conditions have been related to the occurrence of AM, such as a lack of solar 
radiation, strong wind, rain, thunderstorms and a cool temperature without heavy frost (Hosie et al., 
1986; Whitwell et al., 1988; Finno et al., 2006; Votion et al., 2007b). Development of new cases 
during an outbreak ceases after 4-5 days of heavy frost and/or snow (personal observation), which 
suggests that extreme cold may destroy the causative agent. Nevertheless, the occurrence of AM 
remains unpredictable and one should not solely rely on weather forecasts to decide whether horses 
should be submitted to preventive measures for AM. 
Demographic data 
Even though that some horses are more at risk than others as discussed in the previous chapter, all 
equids (all horse breeds, as well as donkeys and zebras, both sexes, all ages, and thin, normal and 
obese horses) can be affected by AM (van Galen et al., 2012b) so preventive measures should ideally 
be applied to all equids. 
Horse management 
Since AM affects severely the horse‟s energy metabolism, it can be suggested to fraction feedings and 
to favour a carbohydrate rich diet (concentrates, good quality of fibres) over a diet rich in fat in order 
to optimally support the energy and nutrient supply. Limiting pasturing has been defined as a 
protective factor, but above this AM has not been described in horses spending less than 6 hours at 
pasture (van Galen et al., 2012b). This demonstrates that contact time with the pasture is of major 
importance to develop the disease. 
Pastures 
Often AM declares on natural and untreated pastures (Votion et al., 2009). A general aspecific 
treatment of pastures can therefore be suggested. Ploughing, sowing, mowing and fertilizing for 
example influence the soil and plant cover and might interfere with the causative agent and/or 
predisposing factors. 
Although the presence of trees was a risk factor for the development of AM, tree species have not 
been evaluated by statistical risk analysis. Nevertheless, one tree in particular has been mentioned 
repeatedly in relation to AM: Acer pseudoplatanus (maple tree; Votion et al., 2007b; van der Kolk et 
al., 2010). It is unknown for the time being if this common European tree plays a role in the 
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pathogenesis of AM. It is strongly advised to avoid using pastures surrounded by or containing trees 
during risk seasons, and this measure counts especially for the maple tree. Nevertheless, cutting down 
trees can for the moment not be supported by scientific data and should be discouraged. It is 
considered sufficient to remove and burn organic waste originating from trees. 
 
Conclusion 
AM is an emerging condition in Europe. It is highly fatal, but survivors have been described. This 
points out the necessity of a rapid and accurate diagnosis, so that supportive treatment can be started as 
soon as possible. A prognostic assessment of the patient can help to decide whether treatment is 
justified. Treatment is indeed often unsuccessful and preventive measures are therefore of major 
importance. Further research is needed on this intriguing condition to improve diagnosis, treatment 
and prevention. 
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Figures and Tables 
Figure 1. The decisional algorithm for atypical myopathy that was suggested and used by van Galen 
et al.(2012b) to categorize cases that were reported to the Atypical Myopathy Alert Group. 
 
Legend: AM = atypical myopathy; (*) repeat analysis 24H later; (**) pathognomonic signs;  
C = confirmed case of AM, based on history, clinical expression and histology; HP = case with a high 
probability of having AM; LP = case with a low probability of having AM; OD = case with another 
diagnosis than AM; D = doubtful case; not enough data available or complementary testing would be 
needed for categorization. 
Not included in the diagram: Disease following anaesthesia or intense exercise  D. 
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Table 1. The frequency of the main clinical features of AM as described by Belgian  
(Votion et al., 2007b), French (Puyalto-Moussu et al., 2004) and European (van Galen et al., 2012b) 
epidemiological studies. 
 France 
(n=82) 
2002-2003 
(%) 
Belgium 
(n=57) 
2000-2005 
(%) 
Europe 
(n=354) 
2006-2009 
(%) 
Depression  74 72 80 
Weakness  not mentioned 100 85 
Stiffness  82 80 83 
Recumbency  90 96 78 
Trembling  frequent 71 68 
Sweating  58 57 64 
Pigmenturia  100 95 93 
Distended bladder on rectal palpation not mentioned 80 58 
Congested mucous membranes not mentioned 69 53 
Tachycardia  76 69 79 
Dyspnoea 70 68 44 
Normothermia  48 36 60 
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Table 2. Risk and protective factors for the development of atypical myopathy following: Votion et al., 
2009 and van Galen et al., 2012a. 
 Risk factors Protective factors 
Demographic data 
Age  Young horses (< 3 years)  
Sex*  Colts 
 Stallions 
 Geldings 
Body condition  Thin 
 Normal weight 
 Thin 
 Overweight 
Management practices at the horse level 
Deworming   Frequent deworming 
Vaccination   Regular vaccination 
Occupation   Training 
Pasturing  Full time pasturing (all year round)  Not at pasture 
 <6H per day at pasture 
 Weather dependant pasturing in spring 
and in autumn 
Food and water 
 Supplementary feeds  Hay in autumn  Supplementary feeds in autumn (except 
hay), in particular silage and complete 
mix 
 Supplementary feeds in winter, in 
particular straw, silage, complete mix 
and corn 
 Supplementary feeds in spring 
 Supplementary feeds in summer 
 Salt block (all year round) 
 Water supply   Distribution network 
 In tank or bath tub 
Pasture characteristics 
 History  Dead horses on the pasture in the past  
 Grass land  Lush pasture in winter  
 Incline  Sloping pasture 
 Steep slope 
 Gentle slope 
 Trees  Surrounded by or containing trees 
 Presence of dead leaves 
 Presence of dead wood 
 
 Humidity  Humid pasture 
 Pasture surrounded by or containing a 
stream/river 
 
 
Management of the pastures 
  Spreading of manure  
(*) Age was identified as a confounding variable regarding the risk factors associated with the 
animal‟s sex. Sex is linked to age, as “gelding” is a status that follows castration, a procedure usually 
performed in males >18 months old (i.e. the most risky age for AM). Because females are more 
frequently kept at pasture than males, a higher percentage of AM cases are females.  
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Table 3. Summary of preventive measures for the development of atypical myopathy. 
 
WHERE? 
All over Europe, but especially in Belgium, France and Germany 
WHEN? 
High risk seasons (mainly autumn and spring) 
Spring after an autumnal outbreak 
During outbreaks 
DURING WHICH WEATHER CONDITIONS? 
Lack of solar radiation 
Strong wind 
Rain and thunderstorms 
Cool temperature without heavy frost 
FOR HOW LONG? 
Until 4-5 days of important frost or snow covering the pasture 
FOR ALL GRAZING EQUIDS, but horses particularly at risk are: 
Young horses 
Horses with normal body condition 
Untrained horses 
HORSE MANAGEMENT 
Regular deworming and vaccination 
Provide supplementary feeding 
Do not feed hay from the ground 
Provide water from the distribution network and in a tank or a bath 
Regular exercise 
Stable horses or limit pasturing during the risky seasons(< 6H a day or weather dependant pasturing) 
Provide a salt block 
PASTURE MANAGEMENT 
Avoid spreading of manure on the pasture; prefer manual removal of faeces 
Avoid pastures where previous deaths have occurred 
Dead leaves and wood should be removed from the pasture and be burned 
Ensure rotation of pastures and avoid (during the risky seasons) (1) sloping pastures, especially those 
with a steep slope, (2) bare pastures, (3) humid pastures or pastures surrounded by or containing a 
stream or river, (4) pastures surrounded by or containing trees, especially the tree species Acer 
pseudoplatanus 
Provide general aspecific pasture treatment such as ploughing, sowing, mowing, fertilizing 
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MANAGEMENT OF CASES SUFFERING FROM ATYPICAL MYOPATHY BASED ON 
INTERPRETATION OF THE CURRENT DESCRIPTIVE, EPIDEMIOLOGICAL AND 
PATHOPHYSIOLOGICAL KNOWLEDGE. 
PART 1: FIRST AID, CARDIOVASCULAR, NUTRITIONAL AND DIGESTIVE CARE 
 
VAN GALEN G., VOTION D.-M. 
Submitted to: Equine Veterinary Education 
 
Abstract 
Atypical myopathy is highly fatal, but about a quarter of affected horses survives. This highlights the 
need for supportive treatment of patients. This review is a practical guideline for equine practitioners 
and includes suggestions for close monitoring of involved organ systems and discusses options of 
supportive treatment based on the current knowledge of the condition. 
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Introduction 
Atypical myopathy (AM) is a severe and often fatal condition that can occur in grazing horses. A 
development of a multiple acyl-CoA dehydrogenase deficiency (MADD) blocks several steps in 
mitochondrial lipid metabolism and causes an accumulation of specific acylcarnitines in plasma and a 
urinary excretion of organic acids, glycine conjugates and metabolites derived from the accumulated 
acyl-CoA ester intermediates (Westermann et al., 2008b). Moreover, respiratory capacity of 
mitochondrial complexes of the ETS is significantly decreased (Westermann et al., 2011). These 
dysfunctions lead to energetic problems in the muscle, up to exhaustion of energy sources, which is 
reflected by the increase of uric acid excretion by purine catabolism and by sarcoplasmatic glycogen 
depletion (Westermann et al., 2011). Rhabdomyolysis is especially seen in muscles that contain a high 
proportion of oxidative type I fibres (Cassart et al., 2007). In addition, in several studies, cardiac 
troponin I activities have been shown to be consistently elevated, when they have been measured 
(Votion et al., 2007b; Verheyen et al., 2011). Cases show therefore clinical signs consistent with 
affection of postural, respiratory and cardiac muscles (Votion et al., 2007b; van Galen et al., 2012b). 
The cause of the development of AM is yet unknown, but an association with Clostridium sordelli‟s 
lethal toxin has been hypothesised (Unger-Torroledo et al., 2010). 
Although the condition is highly fatal, the survival rate during recent European outbreaks was 
reported to be 26% (van Galen et al., 2012b). The possibility for survival indicates the importance of a 
rapid and correct diagnosis and a good patient management in order to increase survival chances. The 
diagnosis is usually established based on the combination of history, clinical signs, blood analysis 
(severely increased serum creatine kinase (CK) activities), urine analysis (presence of myoglobinuria), 
and on histologic analysis of ante- or post mortem samples indicating a multifocal process compatible 
with Zenker degeneration (swollen and hypereosinophilic fibres, devoid of cross-striations and 
myofibrils and displaying a homogenous hyaline glassy appearance; Cassart et al., 2007) and necrosis 
in the targeted muscles (Hosie et al., 1986; Whitwell et al., 1988; Votion et al., 2007b). However, 
these histological findings are not pathognomic for AM and a more definitive diagnosis can be made 
with measuring the concentration of acylcarnitines and organic acids in urine and/or blood 
(Westermann et al., 2008b) and/or with immunohistochemistry to demonstrate excessive 
intramuscular lipid storage mainly in type I myofibres (Cassart et al., 2007; Palencia and Rivero, 
2007). Blood and urine acylcarnitines and organic acids can be measured in most human laboratories, 
since these tests are routinely run for testing human genetic disorders. (Example of a laboratory with 
established equine reference ranges: Genetic Laboratory of the Universitary Hospital CHU, Liege, 
Belgium; contact via Dr. Dominique Votion). Although these two latter diagnostic tools are promising 
for diagnosing AM, they should be interpreted carefully in the face of the entire clinical picture. Some 
acylcarnitines can be abnormal in other myopathies (Westermann et al., 2007; Westermann et al., 
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2008b) and immunohistochemistry of affected muscle samples only demonstrate a problem in lipid 
metabolism. So, future studies are necessary to validate these diagnostic tools. 
Recent studies identified clinical signs and blood parameters that were useful to predict 
survival in AM cases: remaining standing most of the time, normothermia, normal mucous membranes 
and defecation. Prognosis is considered to be poor when horses are recumbent, or show sweating, 
anorexia, dyspnoea, tachypnoea, tachycardia, high packed cell volume (PCV), low chloride 
concentration, low arterial partial pressure of oxygen (PaO2 < 60mmHg) and/or respiratory acidosis 
(Votion et al., 2007b; van Galen et al., 2011; van Galen et al., 2012a). It is probably justified to 
continue treatment in those patients that have none or only a few of these parameters or if they correct 
these abnormalities with treatment. Non-survivors usually die or are euthanized within 72 hours of 
onset of clinical signs, but can remain alive up to10 days (van Galen et al., 2012b). 
This article will discuss in depth the management of AM cases based on descriptive data 
available in the literature, prognostic factors and the recent advances in understanding the 
aetiopathogenesis of the condition. These treatments are based on the current knowledge and future 
research should demonstrate their true clinical impact. This article is a practical guideline and includes 
suggestions for close monitoring of involved organ systems and discusses options of supportive 
treatment. 
 
First aid 
Horses affected by AM are often found recumbent but are in the early stage often still able to get up 
(Votion et al., 2004; Votion et al., 2007b). While still capable of walking, the horse should therefore 
as soon as possible be placed in a well bedded stable. In addition, some horses that are recumbent in a 
cold environment may become severely hypothermic (Brandt et al., 1997; Delguste et al., 2002; 
Votion et al., 2007b; van Galen et al., 2012b) Therapeutic hypothermia has been shown to have 
protective effects on skeletal muscle after ischemia reperfusion injury, the brain and the myocardium 
in humans (Delhaye et al., 2012; Stahl et al., 2012), but its effect on rhabdomyolytic muscle and in 
horses is currently unknown. On the other hand, it has been suggested that hypothermia can also 
induce rhabdomyolysis (Ciapetti et al., 2011). So until further information is available about possible 
positive effects of hypothermia on equine rhabdomyolytic muscle tissue, the authors suggest to avoid 
it if possible and to warm horses if hypothermia occurs. Increasing the body temperature can be 
accomplished by for example placing the horse in a warmer environment (stable instead of pasture), 
administering intravenous or oral fluids at body temperature and using blankets (normal or electric) 
and heat lamps. If the horse has circulatory problems one should be prudent with active external 
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heating since this can cause peripheral vasodilation followed by aggravation of malperfusion. In this 
case, one probably best focuses on passive heating by avoiding loss of heat. 
Moreover, further contact with the pasture and thus the suspected causative agent should be 
avoided. Recumbent horses should be regularly turned in order to limit ischemic muscle damage and 
cardiovascular and /or respiratory problems (Nout and Reed, 2005). However, with the current 
knowledge the authors believe that attempting to get the horse up or to place it in a sling is not 
recommended. 
Physical effort, stress and transport should probably all be avoided as much as possible. They 
might aggravate the myopathy and the energetic imbalance (Westermann et al., 2008b) and might 
through the induction of hyperventilation induce or aggravate a respiratory alkalosis as is commonly 
seen in AM (van Galen et al., 2011). To the authors‟ belief, treatment should be attempted at home 
and the affected horse should only be referred and transported to a clinic if treatment at home is 
impossible. 
 
Cardiovascular monitoring and treatment 
Hydration, acid base and electrolyte status 
Correction of hydration, acid-base and electrolyte status of horses that are affected by AM is of major 
importance to optimize cardiovascular, respiratory, muscular, renal and digestive function and is 
therefore the first treatment to install. 
Monitoring hydration, acid-base and electrolyte status 
Clinical examination 
Heart rate and the colour and capillary refill time (CRT) of the mucous membranes are valuable 
clinical parameters to evaluate hydration status in a sick horse. Normal mucous membranes have been 
associated with survival and tachycardia with mortality (mean heart rate survivors: 53 ± 13 bpm  
(n= 54 cases); mean heart rate non-survivors: 62 ± 18 bpm (n= 155 cases; van Galen et al., 2012a). 
Blood analysis 
Packed cell volume (PCV): PCV is often increased (Votion et al., 2007b) and non-survivors have a 
significantly higher PCV (47.4 ± 7.4%, n= 30 cases) than survivors of AM (38.2 ± 6.6%, n= 4 cases; 
van Galen et al., 2011). 
Lactate: most affected horses have increased lactate levels (up to 19mmol/L) , but this variable 
was not associated with survival (van Galen et al., 2011). 
Venous blood gasses: the majority of affected horses suffers from metabolic acidosis on 
admission with or without respiratory alkalosis (van Galen et al., 2011). Respiratory alkalosis is 
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regularly encountered on admission (van Galen et al., 2011), possibly caused by pain, stress, or 
compensation for the metabolic acidosis or anaerobic muscle metabolism due to hyperventilation. The 
presence of respiratory acidosis, which is related to hypoventilation due to severe affection of 
respiratory muscles, seems to be associated with mortality (van Galen et al., 2011). 
Electrolytes (Na
+
, Cl
-
, K
+
, Ca
2+, 
Mg
2+
): hypocalcaemia, mild hyponatraemia and 
hypochloraemia are common in AM cases, but mild hypernatraemia and mild hyperkalaemia also can 
occur (Delguste et al., 2002; Puyalto-Moussu et al., 2004; Finno et al., 2006; Votion et al., 2007b;  
van Galen et al., 2011). Chloride concentrations are often low in non-survivors  
(van Galen et al., 2011). 
Fluid therapy 
Fluid therapy in AM affected horses should be provided in order to restore circulating volume, 
promote myoglobin excretion and correct acid-base and electrolytic imbalances. Table 1 describes the 
fluid choices for specific metabolic disturbances. Sodium bicarbonate is not indicated to treat lactic 
acidosis, especially if the patient demonstrates respiratory difficulties, hypocalcaemia and/or heart 
failure (Corley and Marr, 1998); all contra-indications that may occur in AM. Calcium 
supplementation is debatable, since it has been shown to exacerbate endotoxaemia and increase 
mortality in rodents (Malcolm et al., 1989; Zaloga et al., 1992). However, hypocalcemia can lead to 
clinical signs such as diaphragmatic flutter, tetani, seizures and cardiac problems (Glazier et al., 1979) 
and may be associated with ileus (Delesalle et al., 2005). Although it seems obvious that the 
development of these clinical signs by hypocalcemia needs to be avoided, the level of intervention in 
the horse is currently unknown. Also, intrasacroplasmatic accumulations of calcium have been 
suggested to be an important part of a common final pathway to muscle fibre degeneration and 
necrosis (Wrogemann and Pena, 1976; MacLeay, 2004). Eventhough calcium accumulations have not 
been demonstrated on histology in AM affected muscles (Cassart et al., 2007), calcium should be used 
prudently since the effects of calcium supplementation in AM are yet unknown. 
Cardiac function 
Horses affected with AM frequently demonstrate significant myocardial damage at post mortem 
(Cassart et al., 2007). Moreover, they can have reduced myocardial function, pericardial effusion, 
increased troponin I levels and arrhythmias (Votion et al., 2007b; Verheyen et al., 2011; van Galen et 
al., 2012b). Although often arrhythmias are not severe, and are mostly ventricular premature 
contractions (Verheyen et al., 2011), some horses develop life-threatening arrhythmias such as 
ventricular tachycardia (personal observation). 
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Monitoring cardiac function 
Cardiac function can be monitored by regular cardiac auscultation, measuring serum troponin I 
concentrations, and by performing an ECG and echocardiography. Complementary monitoring of 
hydration status and cardiac function might be useful with for example pulse oximetry, blood pressure 
measurements, cardiac output monitoring, and central venous pressure measurements. 
Cardiac treatment 
If the horse demonstrates tachycardia, circulating volume and cardiac function should be checked 
and/or more intensive pain management (see below) considered. Administration of digoxin  
(0.0022 mg/kg IV or 0.011 mg/kg PO) might be considered in cases that demonstrate reduced 
myocardial function. Digoxin has a positive inotropic action and improves renal blood flow. If the 
horse develops arrhythmias, electrolytes should be checked and disturbances corrected if present. If 
the arrhythmias are severe, administration of anti-arrhythmic drugs should be considered (Muir and 
McGuirk, 1985; Baggot, 1995; Durando, 2008). 
 
Nutritional support 
Nutritional support is important in all severely ill patients, but is even of bigger impact in AM cases 
because affected fibers have derangements of lipid metabolism and must rely on the less efficient 
carbohydrate metabolism (Westermann et al., 2008b). Moreover anorexia was related to poor 
prognosis (van Galen et al., 2012a). 
Monitoring 
Clinical examination 
Cases should be monitored for appetite and capability of eating. Although they are very sick, usually 
horses show good appetite. However, some are anorexic or dysphagic (van Galen et al., 2012b). 
Blood analysis 
The patient‟s metabolic status can be assessed and monitored with blood analysis (Durham et al., 
2004; Stratton-Phelps, 2008), amongst others: 
Triglycerides: hyperlipaemia occurs frequently (Votion et al., 2007b), even when patients are 
not anorexic (personal observation). 
Glucose: to check for hyperglycaemia (Votion et al., 2007b; Westermann et al., 2008b) and to 
monitor glycaemia during glucose administration. Glycaemia should ideally be maintained between 
4.4-9.0 mmol/L or 80-160 mg/dL and monitored hourly until stable (Corley and Stephen, 2008). 
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Treatment 
Nutrition 
Fasting should be avoided at all times and the horse should be encouraged to eat. It is probably best to 
support the energetic metabolism with a diet poor in lipids and rich in carbohydrates. This is 
contradictory to nutritional advice for other equine myopathies such as polysaccharide storage 
myopathy (PSSM) or recurrent exertional rhabdomyolysis (RER) where a reduction of carbohydrates 
and an increase of lipid content is suggested (MacLeah et al., 1999; McKenzie and Firshman, 2009). 
Although nutritional studies are needed in the future to determine the optimal diet composition for 
these patients, some suggestions can be made. Examples of carbohydrate rich food are grass, good 
quality hay, alfalfa, grains, molasses, sugar water, carrots, and apples. To avoid important peaks and 
drops in glycaemia it is advised to offer the horse multiple times per day small quantities of feed 
instead of one or two large meals per day and to allow free access to structural fibres such as grass, 
hay or alfalfa. It is recommended to give the majority of the diet in the form of these structural fibres 
and not to give too much soluble carbohydrates (grains or concentrates). 
If the horse is anorexic or dysphagic, but its intestinal tract is capable of handling food, the 
horse can be fed through a stomach tube (assisted enteral feeding). Soaked alfalfa pellets are easy to 
use for this manner of feeding, but commercial liquid diets are also available (Sweeney and Hansen, 
1990; Stratton-Phelps, 2008). 
If it is impossible to place a stomach tube without major physical resistance of the horse or if 
the horse has digestive problems, cardiovascular compromise, is in lateral recumbency or is not 
tolerating tube feedings, the option of parenteral nutrition without lipids can be considered. Parenteral 
nutrition is, however, expensive (although less expensive without lipids) and only few studies have 
evaluated its use in adult horses (Lopes and White, 2002; Durham et al., 2003; Durham et al., 2004). 
Following the hypothesis of MADD due to a riboflavin blockage, supplementation with 
riboflavin (vitamin B2) might be useful (Westermann et al., 2008b). Good quality hay, alfalfa or grass 
normally contain largely enough to fulfil normal daily requirements (Rooney, 2004). However, the 
requirements in horses suffering from AM might exceed those for healthy horses (12 mg for a stabled 
mature horse) and therefore it is advised to supplement riboflavin in the form of a vitamin B complex. 
Treat hyperlipaemia and hyperglycaemia 
Affected horses often demonstrate hyperlipaemia (Votion et al., 2007b), even if they are still eating 
(personal observation). The most important part of the treatment of hyperlipaemia consists of 
providing good nutritional support to the patient in order to reverse the negative energy balance. In 
addition, intravenous administration of glucose/dextrose solutions can be administered to provide the 
horse with some additional energy (Dunkel and McKenzie, 2003). Five or 10% glucose/dextrose 
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solutions, however, need to be administered in large amounts in order to meet the energy requirements 
of the patient, which might lead to overhydration or electrolyte imbalances. Therefore  
50% glucose/dextrose solutions might be a better option (0.15-0.25 ml/kg/H of 50% IV;  
Dunkel, 2008). Glucose solutions should not be used as the sole energy provider (Corley, 2008; 
Stratton-Phelps, 2008); it is thus important to provide other nutritional support in addition. Moreover, 
glucose should only be administered while blood glucose levels are closely monitored, especially since 
hyperglycaemia frequently is encountered in AM patients even before glucose supplementation 
(Votion et al., 2007b). Hyperglycaemia should be avoided and treated since it induces osmotic diuresis 
and has been demonstrated in other species to be detrimental in acute renal failure  
(Moursi et al., 1987). Moreover, as in human medicine, preventing hyperglycaemia in sick horses 
might have a positive effect on outcome (Krinsley et al., 2012; Van Herpe et al., 2012). The authors 
belief that even if patients have mild to moderate hyperglycaemia (hyperglycaemia but still under the 
renal threshold of <180mg/dL or 10 mmol/L; Stratton-Phelps, 2008), they still might benefit from 
glucose solutions. Because of the problems in energy metabolism in AM patients, one of the 
hypotheses on the origin of hyperglycaemia is gluconeogenesis. This indicates that glucose levels will 
normalise by giving glucose, because an providing an external energy source will decrease the hepatic 
production of glucose from internal energy sources. However, if hyperglycaemia continues or 
develops while supplementing, insulin should be administered (cfr Table 2). 
Insulin and heparin have been suggested as adjacent therapies for hyperlipaemia (Watson et 
al., 1992; Waitt and Cebra, 2009), however they have not proved to improve outcome in 
hyperlipaemic patients (Dunkel, 2008). 
Corticosteroids and alpha2-agonists induce insulin resistance (Firshman and Valberg, 2007; 
Tiley et al., 2008) and thus should probably best be avoided in AM patients. 
 
Digestive monitoring and treatment 
Colic is a major differential diagnosis for AM and horses suffering from AM have been mistakenly 
diagnosed as colic. Nevertheless, they can develop several digestive complications: buccal ulceration 
and/or necrosis, dysphagia with or without oesophageal obstruction, colic (dry and mucous covered 
faecal matter, impactions of the large and/or small colon, colon displacements) and mild diarrhoea 
(Sherlock and Mair, 2008; van Galen et al., 2012b). In addition, some cases display lesions of 
hemorrhagic gastro-enteritis on post mortem (Cassart et al., 2007). Since it has been suggested that the 
yet undiscovered causative agent is ingested (Votion et al., 2009), the authors hypothesize that some 
of these digestive problems (buccal ulceration, gastro-enteritis, mild diarrhoea) are caused by a local 
irritative/inflammatory reaction. The importance of a well functioning digestive system in cases 
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suffering from AM has been demonstrated by the fact that defecation was related to survival and 
anorexia to mortality (van Galen et al., 2012a). 
Monitoring 
The digestive system can be monitored by evaluating appetite, dysphagia, defecation, amount and 
consistency of faecal matter, borborygmi, and by rectal examination. 
Treatment 
Since the causative agent is believed to enter the body through the digestive system, laxative treatment 
with paraffin and/or electrolytes and intestinal absorbents such as active charcoal (1-3 g/kg diluted in 
water PO; Corley and Stephen, 2008) or di-tri octahedral smectite (Biosponge; 0.5 kg PO q24H; 
Hassel et al., 2009), can be considered. 
Omeprazole (Gastroguard; 1-4 mg/kg PO q24H; Lester et al., 2005; White et al., 2007) and /or 
sucralphate (22mg/kg PO q8H; Galvin et al., 2004) might be indicated because pain, anorexia and 
stress might increase the susceptibility to gastric ulcer development, and hemorrhagic gastro-enteritis 
can occur in AM (Cassart et al., 2007). Moreover, by avoiding or treating gastric ulcers omeprazole 
might help in preserving a good appetite, which is of major importance. However, it should be 
mentioned that the use of omeprazole in foals and humans is a risk factor for infectious complications 
such as diarrhoea (Furr et al., 2012). For the moment, negative effects on adult horses and more 
specifically those suffering from AM are not reported. Nevertheless, the possibility of complications 
should be kept in mind as also the possibility that a decreased gastric acidity enhances the dispersion 
of the unknown etiology through the body. 
An oesophageal obstruction should be treated with the use of sedatives combined or not with 
nasogastric tubing. When the horse develops diarrhoea, antimicrobials and non-steroidal anti-
inflammatory drugs (NSAID‟s) have to be used with caution. Colic signs should be attempted to be 
managed medically; surgical intervention should be avoided if possible, because anaesthesia can 
seriously aggravate rhabdomyolysis and therefore limit survival chances of the horse (Serteyn et al., 
1990; Sherlock and Mair, 2008). If buccal ulcerations or necrosis are present, the mouth of the horse 
can be flushed with water or diluted chlorhexidine to encourage healing and limit interference with 
appetite. 
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Important remark considering drugs 
The directions for use of drugs and their dosage in this article have been compiled on the basis of 
information provided in the scientific literature. As such, some drugs have not been validated 
according to quality, safety, and effectiveness criteria necessary for drug approval and 
commercialization. This list of drugs does not take into account national or community laws, 
regulations or policies regarding the use and commercialization of a series of substances and some 
drugs cited have not received legal approval. 
The authors decline all responsibility in the event of an incident. The veterinary practitioner 
engages his full responsibility. 
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Tables 
Table 1. Choice of fluid therapy for specific metabolic disturbances. 
Based on : Johnson, 1995; Corley, 2004; Corley, 2008. 
DISTURBANCE IDEAL FLUID DOSAGE/RATE SUGGESTIONS ON 
WHEN TO 
INITIATE 
TREATMENT? 
Absence of disturbance Polyionic crystalloids Rate depends on 
requirements 
 
Lactic acidosis Polyionic crystalloids 
 
 
 
Colloids 
Up to 60-80 ml/kg as bolus, 
maintenance rate depends on 
requirements 
 
Up to 10 ml/kg as bolus 
Blood lactate  
> 3.0mmol/L 
Hyponatraemia 
- With hypochloraemia 
 
- Without 
hypochloraemia 
 
Sodium chloride (0.9-1.8%) 
 
Sodium bicarbonate (1.3-5%) 
Sodium should not be 
corrected faster than 1 
mmol/L/H 
Plasma sodium  
< 122mmol/L 
 
Hypernatraemia 
- Mild 
 
 
- Moderate to severe 
 
Polyionic crystalloids 
 
 
5% glucose or dextrose 
2.5% dextrose/0.45% sodium 
chloride 
Sodium should not be 
decreased faster than 0.5 
mmol/L/H 
Mild: 
plasma sodium  
144-150mmol/L 
 
Moderate to severe: 
plasma sodium  
> 150mmol/L 
 
Hypokalaemia KCl IV 
 
KCL PO 
0.2-0.5 mmol/kg/H, not 
exceed 0.5 mmol/kg/H 
0.1-0.2 g/kg PO 
Plasma potassium  
< 3.5mmol/L 
 
Hyperkalaemia 
- No clinical signs 
 
 
- With clinical signs or 
>7mmol/L 
 
Polyionic crystalloids 
 
 
Calcium gluconate 23% 
Calcium borogluconate 40% 
50% glucose (or dextrose) 
solution  
Sodium bicarbonate (1.3-5%) 
 
To effect 
 
 
1 ml/kg IV in 10min 
0.5 ml/kg IV in 10min 
 
2 ml/kg IV in 5min 
 
1-2 mmol/kg IV in 15min 
 
Plasma potassium  
5- 7mmol/L 
 
Plasma potassium 
>7mmol/L 
 
Hypochloraemia Sodium chloride (0.9-1.8%) To effect Plasma chloride  
< 95mmol/L 
Hyperchloraemia 
- Mild  
 
- Moderate to severe 
with hypernatraemia 
 
- Moderate to severe 
without 
hypernatraemia 
 
Polyionic crystalloids 
 
5% glucose (or dextrose) 
 
 
Sodium bicarbonate (1.3-5%) 
 
Sodium should not be 
decreased faster than 0.5 
mmol/L/H Slowly To effect 
Plasma chloride  
> 115mmol/L 
Hypocalcaemia Calcium gluconate 23% 
Calcium borogluconate 40% 
0.2-1.0 ml/kg in 2-3H  
0.1-0.5 ml/kg in 2-3H 
 
Plasma ionized calcium 
< 1mmol/L 
Legend: IV = intravenous; PO = per os; KCl = potassium chloride.  
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Table 2. Insulin therapy. 
Insulin type Action Dose Reference 
Regular 
insulin  
(used by 
preference) 
Fast acting CRI titrated to effect from a starting rate of 
0.01 IU/kg/H 
Not to change by more than 0.02 IU/kg/H 
 
Corley and Stephen, 
2008; Stratton-
Phelps, 2008 
 
  CRI 0.07 IU/kg/H Han et al., 2011 
  0.1-0.5 IU/kg SC q12H Corley and Stephen, 
2008 
  50-100 IU/horse IV up to q2H Barker et al., 2008 
Protamine 
zinc insulin 
Slow acting 0.1-0.3 IU/kg SC every 12H Stratton-Phelps, 
2008 
Legend: IV = intravenous; CRI = continuous rate infusion; SC = subcutaneous. 
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MANAGEMENT OF CASES SUFFERING FROM ATYPICAL MYOPATHY BASED ON 
INTERPRETATION OF THE CURRENT DESCRIPTIVE, EPIDEMIOLOGICAL AND 
PATHOPHYSIOLOGICAL KNOWLEDGE. 
PART 2: MUSCULAR, URINARY, RESPIRATORY AND HEPATIC CARE AND 
INFLAMMATORY/INFECTIOUS STATUS. 
 
VAN GALEN G., VOTION D.-M. 
Submitted to: Equine Veterinary Education 
 
Abstract 
Atypical myopathy is highly fatal, but about a quarter of affected horses survives. This highlights the 
need for supportive treatment of patients. This review is a practical guideline for equine practitioners 
and includes suggestions for close monitoring of involved organ systems and discusses options of 
supportive treatment based on the current knowledge of the condition. Part 2 handles the muscular, 
urinary, respiratory and hepatic system and the general inflammatory/infectious status of the patient. 
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Introduction 
Atypical myopathy (AM) is characterized by a severe rhabdomyolysis of mostly postural and 
respiratory muscles, which leads to the main clinical signs of the condition: pain, muscle weakness, 
stiffness, tremors, recumbency, myoglobinuria and respiratory difficulties (Votion et al., 2007b; van 
Galen et al., 2012b). As a consequence, several organ systems require special attention in the 
management of these cases. The first aid of affected patients and the cardiovascular and digestive 
system, including nutritional support, have been discussed in the first part of this series. 
 
Muscular monitoring and treatment 
The striated skeletal muscle system is the primary target of the condition. However, AM differs from 
other equine myopathies by a myodegenerative process that does not selectively affects locomotory 
muscles (McEwen and Hulland, 1986) given the propensity to preferentially affect type I oxidative 
fibres. Thus, some parts of the supportive therapy are specific to AM. 
Monitoring 
Clinical examination 
The clinical examination should include inspection and palpation of muscle groups, and identifying 
signs of weakness and stiffness. Recumbency is a negative prognostic factor and remaining standing is 
associated with survival (van Galen et al., 2012a). Nevertheless some horses remain standing until 
death occurs (personal observation). 
Blood analysis 
Serum activities of creatine kinase (CK), aspartate aminotransferase (AST) and lactate dehydrogenase 
(LDH) can be measured to detect and monitor ongoing muscle damage. Serum CK, AST and LDH 
levels are very high in affected cases (CK up to several millions IU/L), but this is not pathognomic for 
AM. This only indicates severe muscle damage. In addition, serum CK activities have no prognostic 
value in AM, meaning that a horse with CK levels in the millions does not have a worse prognosis 
than a horse with CK levels in the hundred thousands (Votion et al., 2007b; van Galen et al., 2010; 
van Galen et al., 2012a). Throughout the clinical evolution CK activity should be monitored to check 
for ongoing muscle damage, and if in the same horse CK activities are decreasing, this is considered a 
positive evolution. 
Treatment 
Analgesia 
Horses that suffer from AM show varying degrees of pain, ranging from very mild to severe pain. 
However, most horses have low grade pain compared to the highly painful exercise-induced 
myopathies (Whitwell et al., 1988; Brandt et al., 1997; Votion et al., 2007b; van Galen, 2008). If pain 
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is difficult to control this can be an ethical reason for euthanasia. Table 1 gives examples of analgesic 
drugs for AM patients. The risk for side effects of non steroidal anti-inflammatory drugs (NSAID‟s) 
like renal and gastro-intestinal toxicity (Marshall and Blikslager, 2011) should be considered. 
Muscle relaxants 
Cases often show stiffness and muscle fasciculations, but only few show important muscle cramping. 
Nevertheless, muscle relaxants might give some relief to the patient (Table 2). However, one must 
remember that muscle relaxants can aggravate the already existing muscle weakness. Alpha2-agonists 
are probably not good candidates to achieve muscle relaxation in horses with AM, because they 
increase insulin resistance (Firshman and Valberg, 2007) and compromise optimal muscle blood flow 
(Freeman et al., 2002; Donaldson, 2008b). Having said that, in some situations they might be 
indispensable. 
Muscle metabolism 
Horses suffering from AM have severe metabolic disturbances that cause them to be incapable to use 
their most efficient energy source: the lipids. Therefore they rely on carbohydrate energy metabolism. 
Multiple acyl-CoA dehydrogenase deficiency (MADD) namely affects several dehydrogenase 
enzymes that catalyse important steps in lipid metabolism ( oxidation of fatty acids and the Krebs 
cycle). Those dehydrogenase enzymes use the coenzyme flavin adenine dinucleotide (FAD) that is 
derived from riboflavin (vitamin B2). A FAD-dependent dysfunction was hypothesised that possibly 
resulted from a riboflavin (vitamin B2) deficiency. Nevertheless, plasmatic riboflavin concentrations 
were not different in AM affected horses compared to control horses, but a competition between 
riboflavin and a toxin cannot be ruled out (Westermann et al., 2008b). In addition to MADD, AM 
patients have also very low activity of mitochondrial Complexes (Westermann et al., 2011). In 
conclusion, supportive treatment is therefore required to: 
1) support general muscle function 
2) support mitochondrial and lipid metabolism 
3) stimulate optimal use of carbohydrate metabolism 
4) limit any oxidative damage caused by free radicals. 
The most important part of treating the muscular system consists of fluid therapy. Fluids 
restore circulating volume leading to improvement of oxygen and nutrient delivery and thus support 
aerobic mitochondrial metabolism. Moreover, fluids enable waste removal and correct electrolyte and 
acid-base disturbances that have the potential to worsen clinical signs and muscle malfunction. Fluid 
therapy should be joined by cardiac and respiratory support in order to assure a good circulation and 
oxygenation of the blood. A previous study demonstrated the importance of administering 
antioxidants, vitamins and carnitine: it was the only therapeutic category that was significantly more 
used in survivors compared to non-survivors, and therefore can be suggested to have positive effects 
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on the outcome (van Galen et al., 2012a). This finding, however, does not mean that other treatments 
are of no importance. Table 3 gives some examples of supportive therapy. 
In addition to supportive treatment, inhibitors of energy metabolism should be avoided. 
Dantrolene is a frequently used drug for recurrent exercise induced myopathies for its potential to 
prevent release of excessive amounts of calcium from the sarcoplasmatic reticulum into the cell. But, it 
has inhibitory effects on mitochondrial complex I (Mehta et al., 2008) and therefore might have 
undesirable negative effects in horses that suffer from AM. 
Physiotherapy and support 
Horses suffering from AM can suffer from severe muscle weakness and have difficulties to hold up 
their head. Secondary oedema at the head can occur as a consequence (van Galen et al., 2012b), which 
can severely complicate eating, drinking and breathing (personal observation). Therefore support of 
the head is indicated in severely weak animals. Regular turnings of down patients avoid aggravation of 
myopathy by pressure, improve respiratory function and avoid development of decubital ulcers. 
Sternal recumbency is preferred over lateral, but if the patient is in sternal recumbency the hind limbs 
should still regularly be turned (Nout and Reed, 2005). Massage of the patient and other 
physiotherapeutic measures might aid in pain relief and increase muscular blood flow (Nout and Reed, 
2005; Buchner and Schildboeck, 2006; Sharkey and Herbots, 2008). 
 
Urinary monitoring and treatment 
AM patients frequently are reported with myoglobinuria, distended bladder at rectal palpation, and 
difficulties to urinate (van Galen et al., 2012b). Although histology on kidneys identified consistently 
hyaline, granulous and myoglobin casts (Cassart et al., 2007), and increased creatinine or urea levels 
are common (Delguste et al., 2002; Puyalto-Moussu et al., 2004; Votion et al., 2007b; van Galen et 
al., 2011), only few cases show clinical signs of renal dysfunction (van Galen et al., 2012b). Some 
cases have been seen to have priapism (van Galen et al., 2012b). These observations warrant close 
monitoring and supportive treatment of the urinary system. 
Monitoring 
The horse should be monitored to urinate and a rectal exam is helpful to detect enlargements of the 
bladder. Penile position should be checked in male horses. Further suggestions are summarised in 
Table 4. 
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Treatment 
It is important to avoid clinical and subclinical renal and bladder damage since this might be 
debilitating in survivors in the future. Moreover, dysuria and distension of the bladder can cause great 
discomfort and should therefore be treated. Therapeutic options considering the urinary system in AM 
patients are described in Table 5. 
 
Respiratory monitoring and treatment 
On admission affected horses often are reported to have a respiratory alkalosis (induced by 
hyperventilation), which is probably related to stress, pain, compensation for anaerobic metabolism in 
the muscles (MADD), and/or compensation for metabolic acidosis. Moreover, patients often develop 
dyspnoea because of affection of the respiratory muscles that leads to hypoventilation, and therefore 
arterial hypoxemia and in severe cases respiratory acidosis (venous hypercapnia; Votion et al., 2007b; 
van Galen et al., 2011). Other potential reasons for respiratory problems to develop in these cases are: 
prolonged lateral recumbency leading to ventilation-perfusion mismatching, aspiration pneumonia 
secondary to dysphagia, and oedema of upper respiratory tract due to head lowering secondary to 
muscle weakness. 
Monitoring 
Clinical examination 
A regularly performed clinical exam should focus on respiratory rate, presence of dyspnoea, colour of 
the mucous membranes (cyanosis), nasal oedema following low head position, and both lung fields 
should be auscultated. The use of a rebreathing bag for auscultation is contra-indicated when the horse 
displays tachypnoea or dyspnoea. Tachypnoea and dyspnoea were found to be indicators of poor 
prognosis (van Galen et al., 2012a). 
Venous and arterial blood gasses 
A low arterial partial pressure of oxygen (PaO2 < 60mmHg) and/or respiratory acidosis are associated 
with mortality (Votion et al., 2007b; van Galen et al., 2011). 
Treatment 
Regular turnings of the patient in lateral recumbency are important to improve pulmonary ventilation 
and perfusion, and sternal recumbency is preferred (Nout and Reed, 2005). Fluid therapy to restore 
circulating volume is of major importance to ensure optimal tissue oxygen delivery, removal of CO2 
from the tissues and its consecutive exhalation. 
Treatment of respiratory alkalosis should be corrected by pain management (see above), 
support of mitochondrial aerobic metabolism (see above), correction of metabolic acidosis  
(see above), and avoiding stress situations. If the horse demonstrates dyspnoea and severe hypoxemia 
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(if PaO2 < 65 mmHg), intranasal oxygen insufflations (10-20 L/min unilateral or bilateral; Wilson et 
al., 2006; McKenzie, 2008) is indicated to improve arterial oxygenation, although probably inadequate 
in patients with significant hypoventilation or ventilation-perfusion mismatching. In addition, in small 
patients (less than 200 kg body weight) mechanical ventilation can be attempted to treat hypoxemia 
and hypercapnia (if pCO2 > 60-70 mmHg; Wilkins and Palmer, 2003; McKenzie, 2008). However, 
prognosis is poor when this occurs and euthanasia should be considered. The use of respiratory 
stimulants, such as doxapram or caffeine, is not indicated because central stimulation of the respiratory 
centre does not improve respiratory muscles dysfunction. 
If the horse has a low head carriage and develops dyspnoea and/or stridor, an intranasal or 
intratracheal tube can give relief, but in some cases a tracheostomy will be required (personal 
observation). If aspiration pneumonia is suspected, the patient should be placed on broad spectrum 
antimicrobials. 
 
Hepatic monitoring and treatment 
Bilirubin, biliary acids, sorbitol dehydrogenase (SDH), gamma-glutamyl transpeptidase (GGT) and 
alkaline phosphatase (ALP) are reported to be normal to increased in horses that suffer from AM 
(Delguste et al., 2002; Puyalto-Moussu et al., 2004; Finno et al., 2006; Votion et al., 2007b), 
suggesting hepatic damage in some affected cases. This might have implications considering the 
gluconeogenic role of the liver. Moreover, the liver is the centre of biotransformation of most 
therapeutic agents and therefore dosing regimens might need to be adapted when liver function is 
severely altered. 
Monitoring 
Clinical examination of patients can show icterus, induced by fasting or by hepatic problems. Blood 
analysis (dosage of bilirubin, bile acids, ammonia, GGT, ALP, SDH, glutamate dehydrogenase 
[GLDH]) is indicated to detect hepatic problems, and especially hepatic function needs to be 
considered. 
Treatment 
If hepatic function is altered, it is recommended to administer intravenous glucose/dextrose solutions 
to support hepatic metabolism by decreasing the need for gluconeogenesis (Barton, 2004). 
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Inflammatory/infectious status 
For the moment the cause of AM is still unknown, but an association between AM and  
Clostridium sordelli‟s lethal toxin has been described (Unger-Torroledo et al., 2010). Patients are 
however also at risk to develop infectious complications such as thrombophlebitis, bacterial cystitis 
due to repetitive bladder catheterization, or aspiration pneumonia secondary to dysphagia. 
Monitoring 
Rectal temperature and other clinical signs indicative of infections should be monitored. Blood 
analysis (white blood cell count, inflammatory markers such as haptoglobin, fibrinogen, serum 
amyloid A) can be interesting to detect and follow up systemic inflammatory reactions and be an aid 
to detect infectious complications. 
Treatment 
To the authors belief, and as long as the etiological agent is not definitively found, it is recommended 
to administer metronidazole (25 mg/kg q12H PO, or 35 mg/kg q12H per rectum; Giguere, 2008) or 
penicillin (25000 IU/kg sodium penicillin IV q6H, or 25000 IU/kg penicillin procaine IM q12H; 
Giguere, 2008) to affected horses against a possible Clostridial infection, even though it is not sure if 
the bacteria itself or only the toxin is present in the horse or even if the toxin has a clear defined role in 
the development of AM. NSAID‟s and broad spectrum antimicrobials might be considered if 
infectious complications are suspected. 
 
Other issues 
Decubital ulcer care 
Recumbent horses are prone to develop decubital ulcers over bony prominences (mostly the hip, 
shoulder and antebrachium). In adult horses they can develop within two days of recumbency and 
result from pressure, abrasions from movement, and moisture from sweating and urine scalding. To 
avoid them from developing, heavy padding and thick, dry bedding are necessary. The horse needs to 
be kept quiet and dry, and will need regular turnings. Decubital ulcers need to be kept clean and zinc 
containing creams can be applied to stimulate healing (Nout and Reed, 2005; Furr, 2008). 
Eye care 
Down horses are susceptible to eyelid trauma and corneal ulcer development and regular 
ophthalmological exams are therefore necessary (Nout and Reed, 2005). Artificial tears can be 
administered in the eyes of horses in lateral recumbency. 
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Conclusion 
Although AM is primarily a muscle disorder, multiple organ systems can be involved, making affected 
horses true intensive care patients. But, even though the mortality rate of AM is high, still 26% 
survive. Therefore, if owners are motivated, medical treatment could be worth a try in selected cases. 
Further research on the condition is however needed in order to establish more effective treatment. 
 
Important remark considering drugs 
The directions for use of drugs and their dosage in this article have been compiled on the basis of 
information provided in the scientific literature. As such, some drugs have not been validated 
according to quality, safety, and effectiveness criteria necessary for drug approval and 
commercialization. This list of drugs does not take into account national or community laws, 
regulations or policies regarding the use and commercialization of a series of substances and some 
drugs cited have not received legal approval. 
The authors decline all responsibility in the event of an incident. The veterinary practitioner 
engages his full responsibility. 
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Tables 
Table 1. Drugs that can be useful to provide analgesia in horses suffering from atypical myopathy. 
Dosages from: Corley and Stephen, 2008; Donaldson, 2008a. 
Drug Dosage Administr
ation 
Remarks 
Flunixine meglumine 1.1 mg/kg IV or PO Renal toxicity possible 
Ketoprofen 2.2 mg/kg IV Renal toxicity possible 
Meloxicam 0.6 mg/kg IV Renal toxicity possible 
Morphine 0.02 – 0.2 mg/kg 
0.2 – 0.6 mg/kg 
IV 
IM 
Can cause prolonged intestinal transit 
Lidocaine 30 – 50 µg/kg/min CRI  
Ketamine (sub-anaesthetic 
doses) 
0.2 – 0.8 mg/kg 
6.7 – 13.3 µg/kg/min 
IV 
CRI 
Has been reported to reduce somatic pain 
Legend: IV = intravenous; PO = per os; CRI = continuous rate infusion; IM = intramuscular. 
 
Table 2. Muscle relaxants that can be used for horses suffering from atypical myopathy. 
Dosages from: MacKay, 2007; Donaldson, 2008b. 
Drug Dosage Administration Frequency Effect Remark 
Acepromazine 0.02 – 0.06 mg/kg 
0.03 – 0.1 mg/kg 
 
IV 
IM 
q6-12h Sedative 
Anxiolytic 
Muscular 
relaxant 
Improves 
muscular 
perfusion 
Contra-
indication: 
hypovolaemia 
or 
endotoxaemia, 
penile prolapse 
Diazepam 0.02 – 0.1 mg/kg 
0.1 – 0.2 mg/kg 
IV 
IM 
as needed Benzodiazepine: 
Muscular 
relaxant. 
2ary effects: 
ataxia and 
weakness 
Midazolam 0.02 – 0.1 mg/kg 
0.1 – 0.2 mg/kg 
0.1 – 0.2 mg/kg/H 
IV 
IM 
CRI 
as needed Benzodiazepine: 
Muscular 
relaxant. 
2ary effects: 
ataxia and 
weakness 
Methocarbamol 10 – 50 mg/kg IV 
3x IV dose 
IV 
PO 
q6-12H Central 
spasmolytic. 
To avoid when 
renal failure. 
Magnesium 
sulphate 
25 – 50 mg/kg, 
then 5 – 20 
mg/kg//H 
IV 
CRI 
Continuous 
as long as 
needed 
Muscle relaxant  
Legend: IV = intravenous; PO = per os; CRI = continuous rate infusion; IM = intramuscular. 
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Table 3. Possible treatments to support muscle function in horses affected from atypical myopathy. 
Drug Dosage Administration Reference 
dosage 
Effect Remark 
Vitamin E 2000 – 
5000 
IU/horse 
q24H 
PO Finno et al., 
2006; 
Menzies-Gow, 
2008 
Antioxidant Prefer a product that 
does not combine 
vitamin E and selenium 
in order to avoid 
selenium intoxication 
 
Selenium 1 mg q24H PO Menzies-Gow, 
2008 
Antioxidant Prefer a product that 
does not combine 
vitamin E and selenium 
in order to avoid 
selenium intoxication 
 
Vitamin B 
supplement 
Dosage is 
dependent 
on product 
PO, IM, IV  Riboflavin (Vit B2) and 
other B vitamins are 
essential for 
carbohydrate and fatty 
acid metabolism 
Usually B vitamins are 
produced in the 
gastrointestinal tract, but 
supplementation is 
suggested to avoid them 
from being a limiting 
factor 
 
Carnitine 100 mg/kg 
q24H 
PO Westermann, 
2011 
Improve fatty acid 
metabolism 
The effect of carnitine in 
equine myopathies 
remains to be 
demonstrated 
 
Vitamin C 30 mg/kg 
q12H 
IV infusion Robinson, 
2003; 
Corley and 
Stephen, 2008 
Anti-oxidant Has been demonstrated 
to potentiate the 
reduction of exercise 
induced oxidative stress 
in horses by MSM 
(Maranon et al., 2008) 
5000 mg IV in 5L of 
lactated ringers 
solution 
Finno et al., 
2006 
5 mg/kg 
q24H 
PO Maranon et 
al., 2008 
 
DMSO 0.5 – 1 g/kg 
as a 10% 
solution 
q12H 
IV Corley and 
Stephen, 2008 
Free radical trapper and 
protection of cell 
membranes (Brayton, 
1986) 
 
 
Curcumin 1.2 – 2.4 g 
q24H 
PO Tinworth et 
al., 2010 
Antioxidant, enhances 
insulin sensitivity and 
improves carbohydrate 
metabolic enzymes 
(Tinworth et al., 2010) 
and has anti-
inflammatory effects 
(Franck et al., 2008) 
 
Only limited research on 
horses is available 
MSM 
(frequently 
present in feed 
supplements) 
8 mg/kg 
q24H 
PO Maranon et 
al., 2008 
Antioxidant Has been demonstrated 
to reduce exercise 
induced oxidative stress 
in horses (Maranon et 
al., 2008) 
Legend: IV = intravenous; PO = per os; IM = intramuscular; DMSO = dimethyl sulfoxide; MSM = 
Methyl Sulfonyl Methane.  
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Table 4. Suggestions to monitor the urinary system in horses suffering from atypical myopathy. 
Test Reason Remark 
Blood analysis: urea and 
creatinine 
To monitor renal function and hydration 
status. Urea can also increase due to protein 
catabolism and AMP deamination when 
energy depletion occurs 
Urea has discriminatory 
power for survival (van 
Galen et al., 2011) 
Urine collection and 
macroscopic examination 
Empty bladder and detect the presence of 
myoglobinuria (Votion et al., 2004). 
Monitoring presence of myoglobinuria during 
treatment indicating ongoing rhabdomyolysis 
 
Reagent strips To detect myoglobinuria and/or glucosuria Reagent strips do not 
differentiate between red 
blood cells, hemoglobin and 
myoglobin 
Myoglobinuria dosage at 
laboratory 
To detect myoglobinuria  
Urine sediment examination Presence of tubular casts indicates renal 
tubular damage 
Presence of bacteria and increase in WBC 
indicate bacterial cystitis 
Bacterial cystitis can be 
caused by repetitive bladder 
catheterization 
Ratio of urinary GGT to 
urinary creatinine = urinary 
GGT (IU/L) / urinary creatinine 
(mg/dl) x 0.01 
An increased ratio indicates renal tubular 
damage. (Increases also with dehydration due 
to decrease of renal blood flow) 
Reference range for adult 
horse: < 25UI/g cr (Hollis 
and Corley, 2008) 
Urine specific gravity To monitor hydration status and renal function  
Monitor fluid input and output To monitor hydration status and renal function  
Legend: GGT = gamma glutamyltransferase. 
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Table 5. Considerations for treatment of the urinary system in horses that suffer from atypical 
myopathy. 
Treatment/act Dosage Administration Reason Remark 
Catheterization of 
the bladder 
Until the 
horse is able 
to urinate on 
his own 
 Treat discomfort and empty 
enlarged bladder. 
Diagnose myoglobinuria 
To avoid bacterial 
cystitis when 
bladder 
catheterization is 
repetitive 
trimethoprim 
sulfadiazine can be 
administered 
Penile support with 
the aid of a sling 
and massage 
  to avoid swelling of the penis It is recommended 
to avoid the use of 
acepromazine in 
horses that show 
penile prolapse 
Fluid therapy At least until 
myoglobinuria 
has 
disappeared 
and 
circulating 
volume has 
been restored 
IV (and/or PO) To support renal blood flow 
and function and to promote 
myoglobin excretion 
Fluid therapy should 
be individually 
tailored 
Dobutamine 1 – 20 
µg/kg/min 
(Hollis and 
Corley, 2008) 
CRI Indicated if the horse 
demonstrates anuria or oligo-
uria despite fluid therapy. To 
optimize cardiac output and 
renal blood flow (Lee et al., 
1998) 
Side effects: 
tachycardia and 
dysrrhytmias (Hollis 
and Corley, 2008) 
Furosemide 0.5 – 2 mg/kg 
q4-8H 
 
 
 
0.5 – 4.2 
µg/kg/min 
IV 
(Durando, 
2008; Hollis 
and Corley, 
2008) 
 
CRI 
(Hollis and 
Corley, 2008) 
Indicated if the horse 
demonstrates anuria or oligo-
uria despite fluid therapy. 
Furosemide increases renal 
blood flow, dislodges material 
obstructing tubules and 
reduces O2 demand and 
therefore the potential for 
ischemic damage (Brezis et 
al., 1994; Heyman et al., 
1994; Hollis and Corley, 
2008) 
Side effects: acid 
base and electrolytic 
imbalances  
(Durando, 2008) 
Controversy 
regarding its use 
(Hollis and Corley, 
2008) 
Avoid nephrotoxic 
drugs (NSAIDs and 
aminoglycosides) 
    
Avoid 
hyperglycaemia 
  Hyperglycaemia can induce 
glucosuria and therefore loss 
of fluid and electrolytes 
(osmotic diuresis) 
 
Legend: IV = intravenous; CRI = continuous rate infusion; NSAIDs = non-steroidal anti-
inflammatory drugs; O2 = oxygen. 
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